Original Article
Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation
N Engl J Med 2001; 345:494-502August 16, 2001
- Abstract
Background
Despite current treatments, patients who have acute coronary syndromes without ST-segment elevation have high rates of major vascular events. We evaluated the efficacy and safety of the antiplatelet agent clopidogrel when given with aspirin in such patients.
Methods
We randomly assigned 12,562 patients who had presented within 24 hours after the onset of symptoms to receive clopidogrel (300 mg immediately, followed by 75 mg once daily) (6259 patients) or placebo (6303 patients) in addition to aspirin for 3 to 12 months.
Results
The first primary outcome — a composite of death from cardiovascular causes, nonfatal myocardial infarction, or stroke — occurred in 9.3 percent of the patients in the clopidogrel group and 11.4 percent of the patients in the placebo group (relative risk with clopidogrel as compared with placebo, 0.80; 95 percent confidence interval, 0.72 to 0.90; P<0.001). The second primary outcome — the first primary outcome or refractory ischemia — occurred in 16.5 percent of the patients in the clopidogrel group and 18.8 percent of the patients in the placebo group (relative risk, 0.86, P<0.001). The percentages of patients with in-hospital refractory or severe ischemia, heart failure, and revascularization procedures were also significantly lower with clopidogrel. There were significantly more patients with major bleeding in the clopidogrel group than in the placebo group (3.7 percent vs. 2.7 percent; relative risk, 1.38; P=0.001), but there were not significantly more patients with episodes of life-threatening bleeding (2.1 percent vs. 1.8 percent, P=0.13) or hemorrhagic strokes.
Conclusions
The antiplatelet agent clopidogrel has beneficial effects in patients with acute coronary syndromes without ST-segment elevation. However, the risk of major bleeding is increased among patients treated with clopidogrel.
Media in This Article
Figure 1
Cumulative Hazard Rates for the First Primary Outcome (Death from Cardiovascular Causes, Nonfatal Myocardial Infarction, or Stroke) during the 12 Months of the Study.Figure 4
The Rates and Relative Risks of the First Primary Outcome (Death from Cardiovascular Causes, Nonfatal Myocardial Infarction, or Stroke) in Various Subgroups.Article Activity
- Article
Thrombosis caused by a ruptured or eroded atherosclerotic plaque is the usual underlying mechanism of acute coronary syndromes.1 Aspirin and heparin reduce the risk of death from cardiovascular causes, new myocardial infarction, and recurrent ischemia,2,3 but there is still a substantial risk of such events in both the short term and the long term. Intravenous glycoprotein IIb/IIIa receptor blockers have been shown to reduce the incidence of early events, mainly among patients who are treated according to an invasive strategy,4,5 but long-term oral therapy with glycoprotein IIb/IIIa receptor blockers is not beneficial and may even increase mortality.6 Similarly, continuing treatment with low-molecular-weight heparin beyond one week has not been shown to be effective.7 Although the long-term use of oral anticoagulants may be useful, no convincing evidence of their benefit is yet available.8 Therefore, there is a need to reduce further the risk of ischemic events in a broad spectrum of patients both when they first present with acute coronary syndromes and in the long term.
The thienopyridine derivatives, ticlopidine and clopidogrel, are antiplatelet agents that inhibit the platelet aggregation induced by adenosine diphosphate, thereby reducing ischemic events.9 Combining one of these drugs with aspirin, which blocks the thromboxane-mediated pathway, may have an additive effect. In patients who are undergoing percutaneous transluminal coronary angioplasty (PTCA) with stenting, short-term aspirin treatment plus a thienopyridine derivative results in a substantially lower rate of myocardial infarction than does either aspirin alone or warfarin.10 However, the role of long-term combined therapy with aspirin and an antiplatelet agent in a broader group of patients at high risk for cardiovascular events is unknown. We therefore designed the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) trial to compare the efficacy and safety of the early and long-term use of clopidogrel plus aspirin with those of aspirin alone in patients with acute coronary syndromes and no ST-segment elevation.
Methods
Study Design
We undertook a randomized, double-blind, placebo-controlled trial comparing clopidogrel with placebo in patients who presented with acute coronary syndromes without ST-segment elevation. The design and rationale of the study have been reported previously.9
Study Patients
Patients were eligible for the study if they had been hospitalized within 24 hours after the onset of symptoms and did not have ST-segment elevation. Initially, patients older than 60 years of age with no new electrocardiographic changes but with a history of coronary artery disease were included. However, after a review of the overall rates of events among the first 3000 patients, the steering committee recommended that we enroll only patients who had either electrocardiographic changes or an elevation in the serum level of cardiac enzymes or markers at entry. We excluded patients with contraindications to antithrombotic or antiplatelet therapy, those who were at high risk for bleeding or severe heart failure, those who were taking oral anticoagulants, and those who had undergone coronary revascularization in the previous three months or had received intravenous glycoprotein IIb/IIIa receptor inhibitors in the previous three days.
After we had obtained written informed consent, patients were randomly assigned to either the clopidogrel group or the placebo group by a central, 24-hour, computerized randomization service. Permuted-block randomization, stratified according to clinical center, was used. A loading dose of clopidogrel (300 mg orally) or matching placebo was administered immediately, followed by clopidogrel (75 mg per day) or matching placebo for 3 to 12 months (mean duration of treatment, 9 months). Aspirin (recommended dose, 75 to 325 mg daily) was started or continued simultaneously with the study drug. Follow-up assessments occurred at discharge, at one and three months, and then every three months until the end of the study.
Study Organization
Patients were recruited between December 1998 and September 2000 at 482 centers in 28 countries. The ethics review board at each institution approved the study. The study was organized and coordinated and all the data were managed and analyzed by the Canadian Cardiovascular Collaboration Project Office, McMaster University, Hamilton, Ontario. A steering committee consisting of national coordinators oversaw the study. The data were periodically reviewed by an independent data and safety monitoring board.
Outcomes
The first primary outcome was the composite of death from cardiovascular causes, nonfatal myocardial infarction, or stroke, and the second primary outcome was the composite of the first primary outcome or refractory ischemia. The secondary outcomes were severe ischemia, heart failure, and the need for revascularization. The safety-related outcomes were bleeding complications, which were categorized as life-threatening, major (requiring the transfusion of 2 or more units of blood), or minor. All primary outcomes and life-threatening and major bleeding complications were adjudicated by persons who were unaware of the patients' treatment-group assignments.
Definitions
Death from cardiovascular causes was defined as any death for which there was no clearly documented nonvascular cause. Myocardial infarction was defined by the presence of at least two of the following: ischemic chest pain; the elevation of the serum levels of cardiac markers or enzymes (troponin, creatine kinase, creatine kinase MB isoenzyme, or other cardiac enzymes) to at least twice the upper limit of the normal reference range or three times the upper limit of normal within 48 hours after percutaneous coronary intervention (or to a level 20 percent higher than the previous value if the level had already been elevated because of an early myocardial infarction); and electrocardiographic changes compatible with infarction.9 Stroke was defined as a new focal neurologic deficit of vascular origin lasting more than 24 hours. Stroke was further classified as the result of intracranial hemorrhage, ischemia (if a computed tomographic or magnetic resonance imaging scan was available), or uncertain cause.
Refractory ischemia in the hospital was defined as recurrent chest pain lasting more than five minutes with new ischemic electrocardiographic changes while the patient was receiving optimal medical therapy (two antianginal agents, one of which was intravenous nitrate unless such therapy was contraindicated) and leading to additional interventions (such as thrombolytic therapy, cardiac catheterization, the insertion of an intraaortic balloon pump, coronary revascularization, or transfer to a referral hospital for an invasive procedure) by midnight of the next calendar day. Refractory ischemia after discharge was defined by rehospitalization lasting at least 24 hours for unstable angina, with ischemic electrocardiographic changes. Severe ischemia (in the hospital) was defined as ischemia that was similar to in-hospital refractory ischemia but for which no urgent intervention was performed. Recurrent angina (in the hospital) was defined similarly, but electrocardiographic changes were not required.
Major bleeding episodes were defined as substantially disabling bleeding, intraocular bleeding leading to the loss of vision, or bleeding necessitating the transfusion of at least 2 units of blood. Major bleeding was classified as life-threatening if the bleeding episode was fatal or led to a reduction in the hemoglobin level of at least 5 g per deciliter or to substantial hypotension requiring the use of intravenous inotropic agents, if it necessitated a surgical intervention, if it was a symptomatic intracranial hemorrhage, or if it necessitated the transfusion of 4 or more units of blood. Minor bleeding episodes included other hemorrhages that led to the interruption of the study medication.
Statistical Analysis
The study was initially designed to include 9000 patients, with an expected rate of events in the placebo group of 12 to 14 percent. However, because the rate of events appeared to be lower than had originally been expected, the size of the study was increased. Assuming a rate of 10 percent in the placebo group for the first primary outcome and a two-sided alpha level of 0.045, a study with 12,500 patients would have 90 percent power to detect a 16.9 percent reduction in risk. For the second primary outcome, assuming a 14 percent rate of events in the placebo group and a two-sided alpha level of 0.01, the study had 90 percent power to detect a reduction of 16.4 percent in risk. Partitioning the alpha maintains an overall level of 0.05, after adjustment for the overlap between the two sets of outcomes. All analyses were based on the intention-to-treat principle and used either the log-rank statistic or the chi-square test. Subgroup analyses were conducted with the use of tests for interactions in the Cox regression model.
The data and safety monitoring board monitored the incidence of the primary outcome to determine the benefit of clopidogrel, using a modified Haybittle–Peto boundary of 4 SD in the first half of the study and 3 SD in the second half of the study. The boundary had to be exceeded at two or more consecutive time points, at least three months apart, for the board to consider terminating the study early. There were two formal interim assessments performed at the times when approximately one third and two thirds of the expected events had occurred. Despite the fact that the preset boundary indicating efficacy had been crossed by the time of the second interim analysis, the board recommended that the trial continue until its planned end, in order to define more clearly whether the risks of major bleeding episodes could offset the benefits of therapy.
All unrefuted events that occurred up to the end of the scheduled follow-up period on December 6, 2000, are included in the analyses. Vital status was ascertained for 12,549 of the 12,562 patients who underwent randomization (99.9 percent), with 6 patients in the clopidogrel group and 7 in the placebo group lost to follow-up.
Results
The base-line characteristics of the patients are shown in Table 1Table 1
Base-Line Demographic Characteristics, Medical History, Electrocardiographic Changes, and Drug Therapy..Primary Outcomes
The first primary outcome — death from cardiovascular causes, nonfatal myocardial infarction, or stroke — occurred in 582 of the 6259 patients in the clopidogrel group (9.3 percent) as compared with 719 of the 6303 patients in the placebo group (11.4 percent); relative risk, 0.80; 95 percent confidence interval, 0.72 to 0.90; P<0.001) (Figure 1Figure 1
Cumulative Hazard Rates for the First Primary Outcome (Death from Cardiovascular Causes, Nonfatal Myocardial Infarction, or Stroke) during the 12 Months of the Study. and Figure 2Figure 2
Cumulative Hazard Rates for the First Primary Outcome (Death from Cardiovascular Causes, Nonfatal Myocardial Infarction, or Stroke) during the First 30 Days after Randomization. and Table 2Table 2
Incidence of the Main Study Outcomes.). The rate of the second primary outcome — death from cardiovascular causes, nonfatal myocardial infarction, stroke, or refractory ischemia — was also higher in the placebo group (1187 patients [18.8 percent]) than in the clopidogrel group (1035 patients [16.5 percent]; relative risk, 0.86; 95 percent confidence interval, 0.79 to 0.94; P<0.001). The rate of each component of these composite outcomes also tended to be lower in the clopidogrel group. However, the clearest difference was observed in the rates of myocardial infarction (Table 2). With respect to refractory ischemia, the difference was observed primarily in first events that occurred during the initial hospitalization (85 in the clopidogrel group as compared with 126 in the placebo group; relative risk, 0.68; 95 percent confidence interval, 0.52 to 0.90; P=0.007), with little difference in the rate of rehospitalization for unstable angina.Other In-Hospital Outcomes
Significantly fewer patients in the clopidogrel group than in the placebo group had severe ischemia (176 patients [2.8 percent] vs. 237 patients [3.8 percent]; relative risk, 0.74; 95 percent confidence interval, 0.61 to 0.90; P=0.003) or recurrent angina (1307 [20.9 percent] vs. 1442 [22.9 percent]; relative risk, 0.91; 95 percent confidence interval, 0.85 to 0.98; P=0.01) (Figure 3Figure 3
Proportions of Patients Who Had Events Other Than Those Included in the First Primary Outcome while They Were in the Hospital.). Slightly fewer patients in the clopidogrel group underwent coronary revascularization during the study (36.0 percent vs. 36.9 percent), but the difference was accounted for entirely by a difference in the rate of revascularization during the initial period of hospitalization (20.8 percent in the clopidogrel group vs. 22.7 percent in the placebo group, P=0.03). Radiologic evidence of heart failure was found in fewer patients in the clopidogrel group (229 [3.7 percent], vs. 280 [4.4 percent] in the placebo group; relative risk, 0.82; 95 percent confidence interval, 0.69 to 0.98; P=0.03).Temporal Trends
The rate of the first primary outcome was lower in the clopidogrel group both within the first 30 days after randomization (relative risk, 0.79; 95 percent confidence interval, 0.67 to 0.92) and between 30 days and the end of the study (relative risk, 0.82; 95 percent confidence interval, 0.70 to 0.95) (Figure 1 and Figure 2). Further analysis indicated that the benefit of clopidogrel was apparent within a few hours after randomization, with the rate of death from cardiovascular causes, nonfatal myocardial infarction, stroke, or refractory or severe ischemia significantly lower in the clopidogrel group by 24 hours after randomization (1.4 percent in the clopidogrel group vs. 2.1 percent in the placebo group; relative risk, 0.66; 95 percent confidence interval, 0.51 to 0.86).
Subgroup Analyses
The consistency of the results in a number of key subgroups is documented in Figure 4Figure 4
The Rates and Relative Risks of the First Primary Outcome (Death from Cardiovascular Causes, Nonfatal Myocardial Infarction, or Stroke) in Various Subgroups.. The benefits were also consistent among subgroups receiving different doses of aspirin and among those receiving or not receiving lipid-lowering drugs, beta-blockers, heparin, or angiotensin-converting–enzyme inhibitors at the time of randomization. There was a tendency toward a greater benefit among patients who had previously undergone revascularization (relative risk of the first primary outcome, 0.56; 95 percent confidence interval, 0.43 to 0.72) than among those who had not (relative risk, 0.88; 95 percent confidence interval, 0.78 to 0.99; P for interaction = 0.002). However, these results should be interpreted cautiously, given the large numbers of subgroup analyses that were performed. Furthermore, consistent benefits were observed irrespective of whether patients underwent revascularization procedures after randomization.Safety
Major bleeding was significantly more common in the clopidogrel group (3.7 percent in the clopidogrel group as compared with 2.7 percent in the placebo group; relative risk, 1.38; 95 percent confidence interval, 1.13 to 1.67; P=0.001) (Table 3Table 3
Bleeding Complications.). There were 135 patients with life-threatening bleeding episodes in the clopidogrel group (2.2 percent) as compared with 112 in the placebo group (1.8 percent; relative risk, 1.21; 95 percent confidence interval, 0.95 to 1.56). There was no excess rate of fatal bleeding, bleeding requiring surgical intervention, or hemorrhagic stroke. The excess major bleeding episodes were gastrointestinal hemorrhages and bleeding at the sites of arterial punctures. The number of patients who required the transfusion of 2 or more units of blood was higher in the clopidogrel group (177 [2.8 percent]) than in the placebo group (137 [2.2 percent], P= 0.02). The rate of major bleeding episodes was higher early (within 30 days after randomization: 2.0 percent vs. 1.5 percent; relative risk, 1.31; 95 percent confidence interval, 1.01 to 1.70) and also late (more than 30 days after randomization: 1.7 percent vs. 1.1 percent; relative risk, 1.48; 95 percent confidence interval, 1.10 to 1.99). Overall, there was no significant excess of major bleeding episodes after coronary-artery bypass grafting (CABG) (1.3 percent vs. 1.1 percent; relative risk, 1.26; 95 percent confidence interval, 0.93 to 1.71). However, in most patients scheduled for CABG surgery, the study medication was discontinued before the procedure (median time before the procedure, five days). In the 910 patients in whom the study medication was discontinued more than five days before the procedure (five days being the duration of the effect of clopidogrel), there was no apparent excess of major bleeding within seven days after surgery (4.4 percent of the patients in the clopidogrel group vs. 5.3 percent of those in the placebo group). In the 912 patients who stopped taking the medications within five days before CABG surgery, the rate of major bleeding was 9.6 percent in the clopidogrel group and 6.3 percent in the placebo group (relative risk, 1.53; P=0.06). Overall, the risk of minor bleeding was significantly higher in the clopidogrel group than in the placebo group (322 [5.1 percent] vs. 153 [2.4 percent]; P<0.001). The numbers of patients with thrombocytopenia (28 in the placebo group and 26 in the clopidogrel group) or neutropenia (5 and 8, respectively) were similar.Adherence to Study Medication and Aspirin
A total of 46.2 percent of the patients in the clopidogrel group discontinued the study medication temporarily (for more than five days), as compared with 45.4 percent in the placebo group. The most common reason for the temporary discontinuation of the study medication was the need for revascularization or another surgical procedure; 84 percent of the patients with such a need discontinued the medication before the procedure. A total of 21.1 percent of the patients in the clopidogrel group discontinued the study medication permanently, as compared with 18.8 percent in the placebo group. A total of 99 percent of the patients in both groups were taking aspirin while they were in the hospital, 96 percent were taking it at three months, and 94 percent at the final visit. The use of all other medications (other than thrombolytic therapy and glycoprotein IIb/IIIa receptor inhibitors) was similar in the clopidogrel group and the placebo group.
Thrombolytic Therapy and Glycoprotein IIb/IIIa Receptor Inhibitors
A total of 71 patients in the clopidogrel group (1.1 percent) and 126 patients in the placebo group (2.0 percent) received thrombolytic therapy (relative risk, 0.57; 95 percent confidence interval, 0.43 to 0.76; P<0.001); 369 patients in the clopidogrel group (5.9 percent) and 454 in the placebo group (7.2 percent) received a glycoprotein IIb/IIIa receptor inhibitor (relative risk, 0.82; 95 percent confidence interval, 0.72 to 0.93; P=0.003).
Discussion
Our study demonstrates the benefit of adding clopidogrel to the regimen of treatment for patients with acute coronary syndromes without ST-segment elevation who are receiving aspirin and other medications. Treatment with clopidogrel reduced the risk of myocardial infarction and recurrent ischemia, with a trend toward lower rates of stroke and death from cardiovascular causes. Fewer patients in the clopidogrel group received a thrombolytic agent or an intravenous glycoprotein IIb/IIIa receptor inhibitor. The benefits we observed were in addition to those of aspirin, which was recommended for all patients, indicating that blocking the adenosine diphosphate–receptor pathway with clopidogrel leads to further benefit.
Our study primarily included centers in which there was no routine policy of early use of invasive procedures, since such a policy would have led to a high rate of immediate discontinuation of the study medication and the use of an open-label thienopyridine derivative. Once a patient had been randomly assigned to a treatment group, there were no restrictions on the use of any therapy or intervention. In particular, if the clinician believed that angiography and revascularization were needed or that a thienopyridine derivative was indicated, the study medication could be stopped or open-label clopidogrel or ticlopidine could be used. In fact, 5491 patients (43.7 percent) underwent angiography, 2072 patients (16.5 percent) underwent CABG, and 2658 patients (21.2 percent) underwent PTCA. In 85.8 percent of the patients who underwent PTCA and 84.9 percent of those who underwent CABG, the use of the study medication was temporarily interrupted for more than five days, and the vast majority of the patients who underwent PTCA received a thienopyridine-type antiplatelet agent for about two to four weeks. In the patients who underwent CABG, the study medication was restarted after a median of 11 days. Although these interruptions of therapy with the study medication would tend to result in an underestimate of the difference between the clopidogrel group and the placebo group, they also permit us to make useful estimates of the benefits and risks of clopidogrel when it is used routinely and over the long term, as compared with a strategy of more selective and short-term use among those undergoing implantation of a coronary stent.
Clopidogrel prevented a range of ischemic coronary events — among them, myocardial infarction and severe and refractory ischemia. Clopidogrel was associated with a trend toward fewer ischemic strokes, and there was no increase in the rate of hemorrhagic stroke that would offset these benefits. There was a significant reduction in the incidence of heart failure with clopidogrel that was of about the same magnitude as the reduction in the incidence of ischemic events, suggesting that the reduction of ischemia can prevent heart failure. The benefits of clopidogrel were observed in a range of patients, including both patients who were undergoing revascularization procedures and those who were not. The benefits were also observed in those at low, medium, and high risk of cardiovascular events and those who were receiving various proven therapies such as aspirin, lipid-lowering drugs, angiotensin-converting–enzyme inhibitors, and beta-blockers.13-16 The benefits of clopidogrel were apparent as early as the first 24 hours after randomization, indicating that the oral loading dose was rapidly effective. Thereafter, the differences between the two groups were maintained until the end of the study.
Clopidogrel increased the risk of minor and major bleeding episodes. For every 1000 patients treated with clopidogrel, 6 will require a transfusion. However, there was no excess in bleeding that caused strokes, required surgical intervention or inotropic agents, or caused permanent disability. Furthermore, the excess risk of bleeding we observed is similar to that observed with aspirin alone, as compared with a control, in previous studies and lower than that observed in most trials of the short-term intravenous use or the prolonged oral use of glycoprotein IIb/IIIa receptor inhibitors.4,16,17 The risk of bleeding may have been partly mitigated by the temporary discontinuation of the study medication before surgery. Treatment with clopidogrel was not associated with an excess rate of any other type of adverse event that necessitated the discontinuation of the study drug; this finding indicates that the combination of clopidogrel and aspirin is as well tolerated as aspirin alone.
In summary, clopidogrel significantly reduces the risk of the composite outcome of death from cardiovascular causes, nonfatal myocardial infarction, or stroke, as well as a range of related ischemic events. The use of the drug, in addition to aspirin, is associated with an increased risk of bleeding.
Supported by Sanofi-Synthelabo and Bristol-Myers Squibb. Dr. Yusuf is the recipient of a Senior Scientist award from the Canadian Institutes of Health Research and holds an endowed chair from the Heart and Stroke Foundation of Ontario. Dr. Mehta is a research fellow of the Heart and Stroke Foundation of Canada.
Drs. Yusuf, Mehta, Tognoni, and Fox have received honorariums for educational activities or have served as consultants to Bristol-Myers Squibb and Sanofi-Synthelabo.
The Manuscript Writing Committee (Salim Yusuf, D.Phil., F.R.C.P.C., Feng Zhao, M.Sc., Shamir R. Mehta, M.D., F.R.C.P.C., Susan Chrolavicius, B.Sc., Gianni Tognoni, M.D., and Keith K. Fox, M.D., F.R.C.P.) assumes responsibility for the overall content of the manuscript.
We are indebted to Judy Lindeman for secretarial assistance.
Source Information
Address reprint requests to Dr. Yusuf at the Canadian Cardiovascular Collaboration Project Office, Population Health Research Institute, McMaster University, Hamilton General Hospital, 237 Barton St. E., Hamilton, ON L8L 2X2, Canada, or at yusufs@mcmaster.ca.
The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) trial investigators are listed in the Appendix.
Appendix
The following persons participated in the CURE trial: Steering Committee: S. Yusuf (chair and principal investigator), K.A.A. Fox (cochair), G. Tognoni (cochair), S.R. Mehta (project officer), S. Chrolavicius (study coordinator), S. Anand, A. Avezum, N. Awan, M. Bertrand, A. Budaj, L. Ceremuzynski, J. Col, P.J. Commerford, R. Diaz, M. Flather, M.-G. Franzosi, B. Gersh, W. Grossman, D.A. Halon, D. Hunt, C. Joyner (chair of the Events Adjudication Committee), N. Karatzas, M. Keltai, S. Kopecky, B.S. Lewis, A. Maggioni, K. Malmberg, T. Moccetti, J. Morais, M. Natarajan, E. Paolasso, R. Peters, L. Piegas, A. Pipilis, J. Pogue, M. Ramos-Corrales, H.-J. Rupprecht, E. Sitkei, V. Valentin, J. Varigos, P. Widimsky, T. Wittlinger, M. Blumenthal, J. Bouthier, C. Gaudin, T. Hess, N. Khurmi, M. Sotty; Canadian Cardiovascular Collaboration (CCC) Project Office: I. Copland, B. Cracknell, C. Demers, J. Eikelboom, B. Morris, J. Pasquale, V. Yacyshyn, F. Zhao; Data Safety and Monitoring Board: G. Wyse (chair), J. Cairns, R. Hart, J. Hirsh, M. Gent, T. Ryan, J. Wittes; Investigators who recruited more than 10 patients (the numbers of patients appear in parentheses): Argentina (512) — R. Ahuad Guerrero, V. Arias, F.H. Bello, J.O. Bono, L. Bujan, A. Caccavo, A.A. Fernandez, J.J. Fuselli, A.J. Gambarte, E.G. Hasbani, E. Marzetti, G. Mon, R. Nordaby, G. Quijano, A. Salvati, E. San Martin, P. Schygiel, A. Sosa Liprandi, H. Torre, E. Tuero; Australia (742) — J. Amerena, J.H.N. Bett, J. Botha, A. Buncle, D. Careless, A. Ewart, A. Fagan, D. Fitzpatrick, P. Garrahy, K. Gunawardane, A. Hamer, A. Hill, N. Jepson, G. Lane, H. LeGood, G. Nelson, M. Sallaberger, G. Tulloch, D. Owensby, J. Padley, D. Rees, K. Roberts, D. Rosen, J. Sampson, B. Singh, C. Singh, R. Taylor, A. Thomson, W. Walsh; Austria (5); Belgium (38) — H. De Raedt, J. Rankin; Brazil (598) — J.A. Abrantes, D.C. de Albuquerque, C. Blacher, L.C. Bodanese, A.C. Carvalho, M. Coutinho, O. Dutra, J.P. Esteves, P. Leães, N.S. Lima, N. Lobo, J.A. Marin Neto, R.L. Marino, J.C. Nicolau, R.C. Pedrosa, I. Pereira Filho, W. Rabelo, A. Rabelo Jr., R.F. Ramos, R.M. Rocha, E.C. Schramm, C.V. Serrano, Jr., V.P. Souza, A. Timerman, R. Vaz, S.S. Xavier; Canada (1761) — P. Auger, K. Barbin, I. Bata, L. Bergeron, R.K. Bhargava, P. Bogaty, P. Bolduc, T. Boyne, L. Boyer, B. Bozek, T. Calmusky, Y.K. Chan, D. Cole, M. D'Astous, M. David, T. Davies, L. Desjardins, F.C. Dohaney, M. Doody, F. Dumont, C. Fortin, A. Fung, G. Galdreault, P.B. Gervais, J.P. Giannoccaro, G. Gosselin, D. Grandmont, A. Grover, M. Gupta, H. Hink, J.G. Hiscock, D. Hutton, J.W.H. Hynd, A. Iless, C. Kent, A. Kitching, S. Kouz, K. Kwok, M. LaForest, H. Lee, C. Lefkowitz, B. Lubelsky, P. Ma, J.-F. Marquis, A. McCallum, R. Major, B. May, M. Mercier, M. Montigny, A. Morris, S. Nawaz, J. Norris, S. Pallie, A. Panju, P. Parekh, C. Patterson, Y. Pesant, C. Pilon, A.R.J. Rajakumar, T. Rebane, J. Ricci, M. Ruel, R. Schuld, R. Starra, M. Thornley, A.S. Weeks, L.H. Winkler, G. Wisenberg, I. Witt, K. Woo, E. Yu, R. Zadra, D. Zaniol; Czech Republic (165) — P. Bocek, M. Branny, V. Cepelak, P. Gregor, L. Groch, P. Jansky, P. Svitil, A. Vaclavicek; Denmark (40) — S. Husted, B. Ziegler; Finland (161) — A. Karhu, J. Mustonen, M. Nieminen, K. Nissinen, K. Peuhkurinen, P. Tuomainen, A. Ylitalo; France (360) — M. Adam, G. Amat, K. Asward, G. Bessede, P. Dambrine, E. Decoulx, B. D'Hautefeuille, J. Dujardin, R. Fouche, P. Fournier, Y. Haftel, J.Y. Ketelers, R. Lallemant, M. Lang, F. Leroy, M. Richard; Germany (778) — W. Dippold, J. Gronholz, J. Harenberg, C. Hilpert, T. Horacek, A. Moritz, H. Neuss, K. Nitsche, H.R. Ochs, M. Plumer-Schmidt, B. Pollock, G. Post, M. Sauer, A. Schmidt, H. Schmitt, H.-O. Schulze, P. Schuster, E.-R. von Leitner; Greece (144) — S. Christakos, K. Karidis, K. Kifnidis, K. Papadopoulos, D. Symconidis, A. Tirologos; Hungary (599) — B. Garai, T. Gesztesi, K. Heltai, B. Herczeg, A. Janosi, A. Kadar, E. Kalo, P. Karpati, B. Kiss, A. Nagy, M. Okros, F. Poor, L. Regos, J. Sebo, E. Sitkei, P. Soltesz, J. Stefan, F. Szaboki, S. Timar, Z. Varallyay, K. Veres; Ireland (37) — K. Daly; Israel (694) — G. Cotter, A. Marmor, D. Nazzal, M. Omary, L. Reisin, T. Rosenfeld, M. Shargorodsky, S. Shasha, A. Smulovitz, Z. Vered, R. Zimlichman; Italy (538) — G. Beria, D. Bernardi, E. Bonfanti, V. Ceci, R. De Caterina, S. De Servi, M. DelPinto, A. Di Chiara, G. Di Pasquale, L. Filippucci, M. Galli, E. Gardinale, M.T. Landoni, A. Martoni, F. Mauri, N. Maurea, P. Meneghetti, M. Mennuni, A. Murrone, A. Pani, E. Paolini, P. Passarelli, G. Pettinati, B. Pontillo, L. Rossi, R. Rossi, M. Santini, G. Sabino, P. Tricoci, F.M. Turazza; Mexico (240) — A. Cruz Diaz, A. Garcia-Sosa, I. Hernandez Santamaria, J. Leiva Pons, J.N. Medecigo, F.J. Rangez Rojo, C. Jorges-Sanchez Diaz, J. Trujillo Castro, E. Villegas Morales; the Netherlands (499) — S. Baldew, D.C.G. Basart, N. Bijsterfeld, P. Bronzwaer, A. Chardon, M. den Hartoog, H. Heijmen, J. Heijmeriks, G. Jochemsen, H. Klomps, P. Landsaat, H. Michels, A. Moons, M. Pieterse, A. Sadée, G. van Beek, M. Van Hessen, J. Verheul, E. Viergever; New Zealand (89) — M. Audeau, M. Hills, H. Ikram, M. Johnstone, A. Smart; Norway (61) — J. Erikssen, T. Morstel, J. Winther Haerem; Poland (2050) — P. Achremczyk, A. Baranowska, P. Burduk, D. Cichon, A. Czepiel, H. Danielewicz, P. Danielewicz, W. Dworzanski, J. Gessek, A. Gorecki, J. Gorny, K. Janik, A. Jedrzejowski, G. Kania, T. Kawka-Urbanek, J. Klaudel, D. Kopcik, A. Kozlowski, W. Krasowski, A. Ladach, M. Laniec, J. Maciejewicz, P. Maciejewski, Z. Majcher, S. Malinowski, T. Marczyk, P. Miekus, T. Myczka, M. Ogorek, M. Piepiorka, K. Religa, Z. Reszka, M. Rozwodowska, W. Smielak-Korombel, D. Smiglak, J. Spyra, S. Stec, D. Susol, M. Szpajer, P. Szymanski, G. Szumczyk-Muszytowska, M. Tomzynski, M. Ujda, W. Wasek, T. Waszyrowski, P. Wojewoda, A. Wnorowska, P. Wrobel, J. Zadrozny, A. Zebrowski, Z. Zielinski; Portugal (129) — J.M. Bastos, P. Cardoso, M. Carrageta, C. Catarino, R. Ferreira, M. Veloso Gomes; South Africa (308) — A. Aboo, L. Bobak, B. Brown, S. Cassim, S. Harripersadh, P. Manga, F. Maritz, J. Marx, D. Myburgh, H. Nell, A. Okreglicki, H. Theron; Spain (330) — N. Alonso Orcajo, F. Colomina, I. Echanove, J. Garcia Guerrero, E. Gomez-Martinez, I. Lekuona, L. Miralles, C. Pasaval, A. Rovira, J. San Jose, A. Rodriguez Llorian, V. Valentin; Sweden (260) — N. Abdon, B. Bartholdson, E. Basilier, I. Johansson, B. Kristensson, K. Larsson, P. Lindell, B. Moller, G. Rasmanis, A. Stjerna, K. Tolhagen; Switzerland (225) — B. Caduff, G. Noseda, A. Rossi, D. Schmidt, J. Zerega; United States (462) — K. Carr, R. Detrano, R. Geer, G. Grewal, P. Hermany, N. Lakkis, W.R. Lewis, T.R. Pacheco, G. Papuchis, J. Puma, S. Runckey, U. Thadani, J. Whitaker; United Kingdom (737) — Y.J.A. Adgey, D. Blackman, M. Brack, A. Bridges, A. Cohen, P. Currie, S. Duffy, I. Findlay, J. Goodfellow, K. Gray, D. Hogg, D. Holdright, D. Hughes, N. Irvine, K. Jennings, P. Keeling, P. Ludman, T. Mathew, P. McIntyre, R. Oliver, N. Palmer, E. Rodrigues, L. Smyth, D. Sprigings, J. Stephens, A. Timmis, R. Vincent.
- References
References
1
Yeghiazarians Y ,Braunstein JB ,Askari A ,Stone PH . Unstable angina pectoris. N Engl J Med 2000;342:101-114
Full Text | Web of Science | Medline2
Antiplatelet Trialists' Collaboration
CrossRef | Web of Science3
Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996;347:561-568
Web of Science | Medline4
The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Investigators
Full Text | Web of Science | Medline5
The GUSTO IV-ACS Investigators
CrossRef | Web of Science | Medline6
Chew DP ,Bhatt D ,Sapp S ,Topol EJ . Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation 2001;103:201-206
Web of Science | Medline7
FRagmin and Fast Revascularisation during InStability in Coronary artery disease (FRISC II) Investigators
CrossRef | Web of Science | Medline8
The Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators
CrossRef | Web of Science | Medline9
CAPRIE Steering Committee
CrossRef | Web of Science | Medline10
CURE Study Investigators
CrossRef | Web of Science | Medline11
Rao AK ,Pratt C ,Berke A , et al. Thrombolysis in Myocardial Infarction (TIMI) Trial -- phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988;11:1-11
CrossRef | Web of Science | Medline12
The PURSUIT Trial Investigators
Full Text | Web of Science | Medline13
The Heart Outcomes Prevention Evaluation Study Investigators
Full Text | Web of Science | Medline14
Yusuf S ,Wittes J ,Friedman L . Overview of results of randomized clinical trials in heart disease. II. Unstable angina, heart failure, primary prevention with aspirin, and risk factor modification. JAMA 1988;260:2259-2263
CrossRef | Web of Science | Medline15
Tonkin AM ,Colquhoun D ,Emberson J , et al. Effects of pravastatin in 3260 patients with unstable angina: results from the LIPID study. Lancet 2000;356:1871-1875
CrossRef | Web of Science | Medline16
Anti-thrombotic Trialists Collaboration. Prevention of death, myocardial infarction and stroke by antiplatelet therapy: collaborative meta-analysis of 266 trials involving 200,000 patients at high risk of occlusive vascular disease. BMJ (in press).
17
The SYMPHONY Investigators
CrossRef | Web of Science | Medline
- Citing Articles (1531)
Citing Articles
1
Ulrica Alström, Fredrik Granath, Örjan Friberg, Anders Ekbom, Elisabeth Ståhle. (2012) Risk factors for re-exploration due to bleeding after coronary artery bypass grafting. Scandinavian Cardiovascular Journal 46:1, 39-44
CrossRef2
Joan Chen, Yuhong Cathy Yuan, Grigorios I. Leontiadis, Colin W. Howden. (2012) Recent Safety Concerns With Proton Pump Inhibitors. Journal of Clinical Gastroenterology 46:2, 93-114
CrossRef3
Christian W. Hamm, Jean-Pierre Bassand, Stefan Agewall, Jeroen Bax, Eric Boersma, Hector Bueno, Pio Caso, Dariusz Dudek, Stephan Gielen, Kurt Huber, Magnus Ohman, Mark C. Petrie, Frank Sonntag, Miguel Sousa Uva, Robert F. Storey, William Wijns, Doron Zahger. (2012) Guía de práctica clínica de la ESC para el manejo del síndrome coronario agudo en pacientes sin elevación persistente del segmento ST. Revista Española de Cardiología 65:2, 173.e1-173.e55
CrossRef4
Lucía Cea Soriano, Héctor Bueno, Saga Johansson, Luis A. García Rodríguez. (2012) Predictors and time trends in clopidogrel and proton pump inhibitor coprescription with low-dose acetylsalicylic acid. Pharmacoepidemiology and Drug Safetyn/a-n/a
CrossRef5
Kirk N. Garratt, David P. Lee, Eileen M. Rose, Kellie J. Windle, Hsini Liao, Chuke E. Nwachuku, Kenneth J. Winters, Thomas S. Bowman, Keith D. Dawkins. (2012) Rationale and design of the TAXUS Libertē Post-Approval Study: Examination of patients receiving the TAXUS Liberté stent with concomitant prasugrel therapy in routine interventional cardiology practice. American Heart Journal 163:2, 142-148.e6
CrossRef6
Eira Roth, Chad Purnell, Olga Shabalov, Diego Moguillansky, Caridad A. Hernandez, Michael Elnicki. (2012) Perioperative Management of a Patient with Recently Placed Drug-Eluting Stents Requiring Urgent Spinal Surgery. Journal of General Internal Medicine
CrossRef7
Robert Janknegt, Lex Ruiters, Hugo ten Cate. (2012) InforMatrix: ADP antagonists in acute coronary syndromes. Expert Opinion on Pharmacotherapy1-29
CrossRef8
Tricoci, Pierluigi, Huang, Zhen, Held, Claes, Moliterno, David J., Armstrong, Paul W., Van de Werf, Frans, White, Harvey D., Aylward, Philip E., Wallentin, Lars, Chen, Edmond, Lokhnygina, Yuliya, Pei, Jinglan, Leonardi, Sergio, Rorick, Tyrus L., Kilian, Ann M., Jennings, Lisa H.K., Ambrosio, Giuseppe, Bode, Christoph, Cequier, Angel, Cornel, Jan H., Diaz, Rafael, Erkan, Aycan, Huber, Kurt, Hudson, Michael P., Jiang, Lixin, Jukema, J. Wouter, Lewis, Basil S., Lincoff, A. Michael, Montalescot, Gilles, Nicolau, José Carlos, Ogawa, Hisao, Pfisterer, Matthias, Prieto, Juan Carlos, Ruzyllo, Witold, Sinnaeve, Peter R., Storey, Robert F., Valgimigli, Marco, Whellan, David J., Widimsky, Petr, Strony, John, Harrington, Robert A., Mahaffey, Kenneth W., . (2012) Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes. New England Journal of Medicine 366:1, 20-33
Full Text9
Erin Y Oh, Teena Abraham, Nasser Saad, Jonathan H Rapp, Fabienne L Vastey, Eric Balmir. (2012) A comprehensive comparative review of adenosine diphosphate receptor antagonists. Expert Opinion on Pharmacotherapy1-17
CrossRef10
L. David Hillis, Peter K. Smith, Jeffrey L. Anderson, John A. Bittl, Charles R. Bridges, John G. Byrne, Joaquin E. Cigarroa, Verdi J. DiSesa, Loren F. Hiratzka, Adolph M. Hutter, Michael E. Jessen, Ellen C. Keeley, Stephen J. Lahey, Richard A. Lange, Martin J. London, Michael J. Mack, Manesh R. Patel, John D. Puskas, Joseph F. Sabik, Ola Selnes, David M. Shahian, Jeffrey C. Trost, Michael D. Winniford, Alice K. Jacobs, Jeffrey L. Anderson, Nancy Albert, Mark A. Creager, Steven M. Ettinger, Robert A. Guyton, Jonathan L. Halperin, Judith S. Hochman, Frederick G. Kushner, E. Magnus Ohman, William Stevenson, Clyde W. Yancy. (2012) 2011 ACCF/AHA guideline for coronary artery bypass graft surgery: Executive summary. The Journal of Thoracic and Cardiovascular Surgery 143:1, 4-34
CrossRef11
Craig I. Coleman, Andrew D. Straznitskas, Diana M. Sobieraj, Jeffrey Kluger, Moise W. Anglade. (2012) Cost–Effectiveness of Clopidogrel Plus Aspirin for Stroke Prevention in Patients With Atrial Fibrillation in Whom Warfarin Is Unsuitable. The American Journal of Cardiology
CrossRef12
Alberto Menozzi, Daniela Lina, Giulio Conte, Francesco Mantovani, Diego Ardissino. (2012) Antiplatelet therapy in acute coronary syndromes. Expert Opinion on Pharmacotherapy 13:1, 27-42
CrossRef13
Karthik Balasubramaniam, Girish N. Viswanathan, Sally M. Marshall, Azfar G. Zaman. (2012) Increased Atherothrombotic Burden in Patients with Diabetes Mellitus and Acute Coronary Syndrome: A Review of Antiplatelet Therapy. Cardiology Research and Practice 2012, 1-18
CrossRef14
Hideaki Aihara, Akira Sato, Noriyuki Takeyasu, Hidetaka Nishina, Tomoya Hoshi, Daiki Akiyama, Yuki Kakefuda, Hiroaki Watabe, Kazutaka Aonuma, . (2012) Effect of individual proton pump inhibitors on cardiovascular events in patients treated with clopidogrel following coronary stenting:. Catheterization and Cardiovascular Interventionsn/a-n/a
CrossRef15
GENNARO SARDELLA, MASSIMO MANCONE, GIUSEPPE BIONDI-ZOCCAI, GIULIA CONTI, EMANUELE CANALI, ROCCO STIO, LUIGI LUCISANO, SIMONE CALCAGNO, CARLOTTA DE CARLO, FRANCESCO FEDELE. (2012) Beneficial Impact of Prolonged Dual Antiplatelet Therapy after Drug-Eluting Stent Implantation. Journal of Interventional Cardiologyno-no
CrossRef16
Grzegorz Grzesk, Marek Kozinski, Eliano Pio Navarese, Marek Krzyzanowski, Elzbieta Grzesk, Aldona Kubica, Jolanta Maria Siller-Matula, Fausto Castriota, Jacek Kubica. (2012) Ticagrelor, but not clopidogrel and prasugrel, prevents ADP-induced vascular smooth muscle cell contraction: A placebo-controlled study in rats. Thrombosis Research
CrossRef17
Thomas Cuisset, Pierre-Emmanuel Morange, Marie-Christine Alessi. (2011) Recent advances in the pharmacogenetics of clopidogrel. Human Genetics
CrossRef18
Homam Ibrahim, Srinivas Nadipalli, Timothy DeLao, Sasidhar Guthikonda, Neal S. Kleiman. (2011) Immature platelet fraction (IPF) determined with an automated method predicts clopidogrel hyporesponsiveness. Journal of Thrombosis and Thrombolysis
CrossRef19
Uwe Zeymer, Hans-Richard Arntz, Bernd Mark, Stephan Fichtlscherer, Gerald Werner, Ralph Schöller, Ralf Zahn, Frank Diller, Harald Darius, Thorsten Dill, Kurt Huber. (2011) Efficacy and safety of a high loading dose of clopidogrel administered prehospitally to improve primary percutaneous coronary intervention in acute myocardial infarction: the randomized CIPAMI trial. Clinical Research in Cardiology
CrossRef20
Maria E Tsoumani, Kallirroi I Kalantzi, Andromachi A Dimitriou, Ioannis V Ntalas, Ioannis A Goudevenos, Alexandros D Tselepis. (2011) Effect of clopidogrel besylate on platelet reactivity in patients with acute coronary syndromes. Comparison with clopidogrel hydrogen sulfate. Expert Opinion on Pharmacotherapy1-10
CrossRef21
J T Delaney, A H Ramirez, E Bowton, J M Pulley, M A Basford, J S Schildcrout, Y Shi, R Zink, M Oetjens, H Xu, J H Cleator, E Jahangir, M D Ritchie, D R Masys, D M Roden, D C Crawford, J C Denny. (2011) Predicting Clopidogrel Response Using DNA Samples Linked to an Electronic Health Record. Clinical Pharmacology & Therapeutics
CrossRef22
N. C. Pequeriaux, R. Fijnheer, E. F. Gemen, A. D. Barendrecht, F. W. Dekker, R. T. Krediet, J. J. Beutler, E. W. Boeschoten, M. Roest. (2011) Plasma concentration of von Willebrand factor predicts mortality in patients on chronic renal replacement therapy. Nephrology Dialysis Transplantation
CrossRef23
Mark R. Thomas, Robert F. Storey. (2011) Optimal Management of Antiplatelet Therapy and Proton Pump Inhibition Following Percutaneous Coronary Intervention. Current Treatment Options in Cardiovascular Medicine
CrossRef24
Peter Damman, Pier Woudstra, Wichert J. Kuijt, Robbert J. Winter, Stefan K. James. (2011) P2Y12 platelet inhibition in clinical practice. Journal of Thrombosis and Thrombolysis
CrossRef25
D C Sylvester, A P Coatesworth. (2011) Antiplatelet therapy in ENT surgery: a review. The Journal of Laryngology & Otology1-6
CrossRef26
Paul A. Gurbel, Udaya S. Tantry. 2011. Resistance to Antiplatelet Therapy. .
CrossRef27
Karin Mauer, Jorge F. Saucedo. 2011. Cardiology-In-Depth Look: Advances in Antiplatelet Therapy. .
CrossRef28
Pravin Pratap, Sameer Gupta, Michael Berlowtiz. (2011) Routine Invasive Versus Conservative Management Strategies in Acute Coronary Syndrome: Time for a “Hybrid” Approach. Journal of Cardiovascular Translational Research
CrossRef29
Sergio Leonardi, Pierluigi Tricoci, Kenneth W. Mahaffey. (2011) Promises of PAR-1 Inhibition in Acute Coronary Syndrome. Current Cardiology Reports
CrossRef30
J. A. de Lemos, E. S. Brilakis. (2011) No free lunches: balancing bleeding and efficacy with ticagrelor. European Heart Journal 32:23, 2919-2921
CrossRef31
Giuseppe Musumeci, Emilio Di Lorenzo, Marco Valgimigli. (2011) Dual antiplatelet therapy duration. Current Opinion in Cardiology 26, S4-S14
CrossRef32
Leonardo Bolognese, Dominick J. Angiolillo. (2011) Unravelling the benefit against the risk of long-term dual antiplatelet therapy. Current Opinion in Cardiology 26, S22-S30
CrossRef33
Man Luo, Jiaoxing Li, Xiaowei Xu, Xunsha Sun, Wenli Sheng. (2011) ABCB1 C3435T polymorphism and risk of adverse clinical events in clopidogrel treated patients: A meta-analysis. Thrombosis Research
CrossRef34
Francis K.L. Chan. (2011) JGHF Marshall & Warren Lecture: Anti-platelet therapy and managing ulcer risk. Journal of Gastroenterology and Hepatologyno-no
CrossRef35
U. Alstrom, L.- A. Levin, E. Stahle, R. Svedjeholm, O. Friberg. (2011) Cost analysis of re-exploration for bleeding after coronary artery bypass graft surgery. British Journal of Anaesthesia
CrossRef36
Luke Kim, Konstantinos Charitakis, Rajesh V. Swaminathan, Dmitriy N. Feldman. (2011) Novel Antiplatelet Therapies. Current Atherosclerosis Reports
CrossRef37
Robert W. Harrison, Kenneth W. Mahaffey. (2011) Clopidogrel and PPI Interaction: Clinically Relevant or Not?. Current Cardiology Reports
CrossRef38
Idit Yedidya, Adi Netzer, Muthiah Vaduganathan, Alejandro Solodky, Ran Kornowski, Eli I. Lev. (2011) Clopidogrel tapering as a strategy to attenuate platelet rebound phenomenon in patients with bare-metal stents. Journal of Thrombosis and Thrombolysis
CrossRef39
J. Silvain, G. Cayla, J.-S. Hulot, J. Finzi, M. Kerneis, S. A. O'Connor, A. Bellemain-Appaix, O. Barthelemy, F. Beygui, J.-P. Collet, G. Montalescot. (2011) High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study. European Heart Journal
CrossRef40
Mathieu Pankert, Jacques Quilici, Thomas Cuisset. (2011) Role of Antiplatelet Therapy in Secondary Prevention of Acute Coronary Syndrome. Journal of Cardiovascular Translational Research
CrossRef41
Isabelle Djaffar Jureidini, Nabil Chamseddine, Sose Keleshian, Rania Naoufal, Laila Zahed, Noha Hakime. (2011) Prevalence of CYP2C19 polymorphisms in the Lebanese population. Molecular Biology Reports 38:8, 5449-5452
CrossRef42
Satyendra Giri. (2011) Optimal treatment of ACS patients: Issues and considerations for upstream antiplatelet therapy. International Journal of Cardiology
CrossRef43
Charles V. Pollack, Gerard X. Brogan, Marc Cohen, Deborah Diercks, Cindy Grines, Timothy D. Henry, Neal S. Kleiman, Robert P. Giugliano. (2011) ED to catheterization laboratory: a roundtable integrating trials with practice. The American Journal of Emergency Medicine 29:9, 1203-1216
CrossRef44
Stephen D. Wiviott, Willibald Hochholzer. (2011) On-Clopidogrel Platelet Reactivity. Journal of the American College of Cardiology 58:19, 1955-1957
CrossRef45
Álvaro Merino, Inmaculada Roldán, Francisco Marín, Fernando Worner. (2011) Prevención de complicaciones hemorrágicas en el síndrome coronario agudo. Medicina Clínica 137:14, 650-655
CrossRef46
K. Walenta, J. M. Sinning, C. Werner, M. Böhm. (2011) Hotline update of clinical trials and registries presented at the at the European Society of Cardiology Congress in Paris 2011. Clinical Research in Cardiology 100:11, 955-971
CrossRef47
Sukhdeep S. Basra, Peter Tsai, Nasser M. Lakkis. (2011) Safety and Efficacy of Antiplatelet and Antithrombotic Therapy in Acute Coronary Syndrome Patients With Chronic Kidney Disease. Journal of the American College of Cardiology 58:22, 2263-2269
CrossRef48
Jean-Pierre Bassand. (2011) Current antithrombotic agents for acute coronary syndromes: Focus on bleeding risk. International Journal of Cardiology
CrossRef49
Chee Tang Chin, Tracy Y. Wang, Kevin J. Anstrom, Baojin Zhu, Jen-Fue Maa, John C. Messenger, Kelley A. Ryan, Linda Davidson-Ray, Marjorie Zettler, Mark B. Effron, Daniel B. Mark, Eric D. Peterson. (2011) Treatment with Adenosine Diphosphate Receptor Inhibitors—Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) study design: Expanding the paradigm of longitudinal observational research. American Heart Journal 162:5, 844-851
CrossRef50
Prabowo Tunggal, Fook-Hong Ng, Kwok-Fai Lam, Francis K.L. Chan, Yuk-Kong Lau. (2011) Effect of esomeprazole versus famotidine on platelet inhibition by clopidogrel: A double-blind, randomized trial. American Heart Journal 162:5, 870-874
CrossRef51
Sidney C. Smith, Emelia J. Benjamin, Robert O. Bonow, Lynne T. Braun, Mark A. Creager, Barry A. Franklin, Raymond J. Gibbons, Scott M. Grundy, Loren F. Hiratzka, Daniel W. Jones, Donald M. Lloyd-Jones, Margo Minissian, Lori Mosca, Eric D. Peterson, Ralph L. Sacco, John Spertus, James H. Stein, Kathryn A. Taubert. (2011) AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update. Journal of the American College of Cardiology
CrossRef52
David H. Fitchett, Pierre Theroux, James M. Brophy, Warren J. Cantor, Jafna L. Cox, Milan Gupta, Heather Kertland, Shamir R. Mehta, Robert C. Welsh, Shaun G. Goodman. (2011) Assessment and Management of Acute Coronary Syndromes (ACS): A Canadian Perspective on Current Guideline-Recommended Treatment – Part 1: Non-ST–Segment Elevation ACS. Canadian Journal of Cardiology 27:6, S387-S401
CrossRef53
L. David Hillis, Peter K. Smith, Jeffrey L. Anderson, John A. Bittl, Charles R. Bridges, John G. Byrne, Joaquin E. Cigarroa, Verdi J. DiSesa, Loren F. Hiratzka, Adolph M. Hutter, Michael E. Jessen, Ellen C. Keeley, Stephen J. Lahey, Richard A. Lange, Martin J. London, Michael J. Mack, Manesh R. Patel, John D. Puskas, Joseph F. Sabik, Ola Selnes, David M. Shahian, Jeffrey C. Trost, Michael D. Winniford. (2011) 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: Executive Summary. Journal of the American College of Cardiology
CrossRef54
L. David Hillis, Peter K. Smith, Jeffrey L. Anderson, John A. Bittl, Charles R. Bridges, John G. Byrne, Joaquin E. Cigarroa, Verdi J. DiSesa, Loren F. Hiratzka, Adolph M. Hutter, Michael E. Jessen, Ellen C. Keeley, Stephen J. Lahey, Richard A. Lange, Martin J. London, Michael J. Mack, Manesh R. Patel, John D. Puskas, Joseph F. Sabik, Ola Selnes, David M. Shahian, Jeffrey C. Trost, Michael D. Winniford. (2011) 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery. Journal of the American College of Cardiology
CrossRef55
Eric L. Eisenstein, David F. Kong, Patricia A. Cowper, Jay P. Bae, Krishnan Ramaswamy, Kevin J. Anstrom. (2011) Nonfatal myocardial infarction and long-term outcomes in coronary artery disease. American Heart Journal
CrossRef56
Guliz Erdem, Marcus Flather. (2011) Evaluación del riesgo de hemorragia en los síndromes coronarios agudos. Revista Española de Cardiología
CrossRef57
Guliz Erdem, Marcus Flather. (2011) Assessing Bleeding Risk in Acute Coronary Syndromes. Revista Española de Cardiología (English Edition)
CrossRef58
Y. Li, H.-L. Tang, Y.-F. Hu, H.-G. Xie. (2011) The Gain-of-Function Variant Allele CYP2C19*17: A Double-Edged Sword Between Thrombosis and Bleeding in Clopidogrel-Treated Patients. Journal of Thrombosis and Haemostasisno-no
CrossRef59
Davide Capodanno, Dominick J. Angiolillo. (2011) Antithrombotic Pharmacotherapy in the Elderly: General Issues and Clinical Conundrums. Current Treatment Options in Cardiovascular Medicine
CrossRef60
C. Patrono, F. Andreotti, H. Arnesen, L. Badimon, C. Baigent, J.-P. Collet, R. De Caterina, D. Gulba, K. Huber, S. Husted, S. D. Kristensen, J. Morais, F.-J. Neumann, L. H. Rasmussen, A. Siegbahn, P.-G. Steg, R. F. Storey, F. Van de Werf, F. Verheugt. (2011) Antiplatelet agents for the treatment and prevention of atherothrombosis. European Heart Journal
CrossRef61
Teddy Kosoglou, Larisa Reyderman, Claudia Kasserra, Lisa K. Jennings, Sophia Young, Fengjuan Xuan, Jinglan Pei, Stephen E. Maxwell, James Schiller, Alan G. Meehan, David L. Cutler. (2011) No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects. European Journal of Clinical Pharmacology
CrossRef62
Jeffrey C. Trost, Richard A. Lange. (2011) Treatment of acute coronary syndrome: Part 1: Non-ST-segment acute coronary syndrome. Critical Care Medicine 39:10, 2346-2353
CrossRef63
Ronald J. Dick, Anthony E. Dear, Keith A. Byron. (2011) Clopidogrel Resistance: Case reports of CYP2C19 gene variants in suspected coronary stent thrombosis. Heart, Lung and Circulation 20:10, 657-658
CrossRef64
Inder M. Singh, David R. Holmes. (2011) Myocardial Revascularization by Percutaneous Coronary Intervention: Past, Present, and the Future. Current Problems in Cardiology 36:10, 375-401
CrossRef65
Marcus D. Flather, Daphne Babalis, Jean Booth, Alfredo Bardaji, Jacques Machecourt, Grzegorz Opolski, Filippo Ottani, Héctor Bueno, Winston Banya, Anthony R. Brady, Mats Bojestig, Bertil Lindahl. (2011) Cluster-randomized trial to evaluate the effects of a quality improvement program on management of non–ST-elevation acute coronary syndromes: The European Quality Improvement Programme for Acute Coronary Syndromes (EQUIP-ACS). American Heart Journal 162:4, 700-707.e1
CrossRef66
Tong Yin, Toshiyuki Miyata. (2011) Pharmacogenomics of clopidogrel: Evidence and perspectives. Thrombosis Research 128:4, 307-316
CrossRef67
M.J. Fernández Herranz, M.A. Espinosa Castro, H. Bueno Zamora, A.I. Castuera Gil. (2011) Tratamiento extrahospitalario y en Urgencias del síndrome coronario agudo sin elevación del segmento ST. Medicine - Programa de Formación Médica Continuada Acreditado 10:87, 5903-5906
CrossRef68
David E. Kandzari, Colin S. Barker, Martin B. Leon, Laura Mauri, William Wijns, Jean Fajadet, Roxana Mehran. (2011) Dual Antiplatelet Therapy Duration and Clinical Outcomes Following Treatment With Zotarolimus-Eluting Stents. JACC: Cardiovascular Interventions 4:10, 1119-1128
CrossRef69
Adnan Kastrati, Robert A. Byrne, Stefanie Schulz. (2011) Will We Ever Know the Optimal Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation?. JACC: Cardiovascular Interventions 4:10, 1129-1132
CrossRef70
José Antonio Páramo. (2011) Nueva era en la terapia antiplaquetar basada en los resultados de ensayos clínicos recientes. Medicina Clínica 137:11, 504-508
CrossRef71
A. M. HARMSZE, J. W. VAN WERKUM, P. C. SOUVEREIN, N. J. BREET, H. J. BOUMAN, C. M. HACKENG, H. J. T. RUVEN, J. M. TEN BERG, O. H. KLUNGEL, A. DE BOER, V. H. M. DENEER. (2011) Combined influence of proton-pump inhibitors, calcium-channel blockers and CYP2C19*2 on on-treatment platelet reactivity and on the occurrence of atherothrombotic events after percutaneous coronary intervention. Journal of Thrombosis and Haemostasis 9:10, 1892-1901
CrossRef72
Paul St. Laurent. (2011) Acute Coronary Syndrome: New and Evolving Therapies. Critical Care Nursing Clinics of North America
CrossRef73
Tom J. Parry, Zhihong Huang, Cailin Chen, Margery A. Connelly, Elisabeth Perzborn, Patricia Andrade-Gordon, Bruce P. Damiano. (2011) Arterial antithrombotic activity of rivaroxaban, an orally active factor Xa inhibitor, in a rat electrolytic carotid artery injury model of thrombosis. Blood Coagulation & Fibrinolysis1
CrossRef74
Jeffrey D. Wessler, Fidencio Saldana, Robert P. Giugliano. (2011) Bridging therapy after recent stent implantation: case report and review of data. Cardiovascular Revascularization Medicine
CrossRef75
Teddy Kosoglou, Larisa Reyderman, Renger G. Tiessen, André A. Vliet, Robert R. Fales, Robert Keller, Bo Yang, David L. Cutler. (2011) Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects. European Journal of Clinical Pharmacology
CrossRef76
D. Divchev, C. Nienaber, H. Ince. (2011) Therapiestrategien beim akuten Koronarsyndrom und nach koronaren Interventionen. Der Internist
CrossRef77
Stefano De Servi, Eliano Pio Navarese, Maurizio D’Urbano, Stefano Savonitto. (2011) Treating acute coronary syndromes with new antiplatelet drugs: the mortality issue with prasugrel and ticagrelor. Current Medical Research and Opinion1-6
CrossRef78
Arun Kalyanasundaram, A. Michael Lincoff. (2011) Managing adverse effects and drug–drug interactions of antiplatelet agents. Nature Reviews Cardiology 8:10, 592-600
CrossRef79
D. J. Quinlan, J. W. Eikelboom, S. G. Goodman, R. C. Welsh, D. H. Fitchett, P. Theroux, S. R. Mehta. (2011) Implications of variability in definition and reporting of major bleeding in randomized trials of oral P2Y12 inhibitors for acute coronary syndromes. European Heart Journal 32:18, 2256-2265
CrossRef80
M.J. Cohen. (2011) Does CYP2C19 inhibition lead to clopidogrel thrombogenicity?. Medical Hypotheses 77:3, 448-450
CrossRef81
Matthew J. Reed, Sarah S. Henderson, David E. Newby, Alasdair J. Gray. (2011) One-Year Prognosis After Syncope and the Failure of the ROSE Decision Instrument to Predict One-Year Adverse Events. Annals of Emergency Medicine 58:3, 250-256
CrossRef82
Balazs Borsiczky, Zsolt Sarszegi, Attila Konyi, Sandor Szabados, Balazs Gaszner. (2011) The effect of clopidogrel besylate and clopidogrel hydrogensulfate on platelet aggregation in patients with coronary artery disease: A retrospective study. Thrombosis Research
CrossRef83
Angel Lanas, Ping Wu, Jennie Medin, Edward J. Mills. (2011) Low Doses of Acetylsalicylic Acid Increase Risk of Gastrointestinal Bleeding in a Meta-Analysis. Clinical Gastroenterology and Hepatology 9:9, 762-768.e6
CrossRef84
Gary C. Bird, Christopher P. Cannon, Richard H. Kennison. (2011) Results of a Survey Assessing Provider Beliefs of Adherence Barriers to Antiplatelet Medications. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 10:3, 134-141
CrossRef85
Asim N. Cheema, Atif Mohammad, Tony Hong, Henry R. Jakubovic, Gurpreet S. Parmar, Waseem Sharieff, M. Bernadette Garvey, Michael J.B. Kutryk, Neil P. Fam, John J. Graham, Robert J. Chisholm. (2011) Characterization of Clopidogrel Hypersensitivity Reactions and Management With Oral Steroids Without Clopidogrel Discontinuation. Journal of the American College of Cardiology 58:14, 1445-1454
CrossRef86
Etienne Puymirat, Nadia Aïssaoui, Pierre Coste, Gilles Dentan, Vincent Bataille, Elodie Drouet, Geneviève Mulak, Dider Carrié, Didier Blanchard, Tabassome Simon, Nicolas Danchin. (2011) Comparison of Efficacy and Safety of a Standard Versus a Loading Dose of Clopidogrel for Acute Myocardial Infarction in Patients ≥75 Years of Age (from the FAST-MI Registry). The American Journal of Cardiology 108:6, 755-759
CrossRef87
Nadia Paarup Dridi, Lene Holmvang, Peter Clemmensen. (2011) Oral antiplatelet agents in ischemic heart disease: a review of the latest clinical evidence. Clinical Investigation 1:9, 1315-1328
CrossRef88
R. F. STOREY, K. P. BLIDEN, R. ECOB, A. KARUNAKARAN, K. BUTLER, C. WEI, U. TANTRY, P. A. GURBEL. (2011) Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared with clopidogrel in patients with high antiplatelet responses. Journal of Thrombosis and Haemostasis 9:9, 1730-1737
CrossRef89
Yoshio Shimizu, Hiroaki Io, Shinji Hagiwara, Tomohito Gohda, Chieko Hamada, Satoshi Horikoshi, Yasuhiko Tomino. (2011) Concomitant use of clopidogrel and proton pump inhibitors may attenuate the prognosis of coronary heart disease in hemodialysis patients. Diálisis y Trasplante
CrossRef90
M. LEVI, E. EERENBERG, P. W. KAMPHUISEN. (2011) Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. Journal of Thrombosis and Haemostasis 9:9, 1705-1712
CrossRef91
Thomas Cuisset, Jacques Quilici, William Cohen, Laurent Fourcade, Noémie Saut, Mathieu Pankert, Bénédicte Gaborit, Patrizia Carrieri, Pierre-Emmanuel Morange, Jean Louis Bonnet, Marie-Christine Alessi. (2011) Usefulness of High Clopidogrel Maintenance Dose According to CYP2C19 Genotypes in Clopidogrel Low Responders Undergoing Coronary Stenting for Non ST Elevation Acute Coronary Syndrome. The American Journal of Cardiology 108:6, 760-765
CrossRef92
Danai Khemasuwan, Young Kwang Chae, Shikha Gupta, Alejandra Carpio, Jeong Hyun Yun, Stefan Neagu, Anabella B. Lucca, Matias E. Valsecchi, Jorge I. Mora. (2011) Dose-related Effect of Statins in Venous Thrombosis Risk Reduction. The American Journal of Medicine 124:9, 852-859
CrossRef93
Kadriye O. Kilickesmez, Cuneyt Kocas, Baris Okcun, Okay Abaci, Aysem Kaya, Alev Arat, Bilal Gorcin, Tevfik Gurmen. (2011) Laboratory signs of aspirin response in haemodialysis patients. Scandinavian Journal of Clinical & Laboratory Investigation 71:5, 426-431
CrossRef94
Amir Lotfi, Jiang Cui, Siddharth Wartak, Jesse Columbo, Scott Mulvey, Mary Davis, Marc Schweiger, Gregory R. Giugliano. (2011) Influence of Low-Dose Aspirin (81 mg) on the Incidence of Definite Stent Thrombosis in Patients Receiving Bare-Metal and Drug-Eluting Stents. Clinical Cardiology 34:9, 567-571
CrossRef95
Nobukazu Ishizaka, Aiko Sakamoto, Mitsuhiro Fujishiro, Ryozo Nagai, Kazuhiko Koike. (2011) Gastrointestinal malignancies and cardiovascular diseases—Non-negligible comorbidity in an era of multi-antithrombotic drug use. Journal of Cardiology
CrossRef96
Yung-Lung Chen, Chia-Lo Chang, Huang-Chung Chen, Cheuk-Kwan Sun, Kuo-Ho Yeh, Tzu-Hsien Tsai, Chien-Jen Chen, Shyh-Ming Chen, Cheng-Hsu Yang, Chi-Ling Hang, Chiung-Jen Wu, Hon-Kan Yip. (2011) Major Adverse Upper Gastrointestinal Events in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Coronary Intervention and Dual Antiplatelet Therapy. The American Journal of Cardiology
CrossRef97
Sebastien Armero, Laurent Bonello, Julie Berbis, Laurence Camoin-Jau, Gilles Lemesle, Laurent Jacquin, Caroline Bonello-Burignat, Michel Pansieri, Frederic Collet, Michel Ostorero, Françoise Dignat-George, Franck Paganelli. (2011) Rate of Nuisance Bleedings and Impact on Compliance to Prasugrel in Acute Coronary Syndromes. The American Journal of Cardiology
CrossRef98
Haralampos J. Milionis, Grigorios Gerotziafas, Michael S. Kostapanos, Anastasia Vemmou, Panagiotis Zis, Konstantinos Spengos, Moses Elisaf, Konstantinos N. Vemmos. (2011) Clopidogrel vs. Aspirin Treatment on Admission Improves 5-Year Survival After a First-ever Acute Ischemic Stroke. Data from the Athens Stroke Outcome Project. Archives of Medical Research
CrossRef99
Daniel J. Cushing, Paul F. Souney, Warren D. Cooper, Gerald L. Mosher, Michael P. Adams, Stephen Machatha, Bing Zhang, Peter R. Kowey. (2011) Assessment of the pharmacokinetics and platelet aggregation inhibitory effects of a novel intravenous formulation of clopidogrel in humans. Clinical and Experimental Pharmacology and Physiologyno-no
CrossRef100
S. D. Kristensen. (2011) On the cutting edge of acute coronary syndromes: adding oral factor Xa-inhibition with darexaban to dual antiplatelet therapy: the RUBY-1 trial. European Heart Journal
CrossRef101
R. Boggon, T. P. van Staa, A. Timmis, H. Hemingway, K. K. Ray, A. Begg, C. Emmas, K. A. A. Fox. (2011) Clopidogrel discontinuation after acute coronary syndromes: frequency, predictors and associations with death and myocardial infarction--a hospital registry-primary care linked cohort (MINAP-GPRD). European Heart Journal
CrossRef102
Ramiro Jervis, Andrew Dunn. 2011. Perioperative Management of Oral Anticoagulants and Antiplatelet Agents. , 161-177.
CrossRef103
, C. W. Hamm, J.-P. Bassand, S. Agewall, J. Bax, E. Boersma, H. Bueno, P. Caso, D. Dudek, S. Gielen, K. Huber, M. Ohman, M. C. Petrie, F. Sonntag, M. S. Uva, R. F. Storey, W. Wijns, D. Zahger, , J. J. Bax, A. Auricchio, H. Baumgartner, C. Ceconi, V. Dean, C. Deaton, R. Fagard, C. Funck-Brentano, D. Hasdai, A. Hoes, J. Knuuti, P. Kolh, T. McDonagh, C. Moulin, D. Poldermans, B. A. Popescu, Z. Reiner, U. Sechtem, P. A. Sirnes, A. Torbicki, A. Vahanian, S. Windecker, , S. Windecker, S. Achenbach, L. Badimon, M. Bertrand, H. E. Botker, J.-P. Collet, F. Crea, N. Danchin, E. Falk, J. Goudevenos, D. Gulba, R. Hambrecht, J. Herrmann, A. Kastrati, K. Kjeldsen, S. D. Kristensen, P. Lancellotti, J. Mehilli, B. Merkely, G. Montalescot, F.-J. Neumann, L. Neyses, J. Perk, M. Roffi, F. Romeo, M. Ruda, E. Swahn, M. Valgimigli, C. J. Vrints, P. Widimsky. (2011) ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal
CrossRef104
Alexander, John H., Lopes, Renato D., James, Stefan, Kilaru, Rakhi, He, Yaohua, Mohan, Puneet, Bhatt, Deepak L., Goodman, Shaun, Verheugt, Freek W., Flather, Marcus, Huber, Kurt, Liaw, Danny, Husted, Steen E., Lopez-Sendon, Jose, De Caterina, Raffaele, Jansky, Petr, Darius, Harald, Vinereanu, Dragos, Cornel, Jan H., Cools, Frank, Atar, Dan, Leiva-Pons, Jose Luis, Keltai, Matyas, Ogawa, Hisao, Pais, Prem, Parkhomenko, Alexander, Ruzyllo, Witold, Diaz, Rafael, White, Harvey, Ruda, Mikhail, Geraldes, Margarida, Lawrence, Jack, Harrington, Robert A., Wallentin, Lars, . (2011) Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome. New England Journal of Medicine 365:8, 699-708
Full Text105
Alessandro Squizzato, Erica Romualdi, Francesco Dentali, Walter Ageno, Alessandro Squizzato. 2011. Statins for acute ischemic stroke. .
CrossRef106
Suzanne V. Arnold, David J. Cohen, Elizabeth A. Magnuson. (2011) Cost-effectiveness of oral antiplatelet agents—current and future perspectives. Nature Reviews Cardiology 8:10, 580-591
CrossRef107
Tariq Ahmad, Deepak Voora, Richard C. Becker. (2011) The pharmacogenetics of antiplatelet agents: towards personalized therapy?. Nature Reviews Cardiology 8:10, 560-571
CrossRef108
Kallirroi I. Kalantzi, Andromachi A. Dimitriou, John A. Goudevenos, Alexandros D. Tselepis. (2011) The platelet hyporesponsiveness to clopidogrel in acute coronary syndrome patients treated with 75 mg/day clopidogrel may be overcome within 1 month of treatment. Platelets1-11
CrossRef109
Christopher W. Good, Peter B. Berger. (2011) P2Y12 Antagonists in Acute Coronary Syndrome: In Whom Should They Be Started, and When?. Current Cardiology Reports 13:4, 320-326
CrossRef110
Lawrence Rajan, David J. Moliterno. (2011) Beyond Aspirin and Clopidogrel: Is There a Need for Additional Antiplatelet Therapy in ACS?. Current Cardiology Reports 13:4, 303-311
CrossRef111
Fei-Yuan Hsiao, C. Daniel Mullins, Yu-Wen Wen, Weng-Foung Huang, Pei-Fen Chen, Yi-Wen Tsai. (2011) Relationship between cardiovascular outcomes and proton pump inhibitor use in patients receiving dual antiplatelet therapy after acute coronary syndrome. Pharmacoepidemiology and Drug Safetyn/a-n/a
CrossRef112
Charles F. Jackson, Nanette K. Wenger. (2011) Enfermedad cardiovascular en el anciano. Revista Española de Cardiología 64:8, 697-712
CrossRef113
Renato D. Lopes, Richard C. Becker, John H. Alexander, Paul W. Armstrong, Robert M. Califf, Mark Y. Chan, Mark Crowther, Christopher B. Granger, Robert A. Harrington, Elaine M. Hylek, Stefan K. James, E. Marc Jolicoeur, Kenneth W. Mahaffey, L. Kristin Newby, Eric D. Peterson, Karen S. Pieper, Frans Werf, Lars Wallentin, Harvey D. White, Antonio C. Carvalho, Roberto R. Giraldez, Helio P. Guimaraes, Helena B. Nader, Renato A. K. Kalil, Joyce M. A. Bizzachi, Antonio C. Lopes, David A. Garcia. (2011) Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14–16, 2010, São Paulo, Brazil. Journal of Thrombosis and Thrombolysis 32:2, 242-266
CrossRef114
Seong Hoon Lim, Bo Young Hong, Ye Rim Cho, Han Seung Kim, Jong In Lee, Hye Won Kim, Young Jin Ko. (2011) Relapsed spontaneous spinal epidural hematoma associated with aspirin and clopidogrel. Neurological Sciences 32:4, 687-689
CrossRef115
Rubén Casado-Arroyo, María Muñoz-Villalenguas, Ángel Lanas Arbeloa. (2011) Antiagregantes plaquetarios e inhibidores de la bomba de protones. ¿Cómo optimizar el riesgo-beneficio en los pacientes con riesgo cardiovascular y riesgo de hemorragia gastrointestinal?. Gastroenterología y Hepatología 34:7, 478-491
CrossRef116
Marco Ranucci, Solomon Aronson, Wulf Dietrich, Cornelius M. Dyke, Axel Hofmann, Keyvan Karkouti, Marcel Levi, Gavin J. Murphy, Frank W. Sellke, Linda Shore-Lesserson, Christian von Heymann. (2011) Patient blood management during cardiac surgery: Do we have enough evidence for clinical practice?. The Journal of Thoracic and Cardiovascular Surgery 142:2, 249.e1-249.e32
CrossRef117
Philip Joseph, Koon Teo. (2011) Optimal Medical Therapy, Lifestyle Intervention, and Secondary Prevention Strategies for Cardiovascular Event Reduction in Ischemic Heart Disease. Current Cardiology Reports 13:4, 287-295
CrossRef118
Verónica Diez Diez, Ángeles Morales Martínez. (2011) Tratamiento antiagregante y cirugía. FMC - Formación Médica Continuada en Atención Primaria 18:7, 437-443
CrossRef119
Beau M Hawkins, Jorge F Saucedo, Sunil V Rao. (2011) The rationale and evidence for triple antiplatelet therapy in acute coronary syndromes. Clinical Investigation 1:8, 1155-1165
CrossRef120
Alexander Kulik, Marc Ruel. (2011) Clopidogrel After Coronary Artery Bypass Graft Surgery. Journal of the American College of Cardiology 58:10, 1084-1085
CrossRef121
Isabell Bernlochner, Robert A Byrne, Adnan Kastrati, Dirk Sibbing. (2011) The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders. Expert Review of Cardiovascular Therapy 9:8, 999-1014
CrossRef122
Giuseppe Biondi-Zoccai, Marzia Lotrionte, Pierfrancesco Agostoni, Antonio Abbate, Enrico Romagnoli, Giuseppe Sangiorgi, Dominick J. Angiolillo, Marco Valgimigli, Luca Testa, Fiorenzo Gaita, Imad Sheiban. (2011) Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes. International Journal of Cardiology 150:3, 325-331
CrossRef123
Tamir Ben–Menachem, Jason A. Dominitz. (2011) Acute Upper Gastrointestinal Hemorrhage in an Elderly Woman Taking Aspirin and Clopidogrel. Clinical Gastroenterology and Hepatology 9:8, 649-652
CrossRef124
Charles F. Jackson, Nanette K. Wenger. (2011) Cardiovascular Disease in the Elderly. Revista Española de Cardiología (English Edition) 64:8, 697-712
CrossRef125
T. Burkard, C. A. Kaiser, H. Brunner-La Rocca, S. Osswald, M. E. Pfisterer, R. V. Jeger, . (2011) Combined clopidogrel and proton pump inhibitor therapy is associated with higher cardiovascular event rates after percutaneous coronary intervention: a report from the BASKET trial. Journal of Internal Medicineno-no
CrossRef126
Christopher W. Jones, Timothy F. Platts-Mills. (2011) Understanding Commonly Encountered Limitations in Clinical Research: An Emergency Medicine Resident's Perspective. Annals of Emergency Medicine
CrossRef127
Grigorios I. Leontiadis, Yuhong Yuan, Colin W. Howden. (2011) The Interaction Between Proton Pump Inhibitors and Clopidogrel and Upper Gastrointestinal Bleeding. Gastrointestinal Endoscopy Clinics of North America
CrossRef128
J. Donald Easton. (2011) Antithrombotic Management for Transient Ischemic Attack and Ischemic Stroke (Other than Atrial Fibrillation). Current Atherosclerosis Reports 13:4, 314-320
CrossRef129
Doriana Passaro, Valeria Fadda, Dario Maratea, Andrea Messori. (2011) Anti-platelet treatments in acute coronary syndrome: Simplified network meta-analysis. International Journal of Cardiology 150:3, 364-367
CrossRef130
Thomas Cuisset, Jacques Quilici, Charlotte Grosdidier, Laurent Fourcade, Bénédicte Gaborit, Mathieu Pankert, Laurent Molines, Pierre-Emmanuel Morange, Jean Louis Bonnet, Marie-Christine Alessi. (2011) Comparison of Platelet Reactivity and Clopidogrel Response in Patients ≤75 Years Versus >75 Years Undergoing Percutaneous Coronary Intervention for Non–ST-Segment Elevation Acute Coronary Syndrome. The American Journal of Cardiology
CrossRef131
Haiyun Wu, Quanmin Jing, Junhua Wang, Xinghong Guo. (2011) Pantoprazole for the prevention of gastrointestinal bleeding in high-risk patients with acute coronary syndromes. Journal of Critical Care 26:4, 434.e1-434.e6
CrossRef132
Ahmed Krimly, Raymond T. Yan, Andrew T. Yan, J. Paul DeYoung, Richard Gallo, Gabriel Steg, John Eikelboom, Joel M. Gore, Keith A.A. Fox, David Fitchett, Mackenzie A. Quantz, Shaun G. Goodman. (2011) Use of Clopidogrel Post-Coronary Artery Bypass Surgery in Canadian Patients With Acute Coronary Syndromes. Canadian Journal of Cardiology
CrossRef133
Takamichi Ono, Koichi Kaikita, Seiji Hokimoto, Satomi Iwashita, Koichiro Yamamoto, Yuji Miyazaki, Eiji Horio, Koji Sato, Kenichi Tsujita, Tomohide Abe, Mariko Deguchi, Shinji Tayama, Hitoshi Sumida, Seigo Sugiyama, Hiroshige Yamabe, Sunao Nakamura, Kazuko Nakagawa, Hisao Ogawa. (2011) Determination of cut-off levels for on-clopidogrel platelet aggregation based on functional CYP2C19 gene variants in patients undergoing elective percutaneous coronary intervention. Thrombosis Research
CrossRef134
Morten Schmidt, Martin B. Johansen, Douglas J. Robertson, Michael Maeng, Anne Kaltoft, Lisette O. Jensen, Hans-Henrik Tilsted, Hans E. Bøtker, Henrik Toft Sørensen, John A. Baron. (2011) Use of clopidogrel and calcium channel blockers and risk of major adverse cardiovascular events. European Journal of Clinical Investigationno-no
CrossRef135
M. A. Gaglia, R. Waksman. (2011) Systematic review of thienopyridine discontinuation and its impact upon clinical outcomes. European Heart Journal
CrossRef136
Udaya S. Tantry, Paul A. Gurbel. (2011) Assessment of oral antithrombotic therapy by platelet function testing. Nature Reviews Cardiology 8:10, 572-579
CrossRef137
Omair Yousuf, Deepak L. Bhatt. (2011) The evolution of antiplatelet therapy in cardiovascular disease. Nature Reviews Cardiology 8:10, 547-559
CrossRef138
Harvey D White. (2011) Editorial: do we need another bleeding definition? What does the Bleeding Academic Research Consortium definition have to offer?. Current Opinion in Cardiology 26:4, 275-278
CrossRef139
Hisao Ogawa, Seiji Hokimoto, Koichi Kaikita, Koichiro Yamamoto, Tadasuke Chitose, Takamichi Ono, Kenichi Tsujita. (2011) Current status and prospects of antiplatelet therapy in percutaneous coronary intervention in Japan: Focus on adenosine diphosphate receptor inhibitors. Journal of Cardiology 58:1, 6-17
CrossRef140
E. P. Navarese, M. Verdoia, A. Schaffer, P. Suriano, M. Kozinski, F. Castriota, S. De Servi, J. Kubica, G. De luca. (2011) Ischaemic and bleeding complications with new, compared to standard, ADP-antagonist regimens in acute coronary syndromes: a meta-analysis of randomized trials. QJM 104:7, 561-569
CrossRef141
Edward O. McFalls, Greg Larsen, Gary R. Johnson, Fred S. Apple, Steven Goldman, Andrew Arai, Brahmajee K. Nallamothu, Robert Jesse, Scott T. Holmstrom, Patricia L. Sinnott. (2011) Outcomes of Hospitalized Patients with Non-Acute Coronary Syndrome and Elevated Cardiac Troponin Level. The American Journal of Medicine 124:7, 630-635
CrossRef142
Guang-Ming Tan, Yat-Yin Lam, Bryan P. Yan. (2011) Novel Platelet ADP P2Y12 Inhibitors in the Treatment of Acute Coronary Syndrome. Cardiovascular Therapeuticsno-no
CrossRef143
Zeshan Qureshi, Alex R. Hobson. (2011) Clopidogrel “Resistance”: Where are We Now?. Cardiovascular Therapeuticsno-no
CrossRef144
Neena S. Abraham. (2011) Prescribing proton pump inhibitor and clopidogrel together. Current Opinion in Gastroenterology1
CrossRef145
Marc I. Chimowitz, Michael J. Lynn, Tanya N. Turan, David Fiorella, Bethany F. Lane, Scott Janis, Colin P. Derdeyn. (2011) Design of the Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis Trial. Journal of Stroke and Cerebrovascular Diseases 20:4, 357-368
CrossRef146
Jennifer A. Frontera, Natalia Egorova, Alan J. Moskowitz. (2011) National trend in prevalence, cost, and discharge disposition after subdural hematoma from 1998–2007*. Critical Care Medicine 39:7, 1619-1625
CrossRef147
Brendan Bell, Jamie Layland, Karl Poon, Christian Spaulding, Darren Walters. (2011) Focused Clinical Review: Periprocedural Management of Antiplatelet Therapy in Patients with Coronary Stents. Heart, Lung and Circulation 20:7, 438-445
CrossRef148
S. Koul, J. G. Smith, F. Schersten, S. James, B. Lagerqvist, D. Erlinge. (2011) Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. European Heart Journal
CrossRef149
Alexander Altenburg, Patrick Haage. (2011) Antiplatelet and Anticoagulant Drugs in Interventional Radiology. CardioVascular and Interventional Radiology
CrossRef150
Francesco De Felice, Rosario Fiorilli, Antonio Parma, Carmine Musto, Marco Stefano Nazzaro, Pierpaolo Confessore, Massimiliano Scappaticci, Roberto Violini. (2011) One-year clinical outcome of patients treated with or without abciximab in rescue coronary angioplasty. International Journal of Cardiology
CrossRef151
Judith J. Stephenson, Chun-Lan Chang, Gail DeVecchis Wygant, Ole Hauch, Mark J. Cziraky. (2011) Incidence of death and recurring acute coronary syndrome after stopping clopidogrel therapy in a large commercially-insured population in the US. Current Medical Research and Opinion 27:6, 1079-1087
CrossRef152
RADHAKRISHNAN RAMARAJ, MOHAMMAD REZA MOVAHED, MEHRNOOSH HASHEMZADEH. (2011) Novel Antiplatelet Agent Ticagrelor in the Management of Acute Coronary Syndrome. Journal of Interventional Cardiology 24:3, 199-207
CrossRef153
Michael Mahmoudi, Asmir I. Syed, Itsik Ben-Dor, Manuel Gonzalez, Gabriel Maluenda, Michael A. Gaglia, Gabriel Sardi, Kohei Wakabayashi, Rebecca Torguson, Zhenyi Xue, Lowell F. Satler, William O. Suddath, Augusto D. Pichard, Ron Waksman. (2011) Safety and Efficacy of Clopidogrel Reloading in Patients on Chronic Clopidogrel Therapy Who Present With an Acute Coronary Syndrome and Undergo Percutaneous Coronary Intervention. The American Journal of Cardiology 107:12, 1779-1782
CrossRef154
Mariano A Giorgi, Hernán Cohen Arazi, Claudio D Gonzalez, Guillermo Di Girolamo. (2011) Beyond efficacy: pharmacokinetic differences between clopidogrel, prasugrel and ticagrelor. Expert Opinion on Pharmacotherapy 12:8, 1285-1295
CrossRef155
Fausto Biancari, K. E. Juhani Airaksinen, Gregory Y.H. Lip. (2011) Benefits and risks of using clopidogrel before coronary artery bypass surgery: Systematic review and meta-analysis of randomized trials and observational studies. The Journal of Thoracic and Cardiovascular Surgery
CrossRef156
Dominick J Angiolillo, Marco Roffi, Antonio Fernandez-Ortiz. (2011) Tackling the thrombotic burden in patients with acute coronary syndrome and diabetes mellitus. Expert Review of Cardiovascular Therapy 9:6, 697-710
CrossRef157
DAISUKE KIKUCHI, TOSHIRO IIZUKA, MITSUYO HASHIMOTO, SHU HOTEYA, SATOSHI YAMASHITA, MASANORI NAKAMURA, AKIHIRO YAMADA, TOSHIHUMI MITANI, AI FUJIMOTO, AKIRA MATSUI, YASUJI ARASE, MITSURU KAISE. (2011) SAFETY MEASURES FOR GASTROINTESTINAL ENDOSCOPY IN PATIENTS RECEIVING ANTITHROMBOTIC THERAPY. Digestive Endoscopyno-no
CrossRef158
Daniel J. Crespin, Jerome J. Federspiel, Andrea K. Biddle, Daniel E. Jonas, Joseph S. Rossi. (2011) Ticagrelor versus Genotype-Driven Antiplatelet Therapy for Secondary Prevention after Acute Coronary Syndrome: A Cost-Effectiveness Analysis. Value in Health 14:4, 483-491
CrossRef159
S. S. Nijjer, G. Watson, T. Athanasiou, I. S. Malik. (2011) Safety of clopidogrel being continued until the time of coronary artery bypass grafting in patients with acute coronary syndrome: a meta-analysis of 34 studies. European Heart Journal
CrossRef160
Esben Hjorth Madsen, Norbert Rudolf Gehr, Nils Lauge Johannesen, Erik Berg Schmidt, Søren Risom Kristensen. (2011) Platelet response to aspirin and clopidogrel in patients with peripheral atherosclerosis. Platelets1-10
CrossRef161
J. Oldgren, A. Budaj, C. B. Granger, Y. Khder, J. Roberts, A. Siegbahn, J. G. P. Tijssen, F. Van de Werf, L. Wallentin, . (2011) Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. European Heart Journal
CrossRef162
Peter Bach, Jonas Boström, Kay Brickmann, J.J.J. van Giezen, Ragnar Hovland, Annika U. Petersson, Asim Ray, Fredrik Zetterberg. (2011) A novel series of piperazinyl-pyridine ureas as antagonists of the purinergic P2Y12 receptor. Bioorganic & Medicinal Chemistry Letters 21:10, 2877-2881
CrossRef163
Morten Schou, Nana Valeur, Christian Torp-Pedersen, Finn Gustafsson, Lars Køber. (2011) Plasma sodium and mortality risk in patients with myocardial infarction and a low LVEF. European Journal of Clinical Investigationno-no
CrossRef164
J. Douglas Kirk, Michael Kontos, Deborah B. Diercks. (2011) Upstream treatment of acute coronary syndrome in the ED. The American Journal of Emergency Medicine 29:4, 446-456
CrossRef165
Thomas Cuisset, Jacques Quilici, Lionel Fugon, William Cohen, Perrine Roux, Bénédicte Gaborit, Laurent Molines, Laurent Fourcade, Jean-Louis Bonnet, Patrizia Carrieri. (2011) Non-adherence to aspirin in patients undergoing coronary stenting: Negative impact of comorbid conditions and implications for clinical management. Archives of Cardiovascular Diseases 104:5, 306-312
CrossRef166
Michael A. Burke, Richard Lee, Dan J. Fintel. (2011) Early clopidogrel use in non–ST elevation acute coronary syndrome and subsequent coronary artery bypass grafting. American Heart Journal 161:5, 832-841
CrossRef167
M. Oberhänsli, S. Puricel, M. Togni, S. Cook. (2011) Koronare Stent-Thrombosen. Herz 36:3, 241-253
CrossRef168
C. Michael Gibson, Jessica L. Mega, Paul Burton, Shinya Goto, Freek Verheugt, Christoph Bode, Alexei Plotnikov, Xiang Sun, Nancy Cook-Bruns, Eugene Braunwald. (2011) Rationale and design of the Anti-Xa Therapy to Lower cardiovascular events in Addition to standard therapy in Subjects with Acute Coronary Syndrome–Thrombolysis in Myocardial Infarction 51 (ATLAS-ACS 2 TIMI 51) trial: A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome. American Heart Journal 161:5, 815-821.e6
CrossRef169
R. Scott Wright, Jeffrey L. Anderson, Cynthia D. Adams, Charles R. Bridges, Donald E. Casey, Steven M. Ettinger, Francis M. Fesmire, Theodore G. Ganiats, Hani Jneid, A. Michael Lincoff, Eric D. Peterson, George J. Philippides, Pierre Theroux, Nanette K. Wenger, James Patrick Zidar. (2011) 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction (Updating the 2007 Guideline). Journal of the American College of Cardiology 57:19, 1920-1959
CrossRef170
Thomas Gremmel, Sabine Steiner, Daniela Seidinger, Renate Koppensteiner, Simon Panzer, Christoph W. Kopp. (2011) A high maintenance dose increases the inhibitory response to clopidogrel in patients with high on-treatment residual platelet reactivity. International Journal of Cardiology
CrossRef171
Tiago L. L. Leiria, Renato D. Lopes, Judson B. Williams, Jason N. Katz, Renato A. K. Kalil, John H. Alexander. (2011) Antithrombotic therapies in patients with prosthetic heart valves: guidelines translated for the clinician. Journal of Thrombosis and Thrombolysis 31:4, 514-522
CrossRef172
Davide Capodanno, Corrado Tamburino, George Dangas. (2011) The optimal pharmacological formula for percutaneous coronary intervention. Expert Opinion on Pharmacotherapy 12:7, 1075-1086
CrossRef173
Alan D. Bell, André Roussin, Raymond Cartier, Wee Shian Chan, James D. Douketis, Anil Gupta, Maria E. Kraw, Thomas F. Lindsay, Michael P. Love, Neesh Pannu, Rémi Rabasa-Lhoret, Ashfaq Shuaib, Philip Teal, Pierre Théroux, Alexander G.G. Turpie, Robert C. Welsh, Jean-François Tanguay. (2011) The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines. Canadian Journal of Cardiology 27:3, S1-S59
CrossRef174
Kengo Tsukahara, Kazuo Kimura, Satoshi Morita, Toshiaki Ebina, Masami Kosuge, Kiyoshi Hibi, Noriaki Iwahashi, Mitsuaki Endo, Nobuhiko Maejima, Teruyasu Sugano, Satoshi Umemura. (2011) Impact of concomitant use of proton-pump inhibitors and thienopyridine derivatives on the antiplatelet effects. Journal of Cardiology 57:3, 275-282
CrossRef175
Samir B. Damani, Eric J. Topol. (2011) Emerging Genomic Applications in Coronary Artery Disease. JACC: Cardiovascular Interventions 4:5, 473-482
CrossRef176
R. Scott Wright, Jeffrey L. Anderson, Cynthia D. Adams, Charles R. Bridges, Donald E. Casey, Steven M. Ettinger, Francis M. Fesmire, Theodore G. Ganiats, Hani Jneid, A. Michael Lincoff, Eric D. Peterson, George J. Philippides, Pierre Theroux, Nanette K. Wenger, James Patrick Zidar. (2011) 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology 57:19, e215-e367
CrossRef177
Peter M Rothwell, Ale Algra, Pierre Amarenco. (2011) Medical treatment in acute and long-term secondary prevention after transient ischaemic attack and ischaemic stroke. The Lancet 377:9778, 1681-1692
CrossRef178
G. Y. H. Lip, F. Andreotti, L. Fauchier, K. Huber, E. Hylek, E. Knight, D. A. Lane, M. Levi, F. Marin, G. Palareti, P. Kirchhof, , J.-P. Collet, A. Rubboli, D. Poli, J. Camm. (2011) Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. Europace 13:5, 723-746
CrossRef179
Shahzad G Raja, Shamim Akhtar. (2011) Hypercoagulable state after off-pump coronary artery bypass grafting: evidence, mechanisms and implications. Expert Review of Cardiovascular Therapy 9:5, 599-608
CrossRef180
Mika Skeppholm, Anders Kallner, Karin Malmqvist, Margareta Blombäck, Håkan Wallén. (2011) Is fibrin formation and thrombin generation increased during and after an acute coronary syndrome?. Thrombosis Research
CrossRef181
Oscar R. Benavente, Carole L. White, Lesly Pearce, Pablo Pergola, Ana Roldan, Marie-France Benavente, Christopher Coffey, Leslie A. McClure, Jeff M. Szychowski, Robin Conwit, Patricia A. Heberling, George Howard, Carlos Bazan, Gabriela Vidal-Pergola, Robert Talbert, Robert G. Hart, . (2011) The Secondary Prevention of Small Subcortical Strokes (SPS3) study. International Journal of Stroke 6:2, 164-175
CrossRef182
Gundu HR Rao, Indermohan Thethi, Jawed Fareed. (2011) Vascular disease: obesity and excess weight as modulators of risk. Expert Review of Cardiovascular Therapy 9:4, 525-534
CrossRef183
Juswinder Singh, Russell C. Petter, Thomas A. Baillie, Adrian Whitty. (2011) The resurgence of covalent drugs. Nature Reviews Drug Discovery 10:4, 307-317
CrossRef184
Kevin W. Hatton, Jeremy D. Flynn, Christine Lallos, Brenda G. Fahy. (2011) Integrating Evidence-Based Medicine Into the Perioperative Care of Cardiac Surgery Patients. Journal of Cardiothoracic and Vascular Anesthesia 25:2, 335-346
CrossRef185
Masataka Ikeda, Haruki Tanaka, Kenji Sadamatsu. (2011) Diffuse alveolar hemorrhage as a complication of dual antiplatelet therapy for acute coronary syndrome. Cardiovascular Revascularization Medicine
CrossRef186
Charles Brown, Brijen Joshi, Nauder Faraday, Ashish Shah, David Yuh, Jeffrey J. Rade, Charles W. Hogue. (2011) Emergency Cardiac Surgery in Patients with Acute Coronary Syndromes. Anesthesia & Analgesia 112:4, 777-799
CrossRef187
J. C. Sharma, N. Sharma. (2011) Significance of cardiocoronary pathology in acute stroke. International Journal of Clinical Practice 65:4, 394-396
CrossRef188
K. I. KALANTZI, A. A. DIMITRIOU, H. J. MILIONIS, I. A. GOUDEVENOS, A. D. TSELEPIS. (2011) Clopidogrel differentially affects platelet-mediated thrombosis and inflammatory response in patients with acute coronary syndromes. Journal of Thrombosis and Haemostasis 9:4, 875-878
CrossRef189
Udaya S. Tantry, Dean J. Kereiakes, Paul A. Gurbel. (2011) Clopidogrel and Proton Pump Inhibitors. JACC: Cardiovascular Interventions 4:4, 365-380
CrossRef190
Renato D. Lopes. (2011) Antiplatelet agents in cardiovascular disease. Journal of Thrombosis and Thrombolysis 31:3, 306-309
CrossRef191
Seung-Jung Park, Duk-Woo Park, Jun-Hyok Oh. (2011) Antiplatelet therapy in elderly patients. Aging Health 7:2, 311-320
CrossRef192
Creighton W. Don, Matthew T. Roe, Shuang Li, Elizabeth Fraulo, Eugene Pomerantsev, Igor Palacios, Stephen D. Wiviott. (2011) Temporal trends and practice variations in clopidogrel loading doses in patients with non–ST-segment elevation myocardial infarction, from the National Cardiovascular Data Registry. American Heart Journal 161:4, 689-697
CrossRef193
Giuseppe Patti, Vincenzo Pasceri, Vincenzo Vizzi, Elisabetta Ricottini, Germano Di Sciascio. (2011) Usefulness of Platelet Response to Clopidogrel by Point-of-Care Testing to Predict Bleeding Outcomes in Patients Undergoing Percutaneous Coronary Intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study). The American Journal of Cardiology 107:7, 995-1000
CrossRef194
Jennifer A. Frontera, Kenneth Reyes, Errol Gordon, Arjun Gowda, Christina Grilo, Natalia Egorova, Aman Patel, Joshua B. Bederson. (2011) Trend in Outcome and Financial Impact of Subdural Hemorrhage. Neurocritical Care 14:2, 260-266
CrossRef195
Gilles Montalescot, Leonardo Bolognese, Dariusz Dudek, Patrick Goldstein, Christian Hamm, Jean-Francois Tanguay, Jur ten Berg, Petr Widimsky, Junxiang Luo, Debra L. Miller, Jochen Goedicke. (2011) A Comparison of prasugrel at the time of percutaneous Coronary intervention or as pretreatment at the time of diagnosis in patients with non–ST-segment elevation myocardial infarction: Design and rationale for the ACCOAST study. American Heart Journal 161:4, 650-656.e1
CrossRef196
B. R. Disney, R. D. S. Watson, A. D. Blann, G. Y. H. Lip, M. R. Anderson. (2011) Review article: proton pump inhibitors with clopidogrel - evidence for and against a clinically-important interaction. Alimentary Pharmacology & Therapeutics 33:7, 758-767
CrossRef197
Omer H. Ali, Chika E. Uzoigwe. (2011) Proton pump inhibitor and clopidogrel interaction: have we forgotten aspirin?. British Journal of Haematologyno-no
CrossRef198
Eun Ji Seo, Dong-Ung Lee, Jong Hwan Kwak, Sun-Mee Lee, Yeong Shik Kim, Yi-Sook Jung. (2011) Antiplatelet effects of Cyperus rotundus and its component (+)-nootkatone. Journal of Ethnopharmacology 135:1, 48-54
CrossRef199
Feero, W. Gregory, Guttmacher, Alan E., , Wang, Liewei, McLeod, Howard L., Weinshilboum, Richard M., . (2011) Genomics and Drug Response. New England Journal of Medicine 364:12, 1144-1153
Full Text200
James J. Nawarskas, Sara M. Clark. (2011) Ticagrelor. Cardiology in Review 19:2, 95-100
CrossRef201
Fu-Chun Chiu, Tzung-Dau Wang, Jen-Kuang Lee, Fuh-Yuan Shih, Jong-Wei Lin, Chien-Hua Huang, Wen-Jone Chen, Ming-Fong Chen. (2011) Residual platelet reactivity after aspirin and clopidogrel treatment predicts 2-year major cardiovascular events in patients undergoing percutaneous coronary intervention. European Journal of Internal Medicine
CrossRef202
Harvey D. White. (2011) Oral antiplatelet therapy for atherothrombotic disease: Current evidence and new directions. American Heart Journal 161:3, 450-461
CrossRef203
Neville D Yeomans. (2011) Aspirin: Old drug, new uses and challenges*. Journal of Gastroenterology and Hepatology 26:3, 426-431
CrossRef204
Ping–I. Hsu, Kwok–Hung Lai, Chun–Peng Liu. (2011) Esomeprazole With Clopidogrel Reduces Peptic Ulcer Recurrence, Compared With Clopidogrel Alone, in Patients With Atherosclerosis. Gastroenterology 140:3, 791-798.e2
CrossRef205
Alan D. Bell, André Roussin, Raymond Cartier, Wee Shian Chan, James D. Douketis, Anil Gupta, Maria E. Kraw, Thomas F. Lindsay, Michael P. Love, Neesh Pannu, Rémi Rabasa-Lhoret, Ashfaq Shuaib, Philip Teal, Pierre Théroux, A. Graham Turpie, Robert C. Welsh, Jean-François Tanguay. (2011) The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines Executive Summary. Canadian Journal of Cardiology 27:2, 208-221
CrossRef206
Jersey Chen, Chunxue Shi, Elizabeth M. Mahoney, Elizabeth Schneider Dunn, Stéphane Rinfret, J. Jaime Caro, Judith O'Brien, Wissam El-Hadi, Deepak L. Bhatt, Eric J. Topol, David J. Cohen. (2011) Economic Evaluation of Clopidogrel Plus Aspirin for Secondary Prevention of Cardiovascular Events in Canada for Patients With Established Cardiovascular Disease: Results From the CHARISMA Trial. Canadian Journal of Cardiology 27:2, 222-231
CrossRef207
Hong-Guang Xie, Jian-Jun Zou, Zuo-Ying Hu, Jun-Jie Zhang, Fei Ye, Shao-Liang Chen. (2011) Individual variability in the disposition of and response to clopidogrel: Pharmacogenomics and beyond. Pharmacology & Therapeutics 129:3, 267-289
CrossRef208
Samir B. Damani, Eric J. Topol. (2011) Emerging clinical applications in cardiovascular pharmacogenomics. Wiley Interdisciplinary Reviews: Systems Biology and Medicine 3:2, 206-215
CrossRef209
M. Cattaneo. (2011) The platelet P2Y12 receptor for adenosine diphosphate: congenital and drug-induced defects. Blood 117:7, 2102-2112
CrossRef210
Zsolt Garami, Alan B. Lumsden. 2011. Intra-Operative TCD Monitoring. , 214-227.
CrossRef211
Matthew W. Sherwood, Tracy Y. Wang, Richard C. Becker. (2011) How Should Patients Requiring Dual Antiplatelet Therapy be Managed When Undergoing Elective Endoscopic Gastrointestinal Procedures?. Current Treatment Options in Cardiovascular Medicine 13:1, 46-56
CrossRef212
James A Shand, Ian BA Menown, Robert F Storey. (2011) Ticagrelor: from concept to clinical evaluation. Biomarkers in Medicine 5:1, 53-62
CrossRef213
Giuseppe Patti, Domenico Grieco, Giordano Dicuonzo, Vincenzo Pasceri, Annunziata Nusca, Germano Di Sciascio. (2011) High Versus Standard Clopidogrel Maintenance Dose After Percutaneous Coronary Intervention and Effects on Platelet Inhibition, Endothelial Function, and Inflammation. Journal of the American College of Cardiology 57:7, 771-778
CrossRef214
Fiona Foo, Keith G Oldroyd. (2011) Clinical value of antiplatelet therapy in patients with acute coronary syndromes and in percutaneous coronary intervention. Biomarkers in Medicine 5:1, 9-30
CrossRef215
E. W. Chu, D. A. Telem, A. Chernoguz, C. M. Divino. (2011) Assessing the risk of clopidogrel-related bleeding complications in patients undergoing inguinal herniorrhaphy. Hernia 15:1, 31-35
CrossRef216
M. Shafazand, A. Rosengren, G. Lappas, K. Swedberg, M. Schaufelberger. (2011) Decreasing trends in the incidence of heart failure after acute myocardial infarction from 1993-2004: a study of 175 216 patients with a first acute myocardial infarction in Sweden. European Journal of Heart Failure 13:2, 135-141
CrossRef217
Graeme J. Hankey, S. Claiborne Johnston, J. Donald Easton, Werner Hacke, Jean-Louis Mas, Danielle Brennan, Koon Hou Mak, Deepak L. Bhatt, Keith A. A. Fox, Eric J. Topol, . (2011) Effect of clopidogrel plus ASA vs. ASA early after TIA and ischaemic stroke: a substudy of the CHARISMA trial. International Journal of Stroke 6:1, 3-9
CrossRef218
Claes Held, Nils Åsenblad, Jean Pierre Bassand, Richard C. Becker, Christopher P. Cannon, Marc J. Claeys, Robert A. Harrington, Jay Horrow, Steen Husted, Stefan K. James, Kenneth W. Mahaffey, José C. Nicolau, Benjamin M. Scirica, Robert F. Storey, Marius Vintila, Joseph Ycas, Lars Wallentin. (2011) Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery. Journal of the American College of Cardiology 57:6, 672-684
CrossRef219
Nicholas L.M. Cruden, Kristin Morch, Daniel R. Wong, W. Peter Klinke, John Ofiesh, J. David Hilton. (2011) Clopidogrel loading dose and bleeding outcomes in patients undergoing urgent coronary artery bypass grafting. American Heart Journal 161:2, 404-410
CrossRef220
Eltigani Abdelaal, Jonathan Byrne. (2011) Bleeding avoidance strategies among patients undergoing percutaneous coronary intervention. Interventional Cardiology 3:1, 13-16
CrossRef221
Tobias Gerhard. (2011) Clopidogrel and proton pump inhibitors: a clinically meaningful interaction?. Pharmacoepidemiology and Drug Safety 20:2, 214-218
CrossRef222
Megan M. Donohue, David L. Tirschwell. (2011) Implications of Pharmacogenetic Testing for Patients Taking Warfarin or Clopidogrel. Current Neurology and Neuroscience Reports 11:1, 52-60
CrossRef223
K. M. MUSALLAM, K. CHARAFEDDINE, A. BITAR, M. KHOURY, S. ASSAAD, J. BERESIAN, S. ALAM, A. T. TAHER. (2011) Resistance to aspirin and clopidogrel therapy. International Journal of Laboratory Hematology 33:1, 1-18
CrossRef224
Terry KW Ma, Yat-Yin Lam, Victoria P Tan, Bryan P Yan. (2011) Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions?. British Journal of Clinical Pharmacologyno-no
CrossRef225
Alessandro Squizzato, Tymen Keller, Erica Romualdi, Saskia Middeldorp, Alessandro Squizzato. 2011. Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease. .
CrossRef226
Ming-wei Huang. (2011) Chinese herbal medicine Naoxintong capsule combined with dual antiplatelet therapy in a rat model of coronary microembolization induced by homologous microthrombi. Journal of Chinese Integrative Medicine 9:1, 38-48
CrossRef227
K. Huber, C. W. Hamm, J.-P. Bassand, S. Agewall, J. Bax, E. Boersma, H. Bueno, P. Caso, D. Dudek, S. Gielen. (2011) ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal
CrossRef228
Satoshi Ono, Mitsuhiro Fujishiro, Shinya Kodashima, Chihiro Minatsuki, Kosuke Hirano, Keiko Niimi, Osamu Goto, Nobutake Yamamichi, Kazuhiko Koike. (2011) CONTROVERSY ON THE MANAGEMENT OF ANTICOAGULANTS AND ANTIPLATELET AGENTS FOR SCHEDULED ENDOSCOPY. Digestive Endoscopy 23:1, 1-4
CrossRef229
Yamin Liu, Naifeng Liu, Weilan Li, Hua Shao. (2011) Clopidogrel Response Variability and Its Correlation with Early Recurrent Cardiovascular Events in Chinese Patients Undergoing Percutaneous Coronary Intervention. Pharmacology 87:5-6, 321-330
CrossRef230
A. Schäfer, U. Flierl, J. Kössler, N. Seydelmann, A. Kobsar, S. Störk, J. Bauersachs. (2011) Early determination of clopidogrel responsiveness by platelet reactivity indexidentifies patients at risk for cardiovascular events after myocardial infarction. Thrombosis and Haemostasis 106:1, 141-148
CrossRef231
T. Gremmel, S. Panzer. (2011) Clinical, genetic and confounding factors determine the dynamics of the in vitro response/non response to clopidogrel. Thrombosis and Haemostasis 106:2, 211-218
CrossRef232
S. Ylä-Herttuala, J. F. Bentzon, M. Daemen, E. Falk, H. M. Garcia-Garcia, J. Herrmann, I. Hoefer, J. W. Jukema, R. Krams, B. R. Kwak, N. Marx, M. Naruszewicz, A. Newby, G. Pasterkamp, P. W. J. C. Serruys, J. Waltenberger, C. Weber, L. Tokgözoglu. (2011) Stabilisation of atherosclerotic plaques. Thrombosis and Haemostasis 106:1, 1-19
CrossRef233
Michalis Hamilos, Olivier Muller, Argyrios Ntalianis, Catalina Trana, Jozef Bartunek, Giovanna Sarno, Fabio Mangiacapra, Karen Dierickx, Peter Meeus, Thomas Cuisset, Bernard Bruyne, William Wijns, Emanuele Barbato. (2011) Relationship between peripheral arterial reactive hyperemia and residual platelet reactivity after 600 mg clopidogrel. Journal of Thrombosis and Thrombolysis
CrossRef234
José Luis Ferreiro, Joan Antoni Gómez-Hospital, Dominick J. Angiolillo, Ángel Cequier. (2011) ¿Los nuevos antagonistas del receptor P2Y12 pueden reemplazar a los inhibidores de la glucoproteína IIb/IIIa?. Revista Española de Cardiología Suplementos 11, 14-19
CrossRef235
David Lao, Andrew Boyle. 2011. , 223.
CrossRef236
M. K. Freynhofer, I. Brozovic, V. Bruno, S. Farhan, B. Vogel, G. Jakl, M. Willheim, W. Hübl, J. Wojta, K. Huber. (2011) Multiple electrode aggregometry and vasodilator stimulated phosphoprotein-phosphorylation assay in clinical routine for prediction of postprocedural major adverse cardiovascular events. Thrombosis and Haemostasis 106:2, 230-239
CrossRef237
W. Korte, M. Cattaneo, P.-G. Chassot, S. Eichinger, C. von Heymann, N. Hofmann, H. Rickli, M. Spannagl, B. Ziegler, F. Verheugt, K. Huber. (2011) Peri-operative management of antiplatelet therapy in patients with coronary artery disease. Thrombosis and Haemostasis 105:5, 743-749
CrossRef238
Gwénaëlle Cadiou, Magali Adam, Marie Caussin, Isabelle Landrin, Natacha Mariette, Corinne Capet, Dominique Mouton-Schleifer, Elise Remy, Nadir Kadri, Jean Doucet. (2011) Antiplatelet drugs in the elderly: prescriptions often inappropriate and reduced tolerance by associated diseases and drugs. Fundamental & Clinical Pharmacologyno-no
CrossRef239
David Plitt, William J. Brady. 2011. , 18.
CrossRef240
Jerome L. Fleg, Wilbert S. Aronow, William H. Frishman. (2011) Cardiovascular drug therapy in the elderly: benefits and challenges. Nature Reviews Cardiology 8:1, 13-28
CrossRef241
Joaquín J. Alonso, Alejandro Curcio, Catherine Graupner, Rosa María Jiménez, Pedro Talavera. (2011) ¿Bivalirudina o heparina asociada a inhibidores de la glucoproteína IIb/IIIa en el síndrome coronario agudo sin elevación del ST?. Revista Española de Cardiología Suplementos 11, 20-26
CrossRef242
David Erlinge. 2011. P2Y Receptors in Health and Disease. , 417-439.
CrossRef243
Jie-Hyun Kim. (2011) Does Combination Therapy of Aspirin Plus Antiplatelet Therapy Increase the Risk of Upper Gastrointestinal Hemorrhage?. The Korean Journal of Gastroenterology 57:4, 205
CrossRef244
A. Tufano, E. Cimino, M. N. D. Di Minno, P. Ieranò, E. Marrone, A. Strazzullo, G. Di Minno, A. M. Cerbone. (2011) Diabetes Mellitus and Cardiovascular Prevention: The Role and the Limitations of Currently Available Antiplatelet Drugs. International Journal of Vascular Medicine 2011, 1-5
CrossRef245
Goeng Bae Kim, Jeong Kyung Kim, Sul Park, Jae Jin Jeong, Hyung Sik Yoon, Sang Hun Ko, Jae Ee Ko, Soo Jin Park, Seon Woo Nam, Jae Hwan Lee, Min Soo Hyon. (2011) Effect of Atorvastatin and Clopidogrel Co-Administration After Coronary Stenting in Korean Patients With Stable Angina. Korean Circulation Journal 41:1, 28
CrossRef246
P. A. Gurbel, E. Mahla, U. S. Tantry. (2011) Peri-operative platelet function testing: The potential for reducing ischaemic and bleeding risks. Thrombosis and Haemostasis 106:2, 248-252
CrossRef247
V. L. Serebruany. (2011) Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified. Thrombosis and Haemostasis 105:5, 752-759
CrossRef248
Michael Kornfeld, Joseph R. Munsayac. 2011. , 47.
CrossRef249
Masafumi Ueno, Murali Kodali, Antonio Tello-Montoliu, Dominick Joseph Angiolillo. (2011) Role of Platelets and Antiplatelet Therapy in Cardiovascular Disease. Journal of Atherosclerosis and Thrombosis 18:6, 431-442
CrossRef250
Alf-Aage R Pettersen, Harald Arnesen, Trine B Opstad, Ingebjorg Seljeflot. (2011) The influence of CYP 2C19*2 polymorphism on platelet function testing during single antiplatelet treatment with clopidogrel. Thrombosis Journal 9:1, 4
CrossRef251
A.M. Mellett, R.K. Nakamura, D. Bianco. (2011) A Prospective Study of Clopidogrel Therapy in Dogs with Primary Immune-Mediated Hemolytic Anemia. Journal of Veterinary Internal Medicine 25:1, 71-75
CrossRef252
Heleen J Bouman, Edgar Schömig, Jochem W van Werkum, Janna Velder, Christian M Hackeng, Christoph Hirschhäuser, Christopher Waldmann, Hans-Günther Schmalz, Jurriën M ten Berg, Dirk Taubert. (2011) Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nature Medicine 17:1, 110-116
CrossRef253
L. Yukhanyan, M. K. Freynhofer, J. Siller-Matula, K. Schrör, K. Huber. (2011) Genetic variability in response to clopidogrel therapy and its clinical implications. Thrombosis and Haemostasis 105:Suppl. 1, S55-S59
CrossRef254
Neville D Yeomans. (2011) Reducing the risk of gastroduodenal ulcers with a fixed combination of esomeprazole and low-dose acetyl salicylic acid. Expert Review of Gastroenterology and Hepatology 5:4, 447
CrossRef255
Hee Tae Yu, Kwang Joon Kim, Woo-Dae Bang, Chang-Myung Oh, Ji-Yong Jang, Sung-Soo Cho, Jung-Sun Kim, Young-Guk Ko, Donghoon Choi, Myeong-Ki Hong, Yangsoo Jang. (2011) Gender-Based Differences in the Management and Prognosis of Acute Coronary Syndrome in Korea. Yonsei Medical Journal 52:4, 562
CrossRef256
Nicholaos Kakouros, Jeffrey J. Rade, Antonios Kourliouros, Jon R. Resar. (2011) Platelet Function in Patients with Diabetes Mellitus: From a Theoretical to a Practical Perspective. International Journal of Endocrinology 2011, 1-14
CrossRef257
Shinya Goto, Yasuo Ikeda, Kazuyuki Shimada, Shinichiro Uchiyama, Hideki Origasa, Hiroyuki Kobayashi, The J-TRACE Investigators. (2011) One-Year Cardiovascular Event Rates in Japanese Outpatients With Myocardial Infarction, Stroke, and Atrial Fibrillation. Circulation Journal 75:11, 2598-2604
CrossRef258
David Turner, James Raftery, Keith Cooper, Eleanor Fairbank, Stephen Palmer, Sue Ward, Roberta Ara. (2011) The CHD challenge: Comparing four cost-effectiveness models. Value in Health 14:1, 53-60
CrossRef259
Giovanni Mariscalco, Vito Domenico Bruno, Marzia Cottini, Paolo Borsani, Maciej Banach, Gabriele Piffaretti, Carmelo Dominici, Cesare Beghi, Andrea Sala. (2011) Optimal Timing of Discontinuation of Clopidogrel and Risk of Blood Transfusion After Coronary Surgery. Circulation Journal
CrossRef260
G. Y. H. Lip, F. Andreotti, L. Fauchier, K. Huber, E. Hylek, E. Knight, D. Lane, M. Levi, F. Marín, G. Palareti, P. Kirchhof. (2011) Bleeding risk assessment and management in atrial fibrillation patients. Thrombosis and Haemostasis 106:6,
CrossRef261
John Fani Srour, Gerald W. Smetana. (2011) Triple therapy in hospitalized patients: Facts and controversies. Journal of Hospital Medicinen/a-n/a
CrossRef262
Hiroshi YASUDA. (2011) 3. Risk of Upper Gastrointestinal Bleeding during Clopidogrel Therapy with or without a PPI. Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 42:6, 369-373
CrossRef263
David P. Faxon. (2011) Optimizing antiplatelet therapy in acute coronary syndrome and percutaneous coronary intervention. Catheterization and Cardiovascular Interventionsn/a-n/a
CrossRef264
(2010) Dosing of Clopidogrel and Aspirin in Acute Coronary Syndromes. New England Journal of Medicine 363:25, 2465-2468
Full Text265
P. W. Radke, H. Schunkert. (2010) Diabetics with acute coronary syndrome: advances, challenges, and uncertainties. European Heart Journal 31:24, 2971-2973
CrossRef266
S. James, D. J. Angiolillo, J. H. Cornel, D. Erlinge, S. Husted, F. Kontny, J. Maya, J. C. Nicolau, J. Spinar, R. F. Storey, S. R. Stevens, L. Wallentin, . (2010) Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. European Heart Journal 31:24, 3006-3016
CrossRef267
Annemarie M. Armani. (2010) Prasugrel. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 9:4, 199-202
CrossRef268
T. Simon. (2010) Pharmacogénétique des antagonistes des récepteurs plaquettaire P2Y12 de l’ADP. Annales de Cardiologie et d'Angéiologie 59, S42-S46
CrossRef269
Young-Lan Kwak, Jong-Chan Kim, Yong-Seon Choi, Kyung-Jong Yoo, Young Song, Jae-Kwang Shim. (2010) Clopidogrel Responsiveness Regardless of the Discontinuation Date Predicts Increased Blood Loss and Transfusion Requirement After Off-Pump Coronary Artery Bypass Graft Surgery. Journal of the American College of Cardiology 56:24, 1994-2002
CrossRef270
David S. Small, Nagy A. Farid, Christopher D. Payne, Christopher S. Konkoy, Joseph A. Jakubowski, Kenneth J. Winters, Daniel E. Salazar. (2010) Effect of Intrinsic and Extrinsic Factors on the Clinical Pharmacokinetics and Pharmacodynamics of Prasugrel. Clinical Pharmacokinetics 49:12, 777-798
CrossRef271
Savanna Steele, Craig R Lee. (2010) Research Highlights. Pharmacogenomics 11:12, 1687-1690
CrossRef272
N. Danchin, E. Puymirat, N. Aissaoui, S. Adavane, E. Durand. (2010) Épidémiologie des syndromes coronaires aigus en France et en Europe. Annales de Cardiologie et d'Angéiologie 59, S37-S41
CrossRef273
Ole Fröbert, Bo Lagerqvist, Thórarinn Gudnason, Leif Thuesen, Roger Svensson, Göran K. Olivecrona, Stefan K. James. (2010) Thrombus Aspiration in ST-Elevation myocardial infarction in Scandinavia (TASTE trial). A multicenter, prospective, randomized, controlled clinical registry trial based on the Swedish angiography and angioplasty registry (SCAAR) platform. Study design and rationale. American Heart Journal 160:6, 1042-1048
CrossRef274
Soon Jun Hong, Moo Hyun Kim, Kwang Soo Cha, Hun Sik Park, Shung Chull Chae, Seung Ho Hur, Hyeon Cheol Gwon, Jang Ho Bae, Do-Sun Lim. (2010) Comparison of three-year clinical outcomes between sirolimus-versus paclitaxel-eluting stents in diabetic patients: Prospective randomized multicenter trial. Catheterization and Cardiovascular Interventions 76:7, 924-933
CrossRef275
L. Drouet, C. Bal dit Sollier, P. Henry. (2010) Antiagrégants plaquettaires et diabète. Annales de Cardiologie et d'Angéiologie 59, S56-S64
CrossRef276
Neena S. Abraham, Mark A. Hlatky, Elliott M. Antman, Deepak L. Bhatt, David J. Bjorkman, Craig B. Clark, Curt D. Furberg, David A. Johnson, Charles J. Kahi, Loren Laine, Kenneth W. Mahaffey, Eamonn M. Quigley, James Scheiman, Laurence S. Sperling, Gordon F. Tomaselli. (2010) ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. Journal of the American College of Cardiology 56:24, 2051-2066
CrossRef277
Toshiaki Otsuka, Tomoyuki Kawada, Chikao Ibuki, Yoshihiko Seino. (2010) Elevation of high-sensitivity cardiac troponin T and composite end points in randomized trials: Author reply. American Heart Journal 160:6, e49
CrossRef278
HJ TAN. (2010) Controversy of proton pump inhibitor and clopidogrel interaction: A review. Journal of Digestive Diseases 11:6, 334-342
CrossRef279
Iñigo Lozano, Vicente Barriales, Juan Rondan, Concepcion Suarez. (2010) Elevation of high-sensitivity cardiac troponin T and composite end points in randomized trials. American Heart Journal 160:6, e47
CrossRef280
Raute Sunder-Plassmann, Christine Mannhalter. (2010) Pharmacogenetics guided anticoagulation. Clinical Chemistry and Laboratory Medicine 48:S1, S119-S127
CrossRef281
Mark Y. Chan, Jie L. Sun, Tracy Y. Wang, Renato D. Lopes, Marc E. Jolicoeur, Karen S. Pieper, Sunil V. Rao, L. Kristin Newby, Kenneth W. Mahaffey, Robert A. Harrington. (2010) Patterns of discharge antiplatelet therapy and late outcomes among 8,582 patients with bleeding during acute coronary syndrome: A pooled analysis from PURSUIT, PARAGON-A, PARAGON-B, and SYNERGY. American Heart Journal 160:6, 1056-1064.e2
CrossRef282
Neena S Abraham, Mark A Hlatky, Elliott M Antman, Deepak L Bhatt, David J Bjorkman, Craig B Clark, Curt D Furberg, David A Johnson, Charles J Kahi, Loren Laine, Kenneth W Mahaffey, Eamonn M Quigley, James Scheiman, Laurence S Sperling, Gordon F Tomaselli. (2010) ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. The American Journal of Gastroenterology 105:12, 2533-2549
CrossRef283
Ahmed Abdel-Latif, Debabrata Mukherjee, Paymon Mesgarzadeh, Khaled M. Ziada. (2010) Drug-eluting stents in patients with end-stage renal disease: Meta-analysis and systematic review of the literature. Catheterization and Cardiovascular Interventions 76:7, 942-948
CrossRef284
L. Lorgis, C. Richard, M. Zeller, A. Gudjoncik, P. Buffet, I. L’Huillier, Y. Cottin. (2010) Les anti-agrégants plaquettaires au cours du syndrome coronarien aigu. Données des grandes études. Annales de Cardiologie et d'Angéiologie 59, S47-S55
CrossRef285
V. Wenzel, S.G. Russo, H.R. Arntz, J. Bahr, M.A. Baubin, B.W. Böttiger, B. Dirks, U. Kreimeier, M. Fries, C. Eich. (2010) Kommentar zu den Leitlinien 2010 zur kardiopulmonalen Reanimation des European Resuscitation Council. Der Anaesthesist 59:12, 1105-1123
CrossRef286
Laura Mauri, Dean J. Kereiakes, Sharon-Lise T. Normand, Stephen D. Wiviott, David J. Cohen, David R. Holmes, Sripal Bangalore, Donald E. Cutlip, Michael Pencina, Joseph M. Massaro. (2010) Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions. American Heart Journal 160:6, 1035-1041.e1
CrossRef287
Maddalena Lettino. (2010) Inhibition of the antithrombotic effects of clopidogrel by proton pump inhibitors: Facts or fancies?. European Journal of Internal Medicine 21:6, 484-489
CrossRef288
David M. Greer. (2010) Aspirin and Antiplatelet Agent Resistance. CNS Drugs 24:12, 1027-1040
CrossRef289
J. Hasford, P. Bramlage, G. Koch, W. Lehmacher, K. Einhäupl, P.M. Rothwell. (2010) Inconsistent trial assessments by the National Institute for Health and Clinical Excellence and IQWiG: standards for the performance and interpretation of subgroup analyses are needed. Journal of Clinical Epidemiology 63:12, 1298-1304
CrossRef290
Jack C.J. Sun, Kevin H.T. Teoh, Andre Lamy, Tej Sheth, Mary Lou Ellins, Hyejung Jung, Salim Yusuf, Sonia Anand, Stuart Connolly, Richard P. Whitlock, John W. Eikelboom. (2010) Randomized trial of aspirin and clopidogrel versus aspirin alone for the prevention of coronary artery bypass graft occlusion: the Preoperative Aspirin and Postoperative Antiplatelets in Coronary Artery Bypass Grafting study. American Heart Journal 160:6, 1178-1184
CrossRef291
Antonio Tello-Montoliu, Salvatore D. Tomasello, Masafumi Ueno, Dominick J. Angiolillo. (2010) Anti-platelet therapy: thrombin receptor antagonists. British Journal of Clinical Pharmacologyno-no
CrossRef292
Bhatt, Deepak L., Cryer, Byron L., Contant, Charles F., Cohen, Marc, Lanas, Angel, Schnitzer, Thomas J., Shook, Thomas L., Lapuerta, Pablo, Goldsmith, Mark A., Laine, Loren, Scirica, Benjamin M., Murphy, Sabina A., Cannon, Christopher P., . (2010) Clopidogrel with or without Omeprazole in Coronary Artery Disease. New England Journal of Medicine 363:20, 1909-1917
Full Text293
Guillaume Cayla, Jean-Philippe Collet, Johanne Silvain, Gérard Thiefin, France Woimant, Gilles Montalescot. (2010) Prevalence and clinical impact of Upper Gastrointestinal Symptoms in subjects treated with Low Dose Aspirin: The UGLA survey. International Journal of Cardiology
CrossRef294
Thomas Cuisset, Corinne Frere, Pierre Julien Moro, Jacques Quilici, Coline Pons, Bénédicte Gaborit, Laurence Camoin, Pierre-Emmanuel Morange, Jean-Louis Bonnet, Marie-Christine Alessi. (2010) Lack of effect of chronic kidney disease on clopidogrel response with high loading and maintenance doses of clopidogrel after Acute Coronary Syndrome. Thrombosis Research 126:5, e400-e402
CrossRef295
Nina S. Huang, Huzefa H. Master, Julie A. Fusco, Zoon H. Park. (2010) Ticagrelor: A Novel Oral Antiplatelet Agent. The Consultant Pharmacist 25:11, 745-755
CrossRef296
S. Goto, H. Ogawa, M. Takeuchi, M. D. Flather, D. L. Bhatt, . (2010) Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease. European Heart Journal 31:21, 2601-2613
CrossRef297
Chadi Dib, Elias B. Hanna, Mazen S. Abu-Fadel. (2010) A New Era for Antiplatelet Therapy in Patients With Acute Coronary Syndrome. The American Journal of the Medical Sciences 340:5, 407-411
CrossRef298
Raphaël Poyet, Thomas Cuisset, Corinne Frere, Jacques Quilici, Bénédicte Gaborit, Pierre-Julien Moro, Laurence Camoin, Pierre-Emmanuel Morange, Jean-Louis Bonnet, Marie-Christine Alessi. (2010) Comparison of rosuvastatin and atorvastatin on clopidogrel response and lipidic and inflammatory parameters after coronary stenting for acute coronary syndrome: The prospective, randomized OSCAR study (optimal statin therapy with clopidogrel after coronary revascularisation). Thrombosis Research 126:5, e397-e399
CrossRef299
Davide Capodanno, Dominick J. Angiolillo. (2010) Antithrombotic Therapy in the Elderly. Journal of the American College of Cardiology 56:21, 1683-1692
CrossRef300
Ge Gao, Zhe Zheng, Yi Pi, Bin Lu, Jinguo Lu, Shengshou Hu. (2010) Aspirin Plus Clopidogrel Therapy Increases Early Venous Graft Patency After Coronary Artery Bypass Surgery. Journal of the American College of Cardiology 56:20, 1639-1643
CrossRef301
H. S. Kirshner. (2010) Current issues in antiplatelet therapy for stroke prevention: the importance of stroke subtypes and differences between stroke and MI patients. Journal of Neurology 257:11, 1788-1797
CrossRef302
Hans-Christoph Diener, Christian Weimar, Ralph Weber. (2010) Antiplatelet therapy in secondary stroke prevention - state of the art. Journal of Cellular and Molecular Medicine 14:11, 2552-2560
CrossRef303
Michael S. Kim, Tracy Y. Wang, Fang-Shu Ou, Andrew J. Klein, Paul A. Hudson, John C. Messenger, Frederick A. Masoudi, John S. Rumsfeld, P. Michael Ho. (2010) Association of prior coronary artery bypass graft surgery with quality of care of patients with non–ST-segment elevation myocardial infarction: A report from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With the Guidelines. American Heart Journal 160:5, 951-957
CrossRef304
Matthew Sibbald, Andrew T. Yan, Wei Huang, Keith A.A. Fox, Joel M. Gore, Ph. Gabriel Steg, Kim A. Eagle, David Brieger, Gilles Montalescot, Shaun G. Goodman. (2010) Association between smoking, outcomes, and early clopidogrel use in patients with acute coronary syndrome: Insights from the Global Registry of Acute Coronary Events. American Heart Journal 160:5, 855-861
CrossRef305
Alex G. Ortega-Loayza, Syed Raza, Anthony J. Minisi, On Topaz, Andrew Heller, Ion S. Jovin. (2010) Aspirin Desensitization/Challenge in 3 Patients With Unstable Angina. The American Journal of the Medical Sciences 340:5, 418-420
CrossRef306
Paré, Guillaume, Mehta, Shamir R., Yusuf, Salim, Anand, Sonia S., Connolly, Stuart J., Hirsh, Jack, Simonsen, Katy, Bhatt, Deepak L., Fox, Keith A.A., Eikelboom, John W., . (2010) Effects of CYP2C19 Genotype on Outcomes of Clopidogrel Treatment. New England Journal of Medicine 363:18, 1704-1714
Full Text307
P. A. Ringleb, M.-G. Bousser, G. Ford, P. Bath, M. Brainin, V. Caso, Á. Cervera, A.l Chamorro, Charlotte Cordonnier, L. Csiba, A. Davalos, H.-C. Diener, J. Ferro, W. Hacke, M. Hennerici, M. Kaste, P. Langhorne, K. Lees, D. Leys, J. Lodder, H. S. Markus, J.-L. Mas, H. P. Mattle, K. Muir, B. Norrving, V. Obach, S. Paolucci, E. B. Ringelstein, P. D. Schellinger, J. Sivenius, V. Skvortsova, K. Stibrant Sunnerhagen, L. Thomassen, D. Toni, R.r von Kummer, N. Gunnar Wahlgren, M. F. Walker, J. Wardlaw. 2010. Ischaemic Stroke and Transient Ischaemic Attack. , 101-158.
CrossRef308
Barry H. Greenberg, Denise D. Barnard. 2010. Preventing Heart Failure. , 1-26.
CrossRef309
Timm Bauer, Anselm K. Gitt, Claus Jünger, Ralf Zahn, Oliver Koeth, Frank Towae, Arne K. Schwarz, Kurt Bestehorn, Jochen Senges, Uwe Zeymer. (2010) Guideline-recommended secondary prevention drug therapy after acute myocardial infarction: predictors and outcomes of nonadherence. European Journal of Cardiovascular Prevention & Rehabilitation 17:5, 576-581
CrossRef310
Leo Bossaert, Robert E. O’Connor, Hans-Richard Arntz, Steven C. Brooks, Deborah Diercks, Gilson Feitosa-Filho, Jerry P. Nolan, Terry L. Vanden Hoek, Darren L. Walters, Aaron Wong, Michelle Welsford, Karen Woolfrey. (2010) Part 9: Acute coronary syndromes. Resuscitation 81:1, e175-e212
CrossRef311
Jeffrey J. Siracuse, Michael P. Robich, Shiva Gautam, Ekkehard M. Kasper, Donald W. Moorman, Carl J. Hauser. (2010) Antiplatelet agents, warfarin, and epidemic intracranial hemorrhage. Surgery 148:4, 724-730
CrossRef312
Matthew A. Cavender, Sunil V. Rao. (2010) Bleeding associated with current therapies for acute coronary syndrome: What are the mechanisms?. Journal of Thrombosis and Thrombolysis 30:3, 332-339
CrossRef313
Dmitriy N. Feldman, Robert M. Minutello, Geoffrey Bergman, Issam Moussa, S. Chiu Wong. (2010) Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes. Catheterization and Cardiovascular Interventions 76:4, 513-524
CrossRef314
Alan S Go, Robert W Yeh. (2010) Recent epidemiologic trends in the incidence of myocardial infarction: what have we learned?. Interventional Cardiology 2:5, 623-626
CrossRef315
Shamir R Mehta, Jean-Francois Tanguay, John W Eikelboom, Sanjit S Jolly, Campbell D Joyner, Christopher B Granger, David P Faxon, Hans-Jurgen Rupprecht, Andrzej Budaj, Alvaro Avezum, Petr Widimsky, Philippe Gabriel Steg, Jean-Pierre Bassand, Gilles Montalescot, Carlos Macaya, Giuseppe Di Pasquale, Kari Niemela, Andrew E Ajani, Harvey D White, Susan Chrolavicius, Peggy Gao, Keith AA Fox, Salim Yusuf. (2010) Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. The Lancet 376:9748, 1233-1243
CrossRef316
Michael A. Gaglia, Steven V. Manoukian, Ron Waksman. (2010) Novel antiplatelet therapy. American Heart Journal 160:4, 595-604
CrossRef317
Jerry P. Nolan, Jasmeet Soar, David A. Zideman, Dominique Biarent, Leo L. Bossaert, Charles Deakin, Rudolph W. Koster, Jonathan Wyllie, Bernd Böttiger. (2010) European Resuscitation Council Guidelines for Resuscitation 2010 Section 1. Executive summary. Resuscitation 81:10, 1219-1276
CrossRef318
W. Fischbach, H. Darius, M. Gross, H. Koop, I. Kruck, K.U. Petersen. (2010) Gleichzeitige Anwendung von Thrombozytenaggregationshemmern und Protonenpumpeninhibitoren (PPIs). Der Kardiologe 4:5, 353-364
CrossRef319
Pier Mannuccio Mannucci, Massimo Franchini. (2010) New antiplatelet agents in acute coronary syndromes (ACS): An update. European Journal of Internal Medicine 21:5, 465-466
CrossRef320
Jill J.F. Belch, John Dormandy. (2010) Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. Journal of Vascular Surgery 52:4, 825-833.e2
CrossRef321
Hans-Richard Arntz, Leo L. Bossaert, Nicolas Danchin, Nikolaos I. Nikolaou. (2010) European Resuscitation Council Guidelines for Resuscitation 2010 Section 5. Initial management of acute coronary syndromes. Resuscitation 81:10, 1353-1363
CrossRef322
Olivier Morel, Laurence Kessler, Patrick Ohlmann, Pierre Bareiss. (2010) Diabetes and the platelet: Toward new therapeutic paradigms for diabetic atherothrombosis. Atherosclerosis 212:2, 367-376
CrossRef323
Sergio Leonardi, Pierluigi Tricoci, Richard C. Becker. (2010) Thrombin Receptor Antagonists for the Treatment of Atherothrombosis. Drugs 70:14, 1771-1783
CrossRef324
Ameer E. Hassan, Haralabos Zacharatos, Gabriela Vazquez, Gustavo J. Rodriguez, M. Fareed K. Suri, Ramachandra P. Tummala, Robert A. Taylor, Adnan I. Qureshi. (2010) Low Risk of Intracranial and Systemic Hemorrhages in Patients on Dual Antiplatelet Treatment Beyond 1 Month Following Neuroendovascular Angioplasty and/or Stent Placement. Journal of Neuroimagingno-no
CrossRef325
José Luis Ferreiro, Ángel R. Cequier, Dominick J. Angiolillo. (2010) Oral Antiplatelet Therapy in Patients with Diabetes Mellitus and Acute Coronary Syndromes. Trends in Cardiovascular Medicine 20:7, 211-217
CrossRef326
Samuel Chackalamannil. 2010. Antiplatelet Agents. .
CrossRef327
Xavier Bosch, Jaume Marrugat, Juan Sanchis, Xavier Bosch. 2010. Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes. .
CrossRef328
Bertram Pitt, Faiez Zannad, Mihai Gheorghiade, Felipe Martínez, Thomas E. Love, Casey Daniel, Ali Ahmed. (2010) Transatlantic similarities and differences in major natural history endpoints of heart failure after acute myocardial infarction: A propensity-matched study of the EPHESUS trial. International Journal of Cardiology 143:3, 309-316
CrossRef329
The CURRENT–OASIS 7 Investigators. (2010) Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes. New England Journal of Medicine 363:10, 930-942
Full Text330
N. Uren. (2010) Acute coronary syndromes: assessing risk and choosing optimal pharmacological regimens for a superior outcome. European Heart Journal Supplements 12:Suppl D, D4-D13
CrossRef331
Gregory D. Trachiotis. (2010) Early Antiplatelet Therapy in Coronary Artery Bypass Grafting. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery 5:5, 317-325
CrossRef332
Justin A. Ezekowitz, Padma Kaul. (2010) The epidemiology and management of elderly patients with myocardial infarction or heart failure. Heart Failure Reviews 15:5, 407-413
CrossRef333
Jeremy S. Paikin, John W. Eikelboom, John A. Cairns, Jack Hirsh. (2010) New antithrombotic agents—insights from clinical trials. Nature Reviews Cardiology 7:9, 498-509
CrossRef334
Goran Rudež, Hendricus J. Duckers, Maarten L. Simoons. (2010) Clopidogrel and Endothelial Injury After Percutaneous Coronary Interventions. Journal of the American College of Cardiology 56:13, 1032-1033
CrossRef335
Elisabeth Mahla, Helfried Metzler, Udaya S. Tantry, Paul A. Gurbel. (2010) Controversies in Oral Antiplatelet Therapy in Patients Undergoing Aortocoronary Bypass Surgery. The Annals of Thoracic Surgery 90:3, 1040-1051
CrossRef336
Basem Elbarouni, Omran Elmanfud, Raymond T. Yan, Keith A.A. Fox, Jan M. Kornder, Barry Rose, Frederick A. Spencer, Robert C. Welsh, Graham C. Wong, Shaun G. Goodman. (2010) Temporal trend of in-hospital major bleeding among patients with non ST-elevation acute coronary syndromes. American Heart Journal 160:3, 420-427
CrossRef337
Thomas A. Schwann, Laura Kistler, Milo C. Engoren, Robert H. Habib. (2010) Incidence and Predictors of Postoperative Deep Vein Thrombosis in Cardiac Surgery in the Era of Aggressive Thromboprophylaxis. The Annals of Thoracic Surgery 90:3, 760-768
CrossRef338
Daniel Duerschmied, Christoph Bode, Martin Moser. (2010) Clopidogrel in acute coronary syndrome: implications of recent study findings. Expert Review of Cardiovascular Therapy 8:9, 1215-1229
CrossRef339
Germano Di Sciascio, Giuseppe Patti, Vincenzo Pasceri, Laura Gatto, Giuseppe Colonna, Antonio Montinaro. (2010) Effectiveness of In-Laboratory High-Dose Clopidogrel Loading Versus Routine Pre-Load in Patients Undergoing Percutaneous Coronary Intervention. Journal of the American College of Cardiology 56:7, 550-557
CrossRef340
Prakash A. Patel, John G.T. Augoustides. (2010) Progress in Platelet Medicine: Focus on Stent Thrombosis and Drug Resistance. Journal of Cardiothoracic and Vascular Anesthesia 24:4, 722-727
CrossRef341
Robert A. O'Rourke. (2010) Alternative Strategies for the Management of Chronic Stable Angina. Current Problems in Cardiology 35:8, 384-446
CrossRef342
Noriko Konishi, Katsuhiko Hiroe, Masaki Kawamura. (2010) Synergistic effect of a factor Xa inhibitor, TAK-442, and antiplatelet agents on whole blood coagulation and arterial thrombosis in rats. Thrombosis Research 126:2, 124-129
CrossRef343
Nicolas Danchin, Nadia Aïssaoui. (2010) Pharmacologic Therapy for Non ST-segment Elevation Acute Coronary Syndromes: Focus on Antithrombotic Therapy. Cardiovascular Drugs and Therapy 24:4, 325-330
CrossRef344
Martin Moser, Christoph Bode. (2010) Antiplatelet therapy for atherothrombotic disease: How can we improve the outcomes?. Journal of Thrombosis and Thrombolysis 30:2, 240-249
CrossRef345
Jorge F. Saucedo. (2010) Balancing the benefits and risks of antiplatelet agents in patients with non-ST-segment elevated acute coronary syndromes and undergoing percutaneous coronary intervention. Journal of Thrombosis and Thrombolysis 30:2, 200-209
CrossRef346
H.- S. Kang, B. J. Kwon, J. E. Kim, M. H. Han. (2010) Preinterventional Clopidogrel Response Variability for Coil Embolization of Intracranial Aneurysms: Clinical Implications. American Journal of Neuroradiology 31:7, 1206-1210
CrossRef347
Kumaran Kolandaivelu, Deepak L. Bhatt. (2010) Overcoming 'resistance' to antiplatelet therapy: targeting the issue of nonadherence. Nature Reviews Cardiology 7:8, 461-467
CrossRef348
Kathryn Momary, Larisa H Cavallari. (2010) Clopidogrel and Proton Pump Inhibitors: Between a Rock and a Hard Place. Pharmacotherapy 30:8, 762-765
CrossRef349
M. J. SORICH, A. VITRY, M. B. WARD, J. D. HOROWITZ, R. A. MCKINNON. (2010) Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data. Journal of Thrombosis and Haemostasis 8:8, 1678-1684
CrossRef350
Masafumi Ueno, José Luis Ferreiro, Dominick J Angiolillo. (2010) Update on the clinical development of cangrelor. Expert Review of Cardiovascular Therapy 8:8, 1069-1077
CrossRef351
Ryuichi Ogawa, Hirotoshi Echizen. (2010) Drug-Drug Interaction Profiles of Proton Pump Inhibitors. Clinical Pharmacokinetics 49:8, 509-533
CrossRef352
David Vivas, Dominick J. Angiolillo. (2010) Platelet P2Y12 Receptor Inhibition. American Journal Cardiovascular Drugs 10:4, 217-226
CrossRef353
Masafumi Ueno, José Luis Ferreiro, Dominick J Angiolillo. (2010) Mechanism of action and clinical development of platelet thrombin receptor antagonists. Expert Review of Cardiovascular Therapy 8:8, 1191-1200
CrossRef354
Dimitris Tousoulis, Ioannis Ph. Paroutoglou, Nikolaos Papageorgiou, Marietta Charakida, Christodoulos Stefanadis. (2010) Recent therapeutic approaches to platelet activation in coronary artery disease. Pharmacology & Therapeutics 127:2, 108-120
CrossRef355
F. Felices-Abad, J. Latour-Pérez, M.P. Fuset-Cabanes, M. Ruano-Marco, J. Cuñat-de la Hoz, F. del Nogal-Sáez. (2010) Indicadores de calidad en el síndrome coronario agudo para el análisis del proceso asistencial pre e intrahospitalario. Medicina Intensiva 34:6, 397-417
CrossRef356
C. Heim, S. Eckl, J. Gebhardt, M. Weyand, S.M. Ensminger. (2010) Die unterschätzte Rolle von Thrombozyten bei der Herztransplantation. Zeitschrift für Herz-,Thorax- und Gefäßchirurgie 24:4, 241-250
CrossRef357
H. M. JUDGE, S. B. PATIL, R. J. BUCKLAND, J. A. JAKUBOWSKI, R. F. STOREY. (2010) Potentiation of clopidogrel active metabolite formation by rifampicin leads to greater P2Y12 receptor blockade and inhibition of platelet aggregation after clopidogrel. Journal of Thrombosis and Haemostasis 8:8, 1820-1827
CrossRef358
Alex Hobson, Nick Curzen. 2010. Acute Coronary Syndromes and Myocardial Infarction. , 234-255.
CrossRef359
Jean-Sébastien Hulot, Jean-Philippe Collet, Johanne Silvain, Ana Pena, Anne Bellemain-Appaix, Olivier Barthélémy, Guillaume Cayla, Farzin Beygui, Gilles Montalescot. (2010) Cardiovascular Risk in Clopidogrel-Treated Patients According to Cytochrome P450 2C19*2 Loss-of-Function Allele or Proton Pump Inhibitor Coadministration. Journal of the American College of Cardiology 56:2, 134-143
CrossRef360
Dong Joon Kim, Sang Hyun Suh, Byung Moon Kim, Dong Ik Kim, Seung Kon Huh, Jae Whan Lee. (2010) Hemorrhagic Complications Related to the Stent-Remodeled Coil Embolization of Intracranial Aneurysms. Neurosurgery 67:1, 73-79
CrossRef361
Anne Burdess, Alastair F. Nimmo, O. James Garden, John A. Murie, A. Raymond W. Dawson, Keith A. A. Fox, David E. Newby. (2010) Randomized Controlled Trial of Dual Antiplatelet Therapy in Patients Undergoing Surgery for Critical Limb Ischemia. Annals of Surgery 252:1, 37-42
CrossRef362
R. Casado-Arroyo, J. M. Scheiman, M. Polo-Tomas, S. D. Saini, A. Del Rio, E. Guastello, A. Lanas. (2010) Underutilization of gastroprotection for at-risk patients undergoing percutaneous coronary intervention: Spain compared with the United States. Alimentary Pharmacology & Therapeuticsno-no
CrossRef363
Amit P. Amin, Steven P. Marso. (2010) Acute Coronary Syndrome in the Patient with Diabetes: Is the Management Different?. Current Cardiology Reports 12:4, 321-329
CrossRef364
Masafumi Ueno, Sunil V Rao, Dominick J Angiolillo. (2010) Elinogrel: pharmacological principles, preclinical and early phase clinical testing. Future Cardiology 6:4, 445-453
CrossRef365
M. SCHMIDT, M. B. JOHANSEN, T. L. LASH, C. F. CHRISTIANSEN, S. CHRISTENSEN, H. T. SØRENSEN. (2010) Antiplatelet drugs and risk of subarachnoid hemorrhage: a population-based case-control study. Journal of Thrombosis and Haemostasis 8:7, 1468-1474
CrossRef366
J. Floris S. Logman, Bart M.S. Heeg, Johan Herlitz, Ben A. van Hout. (2010) Costs and Consequences of Clopidogrel versus Aspirin for Secondary Prevention of Ischaemic Events in (High-Risk) Atherosclerotic Patients in Sweden. Applied Health Economics and Health Policy 8:4, 251-265
CrossRef367
Miles W Behan, Derek P Chew, Philip E Aylward. (2010) The role of antiplatelet therapy in the secondary prevention of coronary artery disease. Current Opinion in Cardiology 25:4, 321-328
CrossRef368
Alberto Pilotto, Marilisa Franceschi, Stefania Maggi, Filomena Addante, Daniele Sancarlo. (2010) Optimal Management of Peptic Ulcer Disease in the Elderly. Drugs & Aging 27:7, 545-558
CrossRef369
Kevin R. Bainey, Shamir R. Mehta. (2010) Aspirin for Acute Coronary Syndromes: Have We Learned the Correct Dose Yet?. Current Cardiology Reports 12:4, 344-347
CrossRef370
Sergio Leonardi, Sunil V. Rao, Robert A. Harrington, Deepak L. Bhatt, C. Michael Gibson, Matthew T. Roe, Janusz Kochman, Kurt Huber, Uwe Zeymer, Mina Madan, Daniel D. Gretler, Matthew W. McClure, Gayle E. Paynter, Vivian Thompson, Robert C. Welsh. (2010) Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y12-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI). American Heart Journal 160:1, 65-72
CrossRef371
Kimberly L Campbell, John R Cohn, Michael P Savage. (2010) Clopidogrel hypersensitivity: clinical challenges and options for management. Expert Review of Clinical Pharmacology 3:4, 553-561
CrossRef372
Yeh, Robert W., Sidney, Stephen, Chandra, Malini, Sorel, Michael, Selby, Joseph V., Go, Alan S., . (2010) Population Trends in the Incidence and Outcomes of Acute Myocardial Infarction. New England Journal of Medicine 362:23, 2155-2165
Full Text373
Michael A. Gaglia Jr., Ron Waksman. (2010) Proton Pump Inhibitors and Clopidogrel. Cardiovascular Therapeutics 28:3, 169-176
CrossRef374
Li Liu, Fandian Zeng, Xiaohua Zeng, Qingmei Xue, Shaoping Nie, Cailian Kang, Jianhong Wu, Qingyun Kang, Xingao Wang, Xiaoqing Liu, Tao Li, Jun Chen, Qing Li, Rong Xu, Xiaoyan Yang, Hui Kang, Fagang Jiang, Zongtao Li, Xuwu Wang, Li Zhang, Yu Long. (2010) Revaluation of clopidogrel: let the data speak for themselves. Journal of Huazhong University of Science and Technology [Medical Sciences] 30:3, 299-306
CrossRef375
William E. Boden, Marcus D. Flather, Deepak L. Bhatt. (2010) Role of Dual Antiplatelet Therapy in Symptomatic Patients with Established Vascular Disease: Putting the CHARISMA Trial into Therapeutic Perspective. Cardiovascular Drugs and Therapy 24:3, 207-216
CrossRef376
Cheng-I Cheng, Ching-Pei Chen, Pei-Liang Kuan, Meng-Huan Lei, Chiau-Suong Liau, Kwo-Chang Ueng, Chiung-Jen Wu, Wen-Ter Lai. (2010) The Causes and Outcomes of Inadequate Implementation of Existing Guidelines for Antiplatelet Treatment in Patients With Acute Coronary Syndrome: The Experience From Taiwan Acute Coronary Syndrome Descriptive Registry (T-ACCORD Registry). Clinical Cardiology 33:6, E40-E48
CrossRef377
Sahin Senay, Fevzi Toraman, Hasan Karabulut, Cem Alhan. (2010) Efficiency of Preoperative Tranexamic Acid in Coronary Bypass Surgery: An Analysis Correlated with Preoperative Clopidogrel Use. The Heart Surgery Forum 13:3, E149-E154
CrossRef378
L. Testa, R. Bhindi, W. J. Van Gaal, R. A. Latini, S. Pizzocri, S. Lanotte, G. G. L. Biondi Zoccai, M. Valgimigli, M. L. Laudisa, N. Brambilla, A. P. Banning, F. Bedogni. (2010) What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel. QJM 103:6, 367-377
CrossRef379
Carlos G. Santos-Gallego, Jeremías Bayón, Juan José Badimón. (2010) Thrombi of Different Pathologies: Implications for Diagnosis and Treatment. Current Treatment Options in Cardiovascular Medicine 12:3, 274-291
CrossRef380
J. Hankowitz, P. Bramlage. (2010) Pharmaka zur Thrombozyten- und Gerinnungshemmung in der Behandlung des akuten Koronarsyndroms. Der Kardiologe 4:3, 239-248
CrossRef381
Ashequl M Islam, Pranav M Patel. (2010) Preventing Serious Sequelae After an Acute Coronary Syndrome: The Consequences of Thrombosis Versus Bleeding With Antiplatelet Therapy. Journal of Cardiovascular Pharmacology 55:6, 585-594
CrossRef382
(2010) Section 13: Evaluation and Therapy for Heart Failure in the Setting of Ischemic Heart Disease. Journal of Cardiac Failure 16:6, e157-e165
CrossRef383
Nihar R. Desai, Deepak L. Bhatt. (2010) The State of Periprocedural Antiplatelet Therapy After Recent Trials. JACC: Cardiovascular Interventions 3:6, 571-583
CrossRef384
Jacob George, Alex Doney, Colin N. Palmer, Chim C. Lang. (2010) Pharmacogenetics Testing: Implications for Cardiovascular Therapeutics with Clopidogrel and Warfarin. Cardiovascular Therapeutics 28:3, 135-138
CrossRef385
J.M. Cotton, A.M. Worrall, A.R. Hobson, A. Smallwood, V. Amoah, S. Dunmore, A.M. Nevill, R. Rajendra, J. Vickers, N. Curzen. (2010) Individualised Assessment of Response to Clopidogrel in Patients Presenting with Acute Coronary Syndromes: A Role for Short Thrombelastography?. Cardiovascular Therapeutics 28:3, 139-146
CrossRef386
G. Y. H. Lip, K. Huber, F. Andreotti, H. Arnesen, J. K. Airaksinen, T. Cuisset, P. Kirchhof, F. Marin. (2010) Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary--a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). European Heart Journal 31:11, 1311-1318
CrossRef387
Ganesan Karthikeyan, John W. Eikelboom. (2010) Apixaban in Acute Coronary Syndromes. Cardiovascular Therapeuticsno-no
CrossRef388
Ka Sing Lawrence Wong, Christopher Chen, Jianhui Fu, Hui Meng Chang, Nijasri C Suwanwela, Yining N Huang, Zhao Han, Kay Sin Tan, Disya Ratanakorn, Pavithra Chollate, Yudong Zhao, Angeline Koh, Qing Hao, Hugh S Markus. (2010) Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded-endpoint trial. The Lancet Neurology 9:5, 489-497
CrossRef389
Renli Teng, Kathleen Butler. (2010) Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y12 receptor antagonist, in healthy subjects. European Journal of Clinical Pharmacology 66:5, 487-496
CrossRef390
Helmar Bornemann, Florian Prüller, Helfried Metzler. (2010) The patient with coronary stents and antiplatelet agents: what to do and how to deal?. European Journal of Anaesthesiology 27:5, 406-410
CrossRef391
Till F. Althoff, Matthias Fischer, Elisabeth Langer, Sabine Ziemer, Gert Baumann. (2010) Sustained enhancement of residual platelet reactivity after coronary stenting in patients with myocardial infarction compared to elective patients. Thrombosis Research 125:5, e190-e196
CrossRef392
Claire N. Harrison, David Bareford, Nauman Butt, Peter Campbell, Eibhlean Conneally, Mark Drummond, Wendy Erber, Tamara Everington, Anthony R. Green, Georgina W. Hall, Beverley J. Hunt, Christopher A. Ludlam, Richard Murrin, Catherine Nelson-Piercy, Deepti H. Radia, John T. Reilly, Jon Van der Walt, Bridget Wilkins, Mary F. McMullin, . (2010) Guideline for investigation and management of adults and children presenting with a thrombocytosis. British Journal of Haematology 149:3, 352-375
CrossRef393
Itsik Ben-Dor, Rebecca Torguson, Mickey Scheinowitz, Yanlin Li, Cedric Delhaye, Kohei Wakabayashi, Gabriel Maluenda, Asmir I. Syed, Sara D. Collins, Manuel A. Gonzalez, Michael A. Gaglia, Zhenyi Xue, Kimberly Kaneshige, Lowell F. Satler, William O. Suddath, Kenneth M. Kent, Augusto D. Pichard, Ron Waksman. (2010) Incidence, correlates, and clinical impact of nuisance bleeding after antiplatelet therapy for patients with drug-eluting stents. American Heart Journal 159:5, 871-875
CrossRef394
S. Michael Gharacholou, Renato D. Lopes, Jeffrey B. Washam, L. Kristin Newby, Stefan K. James, John H. Alexander. (2010) Antithrombotic therapy in acute coronary syndromes: guidelines translated for the clinician. Journal of Thrombosis and Thrombolysis 29:4, 516-528
CrossRef395
Takahisa Furuta, Takayuki Iwaki, Kazuo Umemura. (2010) [13C]Pantoprazole breath test as a predictor of the anti-platelet function of clopidogrel. European Journal of Clinical Pharmacology 66:5, 457-463
CrossRef396
M. Luinstra, M. Naunton, G. M. Peterson, L. Bereznicki. (2010) PPI use in patients commenced on clopidogrel: a retrospective cross-sectional evaluation. Journal of Clinical Pharmacy and Therapeutics 35:2, 213-217
CrossRef397
S. SCHULMAN, F. A. SPENCER. (2010) Antithrombotic drugs in coronary artery disease: risk benefit ratio and bleeding. Journal of Thrombosis and Haemostasis 8:4, 641-650
CrossRef398
N. Jones, R.H. Broomhead, J. Kaur, S.V. Mallett. (2010) “To MAP or not to MAP; is that the question?” The role of platelet function tests in the perioperative management of patients on antiplatelet therapy. Current Anaesthesia & Critical Care 21:2, 91-93
CrossRef399
Jonathan Karnon, Mike W. Holmes, Robert Williams, Ameet Bakhai, Alan Brennan. (2010) A cost-utility analysis of clopidogrel in patients with ST elevation acute coronary syndromes in the UK. International Journal of Cardiology 140:3, 315-322
CrossRef400
NEIL GUPTA, RAHUL NAYAK, SCOTT W. GRISOLANO, DANIEL C. BUCKLES, PETER N. TADROS. (2010) Defining Patients at High Risk for Gastrointestinal Hemorrhage after Drug-Eluting Stent Placement: A Cost Utility Analysis. Journal of Interventional Cardiology 23:2, 179-187
CrossRef401
James M. Gebel. (2010) Heterogeneity of Efficacy and Safety of Antiplatelet Therapy in Cardiovascular and Cerebrovascular Disease. American Journal Cardiovascular Drugs 10:2, 115-124
CrossRef402
Tony C. Lee, Shaun G. Goodman, Raymond T. Yan, Francois R. Grondin, Robert C. Welsh, Barry Rose, Gabor Gyenes, Rodney H. Zimmerman, Real Brossoit, Gustavo Saposnik, John J. Graham, Andrew T. Yan. (2010) Disparities in Management Patterns and Outcomes of Patients With Non–ST-Elevation Acute Coronary Syndrome With and Without a History of Cerebrovascular Disease. The American Journal of Cardiology 105:8, 1083-1089
CrossRef403
Harold L. Dauerman, Deepak L. Bhatt, Daniel D. Gretler, Patricia A. French, Susan S. Smyth, Richard C. Becker. (2010) Bridging the gap between clinical trials of antiplatelet therapies and applications among elderly patients. American Heart Journal 159:4, 508-517.e1
CrossRef404
Birgit Linnemann, Jan Schwonberg, Stefan W. Toennes, Helen Mani, Edelgard Lindhoff-Last. (2010) Variability of residual platelet function despite clopidogrel treatment in patients with peripheral arterial occlusive disease. Atherosclerosis 209:2, 504-509
CrossRef405
, T. Lickfeld, C. Hamm, M. Möckel, J. Vollert, M. Haude. (2010) Antithrombotische Therapie beim ST-Streckenhebungsinfarkt. Der Kardiologe 4:2, 107-123
CrossRef406
Nicholas J. Schork, Eric J. Topol. (2010) Genotype-Based Risk and Pharmacogenetic Sampling in Clinical Trials. Journal of Biopharmaceutical Statistics 20:2, 315-333
CrossRef407
Michel R Hoenig, Constantine N Aroney, Ian A Scott, Michel R Hoenig. 2010. Early invasive versus conservative strategies for unstable angina and non-ST elevation myocardial infarction in the stent era. .
CrossRef408
Sebastian Eckl, Christian Heim, Silke Abele-Ohl, Julia Hoffmann, Martina Ramsperger-Gleixner, Michael Weyand, Stephan M. Ensminger. (2010) Combination of clopidogrel and everolimus dramatically reduced the development of transplant arteriosclerosis in murine aortic allografts. Transplant International
CrossRef409
Tina J Liu, Cynthia A Jackevicius. (2010) Drug Interaction Between Clopidogrel and Proton Pump Inhibitors. Pharmacotherapy 30:3, 275-289
CrossRef410
S.J. Thurston, B. Heeg, F. de Charro, B. van Hout. (2010) Cost-effectiveness of clopidogrel in STEMI patients in the Netherlands: a model based on the CLARITY trial. Current Medical Research and Opinion 26:3, 641-651
CrossRef411
Lisbeth Bonde, Rikke Sorensen, Emil Loldrup Fosbøl, Steen Zabell Abildstrøm, Peter Riis Hansen, Lars Kober, Tina Ken Schramm, Ditte-Marie Bretler, Peter Weeke, Jonas Olesen, Christian Torp-Pedersen, Gunnar Hilmar Gislason. (2010) Increased Mortality Associated With Low Use of Clopidogrel in Patients With Heart Failure and Acute Myocardial Infarction Not Undergoing Percutaneous Coronary Intervention. Journal of the American College of Cardiology 55:13, 1300-1307
CrossRef412
Ulrike Flierl, Corinna Schöpp, Juliane Jaitner, Johann Bauersachs, Andreas Schäfer. (2010) The novel P2Y12 antagonist AZD6140 rapidly and reversibly reduces platelet activation in diabetic rats. Thrombosis Research 125:3, e93-e99
CrossRef413
Kyle B. Gibler, Haiden A. Huskamp, Marc S. Sabatine, Sabina A. Murphy, David J. Cohen, Christopher P. Cannon. (2010) Cost-Effectiveness Analysis of Short-Term Clopidogrel Therapy for ST Elevation Myocardial Infarction. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 9:1, 14-18
CrossRef414
M. L. Simoons, S. Windecker. (2010) Chronic stable coronary artery disease: drugs vs. revascularization. European Heart Journal 31:5, 530-541
CrossRef415
Rahul Sakhuja, Robert W. Yeh, Deepak L. Bhatt. (2010) Antiplatelet Agents in Acute Coronary Syndromes. Current Problems in Cardiology 35:3, 123-170
CrossRef416
Michael A. Gaglia, Rebecca Torguson, Nicholas Hanna, Manuel A. Gonzalez, Sara D. Collins, Asmir I. Syed, Itsik Ben-Dor, Gabriel Maluenda, Cedric Delhaye, Kohei Wakabayashi, Zhenyi Xue, William O. Suddath, Kenneth M. Kent, Lowell F. Satler, Augusto D. Pichard, Ron Waksman. (2010) Relation of Proton Pump Inhibitor Use After Percutaneous Coronary Intervention With Drug-Eluting Stents to Outcomes. The American Journal of Cardiology 105:6, 833-838
CrossRef417
Kathryn M Momary, Michael P Dorsch. (2010) Factors associated with clopidogrel nonresponsiveness. Future Cardiology 6:2, 195-210
CrossRef418
Jeffrey J. Popma, Senthil Nathan, Robert C. Hagberg, Kamal R. Khabbaz. (2010) Hybrid myocardial revascularization: An integrated approach to coronary revascularization. Catheterization and Cardiovascular Interventions 75:S1, S28-S34
CrossRef419
Alexandre C. Ferreira, Francisco Yturi Bulcão Macedo. (2010) A review of simple, non-invasive means of assessing peripheral arterial disease and implications for medical management. Annals of Medicine 42:2, 115-126
CrossRef420
Victor L. Serebruany. (2010) Clopidogrel and Heart Failure Survival. Journal of the American College of Cardiology 55:13, 1308-1309
CrossRef421
Kathryn M Momary, Michael P Dorsch, Eric R Bates. (2010) Genetic Causes of Clopidogrel Nonresponsiveness: Which Ones Really Count?. Pharmacotherapy 30:3, 265-274
CrossRef422
John GF Cleland. (2010) Long-term aspirin for coronary artery disease: are we being deceived by a biased presentation of the evidence?. Future Cardiology 6:2, 141-146
CrossRef423
Freek W. A. Verheugt. (2010) Novel oral anticoagulants to prevent stroke in atrial fibrillation. Nature Reviews Cardiology 7:3, 149-154
CrossRef424
John L. Petersen, John J. Barron, Bradley G. Hammill, Mark J. Cziraky, Kevin J. Anstrom, Peter M. Wahl, Eric L. Eisenstein, Mitchell W. Krucoff, Robert M. Califf, Kevin A. Schulman. (2010) Clopidogrel use and clinical events after drug-eluting stent implantation: Findings from the HealthCore Integrated Research Database. American Heart Journal 159:3, 462-470.e1
CrossRef425
Samin K. Sharma. (2010) Oral antiplatelet therapy in PCI patients. Catheterization and Cardiovascular Interventions 75:S1, S7-S14
CrossRef426
Helfried Metzler, Florian Prüller, Andreas Münch, Günter Primus, Johann Kainz, Ronald Hödl, Peter Rehak. (2010) Premature preoperative discontinuation of antiplatelet drug therapy in cardiovascular risk patients: a preliminary study on the role of P2Y12 receptor monitoring. European Journal of Anaesthesiology 27:2, 138-145
CrossRef427
Alan D. Michelson. (2010) Antiplatelet therapies for the treatment of cardiovascular disease. Nature Reviews Drug Discovery 9:2, 154-169
CrossRef428
Elias B. Hanna, David Luke Glancy, Jorge F. Saucedo. (2010) Antiplatelet and Anticoagulant Therapies in Acute Coronary Syndromes. Cardiovascular Drugs and Therapy 24:1, 61-70
CrossRef429
D. SIBBING, S. SCHULZ, S. BRAUN, T. MORATH, J. STEGHERR, J. MEHILLI, A. SCHÖMIG, N. VON BECKERATH, A. KASTRATI. (2010) Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. Journal of Thrombosis and Haemostasis 8:2, 250-256
CrossRef430
Carlo Patrono, Bianca Rocca. (2010) The Future of Antiplatelet Therapy in Cardiovascular Disease. Annual Review of Medicine 61:1, 49-61
CrossRef431
Dmitriy N. Feldman, Foluso Fakorede, Robert M. Minutello, Geoffrey Bergman, Issam Moussa, S. Chiu Wong. (2010) Efficacy of High-Dose Clopidogrel Treatment (600 mg) Less Than Two Hours Before Percutaneous Coronary Intervention in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes. The American Journal of Cardiology 105:3, 323-332
CrossRef432
Chetan Varma. (2010) Clopidogrel and proton pump inhibitors: Are the goal posts shifting?. Thrombosis Research 125:2, 110-111
CrossRef433
Luke Tapp, Eduard Shantsila, Gregory Y.H. Lip. (2010) Aspirin—A Drug Whose Time Has Gone?. The American Journal of Cardiology 105:4, 577-578
CrossRef434
Davide Capodanno, Kodlipet Dharmashankar, Dominick J Angiolillo. (2010) Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y 12 receptor antagonist. Expert Review of Cardiovascular Therapy 8:2, 151-158
CrossRef435
, Katsumi Miyauchi, Yoshihiro Morino, Kengo Tsukahara, Hideki Origasa, Hiroyuki Daida. (2010) The PACIFIC (Prevention of AtherothrombotiC Incidents Following Ischemic Coronary attack) Registry: Rationale and Design of a 2-Year Study in Patients Initially Hospitalised with Acute Coronary Syndrome in Japan. Cardiovascular Drugs and Therapy 24:1, 77-83
CrossRef436
Sanjay Kaul, George A. Diamond. (2010) Trial and Error. Journal of the American College of Cardiology 55:5, 415-427
CrossRef437
Pierre-Frédéric Keller, Marco Roffi. 2010. Acute Coronary Syndromes. , 1-22.
CrossRef438
Nai-Wen Tsai, Wen-Neng Chang, Chen-Fu Shaw, Chung-Ren Jan, Hsueh-Wen Chang, Chi-Ren Huang, Shang-Der Chen, Yao-Chung Chuang, Lian-Hui Lee, Cheng-Hsien Lu. (2010) Serial Change in Platelet Activation Markers With Aspirin and Clopidogrel After Acute Ischemic Stroke. Clinical Neuropharmacology 33:1, 40-45
CrossRef439
Vijay S. Ramanath, David F. Armstrong, Mary Grzybowski, Sahand Rahnama-Mohagdam, Umesh U. Tamhane, Kelly Gordon, James B. Froehlich, Kim A. Eagle, Elizabeth A. Jackson. (2010) Receipt of Cardiac Medications Upon Discharge Among Men and Women With Acute Coronary Syndrome and Nonobstructive Coronary Artery Disease. Clinical Cardiology 33:1, 36-41
CrossRef440
Shinya Goto, Tetsu Yamaguchi, Yasuo Ikeda, Kenichi Kato, Hiroya Yamaguchi, Peder Jensen. (2010) Safety and Exploratory Efficacy of the Novel Thrombin Receptor (PAR-1) Antagonist SCH530348 for Non-ST-Segment Elevation Acute Coronary Syndrome. Journal of Atherosclerosis and Thrombosis 17:2, 156-164
CrossRef441
Christopher M WARD. (2010) [Treatment] Platelet inhibitors of the P2Y12 receptor. Japanese Journal of Thrombosis and Hemostasis 21:4, 457-461
CrossRef442
Shepard D. Weiner, LeRoy E. Rabbani. (2010) Secondary prevention strategies for coronary heart disease. Journal of Thrombosis and Thrombolysis 29:1, 8-24
CrossRef443
Dal-Sung Ryu, Chang-Ki Hong, Yoo-Sik Sim, Chang-Hyun Kim, Jin-Young Jung, Jin-Yang Joo. (2010) Anti-Platelet Drug Resistance in the Prediction of Thromboembolic Complications after Neurointervention. Journal of Korean Neurosurgical Society 48:4, 319
CrossRef444
Loren Laine, Charles Hennekens. (2010) Proton Pump Inhibitor and Clopidogrel Interaction: Fact or Fiction?. The American Journal of Gastroenterology 105:1, 34-41
CrossRef445
Dominick J. Angiolillo, José Luis Ferreiro. (2010) Inhibición del receptor plaquetario P2Y12 de adenosina difosfato plaquetario: efectos beneficiosos y limitaciones de las estrategias terapéuticas actuales y perspectivas futuras. Revista Española de Cardiología 63:1, 60-76
CrossRef446
Álvaro Merino, Andrés Grau, Ignacio Segura. (2010) Novedades en el tratamiento antitrombótico en intervencionismo coronario. Revista Española de Cardiología Suplementos 10:4, 34D-41D
CrossRef447
Haifeng M Wu, LiHui Xu, Daniel D Sedmak, Clay B Marsh, Mark W Wurster. (2010) Personalized healthcare in clotting disorders. Personalized Medicine 7:1, 65-73
CrossRef448
Marc Bonaca, Robert P. Giugliano. (2010) Antithrombotics in Acute Coronary Syndromes: Updates from the Past Year. Current Treatment Options in Cardiovascular Medicine 12:1, 84-99
CrossRef449
Qiang Fu, Naoyuki Yokoyama, Kaoru Takada, Shuichi Ishikawa, Takaaki Isshiki. (2010) Comparison of Platelet P2Y12 ADP Receptor-Mediated Pathway Inhibition in Triple Versus Dual Antiplatelet Therapy as Assessed by VASP-Phosphorylation in Japanese Patients Undergoing Coronary Stenting. International Heart Journal 51:5, 303-307
CrossRef450
Antonio Fernández-Ortiz, David Vivas, Juan C. García-Rubira. (2010) Tratamiento antitrombótico en diabéticos con síndrome coronario agudo. Revista Española de Cardiología Suplementos 10:4, 42D-48D
CrossRef451
A. Bleakley Chandler, Angela D. Earhart, Henry E. Speich, Teddi J. Kueter, Jennifer Hansen, Melanie M. White, Lisa K. Jennings. (2010) Regulation of CD40L (CD154) and CD62P (p-selectin) Surface Expression upon GPIIb-IIIa Blockade of Platelets from Stable Coronary Artery Disease Patients. Thrombosis Research 125:1, 44-52
CrossRef452
Kengo Tsukahara, Kazuo Kimura, Satoshi Morita, Toshiaki Ebina, Masami Kosuge, Kiyoshi Hibi, Jun Okuda, Noriaki Iwahashi, Nobuhiko Maejima, Tatsuya Nakachi, Fumiyuki Ohtsuka, Katsutaka Hashiba, Yoshio Tahara, Teruyasu Sugano, Satoshi Umemura. (2010) Impact of High-Responsiveness to Dual Antiplatelet Therapy on Bleeding Complications in Patients Receiving Drug-Eluting Stents. Circulation Journal 74:4, 679-685
CrossRef453
Guillermo Di Girolamo, Paola Czerniuk, Roberto Bertuola, Guillermo A. Keller. (2010) Bioequivalence of two tablet formulations of clopidogrel in healthy argentinian volunteers: A single-dose, randomized-sequence, open-label crossover study. Clinical Therapeutics 32:1, 161-170
CrossRef454
P. Decavel, E. Medeiros de Bustos, E. Revenco, F. Vuillier, L. Tatu, T. Moulin. (2010) Ematomi intracerebrali spontanei. EMC - Neurologia 10:2, 1-10
CrossRef455
Christopher P Cannon, Robert A Harrington, Stefan James, Diego Ardissino, Richard C Becker, Håkan Emanuelsson, Steen Husted, Hugo Katus, Matyas Keltai, Nardev S Khurmi, Frederic Kontny, Basil S Lewis, Philippe Gabriel Steg, Robert F Storey, Daniel Wojdyla, Lars Wallentin. (2010) Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. The Lancet 375:9711, 283-293
CrossRef456
Serdar Farhan, Thomas Höchtl, Alexandra Kautzky-Willer, Johann Wojta, Kurt Huber. (2010) Antithrombotic therapy in patients with coronary artery disease and with type 2 diabetes mellitus. Wiener Medizinische Wochenschrift 160:1-2, 30-38
CrossRef457
Young-Hoon Jeong, Jin-Sin Koh, Min-Kyung Kang, Yeon-Jeong Ahn, In-Suk Kim, Yongwhi Park, Seok-Jae Hwang, Choong Hwan Kwak, Jin-Yong Hwang. (2010) The Impact of Generic Clopidogrel Bisulfate on Platelet Inhibition in Patients with Coronary Artery Stents: Results of the ACCEL-GENERIC Study. The Korean Journal of Internal Medicine 25:2, 154
CrossRef458
Gregg W Stone. (2010) Ticagrelor in ACS: redefining a new standard of care?. The Lancet 375:9711, 263-265
CrossRef459
Esam Elbarasi, Shaun G. Goodman, Raymond T. Yan, Robert C. Welsh, Jan Kornder, Graham C. Wong, Jean-Pierre Déry, Fred Anderson, Joel M. Gore, Keith A.A. Fox. (2010) Management patterns of non-ST segment elevation acute coronary syndromes in relation to prior coronary revascularization. American Heart Journal 159:1, 40-46
CrossRef460
Joo-Yong Hahn, Young Bin Song, Jin-Ho Choi, Sung-Hyuk Choi, Sung Yun Lee, Hun Sik Park, Seung Ho Hur, Sahng Lee, Kyoo-Rok Han, Seung-Woon Rha, Byung Ryul Cho, Jong-Sun Park, Junghan Yoon, Do Sun Lim, Sang Hoon Lee, Hyeon-Cheol Gwon, The DATE Registry Investigators. (2010) Three-Month Dual Antiplatelet Therapy After Implantation of Zotarolimus-Eluting Stents. Circulation Journal 74:11, 2314-2321
CrossRef461
D. J. Angiolillo, D. Capodanno, S. Goto. (2010) Platelet thrombin receptor antagonism and atherothrombosis. European Heart Journal 31:1, 17-28
CrossRef462
Angel Lanas. (2010) Inhibidores de la bomba de protones y clopidogrel en el paciente cardiovascular: ¿riesgo cardiovascular versus riesgo gastrointestinal?. Gastroenterología y Hepatología 33:1, 1-5
CrossRef463
Erlend Aune, Knut Endresen, Keith A.A. Fox, Jon Erik Steen-Hansen, Jo Roislien, Joran Hjelmesaeth, Jan Erik Otterstad. (2010) Effect of Implementing Routine Early Invasive Strategy on One-Year Mortality in Patients With Acute Myocardial Infarction. The American Journal of Cardiology 105:1, 36-42
CrossRef464
Dominick J. Angiolillo, Masafumi Ueno, Shinya Goto. (2010) Basic Principles of Platelet Biology and Clinical Implications. Circulation Journal 74:4, 597-607
CrossRef465
L. Testa, G. G. L. Biondi Zoccai, M. Valgimigli, R. A. Latini, S. Pizzocri, S. Lanotte, M. L. Laudisa, N. Brambilla, M. R. Ward, G. A. Figtree, F. Bedogni, R. Bhindi. (2010) Current Concepts on Antiplatelet Therapy: Focus on the Novel Thienopyridine and Non-Thienopyridine Agents. Advances in Hematology 2010, 1-7
CrossRef466
H.-R. Arntz, L.L. Bossaert, N. Danchin, N. Nicolau. (2010) Initiales Management des akuten Koronarsyndroms : Sektion 5 der Leitlinien zur Reanimation 2010 des European Resuscitation Council. Notfall + Rettungsmedizin 13:7, 621
CrossRef467
Pawan D Patel, Rohit R Arora. (2010) Practical Implications of ACC/AHA 2007 Guidelines for the Management of Unstable Angina/Non-ST Elevation Myocardial Infarction. American Journal of Therapeutics 17:1, e24-e40
CrossRef468
Bhatt, Deepak L., Lincoff, A. Michael, Gibson, C. Michael, Stone, Gregg W., McNulty, Steven, Montalescot, Gilles, Kleiman, Neal S., Goodman, Shaun G., White, Harvey D., Mahaffey, Kenneth W., Pollack, Charles V. Jr., Manoukian, Steven V., Widimsky, Petr, Chew, Derek P., Cura, Fernando, Manukov, Ivan, Tousek, Frantisek, Jafar, M. Zubair, Arneja, Jaspal, Skerjanec, Simona, Harrington, Robert A., . (2009) Intravenous Platelet Blockade with Cangrelor during PCI. New England Journal of Medicine 361:24, 2330-2341
Full Text469
(2009) Ticagrelor versus Clopidogrel in Acute Coronary Syndromes. New England Journal of Medicine 361:24, 2385-2388
Full Text470
Harrington, Robert A., Stone, Gregg W., McNulty, Steven, White, Harvey D., Lincoff, A. Michael, Gibson, C. Michael, Pollack, Charles V. Jr., Montalescot, Gilles, Mahaffey, Kenneth W., Kleiman, Neal S., Goodman, Shaun G., Amine, Maged, Angiolillo, Dominick J., Becker, Richard C., Chew, Derek P., French, William J., Leisch, Franz, Parikh, Keyur H., Skerjanec, Simona, Bhatt, Deepak L., . (2009) Platelet Inhibition with Cangrelor in Patients Undergoing PCI. New England Journal of Medicine 361:24, 2318-2329
Full Text471
K. A.A. Fox, K. Carruthers, Ph. G. Steg, A. Avezum, C. B. Granger, G. Montalescot, S. G. Goodman, J. M. Gore, A. L. Quill, K. A. Eagle, . (2009) Has the frequency of bleeding changed over time for patients presenting with an acute coronary syndrome? The Global Registry of Acute Coronary Events. European Heart Journal
CrossRef472
B. Chastek, A.A. Riedel, G. Wygant, O. Hauch. (2009) Evaluation of hospitalization and follow-up care costs among patients hospitalized with ACS treated with a stent and clopidogrel. Current Medical Research and Opinion 25:12, 2845-2852
CrossRef473
Behnam Banihashemi, Shaun G. Goodman, Raymond T. Yan, Robert C. Welsh, Shamir R. Mehta, Gilles Montalescot, Jan M. Kornder, Graham C. Wong, Gabor Gyenes, Ph. Gabriel Steg, Andrew T. Yan. (2009) Underutilization of clopidogrel and glycoprotein IIb/IIIa inhibitors in non–ST-elevation acute coronary syndrome patients: The Canadian Global Registry of Acute Coronary Events (GRACE) experience. American Heart Journal 158:6, 917-924
CrossRef474
Patricia A. Howard, James L. Vacek. (2009) Potential Interaction between Clopidogrel and Proton Pump Inhibitors. American Journal Cardiovascular Drugs 9:6, 353-359
CrossRef475
A. M. Cerbone, N. Macarone-Palmieri, G. Saldalamacchia, A. Coppola, G. Di Minno, A. A. Rivellese. (2009) Diabetes, vascular complications and antiplatelet therapy: open problems. Acta Diabetologica 46:4, 253-261
CrossRef476
Andrea Brassard. (2009) Identification of patients at risk of ischemic events for long-term secondary prevention. Journal of the American Academy of Nurse Practitioners 21:12, 677-689
CrossRef477
Steen Husted, J.J.J. van Giezen. (2009) Ticagrelor: The First Reversibly Binding Oral P2Y 12 Receptor Antagonist. Cardiovascular Therapeutics 27:4, 259-274
CrossRef478
Issam D. Moussa, Antonio Colombo. (2009) Antiplatelet therapy discontinuation following drug-eluting stent placement: Dangers, reasons, and management recommendations. Catheterization and Cardiovascular Interventions 74:7, 1047-1054
CrossRef479
Gregory G. Schwartz, Anders G. Olsson, Christie M. Ballantyne, Phillip J. Barter, Ingar M. Holme, David Kallend, Lawrence A. Leiter, Eran Leitersdorf, John J.V. McMurray, Prediman K. Shah, Jean-Claude Tardif, Bernard R. Chaitman, Regina Duttlinger-Maddux, John Mathieson. (2009) Rationale and design of the dal-OUTCOMES trial: Efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. American Heart Journal 158:6, 896-901.e3
CrossRef480
Kurt M Reinhart, C. Michael White, William L Baker. (2009) Prasugrel: A Critical Comparison with Clopidogrel. Pharmacotherapy 29:12, 1441-1451
CrossRef481
Paul P Dobesh. (2009) Clopidogrel versus Prasugrel: Times Are Changing, but Not for Everyone. Pharmacotherapy 29:12, 1393-1396
CrossRef482
David Fitchett, John Eikelboom, Stephen Fremes, David Mazer, Steve Singh, Bindu Bittira, Stephanie Brister, John J. Graham, Milan Gupta, Keyvan Karkouti, Agnes Lee, Michael Love, Rod McArthur, Mark Peterson, Subodh Verma, Terrence M. Yau. (2009) Dual antiplatelet therapy in patients requiring urgent coronary artery bypass grafting surgery: A position statement of the Canadian Cardiovascular Society. Canadian Journal of Cardiology 25:12, 683-689
CrossRef483
Richard C Becker, James Scheiman, Harold L Dauerman, Frederick Spencer, Sunil Rao, Marc Sabatine, David A Johnson, Frances Chan, Neena S Abraham, Eamonn M M Quigley. (2009) Management of Platelet-Directed Pharmacotherapy in Patients With Atherosclerotic Coronary Artery Disease Undergoing Elective Endoscopic Gastrointestinal Procedures. The American Journal of Gastroenterology 104:12, 2903-2917
CrossRef484
Armando Perez de Prado, Carlos Cuellas, Alejandro Diego, Antonio de Miguel, Beatriz Samaniego, Norberto Alonso-Orcajo, Raul Carbonell, Cristina Pascual, Felipe Fernandez-Vazquez, Ramon G. Calabozo. (2009) Influence of platelet reactivity and response to clopidogrel on myocardial damage following percutaneous coronary intervention in patients with non-st-segment elevation acute coronary syndrome. Thrombosis Research 124:6, 678-682
CrossRef485
Frederick G. Kushner, Mary Hand, Sidney C. Smith, Spencer B. King, Jeffrey L. Anderson, Elliott M. Antman, Steven R. Bailey, Eric R. Bates, James C. Blankenship, Donald E. Casey, Lee A. Green, Alice K. Jacobs, Judith S. Hochman, Harlan M. Krumholz, Douglass A. Morrison, Joseph P. Ornato, David L. Pearle, Eric D. Peterson, Michael A. Sloan, Patrick L. Whitlow, David O. Williams. (2009) 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update). Catheterization and Cardiovascular Interventions 74:7, E25-E68
CrossRef486
N. Maskrey, J. Underhill, A. Hutchinson, A. Shaughnessy, D. Slawson. (2009) Getting a better grip on research: A simple system that works. InnovAiT 2:12, 739-749
CrossRef487
C. W. Hamm. (2009) Current practice and limitations of dual antiplatelet therapy in acute coronary syndrome. European Heart Journal Supplements 11:Suppl G, G4-G8
CrossRef488
Frederick G. Kushner, Mary Hand, Sidney C. Smith, Spencer B. King, Jeffrey L. Anderson, Elliott M. Antman, Steven R. Bailey, Eric R. Bates, James C. Blankenship, Donald E. Casey, Lee A. Green, Judith S. Hochman, Alice K. Jacobs, Harlan M. Krumholz, Douglass A. Morrison, Joseph P. Ornato, David L. Pearle, Eric D. Peterson, Michael A. Sloan, Patrick L. Whitlow, David O. Williams. (2009) 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update). Journal of the American College of Cardiology 54:23, 2205-2241
CrossRef489
Edoardo Camenzind, William Wijns, Laura Mauri, Eric Boersma, Keyur Parikh, Volkhard Kurowski, Runlin Gao, Christoph Bode, John P. Greenwood, Anthony Gershlick, William O'Neill, Patrick W. Serruys, Brenda Jorissen, P. Gabriel Steg. (2009) Rationale and design of the Patient Related OuTcomes with Endeavor versus Cypher stenting Trial (PROTECT): Randomized controlled trial comparing the incidence of stent thrombosis and clinical events after sirolimus or zotarolimus drug-eluting stent implantation. American Heart Journal 158:6, 902-909.e5
CrossRef490
Marc Cohen. (2009) Oral Antiplatelet Therapy for Acute and Chronic Management of NSTE ACS: Residual Ischemic Risk and Opportunities for Improvement. Cardiovascular Drugs and Therapy 23:6, 489-499
CrossRef491
Ingo Wickenbrock, Christian Perings, Petra Maagh, Ivo Quack, Marc Bracht, Magnus W. Prull, Gunnar Plehn, Hans-Joachim Trappe, Axel Meissner. (2009) Contrast medium induced nephropathy in patients undergoing percutaneous coronary intervention for acute coronary syndrome: differences in STEMI and NSTEMI. Clinical Research in Cardiology 98:12, 765-772
CrossRef492
Satoshi Ono, Mitsuhiro Fujishiro, Kousuke Hirano, Keiko Niimi, Osamu Goto, Shinya Kodashima, Nobutake Yamamichi, Kazuhiko Koike. (2009) Retrospective analysis on the management of anticoagulants and antiplatelet agents for scheduled endoscopy. Journal of Gastroenterology 44:12, 1185-1189
CrossRef493
Sunil V. Rao, John Eikelboom, Ph. Gabriel Steg, A. Michael Lincoff, William S. Weintraub, Jean-Pierre Bassand, A. Koneti Rao, C. Michael Gibson, John L. Petersen, Roxana Mehran, Steven V. Manoukian, Richard Charnigo, Kerry L. Lee, Mauro Moscucci, Robert A. Harrington. (2009) Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: A proposal from the Academic Bleeding Consensus (ABC) Multidisciplinary Working Group. American Heart Journal 158:6, 881-886.e1
CrossRef494
Welkee Sim, Peter N Gonski. (2009) The management of patients with hip fractures who are taking Clopidogrel. Australasian Journal on Ageing 28:4, 194-197
CrossRef495
Richard C. Becker, James Scheiman, Harold L. Dauerman, Frederick Spencer, Sunil Rao, Marc Sabatine, David A. Johnson, Frances Chan, Neena S. Abraham, Eamonn M.M. Quigley. (2009) Management of Platelet-Directed Pharmacotherapy in Patients With Atherosclerotic Coronary Artery Disease Undergoing Elective Endoscopic Gastrointestinal Procedures. Journal of the American College of Cardiology 54:24, 2261-2276
CrossRef496
Rikke Sørensen, Morten L Hansen, Steen Z Abildstrom, Anders Hvelplund, Charlotte Andersson, Casper Jørgensen, Jan K Madsen, Peter R Hansen, Lars Køber, Christian Torp-Pedersen, Gunnar H Gislason. (2009) Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. The Lancet 374:9706, 1967-1974
CrossRef497
Victor Serebruany, Ganesh Cherala, Craig Williams, Serge Surigin, Christopher Booze, Wiktor Kuliczkowski, Dan Atar. (2009) Association of platelet responsiveness with clopidogrel metabolism: Role of compliance in the assessment of “resistance”. American Heart Journal 158:6, 925-932
CrossRef498
Magdalena Heras, Alfonso del Río. (2009) Update on Antiplatelet Therapy in Acute Coronary Syndromes. American Journal Cardiovascular Drugs 9:Supplement 1, 13-17
CrossRef499
S. Schulz, T. Schuster, J. Mehilli, R. A. Byrne, J. Ellert, S. Massberg, J. Goedel, O. Bruskina, K. Ulm, A. Schomig, A. Kastrati. (2009) Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. European Heart Journal 30:22, 2714-2721
CrossRef500
Madhan Shanmugasundaram, Joseph S. Alpert. (2009) Acute Coronary Syndrome in the Elderly. Clinical Cardiology 32:11, 608-613
CrossRef501
Peter Kriekard, S. Michael Gharacholou, Eric D. Peterson. (2009) Primary and Secondary Prevention of Cardiovascular Disease in Older Adults: A Status Report. Clinics in Geriatric Medicine 25:4, 745-755
CrossRef502
Kyle J Ellis, George A Stouffer, Howard L McLeod, Craig R Lee. (2009) Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations. Pharmacogenomics 10:11, 1799-1817
CrossRef503
Richard C. Becker. (2009) Pharmacogenetics and safety parameters for platelet P2Y12 receptor antagonists. Journal of Thrombosis and Thrombolysis 28:4, 513-514
CrossRef504
Ulrica Alström, Fredrik Granath, Jonas Oldgren, Elisabeth Ståhle, Hans Tydén, Agneta Siegbahn. (2009) Platelet inhibition assessed with VerifyNow, flow cytometry and PlateletMapping in patients undergoing heart surgery. Thrombosis Research 124:5, 572-577
CrossRef505
Daniel R. Guerra, James E. Tcheng. (2009) Prasugrel: Clinical development and therapeutic application. Advances in Therapy 26:11, 999-1011
CrossRef506
Jeffrey S. Berger, Deepak L. Bhatt, Christopher P. Cannon, Zhengming Chen, Lixin Jiang, James B. Jones, Shamir R. Mehta, Marc S. Sabatine, Steven R. Steinhubl, Eric J. Topol, Peter B. Berger. (2009) The Relative Efficacy and Safety of Clopidogrel in Women and Men. Journal of the American College of Cardiology 54:21, 1935-1945
CrossRef507
Stefano F. Rimoldi, Melana Yuzefpolskaya, Yves Allemann, Franz Messerli. (2009) Flash Pulmonary Edema. Progress in Cardiovascular Diseases 52:3, 249-259
CrossRef508
Jan-Peter van Kuijk, Willem-Jan Flu, Olaf Schouten, Sanne E. Hoeks, Lisanne Schenkeveld, Peter P.T. de Jaegere, Jeroen J. Bax, Ron T. van Domburg, Patrick W. Serruys, Don Poldermans. (2009) Timing of Noncardiac Surgery After Coronary Artery Stenting With Bare Metal or Drug-Eluting Stents. The American Journal of Cardiology 104:9, 1229-1234
CrossRef509
Lee A. Fleisher, Joshua A. Beckman, Kenneth A. Brown, Hugh Calkins, Elliot L. Chaikof, Kirsten E. Fleischmann, William K. Freeman, James B. Froehlich, Edward K. Kasper, Judy R. Kersten, Barbara Riegel, John F. Robb. (2009) 2009 ACCF/AHA Focused Update on Perioperative Beta Blockade Incorporated Into the ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery. Journal of the American College of Cardiology 54:22, e13-e118
CrossRef510
Øystein Meen, Frank Brosstad, Stine Bjørnsen, Turid Margrethe Pedersen, Gunnar Erikssen. (2009) Variability in aggregometry response before and after initiation of clopidogrel therapy. Scandinavian Journal of Clinical & Laboratory Investigation 69:6, 673-679
CrossRef511
Christian Weimar, Ralph Weber, Hans-Christoph Diener. (2009) Antithrombotic medication for stroke prevention. Expert Review of Cardiovascular Therapy 7:10, 1245-1254
CrossRef512
Pauline D. Watson, Parijat S. Joy, Chileshe Nkonde, Scott E. Hessen, Dean G. Karalis. (2009) Comparison of Bleeding Complications With Omega-3 Fatty Acids + Aspirin + Clopidogrel—Versus—Aspirin + Clopidogrel in Patients With Cardiovascular Disease. The American Journal of Cardiology 104:8, 1052-1054
CrossRef513
John P Vavalle, Sunil V Rao. (2009) Impact of bleeding complications on outcomes after percutaneous coronary interventions. Interventional Cardiology 1:1, 51-62
CrossRef514
Daniel I. Simon, Sahil A. Parikh. (2009) Hunting for the “Sweet Spot” in P2Y12 Receptor Blockade
Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.. Journal of the American College of Cardiology 54:15, 1447-1449
CrossRef515
José Luis Ferreiro, Masafumi Ueno, Dominick J Angiolillo. (2009) Cangrelor: a review on its mechanism of action and clinical development. Expert Review of Cardiovascular Therapy 7:10, 1195-1201
CrossRef516
Luke Tapp, Ben Wrigley, Gregory Y. H. Lip. (2009) Acute coronary syndromes: Oral factor Xa inhibitors in acute coronary syndromes. Nature Reviews Cardiology 6:10, 619-620
CrossRef517
Martin Norbert Vicenzi. (2009) Perioperative Problematik: Stentthrombose. Wiener Medizinische Wochenschrift 159:19-20, 501-506
CrossRef518
Staffan Bjessmo. (2009) Increased Rehospitalization Rate After Coronary Bypass Operation for Acute Coronary Syndrome: A Prospective Study in 200 Patients. The Annals of Thoracic Surgery 88:4, 1148-1152
CrossRef519
Gabriel Maluenda, Gilles Lemesle, Itsik Ben-Dor, Sara D. Collins, Asmir I. Syed, Yanlin Li, Rebecca Torguson, Kimberly Kaneshige, Zhenyi Xue, William O. Suddath, Lowell F. Satler, Kenneth M. Kent, Joseph Lindsay, Augusto D. Pichard, Ron Waksman. (2009) Value of Blood Transfusion in Patients With a Blood Hematocrit of 24% to 30% After Percutaneous Coronary Intervention. The American Journal of Cardiology 104:8, 1069-1073
CrossRef520
, Tobias Heer, Claus Juenger, Anselm K. Gitt, Timm Bauer, Frank Towae, Ralf Zahn, Jochen Senges, Uwe Zeymer. (2009) Efficacy and safety of optimized antithrombotic therapy with aspirin, clopidogrel and enoxaparin in patients with non-ST segment elevation acute coronary syndromes in clinical practice. Journal of Thrombosis and Thrombolysis 28:3, 325-332
CrossRef521
Elizabeth Shaw, Geoffrey H. Tofler, Thomas Buckley, Beata Bajorek, Michael Ward. (2009) Therapy for Triggered Acute Risk Prevention: A Study of Feasibility. Heart, Lung and Circulation 18:5, 347-352
CrossRef522
Marc Cohen. (2009) Antiplatelet therapy in percutaneous coronary intervention: A critical review of the 2007 AHA/ACC/SCAI guidelines and beyond. Catheterization and Cardiovascular Interventions 74:4, 579-597
CrossRef523
A. Kumar, C. P. Cannon. (2009) Acute Coronary Syndromes: Diagnosis and Management, Part I. Mayo Clinic Proceedings 84:10, 917-938
CrossRef524
Schömig, Albert, . (2009) Ticagrelor — Is There Need for a New Player in the Antiplatelet-Therapy Field?. New England Journal of Medicine 361:11, 1108-1111
Full Text525
Wallentin, Lars, Becker, Richard C., Budaj, Andrzej, Cannon, Christopher P., Emanuelsson, Håkan, Held, Claes, Horrow, Jay, Husted, Steen, James, Stefan, Katus, Hugo, Mahaffey, Kenneth W., Scirica, Benjamin M., Skene, Allan, Steg, Philippe Gabriel, Storey, Robert F., Harrington, Robert A., . (2009) Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. New England Journal of Medicine 361:11, 1045-1057
Full Text526
G. V. Moukarbel, J. E. Signorovitch, M. A. Pfeffer, J. J.V. McMurray, H. D. White, A. P. Maggioni, E. J. Velazquez, R. M. Califf, J. M. Scheiman, S. D. Solomon. (2009) Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial. European Heart Journal 30:18, 2226-2232
CrossRef527
David S. Small, Rebecca E. Wrishko, C. Steven Ernest, Lan Ni, Kenneth J. Winters, Nagy A. Farid, Ying G. Li, Daniel E. Salazar, Christopher D. Payne. (2009) Effect of Age on the Pharmacokinetics and Pharmacodynamics of Prasugrel during Multiple Dosing. Drugs & Aging 26:9, 781-790
CrossRef528
Lawrence A. Notaro, Mohammed H. Usman, James F. Burke, Aqeel Siddiqui, Keith R. Superdock, Michael D. Ezekowitz. (2009) Secondary Prevention in Concurrent Coronary Artery, Cerebrovascular, and Chronic Kidney Disease: Focus on Pharmacological Therapy. Cardiovascular Therapeutics 27:3, 199-215
CrossRef529
Daniel McKenzie, Usha Rao, Alex Hobson, Terry Levy, Suneel Talwar, Rosie Swallow. (2009) A novel strategy for managing clopidogrel-induced adverse skin reactions. EuroIntervention 5:4, 470-474
CrossRef530
Marc P. Bonaca, Philippe Gabriel Steg, Laurent J. Feldman, John F. Canales, James J. Ferguson, Lars Wallentin, Robert M. Califf, Robert A. Harrington, Robert P. Giugliano. (2009) Antithrombotics in Acute Coronary Syndromes. Journal of the American College of Cardiology 54:11, 969-984
CrossRef531
Peter P. Toth, Annemarie Armani. (2009) Thienopyridine therapy and risk for cardiovascular events in secondary prevention. Current Atherosclerosis Reports 11:5, 364-370
CrossRef532
Alan D Michelson. (2009) New P2Y12 antagonists. Current Opinion in Hematology 16:5, 371-377
CrossRef533
Emir Mujanovic, Midhat Nurkic, Jasmin Caluk, Ibrahim Terzic, Emir Kabil, Jacob Bergsland. (2009) The Effect of Combined Clopidogrel and Aspirin Therapy After Off-Pump Coronary Surgery. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery 4:5, 265-268
CrossRef534
Ping-Huei Tseng, Jyh-Ming Liou, Yi-Chia Lee, Lian-Yu Lin, Alyssa Yan-Zhen Liu, Dun-Cheng Chang, Han-Mo Chiu, Ming-Shiang Wu, Jaw-Town Lin, Hsiu-Po Wang. (2009) Emergency endoscopy for upper gastrointestinal bleeding in patients with coronary artery disease
. The American Journal of Emergency Medicine 27:7, 802-809
CrossRef535
Deborah J Cook, James Douketis, Donald Arnold, Mark A Crowther. (2009) Bleeding and venous thromboembolism in the critically ill with emphasis on patients with renal insufficiency. Current Opinion in Pulmonary Medicine 15:5, 455-462
CrossRef536
Alexander Bufe, Simon Frey, Stéphanie Briswalter. (2009) Durch Blutungen verursachte Kosten bei der Therapie des akuten Koronarsyndroms in Deutschland. Herz 34:6, 479-484
CrossRef537
Emanuele Cecchi, Rossella Marcucci, Rita Paniccia, Brunella Bandinelli, Serafina Valente, Cristina Giglioli, Chiara Lazzeri, Gian Franco Gensini, Rosanna Abbate, Lucia Mannini. (2009) Effect of Blood Hematocrit and Erythrocyte Deformability on Adenosine 5′-Diphosphate Platelet Reactivity in Patients With Acute Coronary Syndromes on Dual Antiplatelet Therapy. The American Journal of Cardiology 104:6, 764-768
CrossRef538
Francisco Marín, Rocío González-Conejero, Piera Capranzano, Theodore A. Bass, Vanessa Roldán, Dominick J. Angiolillo. (2009) Pharmacogenetics in Cardiovascular Antithrombotic Therapy. Journal of the American College of Cardiology 54:12, 1041-1057
CrossRef539
Daniel Wiederkehr, Karina Berenson, Roman Casciano, Lee Stern, Dinara Makenbaeva, Essy Mozaffari, Lois Lamerato, John Corbelli. (2009) Clinical impact of early clopidogrel discontinuation following acute myocardial infarction hospitalization or stent implantation: analysis in a single integrated health network. Current Medical Research and Opinion 25:9, 2317-2325
CrossRef540
Horst Neubauer, Jan Christopher Krüger, Sebastian Lask, Heinz G. Endres, Fenena Pepinghege, Andreas Engelhardt, Daniel Bulut, Andreas Mügge. (2009) Comparing the antiplatelet effect of clopidogrel hydrogensulfate and clopidogrel besylate: a crossover study. Clinical Research in Cardiology 98:9, 533-540
CrossRef541
Daniel Wiederkehr, Augustina Ogbonnaya, Roman Casciano, Dinara Makenbaeva, Essy Mozaffari, John Corbelli. (2009) Clinical impact of early clopidogrel discontinuation following acute myocardial infarction hospitalization or stent implantation: analysis in a nationally representative managed-care population. Current Medical Research and Opinion 25:9, 2327-2334
CrossRef542
Jersey Chen, Deepak L. Bhatt, Elizabeth Schneider Dunn, Chunxue Shi, J. Jaime Caro, Elizabeth M. Mahoney, Sylvie Gabriel, Joseph D. Jackson, Eric J. Topol, David J. Cohen. (2009) Cost-Effectiveness of Clopidogrel plus Aspirin versus Aspirin Alone for Secondary Prevention of Cardiovascular Events: Results from the CHARISMA Trial. Value in Health 12:6, 872-879
CrossRef543
C. Verstuyft, T. Simon, R. B. Kim. (2009) Personalized medicine and antiplatelet therapy: ready for prime time?. European Heart Journal 30:16, 1943-1963
CrossRef544
L. Wallentin. (2009) P2Y12 inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. European Heart Journal 30:16, 1964-1977
CrossRef545
Matteo Nicola Dario Di Minno, Domenico Prisco, Anna Lilia Ruocco, Pasquale Mastronardi, Salvatore Massa, Giovanni Di Minno. (2009) Perioperative handling of patients on antiplatelet therapy with need for surgery. Internal and Emergency Medicine 4:4, 279-288
CrossRef546
Vera Jankowski, Markus van der Giet, Harald Mischak, Michael Morgan, Walter Zidek, Joachim Jankowski. (2009) Dinucleoside polyphosphates: strong endogenous agonists of the purinergic system. British Journal of Pharmacology 157:7, 1142-1153
CrossRef547
Freek WA Verheugt. (2009) Who is ineligible for warfarin in atrial fibrillation?. The Lancet 374:9689, 510-511
CrossRef548
M. UROOJ ZAFAR, MICHAEL E. FARKOUH, VALENTIN FUSTER, JAMES H. CHESEBRO. (2009) Crushed Clopidogrel Administered via Nasogastric Tube Has Faster and Greater Absorption than Oral Whole Tablets. Journal of Interventional Cardiology 22:4, 385-389
CrossRef549
Adam B Adamopoulos, George N Sakizlis, Efthimia G Nasothimiou, Ioanna Anastasopoulou, Eugenia Anastasakou, Paraskevi Kotsi, Anastasia Karafoulidou, George S Stergiou. (2009) Do Proton Pump Inhibitors Attenuate the Effect of Aspirin on Platelet Aggregation? A Randomized Crossover Study. Journal of Cardiovascular Pharmacology 54:2, 163-168
CrossRef550
THUY ANH NGUYEN, MARIE LORDKIPANIDZÉ, JEAN G. DIODATI, DONALD A. PALISAITIS, ERICK SCHAMPAERT, JACQUES TURGEON, CHANTAL PHARAND. (2009) Week-Long High-Maintenance Dose Clopidogrel Regimen Achieves Better Platelet Aggregation Inhibition than a Standard Loading Dose before Percutaneous Coronary Intervention: Results of a Double-Blind, Randomized Clinical Trial. Journal of Interventional Cardiology 22:4, 368-377
CrossRef551
José Ma Lobos Bejarano, Miguel Angel Royo-Bordonada, Carlos Brotons, Luís Álvarez-Sala, Pedro Armario, Antonio Maiques, Dídac Mauricio, Susana Sans, Fernando Villar, Angel Lizcano, Antonio Gil-Núñez, Fernando de Álvaro, Pedro Conthe, Emilio Luengo, Alfonso del Río, Olga Cortés, Ana de Santiago, Miguel A. Vargas, Mercedes Martínez, Vicenta Lizarbe. (2009) Guía Europea de Prevención Cardiovascular en la Práctica Clínica. Adaptación española del CEIPC 2008. Atención Primaria 41:8, 463.e1-463.e24
CrossRef552
Thomas J. Kiernan, Bryan P. Yan, Michael R. Jaff. (2009) Antiplatelet therapy for the primary and secondary prevention of cerebrovascular events in patients with extracranial carotid artery disease. Journal of Vascular Surgery 50:2, 431-439
CrossRef553
Thomas Cuisset, Guillaume Cayla, Corinne Frere, Jacques Quilici, Raphael Poyet, Bénédicte Gaborit, Laurent Bali, Pierre Morange, Marie-Christine Alessi, Jean-Louis Bonnet. (2009) Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome.. EuroIntervention 5:3, 325-329
CrossRef554
F. Van de Werf. (2009) New antithrombotic agents: are they needed and what can they offer to patients with a non-ST-elevation acute coronary syndrome?. European Heart Journal 30:14, 1695-1702
CrossRef555
Rick A. Esposito. (2009) Invited Commentary. The Annals of Thoracic Surgery 88:1, 62-63
CrossRef556
Matthew B Sellers, Pierluigi Tricoci, Robert A Harrington. (2009) A new generation of antiplatelet agents. Current Opinion in Cardiology 24:4, 307-312
CrossRef557
Changqing Gao, Chonglei Ren, Dong Li, Libing Li. (2009) Clopidogrel and Aspirin Versus Clopidogrel Alone on Graft Patency After Coronary Artery Bypass Grafting. The Annals of Thoracic Surgery 88:1, 59-62
CrossRef558
Bharat K Kantharia, Arti N Shah. (2009) Combination of clopidogrel and aspirin for reduction of vascular events in patients with atrial fibrillation. Expert Review of Cardiovascular Therapy 7:7, 749-753
CrossRef559
David R. Holmes, Dean J. Kereiakes, Neal S. Kleiman, David J. Moliterno, Giuseppe Patti, Cindy L. Grines. (2009) Combining Antiplatelet and Anticoagulant Therapies. Journal of the American College of Cardiology 54:2, 95-109
CrossRef560
Zefeng Zhang, Paul Kolm, Frederique Mosse, Joseph Jackson, Liping Zhao, William S. Weintraub. (2009) Long-term cost-effectiveness of clopidogrel in STEMI patients. International Journal of Cardiology 135:3, 353-360
CrossRef561
Dominick J. Angiolillo, Piera Capranzano, Bhaloo Desai, Steven B. Shoemaker, Ronald Charlton, Martin M. Zenni, Luis A. Guzman, Theodore A. Bass. (2009) Impact of P2Y12 Inhibitory Effects Induced by Clopidogrel on Platelet Procoagulant Activity in Type 2 Diabetes Mellitus Patients. Thrombosis Research 124:3, 318-322
CrossRef562
Sarah A Spinler. (2009) Safety and Tolerability of Antiplatelet Therapies for the Secondary Prevention of Atherothrombotic Disease. Pharmacotherapy 29:7, 812-821
CrossRef563
P. O'Kane, L. Xie, Z. Liu, L. Queen, G. Jackson, Y. Ji, A. Ferro. (2009) Aspirin acetylates nitric oxide synthase type 3 in platelets thereby increasing its activity. Cardiovascular Research 83:1, 123-130
CrossRef564
Sanjit S. Jolly, David P. Faxon, Keith A.A. Fox, Rizwan Afzal, William E. Boden, Petr Widimsky, P. Gabriel Steg, Vicent Valentin, Andrez Budaj, Christopher B. Granger, Campbell D. Joyner, Susan Chrolavicius, Salim Yusuf, Shamir R. Mehta. (2009) Efficacy and Safety of Fondaparinux Versus Enoxaparin in Patients With Acute Coronary Syndromes Treated With Glycoprotein IIb/IIIa Inhibitors or Thienopyridines. Journal of the American College of Cardiology 54:5, 468-476
CrossRef565
Samer Hermiz, Peter Larsen, Duncan C. Galletly, Scott A. Harding. (2009) Peri-operative management of anti-platelet agents. ANZ Journal of Surgery 79:7-8, 521-525
CrossRef566
Harvey D White. (2009) Strategies to minimize bleeding complications of percutaneous coronary intervention. Current Opinion in Cardiology 24:4, 273-278
CrossRef567
Emile R. Mohler. (2009) Combination antiplatelet therapy in patients with peripheral arterial disease: Is the best therapy aspirin, clopidogrel, or both?. Catheterization and Cardiovascular Interventions 74:S1, S1-S6
CrossRef568
Dmitriy Kireyev, Edward C. Yun, Brian J. Page, William E. Boden. (2009) Medical therapy in acute coronary syndromes: Which medicines and at what doses?. Current Cardiology Reports 11:4, 267-275
CrossRef569
JL Mega, E Braunwald, S Mohanavelu, P Burton, R Poulter, F Misselwitz, V Hricak, ES Barnathan, P Bordes, A Witkowski, V Markov, L Oppenheimer, CM Gibson. (2009) Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. The Lancet 374:9683, 29-38
CrossRef570
(2009) Percutaneous Coronary Intervention versus Coronary-Artery Bypass Grafting. New England Journal of Medicine 360:25, 2672-2675
Full Text571
Ezra A. Amsterdam. (2009) Clopidogrel in the Management of Acute Coronary Syndromes. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 8:2, 49-54
CrossRef572
Dominick J. Angiolillo, Siva Suryadevara. (2009) Aspirin and clopidogrel: efficacy and resistance in diabetes mellitus. Best Practice & Research Clinical Endocrinology & Metabolism 23:3, 375-388
CrossRef573
C.W. Hamm, U. Zeymer. (2009) IQWiG gegen den Rest der Welt. Der Kardiologe 3:3, 207-210
CrossRef574
Theodore A. Bass. (2009) Acknowledging a failed strategy. Catheterization and Cardiovascular Interventions 73:7, 871-873
CrossRef575
Marco Roffi, Franz R. Eberli. (2009) Diabetes and acute coronary syndromes. Best Practice & Research Clinical Endocrinology & Metabolism 23:3, 305-316
CrossRef576
J.M. Lobos, M.Á. Royo-Bordonada, C. Brotons, L. Álvarez-Sala, P. Armario, A. Maiques, D. Mauricio, S. Sans, F. Villar, Á. Lizcano, A. Gil-Núñez, F. de Álvaro, P. Conthe, E. Luengo, A. del Río, O. Cortés, A. de Santiago, M.A. Varga, M. Martínez, V. Lizarbe. (2009) Guía Europea de Prevención Cardiovascular en la Práctica Clínica. Adaptación española del CEIPC 2008. Revista Clínica Española 209:6, 279-302
CrossRef577
Davide Capodanno, Dominick J. Angiolillo. (2009) Contemporary issues on clopidogrel therapy: a critical appraisal. Internal and Emergency Medicine 4:3, 195-198
CrossRef578
H.-C. Diener, C. Weimar. (2009) Update of secondary stroke prevention. Nephrology Dialysis Transplantation 24:6, 1718-1724
CrossRef579
Aino Lepäntalo, Kari S. Virtanen, Julio C. Reséndiz, Jussi Mikkelsson, Leena E. Viiri, Pekka J. Karhunen, Riitta Lassila. (2009) Antiplatelet effect of clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions – Limited inhibition of the P2Y12 receptor. Thrombosis Research 124:2, 193-198
CrossRef580
Giuseppe Patti, Germano Sciascio. (2009) Contemporary issues on clopidogrel therapy. Internal and Emergency Medicine 4:3, 201-211
CrossRef581
Byron Cryer. (2009) Management of Patients with High Gastrointestinal Risk on Antiplatelet Therapy. Gastroenterology Clinics of North America 38:2, 289-303
CrossRef582
Stephen D. Wiviott, Elliott M. Antman. 2009. Three Generations of Thienopyridines: Ticlopidine, Clopidogrel, and Prasugrel. , 471-484.
CrossRef583
W. Rottbauer, H.A. Katus. (2009) Der Patient mit Koronarstent. Der Chirurg 80:6, 515-518
CrossRef584
EDWARD F. EWEN, LIPING ZHAO, PAUL KOLM, CLAUDINE JURKOVITZ, DOGAN FIDAN, HARVEY D. WHITE, RICHARD GALLO, WILLIAM S. WEINTRAUB. (2009) Determining the In-Hospital Cost of Bleeding in Patients Undergoing Percutaneous Coronary Intervention. Journal of Interventional Cardiology 22:3, 266-273
CrossRef585
Michael J. Schneck. (2009) Understanding the PRoFESS study for secondary stroke prevention. Current Treatment Options in Cardiovascular Medicine 11:3, 221-231
CrossRef586
Michael J. Cowley, Louis Kuritzky. (2009) Developments in antiplatelet therapy for acute coronary syndromes and considerations for long-term management. Current Medical Research and Opinion 25:6, 1477-1490
CrossRef587
Sunil K Nadar, Deepak Goyal, Eduard Shantsila, Pritwish Banerjee, Gregory YH Lip. (2009) Fondaparinux: an overview. Expert Review of Cardiovascular Therapy 7:6, 577-585
CrossRef588
José M. Lobos, Miguel Ángel Royo-Bordonada, Carlos Brotons, Luis Álvarez-Sala, Pedro Armario, Antonio Maiques, Dídac Mauricio, Susana Sans, Fernando Villar, Ángel Lizcano. (2009) Guía Europea de Prevención Cardiovascular en la Práctica Clínica. Adaptación española del CEIPC 2008
CrossRef589
The ACTIVE Investigators. (2009) Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation. New England Journal of Medicine 360:20, 2066-2078
Full Text590
Steen Husted. (2009) Evidence-based prescribing and adherence to antiplatelet therapy—How much difference do they make to patients with atherothrombosis?. International Journal of Cardiology 134:2, 150-159
CrossRef591
Thomas Cuisset, Corinne Frere, Jacques Quilici, Bénédicte Gaborit, Laurent Bali, Raphaël Poyet, Dorothée Faille, Pierre Emmanuel Morange, Marie-Christine Alessi, Jean-Louis Bonnet. (2009) Aspirin noncompliance is the major cause of “aspirin resistance” in patients undergoing coronary stenting. American Heart Journal 157:5, 889-893
CrossRef592
Erik L Grove, Steen D Kristensen. (2009) Update on oral antiplatelet therapy: principles, problems and promises. Future Cardiology 5:3, 247-258
CrossRef593
John F. Reavey-Cantwell, W. Christopher Fox, Brett D. Reichwage, Gregory L. Fautheree, Gregory J. Velat, Jobyna H. Whiting, Yueh-Yun Chi, Brian L. Hoh. (2009) FACTORS ASSOCIATED WITH ASPIRIN RESISTANCE IN PATIENTS PREMEDICATED WITH ASPIRIN AND CLOPIDOGREL FOR ENDOVASCULAR NEUROSURGERY. Neurosurgery 64:5, 890-896
CrossRef594
Antwon Robinson, Kanak Das, Santosh KG Koshy, Pranab Das. (2009) Prasugrel: newest antiplatelet agent and its emerging role in management of acute coronary syndrome and percutaneous coronary intervention. Future Cardiology 5:3, 237-246
CrossRef595
Marzia Lotrionte, Davide Castagno, Pierfrancesco Agostoni, Antonio Abbate, Giuseppe Sangiorgi, Imad Sheiban, Giuseppe GL Biondi-Zoccai. (2009) Long-term effect of chronic oral anticoagulation: focus on coronary artery disease. Future Cardiology 5:3, 259-271
CrossRef596
Jan Smid, Ruediger Braun-Dullaeus, Meinrad Gawaz, Harald F Langer. (2009) Platelet interactions as therapeutic targets for prevention of atherothrombosis. Future Cardiology 5:3, 285-296
CrossRef597
Arnon Afek, Evgeny Kogan, Sofia Maysel-Auslender, Adi Mor, Ehud Regev, Ardon Rubinstein, Gad Keren, Jacob George. (2009) Clopidogrel attenuates atheroma formation and induces a stable plaque phenotype in apolipoprotein E knockout mice. Microvascular Research 77:3, 364-369
CrossRef598
José López-Sendón, Omar H. Dabbous, Esteban López de Sá, Martin Stiles, Joel M. Gore, David Brieger, Frans Van de Werf, Andrzej Budaj, Enrique P. Gurfinkel, Keith A.A. Fox. (2009) Evolución hospitalaria asociada al empleo de fibrinolíticos y tienopiridinas en pacientes con infarto agudo de miocardio y elevación del segmento ST. The Global Registry of Acute Coronary Events. Revista Española de Cardiología 62:5, 501-509
CrossRef599
Rakesh K Goyal, Dimple Srivastava, Klaus-Dieter Lessnau. (2009) Clopidogrel-Induced Hepatocellular Injury and Cholestatic Jaundice in an Elderly Patient: Case Report and Review of the Literature. Pharmacotherapy 29:5, 608-612
CrossRef600
Shiny Mathewkutty, Darren K McGuire. (2009) Platelet perturbations in diabetes: implications for cardiovascular disease risk and treatment. Expert Review of Cardiovascular Therapy 7:5, 541-549
CrossRef601
Ana Blagojevic, Joseph A.C. Delaney, Linda E. Lévesque, Nandini Dendukuri, Jean-Francois Boivin, James M. Brophy. (2009) Investigation of an interaction between statins and clopidogrel after percutaneous coronary intervention: a cohort study. Pharmacoepidemiology and Drug Safety 18:5, 362-369
CrossRef602
Thomas Cuisset, Corinne Frere, Jacques Quilici, Sabrina Uhry, Pierre-Emmanuel Morange, Jean-Philippe Mouret, Benedicte Gaborit, Laurent Bali, Pierre-Julien Moro, Marc Lambert, Jean Louis Bonnet. (2009) Effect of increased aspirin dose after Stenting in association with ClOpidogrel: The FIASCO randomized study. Thrombosis Research 124:1, 33-36
CrossRef603
Ramin Ebrahimi, Cornelius Dyke, Roxana Mehran, Steven V. Manoukian, Frederick Feit, David A. Cox, Bernard J. Gersh, E. Magnus Ohman, Harvey D. White, Jeffrey W. Moses, James H. Ware, A. Michael Lincoff, Gregg W. Stone. (2009) Outcomes Following Pre-Operative Clopidogrel Administration in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery. Journal of the American College of Cardiology 53:21, 1965-1972
CrossRef604
Julie H. Oestreich, John Holt, Steven P. Dunn, Susan S. Smyth, Charles L. Campbell, Richard Charnigo, Wendell S. Akers, Steven R. Steinhubl. (2009) Considerable variability in platelet activity among patients with coronary artery disease in response to an increased maintenance dose of clopidogrel. Coronary Artery Disease 20:3, 207-213
CrossRef605
S. Husted, R. A. Harrington, C. P. Cannon, R. F. Storey, P. Mitchell, H. Emanuelsson. (2009) Bleeding risk with AZD6140, a reversible P2Y 12 receptor antagonist, vs. clopidogrel in patients undergoing coronary artery bypass grafting in the DISPERSE2 trial. International Journal of Clinical Practice 63:4, 667-670
CrossRef606
Robert A. Byrne, Stefanie Schulz, Julinda Mehilli, Raisuke Iijima, Steffen Massberg, Franz-Josef Neumann, Jurriёn M. ten Berg, Albert Schömig, Adnan Kastrati. (2009) Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: The Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) study. American Heart Journal 157:4, 620-624.e2
CrossRef607
M. Haris U. Usman, Lawrence A. Notaro, Rangadham Nagarakanti, Eric Brahin, Scott Dessain, Edward Gracely, Michael D. Ezekowitz. (2009) Combination Antiplatelet Therapy for Secondary Stroke Prevention: Enhanced Efficacy or Double Trouble?. The American Journal of Cardiology 103:8, 1107-1112
CrossRef608
Srinivas Iyengar, LeRoy E. Rabbani. (2009) Beyond platelet inhibition: potential pleiotropic effects of ADP-receptor antagonists. Journal of Thrombosis and Thrombolysis 27:3, 300-306
CrossRef609
Yaling Han, Yi Li, Shouli Wang, Quanmin Jing, Zhulu Wang, Dongmei Wang, Qingfen Shu, Xiuying Tang. (2009) Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: A randomized, controlled study. American Heart Journal 157:4, 733-739
CrossRef610
Piera Capranzano, Jose Luis Ferreiro, Dominick J Angiolillo. (2009) Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention. Expert Review of Cardiovascular Therapy 7:4, 361-369
CrossRef611
Sung-Doo Kim, Wonku Kang, Hae Won Lee, Dae Jin Park, Ju Hee Ahn, Mi Jin Kim, Eun Young Kim, Sung Wuk Kim, Hee Sook Nam, Hye Jung Na, Young-Ran Yoon. (2009) Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: A randomized, open-label, crossover study in healthy Korean male subjects. Clinical Therapeutics 31:4, 793-803
CrossRef612
Diane K. Dressler. (2009) Death by Clot. AACN Advanced Critical Care 20:2, 166-176
CrossRef613
Lidia Argüello Viudez. (2009) Los antiagregantes plaquetarios (aspirina y otros, como por ejemplo clopidogrel): ¿incrementan el riesgo de complicaciones hemorrágicas tras la polipectomía endoscópica o tras la esfinterotomía endoscópica y por este motivo deben suspenderse de 7 a 10 días antes de realizar estas técnicas?. Gastroenterología y Hepatología 32:4, 318-320
CrossRef614
C.D. Liapis, Sir P.R.F. Bell, D. Mikhailidis, J. Sivenius, A. Nicolaides, J. Fernandes e Fernandes, G. Biasi, L. Norgren. (2009) ESVS Guidelines. Invasive Treatment for Carotid Stenosis: Indications, Techniques. European Journal of Vascular and Endovascular Surgery 37:4, 1-19
CrossRef615
Rajeev V. Rao, Shaun G. Goodman, Raymond T. Yan, Frederick A. Spencer, Keith A. Fox, J. Paul DeYoung, Barry Rose, François R. Grondin, Richard Gallo, Joel M. Gore, Andrew T. Yan. (2009) Temporal trends and patterns of early clopidogrel use across the spectrum of acute coronary syndromes. American Heart Journal 157:4, 642-650.e1
CrossRef616
Stefan James, Axel Åkerblom, Christopher P. Cannon, Håkan Emanuelsson, Steen Husted, Hugo Katus, Allan Skene, Philippe Gabriel Steg, Robert F. Storey, Robert Harrington, Richard Becker, Lars Wallentin. (2009) Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. American Heart Journal 157:4, 599-605
CrossRef617
Marcel Levi. (2009) Emergency reversal of antithrombotic treatment. Internal and Emergency Medicine 4:2, 137-145
CrossRef618
Howard S. Kirshner. (2009) Differentiating ischemic stroke subtypes: Risk factors and secondary prevention. Journal of the Neurological Sciences 279:1-2, 1-8
CrossRef619
C.W. Hamm. (2009) Kommentar zu den Leitlinien der European Society of Cardiology (ESC) zur Diagnose und Therapie des akuten Koronarsyndroms ohne ST-Strecken-Hebung (NSTE-ACS). Der Kardiologe 3:2, 81-100
CrossRef620
Joseph M. Sweeny, Diana A. Gorog, Valentin Fuster. (2009) Antiplatelet drug 'resistance'. Part 1: mechanisms and clinical measurements. Nature Reviews Cardiology 6:4, 273-282
CrossRef621
Nihar R. Desai, Jessica L. Mega, Songtao Jiang, Christopher P. Cannon, Marc S. Sabatine. (2009) Interaction Between Cigarette Smoking and Clinical Benefit of Clopidogrel. Journal of the American College of Cardiology 53:15, 1273-1278
CrossRef622
Lisa K. Jennings. (2009) Variability in Platelet Response to the Antiplatelet Agents Aspirin and Clopidogrel. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 8:1, 20-28
CrossRef623
Richard C Becker, David J Moliterno, Lisa K Jennings, Karen S Pieper, Jinglan Pei, Alan Niederman, Khaled M Ziada, Gail Berman, John Strony, Diane Joseph, Kenneth W Mahaffey, Frans Van de Werf, Enrico Veltri, Robert A Harrington. (2009) Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. The Lancet 373:9667, 919-928
CrossRef624
Carla Sueta Dupree. (2009) Primary prevention of heart failure: what is the evidence?. Current Opinion in Cardiology 24:2, 142-147
CrossRef625
Nicolas Danchin, François Diévart, Jean-François Thébaut, Olivier Grenier, Esvet Mihci, Marie-Annick Herrmann, Jean Ferrières. (2009) Predictors of long-term use of evidence-based therapies after non-ST-segment elevation acute coronary syndrome. The S-Témoin survey. International Journal of Cardiology 133:1, 32-40
CrossRef626
Gilead I. Lancaster, Janardhan Srinivasan, Hitender Jain. (2009) Aspirin resistance: An update. Current Atherosclerosis Reports 11:2, 105-110
CrossRef627
David P. Faxon, Jane E. Freedman. (2009) Facts and controversies of aspirin and clopidogrel therapy. American Heart Journal 157:3, 412-422
CrossRef628
Young-Hoon Jeong, Seung-Whan Lee, Bong-Ryong Choi, In-Suk Kim, Myung-Ki Seo, Choong Hwan Kwak, Jin-Yong Hwang, Seong-Wook Park. (2009) Randomized Comparison of Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With High Post-Treatment Platelet Reactivity. Journal of the American College of Cardiology 53:13, 1101-1109
CrossRef629
David Slattery, Charles V. Pollack. (2009) Does timing matter? Upstream or downstream administration of antiplatelet therapy. The American Journal of Emergency Medicine 27:3, 348-361
CrossRef630
Paul J.P.C. van den Bergh, Peter C. Kievit, Marc A. Brouwer, Wim R.M. Aengevaeren, Gerrit Veen, Freek W.A. Verheugt. (2009) Prolonged anticoagulation therapy adjunctive to aspirin after successful fibrinolysis: From early reduction in reocclusion to improved long-term clinical outcome. American Heart Journal 157:3, 532-540
CrossRef631
Susana Ayyanathan, David Hersh, Neil L. Coplan, Kirk Garratt. (2009) The Problem of Stent Thrombosis Associated With Drug-Eluting Stents and the Optimal Duration of Dual Antiplatelet Therapy. Preventive Cardiology 12:2, 59-64
CrossRef632
Christoph Varenhorst, Stefan James, David Erlinge, Oscar Ö. Braun, John T. Brandt, Kenneth J. Winters, Joseph A. Jakubowski, Sylvia Olofsson, Lars Wallentin, Agneta Siegbahn. (2009) Assessment of P2Y12 inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin. American Heart Journal 157:3, 562.e1-562.e9
CrossRef633
Probal Roy, Laurent Bonello, Rebecca Torguson, Teruo Okabe, Tina L. Pinto Slottow, Daniel H. Steinberg, Kimberly Kaneshige, Zhenyi Xue, Lowell F. Satler, Kenneth M. Kent, William O. Suddath, Augusto D. Pichard, Joseph Lindsay, Ron Waksman. (2009) Temporal Relation Between Clopidogrel Cessation and Stent Thrombosis After Drug-Eluting Stent Implantation. The American Journal of Cardiology 103:6, 801-805
CrossRef634
A. ROSTOM, P. MOAYYEDI, R. HUNT, . (2009) Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks. Alimentary Pharmacology & Therapeutics 29:5, 481-496
CrossRef635
L. Björklund, M.-A. Wallander, S. Johansson, E. Lesén. (2009) Aspirin in cardiology - benefits and risks. International Journal of Clinical Practice 63:3, 468-477
CrossRef636
Jae-Hun Jung, Pil-Ki Min, Sang-Hak Lee, Chong Won Sung, Seonghoon Choi, Jung Rae Cho, Namho Lee, Ki Hyun Byun. (2009) Clopidogrel pretreatment before primary percutaneous coronary stenting in patients with acute ST-segment elevation myocardial infarction: comparison of high loading dose (600 mg) versus low loading dose (300 mg). Coronary Artery Disease 20:2, 150-154
CrossRef637
Jean-Philippe Collet, Gilles Montalescot. (2009) Optimizing long-term dual aspirin/clopidogrel therapy in acute coronary syndromes: When does the risk outweigh the benefit?. International Journal of Cardiology 133:1, 8-17
CrossRef638
K. Pels, P. L. Schwimmbeck, P. Rosenthal, C. Loddenkemper, C. Dang-Heine, U. Rauch, H. Martens, H.-P. Schultheiss, R. Dechend, C. Deiner. (2009) Long-term clopidogrel administration following severe coronary injury reduces proliferation and inflammation via inhibition of nuclear factor-kappaB and activator protein 1 activation in pigs. European Journal of Clinical Investigation 39:3, 174-182
CrossRef639
(2009) Guías de Práctica Clínica de la Sociedad Europea de Cardiología (ESC). Manejo del infarto agudo de miocardio en pacientes con elevación persistente del segmento ST. Revista Española de Cardiología 62:3, 293.e1-293.e47
CrossRef640
Campbell D. Joyner, Ron J.G. Peters, Rizwan Afzal, Susan Chrolavicius, Shamir R. Mehta, Keith A.A. Fox, Christopher B. Granger, Maria Grazia Franzosi, Marcus Flather, Andrzej Budaj. (2009) Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: Outcomes and treatment effect across different levels of risk. American Heart Journal 157:3, 502-508
CrossRef641
Deepak Thomas, Robert P. Giugliano. (2009) Antiplatelet Therapy in Percutaneous Coronary Intervention. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 8:1, 12-19
CrossRef642
Renato D. Lopes, Karen P. Alexander, Steven V. Manoukian, Michel E. Bertrand, Frederick Feit, Harvey D. White, Charles V. Pollack, James Hoekstra, Bernard J. Gersh, Gregg W. Stone, E. Magnus Ohman. (2009) Advanced Age, Antithrombotic Strategy, and Bleeding in Non–ST-Segment Elevation Acute Coronary Syndromes. Journal of the American College of Cardiology 53:12, 1021-1030
CrossRef643
Julie H Oestreich, Steven R Steinhubl. (2009) Cangrelor in percutaneous coronary intervention. Expert Review of Clinical Pharmacology 2:2, 137-145
CrossRef644
T. C. Collyer, D. J. Gray, R. Sandhu, J. Berridge, G. Lyons. (2009) Assessment of platelet inhibition secondary to clopidogrel and aspirin therapy in preoperative acute surgical patients measured by Thrombelastography(R) Platelet MappingTM. British Journal of Anaesthesia 102:4, 492-498
CrossRef645
Dimitris Tousoulis, Gerasimos Siasos, Christodoulos Stefanadis. (2009) Aspirin resistance: What the cardiologist needs to know?. International Journal of Cardiology 132:2, 153-156
CrossRef646
Helge Möllmann, Holger Nef, Christian W. Hamm. (2009) Das akute Koronarsyndrom ohne ST-Hebung. Herz 34:1, 30-38
CrossRef647
Lily A. Maltz, Kimberlee Gauvreau, Jean A. Connor, Kathy J. Jenkins. (2009) Clopidogrel in a Pediatric Population: Prescribing Practice and Outcomes from a Single Center. Pediatric Cardiology 30:2, 99-105
CrossRef648
Herbert D. Aronow, Steven R. Steinhubl, Danielle M. Brennan, Peter B. Berger, Eric J. Topol. (2009) Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. American Heart Journal 157:2, 369-374
CrossRef649
Rodrigo M. Lago, Richard W. Nesto. (2009) Type 2 diabetes and coronary heart disease: Focus on myocardial infarction. Current Diabetes Reports 9:1, 73-78
CrossRef650
Antonio de Miguel Castro, Carlos Cuellas Ramón, Alejandro Diego Nieto, Beatriz Samaniego Lampón, David Alonso Rodríguez, Felipe Fernández Vázquez, Norberto Alonso Orcajo, Raúl Carbonell de Blas, Cristina Pascual Vicente, Armando Pérez de Prado. (2009) La reactividad plaquetaria post-tratamiento predice los eventos adversos a largo plazo mejor que la respuesta al clopidogrel en pacientes con síndrome coronario agudo sin elevación del ST. Revista Española de Cardiología 62:2, 126-135
CrossRef651
Steen Husted. (2009) Unmet needs in oral antiplatelet therapy with ADP receptor blocking agents. Fundamental & Clinical Pharmacology 23:1, 1-9
CrossRef652
Sabine Loeffert, Oliver Ommen, Nicole Ernstmann, Holger Pfaff. (2009) Changes in secondary pharmacological prevention of acute coronary syndromes and stroke after hospital discharge: a 6-month follow-up study of German primary care patients. Journal of Public Health 17:1, 3-7
CrossRef653
Willem-Jan Flu, Sanne E. Hoeks, Jan-Peter Kuijk, Jeroen J. Bax, Don Poldermans. (2009) Treatment recommendations to prevent myocardial ischemia and infarction in patients undergoing vascular surgery. Current Treatment Options in Cardiovascular Medicine 11:1, 33-44
CrossRef654
Cedric W. Lefebvre, James W. Hoekstra, Marc Bonaca, Robert Giugliano. (2009) Glycoprotein IIb-IIIa Inhibitors in the Emergency Department for Patients with Non-ST-Elevation Acute Coronary Syndromes: Principles and Practices. Journal of Emergency Medicine 36:2, 162-170
CrossRef655
Victor L. Serebruany, Christian Eisert, Dan Atar, James J. Ferguson. (2009) Antiplatelet ‘resistance’ and ‘non-responders’: what do these terms really mean?. Fundamental & Clinical Pharmacology 23:1, 11-18
CrossRef656
T WALLACE, J BERGER, A WANG, E VELAZQUEZ, D BROWN. (2009) Impact of Left Ventricular Dysfunction on Hospital Mortality Among Patients Undergoing Elective Percutaneous Coronary Intervention. The American Journal of Cardiology 103:3, 355-360
CrossRef657
Akiko Shiotani, Takashi Sakakibara, Yoshiyuki Yamanaka, Hiroshi Imamura, Ken-Ichi Tarumi, Noriaki Manabe, Tomoari Kamada, Hiroaki Kusunoki, Jiro Hata, Ken Haruma. (2009) Upper gastrointestinal ulcer in Japanese patients taking low-dose aspirin. Journal of Gastroenterology 44:2, 126-131
CrossRef658
T CUISSET, C FRERE, J QUILICI, P MORANGE, L CAMOIN, L BALI, M LAMBERT, I JUHANVAGUE, M ALESSI, J BONNET. (2009) Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response. Thrombosis Research 123:4, 597-603
CrossRef659
M. Cohen. (2009) Expanding the Recognition and Assessment of Bleeding Events Associated With Antiplatelet Therapy in Primary Care. Mayo Clinic Proceedings 84:2, 149-160
CrossRef660
Mega, Jessica L., Close, Sandra L., Wiviott, Stephen D., Shen, Lei, Hockett, Richard D., Brandt, John T., Walker, Joseph R., Antman, Elliott M., Macias, William, Braunwald, Eugene, Sabatine, Marc S., . (2009) Cytochrome P-450 Polymorphisms and Response to Clopidogrel. New England Journal of Medicine 360:4, 354-362
Full Text661
Simon, Tabassome, Verstuyft, Céline, Mary-Krause, Murielle, Quteineh, Lina, Drouet, Elodie, Méneveau, Nicolas, Steg, P. Gabriel, Ferrières, Jean, Danchin, Nicolas, Becquemont, Laurent, . (2009) Genetic Determinants of Response to Clopidogrel and Cardiovascular Events. New England Journal of Medicine 360:4, 363-375
Full Text662
Khaled Mansour, Ali T. Taher, Khaled M. Musallam, Samir Alam. (2009) Aspirin Resistance. Advances in Hematology 2009, 1-10
CrossRef663
Victoria P. Tan, Bryan P. Yan, Thomas J. Kiernan, Andrew E. Ajani. (2009) Risk and management of upper gastrointestinal bleeding associated with prolonged dual-antiplatelet therapy after percutaneous coronary intervention. Cardiovascular Revascularization Medicine 10:1, 36-44
CrossRef664
Emilia Solinas, Giuliana Gobbi, George Dangas, Roxana Mehran, Martin Fahy, Luigi Ippolito, Maria Giulia Bolognesi, Ruben Ruenes, Piera Angelica Merlini, Diego Ardissino, Marco Vitale. (2009) Comparison of the effects of pretreatment with tirofiban, clopidogrel or both on the inhibition of platelet aggregation and activation in patients with acute coronary syndromes. Journal of Thrombosis and Thrombolysis 27:1, 36-43
CrossRef665
Keun-Ho Park, Myung Ho Jeong, Min Goo Lee, Jum Suk Ko, Shin Eun Lee, Won Yu Kang, Soo Hyun Kim, Doo Sun Sim, Nam Sik Yoon, Hyun Ju Youn, Young Joon Hong, Hyung Wook Park, Ju Han Kim, Youngkeun Ahn, Jeong Gwan Cho, Jong Chun Park, Jung Chaee Kang. (2009) Efficacy of Triple Anti-Platelet Therapy Including Cilostazol in Acute Myocardial Infarction Patients Undergoing Drug-Eluting Stent Implantation. Korean Circulation Journal 39:5, 190
CrossRef666
Rohit Arora, Fasi Rai. (2009) Atherothrombosis and the Management of the Vulnerable Vascular Patient. American Journal of Therapeutics 16:1, 24-34
CrossRef667
Hiroshi Yasuda, Masaya Yamada, Susumu Sawada, Yutaka Endo, Kazuaki Inoue, Fuyuki Asano, Youichi Takeyama, Makoto Yoshiba. (2009) Upper Gastrointestinal Bleeding in Patients Receiving Dual Antiplatelet Therapy after Coronary Stenting. Internal Medicine 48:19, 1725-1730
CrossRef668
Peter M. Vila, M. Urooj Zafar, Juan J. Badimon. (2009) Platelet reactivity and nonresponse to dual antiplatelet therapy: A review. Platelets 20:8, 531-538
CrossRef669
Silke Abele, Bernd M. Spriewald, Martina Ramsperger-Gleixner, Martina Wollin, Nicola E. Hiemann, Bernhard Nieswandt, Michael Weyand, Stephan M. Ensminger. (2009) Attenuation of Transplant Arteriosclerosis With Clopidogrel Is Associated With a Reduction of Infiltrating Dendritic Cells and Macrophages in Murine Aortic Allografts. Transplantation 87:2, 207-216
CrossRef670
Helge Möllmann, Holger M. Nef, Christian W. Hamm, Albrecht Elsässer. (2009) How to manage patients with need for antiplatelet therapy in the setting of (un-)planned surgery. Clinical Research in Cardiology 98:1, 8-15
CrossRef671
Shinya GOTO. (2009) [Clinical] RISK/BENEFIT of Antithrombotic Intervention. Japanese Journal of Thrombosis and Hemostasis 20:5, 551-554
CrossRef672
Dae Hyun Kim, Constantine Daskalakis, Scott C. Silvestry, Mital P. Sheth, Andrew N. Lee, Suzanne Adams, Sam Hohmann, Sofia Medvedev, David J. Whellan. (2009) Aspirin and clopidogrel use in the early postoperative period following on-pump and off-pump coronary artery bypass grafting. Journal of Thoracic and Cardiovascular Surgery 138:6, 1377
CrossRef673
Yuichiro YANO. (2009) Determinants of thrombin generation, fibrinolytic activity and endothelial dysfunction in dual antiplatelet therapy: involvement of factors other than platelet aggregability in Virchow's triad. Japanese Journal of Thrombosis and Hemostasis 20:1, 48-55
CrossRef674
Sary F. Aranki, Simon C. Body. (2009) Antiplatelet agents used for early intervention in acute coronary syndrome: Myocardial salvage versus bleeding complications. Journal of Thoracic and Cardiovascular Surgery 138:4, 807
CrossRef675
Yasuhiro NISHIKAWA. (2009) 4. Clinical Perspectives of New Antiplatelet Drugs. Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 40:6, 273-278
CrossRef676
Matteo Mariani, Giuseppe Mariani, Stefano De Servi. (2009) Efficacy and safety of prasugrel compared with clopidogrel in patients with acute coronary syndromes: results of TRITON-TIMI 38 trials. Expert Review of Cardiovascular Therapy 7:1, 17-23
CrossRef677
Soon Jun Hong, Ji-Young Park, Kyoung-Ah Kim, Chul Min Ahn, Jae Suk Park, Yong Hyun Kim, Wan Joo Shim, Seong Mi Park, Do-Sun Lim. (2009) Comparison of Low vs Moderate Dose of Atorvastatin in Clopidogrel Resistance After Coronary Stenting in Korean Patients With Acute Coronary Syndrome. Circulation Journal 73:6, 1111-1118
CrossRef678
Toshikazu Jinnai, Hisanori Horiuchi, Takeru Makiyama, Junichi Tazaki, Tomohisa Tada, Masaharu Akao, Koh Ono, Kozo Hoshino, Yumiko Naruse, Kanako Takahashi, Haruyo Watanabe, Toru Kita, Takeshi Kimura. (2009) Impact of CYP2C19 Polymorphisms on the Antiplatelet Effect of Clopidogrel in an Actual Clinical Setting in Japan. Circulation Journal 73:8, 1498-1503
CrossRef679
Stefano Savonitto, Nuccia Morici, Alice Sacco, Silvio Klugmann. (2009) Target populations and relevant therapeutic end points to further improve outcomes in NSTEACS patients. Future Cardiology 5:1, 27-41
CrossRef680
Jean-Philippe Collet, Jean-Sébastien Hulot, Anna Pena, Eric Villard, Jean-Baptiste Esteve, Johanne Silvain, Laurent Payot, Delphine Brugier, Guillaume Cayla, Farzin Beygui, Gilbert Bensimon, Christian Funck-Brentano, Gilles Montalescot. (2009) Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. The Lancet 373:9660, 309-317
CrossRef681
Kozo Hoshino, Hisanori Horiuchi, Tomohisa Tada, Junichi Tazaki, Eiichiro Nishi, Mitsunori Kawato, Tomoyuki Ikeda, Hiromi Yamamoto, Masaharu Akao, Yutaka Furukawa, Satoshi Shizuta, Masanao Toma, Toshihiro Tamura, Naritatsu Saito, Takahiro Doi, Neiko Ozasa, Toshikazu Jinnai, Kanako Takahashi, Haruyo Watanabe, Yuka Yoshikawa, Naoko Nishimoto, Chiho Ouchi, Takeshi Morimoto, Toru Kita, Takeshi Kimura. (2009) Clopidogrel Resistance in Japanese Patients Scheduled forPercutaneous Coronary Intervention. Circulation Journal 73:2, 336-342
CrossRef682
Thomas E. Kottke, Dennis A. Faith, Courtney O. Jordan, Nicolaas P. Pronk, Randal J. Thomas, Simon Capewell. (2009) The Comparative Effectiveness of Heart Disease Prevention and Treatment Strategies. American Journal of Preventive Medicine 36:1, 82-88.e5
CrossRef683
Kassem Barada, Heitham Abdul-Baki, Ihab I. El Hajj, Jana G. Hashash, Peter H. Green. (2009) Gastrointestinal Bleeding in the Setting of Anticoagulation and Antiplatelet Therapy. Journal of Clinical Gastroenterology 43:1, 5-12
CrossRef684
C. Steven Ernest, David S. Small, Shashank Rohatagi, Daniel E. Salazar, Lars Wallentin, Kenneth J. Winters, Rebecca E. Wrishko. (2008) Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease. Journal of Pharmacokinetics and Pharmacodynamics 35:6, 593-618
CrossRef685
Corinna Velik-Salchner, Stephan Maier, Petra Innerhofer, Werner Streif, Anton Klingler, Christian Kolbitsch, Dietmar Fries. (2008) Point-of-Care Whole Blood Impedance Aggregometry Versus Classical Light Transmission Aggregometry for Detecting Aspirin and Clopidogrel: The Results of a Pilot Study. Anesthesia & Analgesia 107:6, 1798-1806
CrossRef686
Eric D. Peterson, Bimal R. Shah, Lori Parsons, Charles V. Pollack, William J. French, John G. Canto, C. Michael Gibson, William J. Rogers. (2008) Trends in quality of care for patients with acute myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006. American Heart Journal 156:6, 1045-1055
CrossRef687
N. S. Vermeer, B. V. Bajorek. (2008) Utilization of evidence-based therapy for the secondary prevention of acute coronary syndromes in Australian practice. Journal of Clinical Pharmacy and Therapeutics 33:6, 591-601
CrossRef688
P GLADDING, M WEBSTER, I ZENG, H FARRELL, J STEWART, P RUYGROK, J ORMISTON, S ELJACK, G ARMSTRONG, P KAY. (2008) The Antiplatelet Effect of Higher Loading and Maintenance Dose Regimens of ClopidogrelThe PRINC (Plavix Response in Coronary Intervention) Trial. JACC: Cardiovascular Interventions 1:6, 612-619
CrossRef689
Nina C Raju, John W Eikelboom, Jack Hirsh. (2008) Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future. Nature Clinical Practice Cardiovascular Medicine 5:12, 766-780
CrossRef690
Rikke Sørensen, G. H. Gislason, E. L. Fosbøl, S. Rasmussen, L. Køber, J. K. Madsen, C. Torp-Pedersen, S. Z. Abildstrom. (2008) Initiation and persistence with clopidogrel treatment after acute myocardial infarction - a nationwide study. British Journal of Clinical Pharmacology 66:6, 875-884
CrossRef691
Shamir R. Mehta, Jean-Pierre Bassand, Susan Chrolavicius, Rafael Diaz, Keith A.A. Fox, Christopher B. Granger, Sanjit Jolly, Hans-Jurgen Rupprecht, Petr Widimsky, Salim Yusuf. (2008) Design and rationale of CURRENT-OASIS 7: A randomized, 2 × 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non–ST-elevation acute coronary syndromes managed with an early invasive strategy. American Heart Journal 156:6, 1080-1088.e1
CrossRef692
David Erlinge, Christoph Varenhorst, Oscar Ö. Braun, Stefan James, Kenneth J. Winters, Joseph A. Jakubowski, John T. Brandt, Atsuhiro Sugidachi, Agneta Siegbahn, Lars Wallentin. (2008) Patients With Poor Responsiveness to Thienopyridine Treatment or With Diabetes Have Lower Levels of Circulating Active Metabolite, but Their Platelets Respond Normally to Active Metabolite Added Ex Vivo. Journal of the American College of Cardiology 52:24, 1968-1977
CrossRef693
H.-C. Diener, C. Weimar, M. Böhm, C. Bode, M. Grond, J. Röther. (2008) Patienten mit kardialen und zerebralen Durchblutungsstörungen. Der Kardiologe 2:6, 491-499
CrossRef694
Alexandra J. Lansky, Yoshihiro Tsuchiya, Micheal Brener, Roxana Mehran, Ecaterina Cristea, Cody Pietras, Cindy L. Grines, David A. Cox, Eulogio Garcia, James E. Tcheng, Giulio Guagliumi, Thomas Stuckey, Mark Turco, John D. Carroll, Barry D. Rutherford, Martin B. Leon, Jeffrey Moses, Gregg W. Stone. (2008) Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: Results from the CADILLAC trial. Catheterization and Cardiovascular Interventions 72:7, 917-924
CrossRef695
ROBERT L. WILENSKY. (2008) Vulnerable Plaque: Scope of the Problem. Journal of Interventional Cardiology 21:6, 443-451
CrossRef696
S. Husted. (2008) Benefits and risks with antiplatelet therapy: how great a problem is bleeding?. European Heart Journal Supplements 10:Suppl I, I19-I24
CrossRef697
Brian G. Kral, Lookman Lawal, Lewis C. Becker. (2008) Genetic determinants of responsiveness to antiplatelet therapy. Current Cardiovascular Risk Reports 2:6, 476-484
CrossRef698
Deepak L. Bhatt, James Scheiman, Neena S. Abraham, Elliott M. Antman, Francis K.L. Chan, Curt D. Furberg, David A. Johnson, Kenneth W. Mahaffey, Eamonn M. Quigley, Robert A. Harrington, Eric R. Bates, Charles R. Bridges, Mark J. Eisenberg, Victor A. Ferrari, Mark A. Hlatky, Sanjay Kaul, Jonathan R. Lindner, David J. Moliterno, Debabrata Mukherjee, Richard S. Schofield, Robert S. Rosenson, James H. Stein, Howard H. Weitz, Deborah J. Wesley. (2008) ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. The American Journal of Gastroenterology 103:11, 2890-2907
CrossRef699
B WYSOTA, D GORARD. (2008) Colonic carcinoma unmasked by dual antiplatelet therapy. European Journal of Internal Medicine 19:7, 558-558
CrossRef700
R. Charles Callison, Harold P. Adams. (2008) Use of Antiplatelet Agents for Prevention of Ischemic Stroke. Neurologic Clinics 26:4, 1047-1077
CrossRef701
Jeffrey S. Berger, Carla B. Frye, Qing Harshaw, Fred H. Edwards, Steven R. Steinhubl, Richard C. Becker. (2008) Impact of Clopidogrel in Patients With Acute Coronary Syndromes Requiring Coronary Artery Bypass Surgery. Journal of the American College of Cardiology 52:21, 1693-1701
CrossRef702
R. Ostini, D. Hegney, J. M. Mackson, M. Williamson, S. E. Tett. (2008) Why is the use of clopidogrel increasing rapidly in Australia? An exploration of geographical location, age, sex and cardiac stenting rates as possible influences on clopidogrel use. Pharmacoepidemiology and Drug Safety 17:11, 1077-1090
CrossRef703
Dominick J Angiolillo, Siva Suryadevara, Piera Capranzano, Theodore A Bass. (2008) Prasugrel: a novel platelet ADP P2Y 12 receptor antagonist. A review on its mechanism of action and clinical development. Expert Opinion on Pharmacotherapy 9:16, 2893-2900
CrossRef704
S GOTO, D BHATT, J ROTHER, M ALBERTS, M HILL, Y IKEDA, S UCHIYAMA, R DAGOSTINO, E OHMAN, C LIAU. (2008) Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. American Heart Journal 156:5, 855-863.e2
CrossRef705
Dominic Kelly, Iain B. Squire, Sohail Q. Khan, Paulene Quinn, Joachim Struck, Nils G. Morgenthaler, Joan E. Davies, Leong L. NG. (2008) C-Terminal Provasopressin (Copeptin) is Associated With Left Ventricular Dysfunction, Remodeling, and Clinical Heart Failure in Survivors of Myocardial Infarction. Journal of Cardiac Failure 14:9, 739-745
CrossRef706
R. A. Byrne, A. Kastrati. (2008) Duration of antiplatelet therapy following intracoronary stenting: are changes needed?. European Heart Journal Supplements 10:Suppl I, I25-I29
CrossRef707
M. Zimarino, R. De Caterina. (2008) Long-term treatment strategies for atherothrombotic disease: do platelets define the course?. European Heart Journal Supplements 10:Suppl I, I8-I13
CrossRef708
, F. Van de Werf, J. Bax, A. Betriu, C. Blomstrom-Lundqvist, F. Crea, V. Falk, G. Filippatos, K. Fox, K. Huber, A. Kastrati, A. Rosengren, P. G. Steg, M. Tubaro, F. Verheugt, F. Weidinger, M. Weis, , A. Vahanian, J. Camm, R. De Caterina, V. Dean, K. Dickstein, G. Filippatos, C. Funck-Brentano, I. Hellemans, S. D. Kristensen, K. McGregor, U. Sechtem, S. Silber, M. Tendera, P. Widimsky, J. L. Zamorano, , S. Silber, F. V. Aguirre, N. Al-Attar, E. Alegria, F. Andreotti, W. Benzer, O. Breithardt, N. Danchin, C. D. Mario, D. Dudek, D. Gulba, S. Halvorsen, P. Kaufmann, R. Kornowski, G. Y. H. Lip, F. Rutten. (2008) Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology:. European Heart Journal 29:23, 2909-2945
CrossRef709
Deepak L. Bhatt, James Scheiman, Neena S. Abraham, Elliott M. Antman, Francis K.L. Chan, Curt D. Furberg, David A. Johnson, Kenneth W. Mahaffey, Eamonn M. Quigley, Robert A. Harrington, Eric R. Bates, Charles R. Bridges, Mark J. Eisenberg, Victor A. Ferrari, Mark A. Hlatky, Sanjay Kaul, Jonathan R. Lindner, David J. Moliterno, Debabrata Mukherjee, Richard S. Schofield, Robert S. Rosenson, James H. Stein, Howard H. Weitz, Deborah J. Wesley. (2008) ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. Journal of the American College of Cardiology 52:18, 1502-1517
CrossRef710
P.D. Schellinger, P. Ringleb, W. Hacke. (2008) Leitlinien zum Management von Patienten mit akutem Hirninfarkt oder TIA der Europäischen Schlaganfallorganisation 2008. Der Nervenarzt 79:10, 1180-1202
CrossRef711
Gregory A. Nuttall, Michael J. Brown, John W. Stombaugh, Peter B. Michon, Matthew F. Hathaway, Kevin C. Lindeen, Andrew C. Hanson, Darrell R. Schroeder, William C. Oliver, David R. Holmes, Charanjit S. Rihal. (2008) Time and Cardiac Risk of Surgery after Bare-metal Stent Percutaneous Coronary Intervention. Anesthesiology 109:4, 588-595
CrossRef712
Joseph P Vande Griend, Joseph J Saseen. (2008) Combination Antiplatelet Agents for Secondary Prevention of Ischemic Stroke. Pharmacotherapy 28:10, 1233-1242
CrossRef713
Gregg W. Stone, Stephen G. Ellis, Antonio Colombo, Eberhard Grube, Keith D. Dawkins, Mark Friedman, Donald S. Baim. (2008) Effect of Prolonged Thienopyridine Use After Drug-Eluting Stent Implantation (from the TAXUS Landmark Trials Data). The American Journal of Cardiology 102:8, 1017-1022
CrossRef714
Deepak L. Bhatt. (2008) Prasugrel versus clopidogrel in acute coronary syndrome patients undergoing percutaneous coronary intervention. Current Atherosclerosis Reports 10:5, 367-368
CrossRef715
A BERGER. (2008) Letter to the Editor. American Heart Journal 156:4, e43-e43
CrossRef716
Stephen H. McKellar, Jess L. Thompson, Raul F. Garcia-Rinaldi, Ryan J. MacDonald, Thoralf M. Sundt, Hartzell V. Schaff. (2008) Short- and long-term efficacy of aspirin and clopidogrel for thromboprophylaxis for mechanical heart valves: An in vivo study in swine. The Journal of Thoracic and Cardiovascular Surgery 136:4, 908-914
CrossRef717
P. C. WONG, C. A. WATSON, E. J. CRAIN. (2008) Arterial antithrombotic and bleeding time effects of apixaban, a direct factor Xa inhibitor, in combination with antiplatelet therapy in rabbits. Journal of Thrombosis and Haemostasis 6:10, 1736-1741
CrossRef718
Selcuk Dagdelen. (2008) Diabetic Cardiovascular Disease Lost in Translation Between Endocrinology and Cardiology. The American Journal of Cardiology 102:8, 1115-1116
CrossRef719
W. Kuliczkowski, A. Witkowski, L. Polonski, C. Watala, K. Filipiak, A. Budaj, J. Golanski, D. Sitkiewicz, J. Pregowski, J. Gorski, M. Zembala, G. Opolski, K. Huber, H. Arnesen, S. D. Kristensen, R. De Caterina. (2008) Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. European Heart Journal 30:4, 426-435
CrossRef720
S. S. Jolly, J. Pogue, K. Haladyn, R. J.G. Peters, K. A.A. Fox, A. Avezum, B. J. Gersh, H. J. Rupprecht, S. Yusuf, S. R. Mehta. (2008) Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. European Heart Journal 30:8, 900-907
CrossRef721
F. Schiele, N. Meneveau, M. F. Seronde, V. Descotes-Genon, J. Oettinger, F. Ecarnot, J.-P. Bassand, . (2008) Changes in management of elderly patients with myocardial infarction. European Heart Journal 30:8, 987-994
CrossRef722
J. M. Ruiz-Nodar, F. Marin, J. Sanchez-Paya, J. A. Hurtado, J. Valencia-Martin, S. Manzano-Fernandez, V. Roldan, V. Perez-Andreu, F. Sogorb, M. Valdes, G. Y.H. Lip. (2008) Efficacy and safety of drug-eluting stent use in patients with atrial fibrillation. European Heart Journal 30:8, 932-939
CrossRef723
Sacco, Ralph L., Diener, Hans-Christoph, Yusuf, Salim, Cotton, Daniel, Ôunpuu, Stephanie, Lawton, William A., Palesch, Yuko, Martin, Reneé H., Albers, Gregory W., Bath, Philip, Bornstein, Natan, Chan, Bernard P.L., Chen, Sien-Tsong, Cunha, Luis, Dahlöf, Björn, De Keyser, Jacques, Donnan, Geoffrey A., Estol, Conrado, Gorelick, Philip, Gu, Vivian, Hermansson, Karin, Hilbrich, Lutz, Kaste, Markku, Lu, Chuanzhen, Machnig, Thomas, Pais, Prem, Roberts, Robin, Skvortsova, Veronika, Teal, Philip, Toni, Danilo, VanderMaelen, Cam, Voigt, Thor, Weber, Michael, Yoon, Byung-Woo, . (2008) Aspirin and Extended-Release Dipyridamole versus Clopidogrel for Recurrent Stroke. New England Journal of Medicine 359:12, 1238-1251
Full Text724
Mehdi H. Shishehbor, Sachin S. Goel, Samir R. Kapadia, Deepak L. Bhatt, Peter Kelly, Russell E. Raymond, John M. Galla, Sorin J. Brener, Patrick L. Whitlow, Stephen G. Ellis. (2008) Long-Term Impact of Drug-Eluting Stents Versus Bare-Metal Stents on All-Cause Mortality. Journal of the American College of Cardiology 52:13, 1041-1048
CrossRef725
J.E. Pflumm, T. Pomykaj, M.P. Heintzen. (2008) Sekundärprävention nach Myokardinfarkt. Der Internist 49:9, 1052-1060
CrossRef726
Pieter Stolk, Svetlana V. Belitser, Hubert G.M. Leufkens, Eibert R. Heerdink. (2008) Variable Access to Clopidogrel in a Harmonized EU Market. Value in Health 11:5, 989-995
CrossRef727
B. Stratmann. (2008) Thrombozytenfunktion bei Diabetes mellitus. Der Diabetologe 4:6, 429-434
CrossRef728
Fook Hong Ng, Pierre Chan, Chi Pong Kwanching, Ching Kong Loo, Ting Kin Cheung, Siu Yin Wong, Carolyn Kng, Ka Man Ng, Sik To Lai, Benjamin Chun Yu Wong. (2008) Management and outcome of peptic ulcers or erosions in patients receiving a combination of aspirin plus clopidogrel. Journal of Gastroenterology 43:9, 679-686
CrossRef729
Joshua F. Zeidner, William H. Frishman, Robert G. Lerner. (2008) Investigational Antiplatelet Drugs for the Treatment and Prevention of Coronary Artery Disease. Cardiology in Review 16:5, 250-259
CrossRef730
P PANAGOS. (2008) The approach to optimizing stroke care
CrossRef731
Anna C Seto, Kenneth Kenyon, Ann K Wittkowsky. (2008) Discrepancies in Identification of Major Bleeding Events in Patients Taking Warfarin. Pharmacotherapy 28:9, 1098-1103
CrossRef732
H. Darius. (2008) Antithrombotische Therapie. Der Diabetologe 4:6, 435-439
CrossRef733
A. Budaj, J. W. Eikelboom, S. R. Mehta, R. Afzal, S. Chrolavicius, J.-P. Bassand, K. A.A. Fox, L. Wallentin, R. J.G. Peters, C. B. Granger, C. D. Joyner, S. Yusuf, . (2008) Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. European Heart Journal 30:6, 655-661
CrossRef734
Akiko Shiotani, Tomoari Kamada, Ken Haruma. (2008) Low-dose aspirin-induced gastrointestinal diseases: past, present, and future. Journal of Gastroenterology 43:8, 581-588
CrossRef735
Bi-Lian Chen, Wei Zhang, Qing Li, Ya-Lin Li, Yi-Jing He, Lan Fan, Lian-Sheng Wang, Zhao-Qian Liu, Hong-Hao Zhou. (2008) INHIBITION OF ADP-INDUCED PLATELET AGGREGATION BY CLOPIDOGREL IS RELATED TO CYP2C19 GENETIC POLYMORPHISMS. Clinical and Experimental Pharmacology and Physiology 35:8, 904-908
CrossRef736
Lisa T. Newsome, Robert S. Weller, J C. Gerancher, Michael A. Kutcher, Roger L. Royster. (2008) Coronary Artery Stents: II. Perioperative Considerations and Management. Anesthesia & Analgesia 107:2, 570-590
CrossRef737
Harvey D White, Derek P Chew. (2008) Acute myocardial infarction. The Lancet 372:9638, 570-584
CrossRef738
J. McCaslin, H. Ashour, V. Bhattacharya, M. Cleanthis, A. Daly, G. Stansby. (2008) Increased Platelet-monocyte Aggregation in Male Claudicants with the PlA1/A2 Polymorphism of Gp IIb/IIIa. European Journal of Vascular and Endovascular Surgery 36:2, 132-137
CrossRef739
R. Bhindi, O. Ormerod, J. Newton, A.P. Banning, L. Testa. (2008) Interaction between statins and clopidogrel: is there anything clinically relevant?. QJM 101:12, 915-925
CrossRef740
Yelda Tayyareci. (2008) Acute Arthritis Associated With Loading Dose of Clopidogrel. JCR: Journal of Clinical Rheumatology 14:4, 254-255
CrossRef741
Lisa T. Newsome, Michael A. Kutcher, Roger L. Royster. (2008) Coronary Artery Stents: Part I. Evolution of Percutaneous Coronary Intervention. Anesthesia & Analgesia 107:2, 552-569
CrossRef742
Matthew A Cavender, Sunil V Rao, E Magnus Ohman. (2008) Major bleeding: management and risk reduction in acute coronary syndromes. Expert Opinion on Pharmacotherapy 9:11, 1869-1883
CrossRef743
HEATHER R. BREAM-ROUWENHORST, RYAN A. HOBBS, PHILLIP A HORWITZ. (2008) Thrombocytopenia in Patients Treated with Heparin, Combination Antiplatelet Therapy, and Intra-Aortic Balloon Pump Counterpulsation. Journal of Interventional Cardiology 21:4, 350-356
CrossRef744
Mohammed Abuzahra, Manu Pillai, Angel Caldera, W. Bryan Hartley, Rafael Gonzalez, Jaromir Bobek, Hisham Dokainish, Nasser Lakkis. (2008) Comparison of Higher Clopidogrel Loading and Maintenance Dose to Standard Dose on Platelet Function and Outcomes After Percutaneous Coronary Intervention Using Drug-Eluting Stents. The American Journal of Cardiology 102:4, 401-403
CrossRef745
Antoine Sarkis, Rabih Azar, Zena Kadri, Ronald Moussa, Noêl Aoun. (2008) Cerebellar hematoma complicating 600 mg loading dose of Clopidogrel in combination with Tirofiban. International Journal of Cardiology 127:3, e170-e171
CrossRef746
Norbert Zimmermann, Emmeran Gams, Thomas Hohlfeld. (2008) Aspirin in coronary artery bypass surgery: new aspects of and alternatives for an old antithrombotic agent. European Journal of Cardio-Thoracic Surgery 34:1, 93-108
CrossRef747
C POLLACKJR, J HOLLANDER. (2008) Antiplatelet Therapy in Acute Coronary Syndromes: The Emergency Physician's Perspective. Journal of Emergency Medicine 35:1, 5-13
CrossRef748
Gabriella Lindvall, Ulrik Sartipy, Torbjörn Ivert, Jan van der Linden. (2008) Aprotinin is Not Associated With Postoperative Renal Impairment After Primary Coronary Surgery. The Annals of Thoracic Surgery 86:1, 13-19
CrossRef749
Jenny Berg, Dogan Fidan, Peter Lindgren. (2008) Cost-effectiveness of clopidogrel treatment in percutaneous coronary intervention: a European model based on a meta-analysis of the PCI-CURE, CREDO and PCI-CLARITY trials*. Current Medical Research and Opinion 24:7, 2089-2101
CrossRef750
Luc Mertens, Bénédicte Eyskens, Derize Boshoff, Marc Gewillig. (2008) Safety and Efficacy of Clopidogrel in Children with Heart Disease. The Journal of Pediatrics 153:1, 61-64
CrossRef751
Joel Dunning, Michel Versteegh, Alessandro Fabbri, Alain Pavie, Philippe Kolh, Ulf Lockowandt, Samer A.M. Nashef. (2008) Guideline on antiplatelet and anticoagulation management in cardiac surgery. European Journal of Cardio-Thoracic Surgery 34:1, 73-92
CrossRef752
Sameer Bansilal, Michael E. Farkouh, Valentin Fuster. (2008) Optimal treatment of the diabetic patient with multivessel disease. Current Cardiology Reports 10:4, 272-284
CrossRef753
Colin M. Barker, Matthew J. Price. (2008) Antiplatelet therapy in acute coronary syndromes. Current Cardiology Reports 10:4, 327-333
CrossRef754
Simon Maltais, Louis P. Perrault, Quoc-Bao Do. (2008) Effect of clopidogrel on bleeding and transfusions after off-pump coronary artery bypass graft surgery: impact of discontinuation prior to surgery. European Journal of Cardio-Thoracic Surgery 34:1, 127-131
CrossRef755
Magdalena Sobieraj-Teague, Alexander S Gallus, John W Eikelboom. (2008) The risk of iatrogenic bleeding in acute coronary syndromes and long-term mortality. Current Opinion in Cardiology 23:4, 327-334
CrossRef756
Eric D. Peterson, David Z. Bynum, Matthew T. Roe. (2008) Lessons learned from the CRUSADE National Quality Improvement Initiative. Current Cardiology Reports 10:4, 285-290
CrossRef757
T. Geisler, C. Zurn, M. Paterok, K. Gohring-Frischholz, B. Bigalke, K. Stellos, P. Seizer, B. F. Kraemer, J. Dippon, A. E. May, C. Herdeg, M. Gawaz. (2008) Statins do not adversely affect post-interventional residual platelet aggregation and outcomes in patients undergoing coronary stenting treated by dual antiplatelet therapy. European Heart Journal 29:13, 1635-1643
CrossRef758
Y. Yano, T. Ohmori, S. Hoshide, S. Madoiwa, K. Yamamoto, T. Katsuki, T. Mitsuhashi, J. Mimuro, K. Shimada, K. Kario, Y. Sakata. (2008) Determinants of thrombin generation, fibrinolytic activity, and endothelial dysfunction in patients on dual antiplatelet therapy: involvement of factors other than platelet aggregability in Virchow's triad. European Heart Journal 29:14, 1729-1738
CrossRef759
P. W. Kamphuisen. (2008) Thrombogenicity in patients with percutaneous coronary artery intervention and dual antiplatelet treatment. European Heart Journal 29:14, 1699-1700
CrossRef760
(2008) Bare-Metal versus Drug-Eluting Coronary Stents. New England Journal of Medicine 358:23, 2516-2518
Full Text761
Richard A. Bernstein. (2008) Antiplatelet agents for secondary prevention of stroke. Current Treatment Options in Cardiovascular Medicine 10:3, 223-228
CrossRef762
MOO HYUN KIM, SOON JUN HONG, KWANG SOO CHA, HUN SIK PARK, SHUNG CHULL CHAE, SEUNG HO HUR, HYEON CHEOL GWON, JANG HO BAE, DO-SUN LIM. (2008) Effect of Paclitaxel-Eluting Versus Sirolimus-Eluting Stents on Coronary Restenosis in Korean Diabetic Patients. Journal of Interventional Cardiology 21:3, 225-231
CrossRef763
Victor L. Serebruany, Alex I. Malinin, James J. Ferguson, Javad Vahabi, Dan Atar, Charles H. Hennekens. (2008) Bleeding risks of combination vs. single antiplatelet therapy: a meta-analysis of 18 randomized trials comprising 129 314 patients. Fundamental & Clinical Pharmacology 22:3, 315-321
CrossRef764
Sharmalar Rajendran, Yuliy Y. Chirkov. (2008) Platelet Hyperaggregability: Impaired Responsiveness to Nitric Oxide (“Platelet NO Resistance”) as a Therapeutic Target. Cardiovascular Drugs and Therapy 22:3, 193-203
CrossRef765
Ranil de Silva, Kim Fox. (2008) Early intervention in acute coronary syndrome: is bivalirudin monotherapy an effective antithrombotic strategy?. Nature Clinical Practice Cardiovascular Medicine 5:6, 308-309
CrossRef766
Thomas Walter, Sebastian Szabo MD, Silke Kazmaier, Stefanie Swoboda, Tim Suselbeck, Martina Brueckmann MD, M Borggrefe, Martin E Beyer, Hans Martin Hoffmeister. (2008) Effect of Clopidogrel on Adhesion Molecules, Hemostasis, and Fibrinolysis in Coronary Heart Disease. Journal of Cardiovascular Pharmacology 51:6, 616-620
CrossRef767
Somjot S. Brar, John Kim, Simerjeet K. Brar, Ray Zadegan, Michael Ree, In-Lu A. Liu, Prakash Mansukhani, Vicken Aharonian, Ric Hyett, Albert Yuh-Jer Shen. (2008) Long-Term Outcomes by Clopidogrel Duration and Stent Type in a Diabetic Population With De Novo Coronary Artery Lesions. Journal of the American College of Cardiology 51:23, 2220-2227
CrossRef768
P. P. Cacoub, D. L. Bhatt, P.G. Steg, E. J. Topol, M. A. Creager, . (2008) Patients with peripheral arterial disease in the CHARISMA trial. European Heart Journal 30:2, 192-201
CrossRef769
M. T. NIEMAN, F. BURKE, M. WARNOCK, Y. ZHOU, J. SWEIGART, A. CHEN, D. RICKETTS, B. R. LUCCHESI, Z. CHEN, E. DI CERA, J. HILFINGER, J. S. KIM, H. I. MOSBERG, A. H. SCHMAIER. (2008) Thrombostatin FM compounds: direct thrombin inhibitors – mechanism of action in vitro and in vivo. Journal of Thrombosis and Haemostasis 6:5, 837-845
CrossRef770
Victor L. Serebruany. (2008) Excess Rates of Nonfatal Myocardial Infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel (Preventing Clinical Events or Chasing Enzymatic Ghosts?†)†Conflict of interest: Dr. Serebruany is listed as an inventor and received compensation for U.S. Patent Application P-17232, “Method for Treating Vascular Diseases With Prasugrel,” assigned to Eli Lilly and Company, Indianapolis, Indiana. He has received funding for research studies with clopidogrel and prasugrel.. The American Journal of Cardiology 101:9, 1364-1366
CrossRef771
Niteesh K. Choudhry, Raisa Levin, Jerry Avorn. (2008) The economic consequences of non–evidence-based clopidogrel use. American Heart Journal 155:5, 904-909
CrossRef772
Armen Yuri Gasparyan, Timothy Watson, Gregory Y.H. Lip. (2008) The Role of Aspirin in Cardiovascular Prevention. Journal of the American College of Cardiology 51:19, 1829-1843
CrossRef773
C POLLACKJR, E BRAUNWALD. (2008) 2007 Update to the ACC/AHA Guidelines for the Management of Patients With Unstable Angina and Non–ST-Segment Elevation Myocardial Infarction: Implications for Emergency Department Practice. Annals of Emergency Medicine 51:5, 591-606
CrossRef774
Tomás Segura, Sergio Calleja, Joaquin Jordan. (2008) Recommendations and treatment strategies for the management of acute ischemic stroke. Expert Opinion on Pharmacotherapy 9:7, 1071-1085
CrossRef775
S. Abdulla, A. Vasireddy, H. Sims. (2008) The use of integrated care pathways in the management of acute coronary syndrome. Resuscitation 77, S39
CrossRef776
Stephen D. Wiviott, Eugene Braunwald, Sabina A. Murphy, Elliott M. Antman. (2008) A Perspective on the Efficacy and Safety of Intensive Antiplatelet Therapy in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38. The American Journal of Cardiology 101:9, 1367-1370
CrossRef777
Marc S. Sabatine, Hussam N. Hamdalla, Shamir R. Mehta, Keith A.A. Fox, Eric J. Topol, Steven R. Steinhubl, Christopher P. Cannon. (2008) Efficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor use. American Heart Journal 155:5, 910-917
CrossRef778
Ikue Shimizu, Nathaniel J. Jellinek, Raymond G. Dufresne, Tianyu Li, Karthik Devarajan, Clifford Perlis. (2008) Multiple antithrombotic agents increase the risk of postoperative hemorrhage in dermatologic surgery. Journal of the American Academy of Dermatology 58:5, 810-816
CrossRef779
John A. Cairns, John Eikelboom. (2008) Clopidogrel Resistance. Journal of the American College of Cardiology 51:20, 1935-1937
CrossRef780
Deepak L Bhatt. (2008) Is prasugrel superior to clopidogrel for patients with acute coronary syndromes undergoing PCI?. Nature Clinical Practice Cardiovascular Medicine 5:5, 252-253
CrossRef781
Deepak Thomas, Robert P Giugliano. (2008) Antiplatelet Therapy in Early Management of Non-ST-segment Elevation Acute Coronary Syndrome: The 2002 and 2007 Guidelines From North America and Europe. Journal of Cardiovascular Pharmacology 51:5, 425-433
CrossRef782
K JACKSON, B GERSH, N STOCKBRIDGE, T FLEMING, R TEMPLE, R CALIFF, S CONNOLLY, L WALLENTIN, C GRANGER. (2008) Antithrombotic drug development for atrial fibrillation: Proceedings, Washington, DC, July 25-27, 2005. American Heart Journal 155:5, 829-840
CrossRef783
C POLLACKJR, A GOLDBERG. (2008) The Medical Management of Acute Coronary Syndromes and Potential Roles for New Antithrombotic Agents. Journal of Emergency Medicine 34:4, 417-428
CrossRef784
Lisa M. Ho, Kimberly L. Hodulik, Paul V. Suhocki, Lynne M. Hurwitz, Erik K. Paulson. (2008) New Classes of Anticoagulation and Antiplatelet Agents. Journal of Computer Assisted Tomography 32:3, 475-479
CrossRef785
Yvonne Smyth, Kieran Daly. 2008. Pharmacological Management of Atrial Fibrillation. , 37-47.
CrossRef786
(2008) Platelet Activation and Atherothrombosis. New England Journal of Medicine 358:15, 1638-1639
Full Text787
Patricia J.M. Best, Steven R. Steinhubl, Peter B. Berger, Arijit Dasgupta, Danielle M. Brennan, Lynda A. Szczech, Robert M. Califf, Eric J. Topol. (2008) The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: Results from the Clopidogrel for the Reduction of Events During Observation (CREDO) Trial. American Heart Journal 155:4, 687-693
CrossRef788
Price Blair, Jane E. Freedman. (2008) Aspirin resistance in atherosclerosis. Current Atherosclerosis Reports 10:2, 149-157
CrossRef789
RON WAKSMAN, RAJBABU PAKALA, PROBAL ROY, RICHARD BAFFOUR, DAVID HELLINGA, RUFUS SEABRON, ROSANNA CHAN, MICKEY SCHEINOWITZ, FRANK KOLODGIE, RENU VIRMANI. (2008) Effect of Clopidogrel on Neointimal Formation and Inflammation in Balloon-Denuded and Radiated Hypercholesterolemic Rabbit Iliac Arteries. Journal of Interventional Cardiology 21:2, 122-128
CrossRef790
Stephen D Wiviott, Eugene Braunwald, Carolyn H McCabe, Ivan Horvath, Matyas Keltai, Jean-Paul R Herrman, Frans Van de Werf, William E Downey, Benjamin M Scirica, Sabina A Murphy, Elliott M Antman. (2008) Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. The Lancet 371:9621, 1353-1363
CrossRef791
Christopher J. Lockhart, Paul K. Hamilton, Katherine A. McVeigh, Gary E. McVeigh. (2008) A cardiologist view of vascular disease in diabetes. Diabetes, Obesity and Metabolism 10:4, 279-292
CrossRef792
Colin R. Simpson, Karen Alford, David Williams. (2008) Evidence for prolonged prescribing of aspirin–clopidogrel combination in Scottish primary care. Pharmacoepidemiology and Drug Safety 17:4, 397-400
CrossRef793
Patrick Gladding, Mark Webster, John Ormiston, Sarah Olsen, Harvey White. (2008) Antiplatelet drug nonresponsiveness. American Heart Journal 155:4, 591-599
CrossRef794
Andrew E Ajani, Jeffrey Lefkovits. (2008) Approaching an age of reason with antiplatelet therapy. The Lancet 371:9621, 1315-1316
CrossRef795
Fook-Hong Ng, Siu-Yin Wong, Kwok-Fai Lam, Chee-My Chang, Yuk-Kong Lau, Wai-Ming Chu, Benjamin C.Y. Wong. (2008) Gastrointestinal Bleeding in Patients Receiving a Combination of Aspirin, Clopidogrel, and Enoxaparin in Acute Coronary Syndrome. The American Journal of Gastroenterology 103:4, 865-871
CrossRef796
Neal S. Kleiman. (2008) Will Measuring Vasodilator-Stimulated Phosphoprotein Phosphorylation Help Us Optimize the Loading Dose of Clopidogrel?
CrossRef797
Ashna D.K. Bowry, M. Alan Brookhart, Niteesh K. Choudhry. (2008) Meta-Analysis of the Efficacy and Safety of Clopidogrel Plus Aspirin as Compared to Antiplatelet Monotherapy for the Prevention of Vascular Events. The American Journal of Cardiology 101:7, 960-966
CrossRef798
D. J. Angiolillo, P. Capranzano, S. Goto, M. Aslam, B. Desai, R. K. Charlton, Y. Suzuki, L. C. Box, S. B. Shoemaker, M. M. Zenni, L. A. Guzman, T. A. Bass. (2008) A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. European Heart Journal 29:18, 2202-2211
CrossRef799
A. Simon Pickard, Richard C Becker, Glen T Schumock, Carla B Frye. (2008) Clopidogrel-Associated Bleeding and Related Complications in Patients Undergoing Coronary Artery Bypass Grafting. Pharmacotherapy 28:3, 376-392
CrossRef800
Stefano Savonitto, Stefano De Servi, Anna Sonia Petronio, Leonardo Bolognese, Claudio Cavallini, Cesare Greco, Ciro Indolfi, Luigi Oltrona Visconti, Federico Piscione, Giuseppe Ambrosio, Marcello Galvani, Antonio Marzocchi, Ignazio Santilli, Giuseppe Steffenino, Attilio Maseri. (2008) Early aggressive vs. initially conservative treatment in elderly patients with non-ST-elevation acute coronary syndrome: The Italian Elderly ACS study. Journal of Cardiovascular Medicine 9:3, 217-226
CrossRef801
Helfried Metzler, Sibylle Kozek-Langenecker, Kurt Huber. (2008) Antiplatelet therapy and coronary stents in perioperative medicine – the two sides of the coin. Best Practice & Research Clinical Anaesthesiology 22:1, 81-94
CrossRef802
Eugene Braunwald, Dominick Angiolillo, Eric Bates, Peter B. Berger, Deepak Bhatt, Christopher P. Cannon, Mark I. Furman, Paul Gurbel, Alan D. Michelson, Eric Peterson, Stephen Wiviott. (2008) Antiplatelet Strategies: Evaluating Their Current Role in the Setting of Acute Coronary Syndromes. Clinical Cardiology 31:S1, I2-I9
CrossRef803
Pierluigi Tricoci, L Kristin Newby. (2008) GP IIb???IIIa Inhibitors Administered Upstream. Cardiology in Review 16:2, 89-94
CrossRef804
William E. Boden, Prediman K. Shah, Vipul Gupta, E. Magnus Ohman. (2008) Contemporary Approach to the Diagnosis and Management of Non–ST-Segment Elevation Acute Coronary Syndromes. Progress in Cardiovascular Diseases 50:5, 311-351
CrossRef805
E. Marc Jolicoeur, Christopher B. Granger, Timothy D. Henry, David J. Holmes, Carl J. Pepine, Daniel Mark, Bernard R. Chaitman, Bernard J. Gersh, E. Magnus Ohman. (2008) Clinical and research issues regarding chronic advanced coronary artery disease. American Heart Journal 155:3, 418-434
CrossRef806
Jaspal S Taggar, Gregory YH Lip, Aravinda Nanjundappa, Robert S Dieter, Sangeeta Mandapaka, Pranab Das, Shakeel Ahmad. (2008) Idraparinux for the prevention of thromboembolism in patients with atrial fibrillation. Therapy 5:2, 139-144
CrossRef807
Samer Ellahham. (2008) Role of Antiplatelet Agents in the Primary and Secondary Prevention of Atherothrombotic Events in High Risk-Patients. Southern Medical Journal 101:3, 273-283
CrossRef808
James W. Hoekstra. (2008) Managing antiplatelet therapy in the ACS patient: Straight from the emergency department to you. Journal of Hospital Medicine 3:S2, S15-S19
CrossRef809
Raisuke Iijima, Gjin Ndrepepa, Julinda Mehilli, Franz-Josef Neumann, Stefanie Schulz, Jurriën Berg, Olga Bruskina, Franz Dotzer, Josef Dirschinger, Peter B. Berger, Albert Schömig, Adnan Kastrati. (2008) Troponin level and efficacy of abciximab in patients with acute coronary syndromes undergoing early intervention after clopidogrel pretreatment. Clinical Research in Cardiology 97:3, 160-168
CrossRef810
J George, M Fisher, G McKay. (2008) Clopidogrel. Practical Diabetes International 25:2, 80-81
CrossRef811
Mark Y. Chan, Richard C. Becker, Robert A. Harrington, Eric D. Peterson, Paul W. Armstrong, Harvey White, Keith A.A. Fox, E. Magnus Ohman, Matthew T. Roe. (2008) Noninvasive, medical management for non–ST-elevation acute coronary syndromes. American Heart Journal 155:3, 397-407
CrossRef812
David Faxon, Marie Brown. (2008) Antiplatelet Therapy for Postdischarge Medical Management of Acute Coronary Syndrome. The American Journal of Medicine 121:3, 171-178
CrossRef813
Eugene Braunwald, Dominick Angiolillo, Eric Bates, Peter B. Berger, Deepak Bhatt, Christopher P. Cannon, Mark I. Furman, Paul Gurbel, Alan D. Michelson, Eric Peterson, Stephen Wiviott. (2008) Investigating the Mechanisms of Hyporesponse to Antiplatelet Approaches. Clinical Cardiology 31:S1, I21-I27
CrossRef814
Geoffrey S. F. Ling. (2008) Aggressive management of ischemic stroke: The case for the hospitalist. Journal of Hospital Medicine 3:S2, S9-S14
CrossRef815
Marc Fisher, Edward Folland. (2008) Acute Ischemic Coronary Artery Disease and Ischemic Stroke: Similarities and Differences. American Journal of Therapeutics 15:2, 137-149
CrossRef816
Jan van der Linden. (2008) Novel antithrombotic agents and the risk of bleeding. Transfusion 48:s1, 47S-50S
CrossRef817
Mátyás Keltai. (2008) Thrombocytaaggregáció-gátló kezelés akut ischaemiás szindrómában. Tények és várakozások. Orvosi Hetilap 149:11, 483-491
CrossRef818
Nigel Mackman. (2008) Triggers, targets and treatments for thrombosis. Nature 451:7181, 914-918
CrossRef819
Farzan Filsoufi, Parwis B. Rahmanian, Javier G. Castillo, Ronald A. Kahn, Gregory Fischer, David H. Adams. (2008) Clopidogrel Treatment Before Coronary Artery Bypass Graft Surgery Increases Postoperative Morbidity and Blood Product Requirements. Journal of Cardiothoracic and Vascular Anesthesia 22:1, 60-66
CrossRef820
Marco J.D. Tangelder, Lars Frison, Douglas Weaver, Robbert G. Wilcox, Anders Bylock, Håkan Emanuelsson, Peter Held, Jonas Oldgren. (2008) Effect of ximelagatran on ischemic events and death in patients with atrial fibrillation after acute myocardial infarction in the efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial damage (ESTEEM) trial. American Heart Journal 155:2, 382-387
CrossRef821
Gregory G Schwartz. (2008) Lipid management after acute coronary syndrome. Current Opinion in Internal Medicine 7:1, 75-81
CrossRef822
Jesse Weinberger. 2008. Cerebrovascular Disease in the Elderly Patient. , 645-672.
CrossRef823
Steven Francescone, Jonathan L. Halperin. (2008) “Triple Therapy” or Triple Threat?. Journal of the American College of Cardiology 51:8, 826-827
CrossRef824
Gabriel Gregoratos, Gordon Leung. 2008. Diabetes Mellitus and Cardiovascular Disease in the Elderly. , 179-214.
CrossRef825
Mark J. Alberts. (2008) CHARISMA revisited: is the glass half full or just empty?. International Journal of Stroke 3:1, 16-19
CrossRef826
Ascan Warnholtz, Mir Abolfazl Ostad, Nathalie Velich, Christine Trautmann, Reinhard Schinzel, Ulrich Walter, Thomas Munzel. (2008) A single loading dose of clopidogrel causes dose-dependent improvement of endothelial dysfunction in patients with stable coronary artery disease: Results of a double-blind, randomized study. Atherosclerosis 196:2, 689-695
CrossRef827
Min-Hyo Ki, Mee-Hwa Choi, Kwang-Bok Ahn, Byoung-Su Kim, Dai Sig Im, Soon-Kil Ahn, Hee-Jong Shin. (2008) The efficacy and safety of clopidogrel resinate as a novel polymeric salt form of clopidogrel. Archives of Pharmacal Research 31:2, 250-258
CrossRef828
R. Cubbon, M. Kahn, M. T. Kearney. (2008) Secondary prevention of cardiovascular disease in type 2 diabetes and prediabetes: a cardiologist's perspective. International Journal of Clinical Practice 62:2, 287-299
CrossRef829
Helfried Metzler, Kurt Huber, Sibylle Kozek-Langenecker. (2008) Anaesthesia in patients with drug-eluting stents. Current Opinion in Anaesthesiology 21:1, 55-59
CrossRef830
William E. Boden, James Hoekstra, Chadwick D. Miller. (2008) ST-elevation myocardial infarction: the role of adjunctive antiplatelet therapy. The American Journal of Emergency Medicine 26:2, 212-220
CrossRef831
Tracy Y. Wang, Lee A. Robinson, Fang-Shu Ou, Matthew T. Roe, E. Magnus Ohman, W. Brian Gibler, Sidney C. Smith, Eric D. Peterson, Richard C. Becker. (2008) Discharge antithrombotic strategies among patients with acute coronary syndrome previously on warfarin anticoagulation: Physician practice in the CRUSADE registry. American Heart Journal 155:2, 361-368
CrossRef832
D.H. Lee, A. Arat, H. Morsi, H. Shaltoni, J.R. Harris, M.E. Mawad. (2008) Dual Antiplatelet Therapy Monitoring for Neurointerventional Procedures Using a Point-of-Care Platelet Function Test: A Single-Center Experience. American Journal of Neuroradiology 29:7, 1389-1394
CrossRef833
M GILARD, B ARNAUD, J CORNILY, G LEGAL, K LACUT, G LECALVEZ, J MANSOURATI, D MOTTIER, J ABGRALL, J BOSCHAT. (2008) Influence of Omeprazole on the Antiplatelet Action of Clopidogrel Associated With AspirinThe Randomized, Double-Blind OCLA (Omeprazole CLopidogrel Aspirin) Study. Journal of the American College of Cardiology 51:3, 256-260
CrossRef834
S SAHA, M BERGLUND, C SYLVEN, A GORDON, S AGEWALL. (2008) Clopidogrel inhibits platelet aggregation in patients on aspirin with stable chronic angina pectoris. International Journal of Cardiology 123:2, 195-196
CrossRef835
D. Sibbing, G. Busch, S. Braun, S. Jawansky, A. Schomig, A. Kastrati, I. Ott, N. von Beckerath. (2008) Impact of bivalirudin or unfractionated heparin on platelet aggregation in patients pretreated with 600 mg clopidogrel undergoing elective percutaneous coronary intervention. European Heart Journal 29:12, 1504-1509
CrossRef836
(2008) Guidelines for Management of Ischaemic Stroke and Transient Ischaemic Attack 2008. Cerebrovascular Diseases 25:5, 457-507
CrossRef837
T. GEISLER, D. GRAß, B. BIGALKE, K. STELLOS, T. DROSCH, K. DIETZ, C. HERDEG, M. GAWAZ. (2008) The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score. Journal of Thrombosis and Haemostasis 6:1, 54-61
CrossRef838
(2008) 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. Catheterization and Cardiovascular Interventions 71:1, E1-E40
CrossRef839
Viktor Szeder, Michel T. Torbey. (2008) Prevention and Treatment of Perioperative Stroke. The Neurologist 14:1, 30-36
CrossRef840
Madhu Chintala, Kenji Shimizu, Masami Ogawa, Hiroya Yamaguchi, Masaki Doi, Peder Jensen. (2008) Basic and Translational Research on Proteinase-Activated Receptors: Antagonism of the Proteinase-Activated Receptor 1 for Thrombin, a Novel Approach to Antiplatelet Therapy for Atherothrombotic Disease. Journal of Pharmacological Sciences 108:4, 433-438
CrossRef841
Hideki Origasa, Shinya Goto, Shinichiro Uchiyama, Kazuyuki Shimada, Yasuo Ikeda, The J-TRACE Investigators. (2008) The Japan Thrombosis Registry for Atrial Fibrillation, Coronary or Cerebrovascular Events (J-TRACE). Circulation Journal 72:6, 991-997
CrossRef842
J. Eileen Bird, Mary R. Giancarli, Nick Allegretto, Frank Barbera, Pancras Wong, William A. Schumacher, Martin L. Ogletree, Dietmar Seiffert. (2008) Prediction of the therapeutic index of marketed anti-coagulants and anti-platelet agents by guinea pig models of thrombosis and hemostasis. Thrombosis Research 123:1, 146-158
CrossRef843
K Nayan S Rao, Azan S Binbrek, Burton E Sobel. (2008) Heart disease and erythropoietin. Future Cardiology 4:1, 57-64
CrossRef844
Uwe Zeymer, Anselm K. Gitt, Ralf Zahn, Claus Jünger, Timm Bauer, Oliver Köth, Tobias Heer, Harm Wienbergen, Martin Gottwik, Jochen Senges. (2008) Clopidogrel in addition to aspirin reduces one‐year major adverse cardiac and cerebrovascular events in unselected patients with non‐ST segment elevation myocardial infarction. Acute Cardiac Care 10:1, 43-48
CrossRef845
Tsukasa OHMORI. (2008) Anti-platelet treatment for acute coronary syndrome in Japan. Japanese Journal of Thrombosis and Hemostasis 19:4, 504-509
CrossRef846
Sean Ruland. (2008) Safety of Clopidogrel and Aspirin for??Stroke Prevention. Drug Safety 31:6, 449-458
CrossRef847
Dawn M. Meyer, Karen C. Albright, Teresa A. Allison, James C. Grotta. (2008) LOAD: A Pilot Study of the Safety of Loading of Aspirin and Clopidogrel in Acute Ischemic Stroke and Transient Ischemic Attack. Journal of Stroke and Cerebrovascular Diseases 17:1, 26-29
CrossRef848
JOHN M. GALLA, A. MICHAEL LINCOFF. 2008. Adjunctive pharmacotherapy during PCI. , 53-64.
CrossRef849
Gilead I. Lancaster, Hitender Jain, Stuart W. Zarich. (2008) The Role of Aspirin Resistance in the Treatment of Acute Coronary Syndromes. Clinical Cardiology 31:1, 11-17
CrossRef850
Spencer B. King, Sidney C. Smith, John W. Hirshfeld, Alice K. Jacobs, Douglass A. Morrison, David O. Williams. (2008) 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention. Journal of the American College of Cardiology 51:2, 172-209
CrossRef851
Kazuo UMEMURA. (2008) Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 39:6, 238-242
CrossRef852
Arif Mutwali, Liam G Glynn, Donal Reddan. (2008) Management of Ischemic Heart Disease in Patients with Chronic Kidney Disease. American Journal of Cardiovascular Drugs 8:4, 219-231
CrossRef853
Masami Kosuge, Toshiaki Ebina, Kiyoshi Hibi, Mitsuaki Endo, Naohiro Komura, Katsutaka Hashiba, Masayoshi Kiyokuni, Naoki Nakayama, Satoshi Umemura, Kazuo Kimura. (2008) ST-Segment Elevation Resolution in Lead aVR. Circulation Journal 72:7, 1047-1053
CrossRef854
D. Adam Lauver, Edward M. Driscoll, Benedict R. Lucchesi. (2008) Disodium Disuccinate Astaxanthin Prevents Carotid Artery Rethrombosis and ex vivo Platelet Activation. Pharmacology 82:1, 67-73
CrossRef855
Charles H Hennekens, Wendy R Schneider. (2008) The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease. Expert Review of Cardiovascular Therapy 6:1, 95-107
CrossRef856
Yoichi Niitsu, Atsuhiro Sugidachi, Taketoshi Ogawa, Joseph A. Jakubowski, Masami Hashimoto, Takashi Isobe, Ken-ichi Otsuguro, Fumitoshi Asai. (2008) Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species. European Journal of Pharmacology 579:1-3, 276-282
CrossRef857
(2008) Guías de práctica clínica sobre prevención de la enfermedad cardiovascular: versión resumida. Revista Española de Cardiología 61:1, 82.e1-82.e49
CrossRef858
Silverio Sbrana, Francesca Della Pina, Antonio Rizza, Manuela Buffa, Rossella De Filippis, Jacopo Gianetti, Aldo Clerico. (2008) Relationships between optical aggregometry (type born) and flow cytometry in evaluating ADP-induced platelet activation. Cytometry Part B: Clinical Cytometry 74B:1, 30-39
CrossRef859
Jesse Weinberger. (2008) Antiplatelet Agents for Stroke Prevention Following Transient Ischemic Attack. Southern Medical Journal 101:1, 70-78
CrossRef860
Jochem W van Werkum, Christian M Hackeng, Jaap-Jan J Smit, Arnoud WJ van’t Hof, Freek WA Verheugt, Jurriën M ten Berg. (2008) Monitoring antiplatelet therapy with point-of-care platelet function assays: a review of the evidence. Future Cardiology 4:1, 33-55
CrossRef861
Marcus Shaker, Ano Lobb, Pamela Jenkins, Daniel O'Rourke, Steve K. Takemoto, Salil Sheth, Thomas Burroughs, Mark S. Dykewicz. (2008) An economic analysis of aspirin desensitization in aspirin-exacerbated respiratory disease. Journal of Allergy and Clinical Immunology 121:1, 81-87
CrossRef862
Fook-Hong Ng, Kwok-Fai Lam, Siu-Yin Wong, Chee-My Chang, Yuk-Kong Lau, Wai-Cheung Yuen, Wai-Ming Chu, Benjamin C.Y. Wong. (2008) Upper Gastrointestinal Bleeding in Patients with Aspirin and Clopidogrel Co-Therapy. Digestion 77:3-4, 173-177
CrossRef863
Cindy Grines, Leslie Cho. (2008) Atherothrombotic Disease and the Role of Antiplatelet Therapy in Women. Journal of Women's Health 17:1, 35-46
CrossRef864
Neil E. Schwartz, Gregory W. Albers. (2008) Use of antiplatelet agents to prevent stroke: What is the role for combinations of medications?. Current Neurology and Neuroscience Reports 8:1, 29-34
CrossRef865
Xavier Dode, Cécile Djian, Xavier Armoiry, Éric Bonnefoy, Denis Angoulvant, Gilles Aulagner, Martine Postaire, François Gimenez†, Éric François. 2008. Traitement de l'angor stable et des syndromes coronariens aigus sans sus-décalage du segment ST. , 73-100.
CrossRef866
Davì, Giovanni, Patrono, Carlo, . (2007) Platelet Activation and Atherothrombosis. New England Journal of Medicine 357:24, 2482-2494
Full Text867
Dan James Fintel. (2007) Antiplatelet Therapy in Cerebrovascular Disease: Implications of MATCH and CHARISMA Results for Cardiologists. Clinical Cardiology 30:12, 604-614
CrossRef868
V. Schächinger. (2007) Betreuung von Patienten nach Koronarstentimplantation. Der Internist 48:12, 1365-1375
CrossRef869
C. Setacci, E. Chisci, G. de Donato, F. Setacci, P. Sirignano, G. Galzerano. (2007) Carotid Artery Stenting in a Single Center: Are Six Years of Experience Enough to Achieve the Standard of Care?. European Journal of Vascular and Endovascular Surgery 34:6, 655-662
CrossRef870
Betti Giusti, Anna Maria Gori, Rossella Marcucci, Claudia Saracini, Ilaria Sestini, Rita Paniccia, Serafina Valente, Davide Antoniucci, Rosanna Abbate, Gian Franco Gensini. (2007) Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10+12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenetics and Genomics 17:12, 1057-1064
CrossRef871
Joseph A. Jakubowski, Kenneth J. Winters, Hideo Naganuma, Lars Wallentin. (2007) Prasugrel: A Novel Thienopyridine Antiplatelet Agent. A Review of Preclinical and Clinical Studies and the Mechanistic Basis for Its Distinct Antiplatelet Profile. Cardiovascular Drug Reviews 25:4, 357-374
CrossRef872
J. T. BRANDT, S. L. CLOSE, S. J. ITURRIA, C. D. PAYNE, N. A. FARID, C. S. ERNEST, D. R. LACHNO, D. SALAZAR, K. J. WINTERS. (2007) Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. Journal of Thrombosis and Haemostasis 5:12, 2429-2436
CrossRef873
Alipio Mangas Rojas, Francisco Gómez Rodríguez. (2007) Tratamiento multifactorial de la arteriosclerosis. Medicina Clínica 129:20, 785-796
CrossRef874
Wiviott, Stephen D., Braunwald, Eugene, McCabe, Carolyn H., Montalescot, Gilles, Ruzyllo, Witold, Gottlieb, Shmuel, Neumann, Franz-Joseph, Ardissino, Diego, De Servi, Stefano, Murphy, Sabina A., Riesmeyer, Jeffrey, Weerakkody, Govinda, Gibson, C. Michael, Antman, Elliott M., . (2007) Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. New England Journal of Medicine 357:20, 2001-2015
Full Text875
Bhatt, Deepak L., . (2007) Intensifying Platelet Inhibition — Navigating between Scylla and Charybdis. New England Journal of Medicine 357:20, 2078-2081
Full Text876
Charles H. Hennekens. (2007) Aspirin in the treatment and prevention of cardiovascular disease: Current perspectives and future directions. Current Atherosclerosis Reports 9:5, 409-416
CrossRef877
H.R. Arntz. (2007) Frühe Antiplättchentherapie und Gerinnungshemmung bei akutem Koronarsyndrom. Notfall + Rettungsmedizin 10:7, 500-510
CrossRef878
Pallav Garg, Laura Mauri. (2007) The conundrum of late and very late stent thrombosis following drug-eluting stent implantation. Current Opinion in Cardiology 22:6, 565-571
CrossRef879
Christopher P. Cannon, Steen Husted, Robert A. Harrington, Benjamin M. Scirica, Håkan Emanuelsson, Gary Peters, Robert F. Storey. (2007) Safety, Tolerability, and Initial Efficacy of AZD6140, the First Reversible Oral Adenosine Diphosphate Receptor Antagonist, Compared With Clopidogrel, in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome. Journal of the American College of Cardiology 50:19, 1844-1851
CrossRef880
James M. Brophy. (2007) Risk stratification following non-ST segment elevation myocardial infarction: Is the glass half-full or half-empty?. Canadian Journal of Cardiology 23:13, 1080-1081
CrossRef881
Andra L. Blomkalns, Matthew T. Roe, Eric D. Peterson, E. Magnus Ohman, Elizabeth S. Fraulo, W. Brian Gibler. (2007) Guideline Implementation Research: Exploring the Gap between Evidence and Practice in the CRUSADE Quality Improvement Initiative. Academic Emergency Medicine 14:11, 949-954
CrossRef882
Robert F. Storey, Steen Husted, Robert A. Harrington, Stanley Heptinstall, Robert G. Wilcox, Gary Peters, Mark Wickens, Håkan Emanuelsson, Paul Gurbel, Peer Grande, Christopher P. Cannon. (2007) Inhibition of Platelet Aggregation by AZD6140, A Reversible Oral P2Y12 Receptor Antagonist, Compared With Clopidogrel in Patients With Acute Coronary Syndromes. Journal of the American College of Cardiology 50:19, 1852-1856
CrossRef883
Arnoud van ‘t Hof, Christian Hamm, Saman Rasoul, Soneil Guptha, John Paolini, Jurriën ten Berg. (2007) Ongoing tirofiban in myocardial infarction evaluation (On-TIME) 2 trial: rationale and study design. EuroIntervention 3:3, 371-380
CrossRef884
Neil E. Schwartz, Gregory W. Albers. (2007) Is there a role for combinations of antiplatelet agents in stroke prevention?. Current Treatment Options in Neurology 9:6, 442-450
CrossRef885
A MOTIVALA, U TAMHANE, F SAAB, J LI, E ROGERS, J FROEHLICH, M MOSCUCCI, K EAGLE, H GURM. (2007) Temporal Trends in Antiplatelet/Antithrombotic Use in Acute Coronary Syndromes and In-Hospital Major Bleeding Complications. The American Journal of Cardiology 100:9, 1359-1363
CrossRef886
Paul Kolm, Yong Yuan, Emir Veledar, Shamir R. Mehta, Judith A. O’Brien, William S. Weintraub. (2007) Cost-effectiveness of clopidogrel in acute coronary syndromes in Canada: A long-term analysis based on the CURE trial. Canadian Journal of Cardiology 23:13, 1037-1042
CrossRef887
Vincent Chan, Alexander Kulik, Michael E. Bourke, Ladislaus Ressler, Thierry G. Mesana, Marc Ruel. (2007) Clopidogrel Is Safe Early after On- and Off-pump Coronary Artery Bypass Surgery. Journal of Cardiac Surgery 22:6, 493-497
CrossRef888
S Claiborne Johnston. (2007) Towards FASTER treatment of TIA and minor stroke. The Lancet Neurology 6:11, 941-943
CrossRef889
Girish R. Mood, Deepak L. Bhatt. (2007) Clopidogrel and risk for acute coronary events. Current Atherosclerosis Reports 9:5, 401-408
CrossRef890
Christopher D Payne, Ying Grace Li, David S Small, C Steven Ernest, Nagy A Farid, Joseph A Jakubowski, John T Brandt, Daniel E Salazar, Kenneth J Winters. (2007) Increased Active Metabolite Formation Explains the Greater Platelet Inhibition With Prasugrel Compared to High-dose Clopidogrel. Journal of Cardiovascular Pharmacology 50:5, 555-562
CrossRef891
Stanley G. Rockson, Emil M. deGoma, Gregg C. Fonarow. (2007) Reinforcing a Continuum of Care: In-Hospital Initiation of Long-Term Secondary Prevention Following Acute Coronary Syndromes. Cardiovascular Drugs and Therapy 21:5, 375-388
CrossRef892
Nauder Faraday, Diane M Becker, Lewis C Becker. (2007) Pharmacogenomics of platelet responsiveness to aspirin. Pharmacogenomics 8:10, 1413-1425
CrossRef893
Thomas W. Wallace, Sunil V. Rao. (2007) The Challenge of Defining Bleeding Among Patients with Acute Coronary Syndromes. Clinical Cardiology 30:S2, II16-II23
CrossRef894
Karol Watson, Constance H. Fung, Matthew Budoff. (2007) Quality Indicators for the Care of Ischemic Heart Disease in Vulnerable Elders. Journal of the American Geriatrics Society 55, S366-S372
CrossRef895
(2007) Guía de Práctica Clínica para el diagnóstico y tratamiento del síndrome coronario agudo sin elevación del segmento ST. Revista Española de Cardiología 60:10, 1070.e1-1070.e80
CrossRef896
Yoshiko Tamai, Tomoko Komatsu-Ishizawa, Hideki Takami, Hitoshi Nakajima, Shinsaku Fukuda, Akihiro Munakata. (2007) MANAGEMENT OF ANTIPLATELET THERAPY FOR ENDOSCOPIC PROCEDURES: OPTIMAL CESSATION PERIOD OF ANTIPLATELET THERAPY FOR JAPANESE. Digestive Endoscopy 19:4, 161-166
CrossRef897
Lee A. Fleisher, Joshua A. Beckman, Kenneth A. Brown, Hugh Calkins, Elliott L. Chaikof, Kirsten E. Fleischmann, William K. Freeman, James B. Froehlich, Edward K. Kasper, Judy R. Kersten, Barbara Riegel, John F. Robb, Sidney C. Smith, Alice K. Jacobs, Cynthia D. Adams, Jeffrey L. Anderson, Elliott M. Antman, Christopher E. Buller, Mark A. Creager, Steven M. Ettinger, David P. Faxon, Valentin Fuster, Jonathan L. Halperin, Loren F. Hiratzka, Sharon A. Hunt, Bruce W. Lytle, Rick Nishimura, Joseph P. Ornato, Richard L. Page, Barbara Riegel, Lynn G. Tarkington, Clyde W. Yancy. (2007) ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery. Journal of the American College of Cardiology 50:17, e159-e242
CrossRef898
John M Galla, A Michael Lincoff. (2007) The role of clopidogrel in the management of ischemic heart disease. Current Opinion in Internal Medicine 6:5, 454-460
CrossRef899
D. Härtel, E. Christel, J. Brockmeier, A. Cuneo, C. Zellerhoff, J. Götz, T. Hundhausen, T. Dammann, U. Tebbe. (2007) Verbesserung der Behandlung von Patienten mit akutem Koronarsyndrom durch Aufbau einer Netzwerkstruktur im ländlichen Raum. Notfall + Rettungsmedizin 10:6, 423-431
CrossRef900
Steeve Brulotte, Mario Sénéchal, Paul Poirier, Can Manh Nguyen, Ariane Lemieux, Julien Magne, Sébastien Bergeron. (2007) Safety of the cardiac triple therapy: The experience of the Quebec Heart Institute. Canadian Journal of Cardiology 23, 80B-83B
CrossRef901
M. J. Alberts, B. Ovbiagele. (2007) Current strategies for ischemic stroke prevention: role of multimodal combination therapies. Journal of Neurology 254:10, 1414-1426
CrossRef902
Daniel I. Simon, Alvin H. Schmaier. (2007) Sweet and Sticky. Journal of the American College of Cardiology 50:16, 1548-1550
CrossRef903
Peter M Rothwell, Matthew F Giles, Arvind Chandratheva, Lars Marquardt, Olivia Geraghty, Jessica NE Redgrave, Caroline E Lovelock, Lucy E Binney, Linda M Bull, Fiona C Cuthbertson, Sarah JV Welch, Shelley Bosch, Faye Carasco-Alexander, Louise E Silver, Sergei A Gutnikov, Ziyah Mehta. (2007) Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison. The Lancet 370:9596, 1432-1442
CrossRef904
Deepak L. Bhatt, Marcus D. Flather. (2007) Reply. Journal of the American College of Cardiology 50:17, 1704-1705
CrossRef905
Rohit Bhatheja, Debabrata Mukherjee. (2007) Acute Coronary Syndromes: Unstable Angina/Non-ST Elevation Myocardial Infarction. Critical Care Clinics 23:4, 709-735
CrossRef906
Fons Windhausen, Alexander Hirsch, Jan G.P. Tijssen, Jan Hein Cornel, Freek W.A. Verheugt, Margriet I. Klees, Robbert J. de Winter. (2007) ST-segment deviation on the admission electrocardiogram, treatment strategy, and outcome in non–ST-elevation acute coronary syndromes. Journal of Electrocardiology 40:5, 408-415
CrossRef907
Ana C. Montes-Gil, Marcos Zanfolin, Cristina E. Okuyama, Sergio Lilla, Delma P. Alves, Vincenzo Santagada, Elisa Perissutti, Antonio Lavecchia, Ferdinando Fiorino, Beatrice Severino, Giuseppe Caliendo, Fernanda B. M. Priviero, Gustavo D. Mendes, Jose L. Donato, Gilberto de Nucci. (2007) Pharmacokinetic Profile of Atenolol Aspirinate. Archiv der Pharmazie 340:9, 445-455
CrossRef908
Victor L. Serebruany. (2007) The “Clopidogrel Resistance” Trap. The American Journal of Cardiology 100:6, 1044-1046
CrossRef909
Surachet Niruntraporn, Nathorn Chaiyakunapruk, Surakit Nathisuwan, Visanu Thamlikitkul. (2007) Utilisation review of clopidogrel: are they used under the FDA-approved indications?. Pharmacoepidemiology and Drug Safety 16:9, 1031-1037
CrossRef910
Ian Graham. (2007) European guidelines on cardiovascular disease prevention in clinical practice: Executive summary. Atherosclerosis 194:1, 1-45
CrossRef911
&NA;. (2007) FULL TEXT Chapter 1: Introduction. European Journal of Cardiovascular Prevention & Rehabilitation 14:Supplement 2, S2-S113
CrossRef912
Rajeev Garg, Barry F. Uretsky, Eli I. Lev. (2007) Anti-platelet and anti-thrombotic approaches in patients undergoing percutaneous coronary intervention. Catheterization and Cardiovascular Interventions 70:3, 388-406
CrossRef913
Dalton S. McLean, Marc S. Sabatine, Wei Guo, Carolyn H. McCabe, Christopher P. Cannon. (2007) Benefits and risks of clopidogrel pretreatment before coronary artery bypass grafting in patients with ST-elevation myocardial infarction treated with fibrinolytics in CLARITY-TIMI 28. Journal of Thrombosis and Thrombolysis 24:2, 85-91
CrossRef914
Eric Durand, Christian Hamm, Carlos Macaya, Jean-Louis Georges, Pierre Coste, Jean Wolf, Michel Slama, Steen Husted, Morris Mosseri, Antoine Lafont. (2007) A randomised controlled trial of upstream administration of eptifibatide in patients presenting non-ST segment elevation acute coronary syndrome treated with an invasive strategy. EuroIntervention 3:2, 228-234
CrossRef915
S. Silber, M. Borggrefe, M. Böhm, H.M. Hoffmeister, R. Dietz, G. Ertl, G. Heusch. (2007) Positionspapier der DGK zur Wirksamkeit und Sicherheit von Medikamente freisetzenden Koronarstents (DES). Der Kardiologe 1:2, 84-111
CrossRef916
Justin R Hamilton, Zane Kaplan, Shaun P Jackson, Stephen Opat. (2007) Antiplatelet therapy: present status and future prospects. Expert Opinion on Drug Discovery 2:8, 1035-1040
CrossRef917
Michael B Bottorff, Edith A Nutescu, Sarah Spinler. (2007) Antiplatelet Therapy in Patients with Unstable Angina and Non–ST-Segment-Elevation Myocardial Infarction: Findings from the CRUSADE National Quality Improvement Initiative. Pharmacotherapy 27:8, 1145-1162
CrossRef918
Jeffrey L. Anderson, Cynthia D. Adams, Elliott M. Antman, Charles R. Bridges, Robert M. Califf, Donald E. Casey, William E. Chavey, Francis M. Fesmire, Judith S. Hochman, Thomas N. Levin, A. Michael Lincoff, Eric D. Peterson, Pierre Theroux, Nanette Kass Wenger, R. Scott Wright, Sidney C. Smith, Alice K. Jacobs, Cynthia D. Adams, Jeffrey L. Anderson, Elliot M. Antman, Jonathan L. Halperin, Sharon A. Hunt, Harlan M. Krumholz, Frederick G. Kushner, Bruce W. Lytle, Rick Nishimura, Joseph P. Ornato, Richard L. Page, Barbara Riegel. (2007) ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction—Executive Summary. Journal of the American College of Cardiology 50:7, 652-726
CrossRef919
Jeffrey L. Anderson, Cynthia D. Adams, Elliott M. Antman, Charles R. Bridges, Robert M. Califf, Donald E. Casey, William E. Chavey, Francis M. Fesmire, Judith S. Hochman, Thomas N. Levin, A. Michael Lincoff, Eric D. Peterson, Pierre Theroux, Nanette Kass Wenger, R. Scott Wright, Sidney C. Smith, Alice K. Jacobs, Cynthia D. Adams, Jeffrey L. Anderson, Elliott M. Antman, Jonathan L. Halperin, Sharon A. Hunt, Harlan M. Krumholz, Frederick G. Kushner, Bruce W. Lytle, Rick Nishimura, Joseph P. Ornato, Richard L. Page, Barbara Riegel. (2007) ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology 50:7, e1-e157
CrossRef920
Princess U. Ogbogu, Douglas R. Rosing, McDonald K. Horne. (2007) Cardiovascular Manifestations of Hypereosinophilic Syndromes. Immunology and Allergy Clinics of North America 27:3, 457-475
CrossRef921
Gennaro Sardella, Chiara Bucciarelli-Ducci, Massimo Mancone, Riccardo Colantonio, Giuseppe Massimo Sangiorgi, Francesco Fedele. (2007) Very late paclitaxel-eluting stent thrombosis despite 21 months of clopidogrel treatment after percutaneous coronary intervention. Journal of Cardiovascular Medicine 8:8, 625-628
CrossRef922
Keith AA Fox, Raj Chelliah. (2007) Clopidogrel: an updated and comprehensive review. Expert Opinion on Drug Metabolism & Toxicology 3:4, 621-631
CrossRef923
Wendy Gattis Stough, Faiez Zannad, Bertram Pitt, Sidney Goldstein. (2007) Globalization of cardiovascular clinical research: The balance between meeting medical needs and maintaining scientific standards. American Heart Journal 154:2, 232-238
CrossRef924
D ANGIOLILLO, F ALFONSO. (2007) Clopidogrel–Statin InteractionMyth or Reality?
CrossRef925
Alessandro Squizzato, Tymen Keller, Saskia Middeldorp, Alessandro Squizzato. 2007. Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease. .
CrossRef926
P. Fontana, J.-L. Reny. (2007) New Antiplatelet Strategies in Atherothrombosis and Their Indications. European Journal of Vascular and Endovascular Surgery 34:1, 10-17
CrossRef927
J. W. EIKELBOOM, J. HIRSH. (2007) Combined antiplatelet and anticoagulant therapy: clinical benefits and risks. Journal of Thrombosis and Haemostasis 5, 255-263
CrossRef928
Sahil A. Parikh, Joshua A. Beckman. (2007) Contemporary use of clopidogrel in patients with coronary artery disease. Current Cardiology Reports 9:4, 257-263
CrossRef929
Stephen E. Van Horn, Calin V. Maniu. (2007) Management of non–ST-Segment Elevation Myocardial Infarction. Medical Clinics of North America 91:4, 683-700
CrossRef930
Adrian Fluture, Gregory R Giugliano, Robert P Giugliano. (2007) Recombinant nematode anticoagulant protein c2 in non-ST segment elevation acute coronary syndrome and beyond. Future Cardiology 3:4, 365-375
CrossRef931
Steven R. Steinhubl, Adnan Kastrati, Peter B. Berger. (2007) Variation in the definitions of bleeding in clinical trials of patients with acute coronary syndromes and undergoing percutaneous coronary interventions and its impact on the apparent safety of antithrombotic drugs. American Heart Journal 154:1, 3-11
CrossRef932
Eugenia Nikolsky, Gregg W Stone. (2007) Antithrombotic strategies in non-ST elevation acute coronary syndromes: focus on bivalirudin. Future Cardiology 3:4, 345-364
CrossRef933
Amy K. Saenger, Allan S. Jaffe. (2007) The Use of Biomarkers for the Evaluation and Treatment of Patients with Acute Coronary Syndromes. Medical Clinics of North America 91:4, 657-681
CrossRef934
A. SUGIDACHI, T. OGAWA, A. KURIHARA, K. HAGIHARA, J.A. JAKUBOWSKI, M. HASHIMOTO, Y. NIITSU, F. ASAI. (2007) The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel?s active metabolite. Journal of Thrombosis and Haemostasis 5:7, 1545-1551
CrossRef935
Jonathan D. Rich, Stephen D. Wiviott. (2007) New antiplatelet therapies for acute coronary syndromes. Current Cardiology Reports 9:4, 303-311
CrossRef936
E. V. Gelfand, C. P. Cannon. (2007) Myocardial infarction: contemporary management strategies. Journal of Internal Medicine 262:1, 59-77
CrossRef937
Jae Kwang Shim, Yong Seon Choi, Young Jun Oh, Sou Ouk Bang, Kyung Jong Yoo, Young Lan Kwak. (2007) Effects of preoperative aspirin and clopidogrel therapy on perioperative blood loss and blood transfusion requirements in patients undergoing off-pump coronary artery bypass graft surgery. The Journal of Thoracic and Cardiovascular Surgery 134:1, 59-64
CrossRef938
Steven Steinhubl, Matthew T. Roe. (2007) Optimizing Platelet P2Y 12 Inhibition for Patients Undergoing PCI. Cardiovascular Drug Reviews 25:2, 188-203
CrossRef939
S TICKOO, M ROE, E PETERSON, S MILFORDBELAND, E OHMAN, W GIBLER, C POLLACKJR, C CANNON. (2007) Patterns of Aspirin Dosing in Non–ST-Elevation Acute Coronary Syndromes in the CRUSADE Quality Improvement Initiative. The American Journal of Cardiology 99:11, 1496-1499
CrossRef940
A BUCH, S SINGH, P ROY, A JAVAID, K SMITH, C GEORGE, A PICHARD, L SATLER, K KENT, W SUDDATH. (2007) Measuring Aspirin Resistance, Clopidogrel Responsiveness, and Postprocedural Markers of Myonecrosis in Patients Undergoing Percutaneous Coronary Intervention. The American Journal of Cardiology 99:11, 1518-1522
CrossRef941
Luca Testa, Giuseppe Biondi Zoccai, Italo Porto, Graziana Trotta, Pierfrancesco Agostoni, Felicita Andreotti, Filippo Crea. (2007) Adjusted Indirect Meta-Analysis of Aspirin Plus Warfarin at International Normalized Ratios 2 to 3 Versus Aspirin Plus Clopidogrel After Acute Coronary Syndromes. The American Journal of Cardiology 99:12, 1637-1642
CrossRef942
Nancy Albert. (2007) Non?ST segment elevation acute coronary syndromes: Treatment guidelines for the nurse practitioner. Journal of the American Academy of Nurse Practitioners 19:6, 277-289
CrossRef943
Jenny Berg, Peter Lindgren, Julie Spiesser, David Parry, Bengt Jönsson. (2007) Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: A European model based on the CLARITY and COMMIT trials. Clinical Therapeutics 29:6, 1184-1202
CrossRef944
Bernhard Meier. (2007) Drug-Eluting Stents: The Next Chapter of the Coronary Stent Saga. The American Heart Hospital Journal 5:3, 173-176
CrossRef945
Pierre-Guy Chassot, Alain Delabays, Donat R. Spahn. (2007) Perioperative use of anti-platelet drugs. Best Practice & Research Clinical Anaesthesiology 21:2, 241-256
CrossRef946
David Fitchett. (2007) The impact of bleeding in patients with acute coronary syndromes: How to optimize the benefits of treatment and minimize the risk. Canadian Journal of Cardiology 23:8, 663-671
CrossRef947
L. Lorgis, M. Zeller, J.-C. Beer, P. Buffet, I. L'Huillier, C. Nguyen, F. Schaad, P. Obbee, A.-C. Lagrost, Y. Cottin. (2007) Prise en charge au long cours par les anti-agrégants plaquettaires oraux après un syndrome coronaire aigu. Annales de Cardiologie et d'Angéiologie 56, S29-S35
CrossRef948
Tina L. Pinto Slottow, Ron Waksman. (2007) Overview of the 2006 Food and Drug Administration Circulatory System Devices Panel meeting on drug-eluting stent thrombosis. Catheterization and Cardiovascular Interventions 69:7, 1064-1074
CrossRef949
Dirk Sibbing, Olga von Beckerath, Albert Schömig, Adnan Kastrati, Nicolas von Beckerath. (2007) Platelet function in clopidogrel-treated patients with acute coronary syndrome. Blood Coagulation & Fibrinolysis 18:4, 335-339
CrossRef950
W. Lepper, M. Kelm. (2007) Perioperative Therapie mit Thrombozytenaggregationshemmern. Der Anaesthesist 56:6, 592-598
CrossRef951
William J. Mauermann, Kent H. Rehfeldt, Malcolm R. Bell, Stuart M. Lowson. (2007) Percutaneous Coronary Interventions and Antiplatelet Therapy in the Perioperative Period. Journal of Cardiothoracic and Vascular Anesthesia 21:3, 436-442
CrossRef952
M. Troxler, K. Dickinson, S. Homer-Vanniasinkam. (2007) Platelet function and antiplatelet therapy. British Journal of Surgery 94:6, 674-682
CrossRef953
Oscar Ö Braun, Stefan Amisten, Anna-Karin Wihlborg, Karen Hunting, David Nilsson, David Erlinge. (2007) Residual platelet ADP reactivity after clopidogrel treatment is dependent on activation of both the unblocked P2Y1 and the P2Y12 receptor and is correlated with protein expression of P2Y12. Purinergic Signalling 3:3, 195-201
CrossRef954
Marten Otten. (2007) Maagbescherming bij vaatbescherming?. Huisarts en Wetenschap 50:5, 348-353
CrossRef955
Timothy Goodman, Pankaj Sharma, Albert Ferro. (2007) The genetics of aspirin resistance. International Journal of Clinical Practice 61:5, 826-834
CrossRef956
Marc Husmann, Matthias Barton. (2007) Therapeutical potential of direct thrombin inhibitors for atherosclerotic vascular disease. Expert Opinion on Investigational Drugs 16:5, 563-567
CrossRef957
Izzet Celal Erdinler, Ekrem Ucer, Abdurrahman Eksik, Ahmet Akyol, Selcuk Yazici. (2007) Noncardiogenic pulmonary edema associated with clopidogrel: A serious but unexpected side effect of clopidogrel. Canadian Journal of Cardiology 23:6, 478-480
CrossRef958
Gautam Kedia, Michael S. Lee. (2007) Stent thrombosis with drug-eluting stents: A re-examination of the evidence. Catheterization and Cardiovascular Interventions 69:6, 782-789
CrossRef959
M. Heikkinen, M. Salmenperä, A. Lepäntalo, M. Lepäntalo. (2007) Diabetes Care for Patients with Peripheral Arterial Disease. European Journal of Vascular and Endovascular Surgery 33:5, 583-591
CrossRef960
D INMAN, Y MICHLA, P PARTINGTON. (2007) Perioperative management of trauma patients admitted on clopidogrel (Plavix)A survey of orthopaedic departments across the United Kingdom. Injury 38:5, 625-630
CrossRef961
(2007) Guías de práctica clínica sobre diabetes, prediabetes y enfermedades cardiovasculares: versión resumida. Revista Española de Cardiología 60:5, 525.e1-525.e64
CrossRef962
Deepak L. Bhatt, Marcus D. Flather, Werner Hacke, Peter B. Berger, Henry R. Black, William E. Boden, Patrice Cacoub, Eric A. Cohen, Mark A. Creager, J. Donald Easton, Christian W. Hamm, Graeme J. Hankey, S. Claiborne Johnston, Koon-Hou Mak, Jean-Louis Mas, Gilles Montalescot, Thomas A. Pearson, P. Gabriel Steg, Steven R. Steinhubl, Michael A. Weber, Liz Fabry-Ribaudo, Tingfei Hu, Eric J. Topol, Keith A.A. Fox. (2007) Patients With Prior Myocardial Infarction, Stroke, or Symptomatic Peripheral Arterial Disease in the CHARISMA Trial. Journal of the American College of Cardiology 49:19, 1982-1988
CrossRef963
N A Farid, C D Payne, D S Small, K J Winters, C S Ernest, J T Brandt, C Darstein, J A Jakubowski, D E Salazar. (2007) Cytochrome P450 3A Inhibition by Ketoconazole Affects Prasugrel and Clopidogrel Pharmacokinetics and Pharmacodynamics Differently. Clinical Pharmacology & Therapeutics 81:5, 735-741
CrossRef964
W. S. Aronow. (2007) Use of Antiplatelet Drugs in Secondary Prevention in Older Persons With Atherothrombotic Disease. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 62:5, 518-524
CrossRef965
G. E. Kikano, M. T. Brown. (2007) Antiplatelet Therapy for Atherothrombotic Disease: An Update for the Primary Care Physician. Mayo Clinic Proceedings 82:5, 583-593
CrossRef966
Boden, William E., O'Rourke, Robert A., Teo, Koon K., Hartigan, Pamela M., Maron, David J., Kostuk, William J., Knudtson, Merril, Dada, Marcin, Casperson, Paul, Harris, Crystal L., Chaitman, Bernard R., Shaw, Leslee, Gosselin, Gilbert, Nawaz, Shah, Title, Lawrence M., Gau, Gerald, Blaustein, Alvin S., Booth, David C., Bates, Eric R., Spertus, John A., Berman, Daniel S., Mancini, G.B. John, Weintraub, William S., . (2007) Optimal Medical Therapy with or without PCI for Stable Coronary Disease. New England Journal of Medicine 356:15, 1503-1516
Full Text967
Burak Pamukcu. (2007) A review of aspirin resistance; definition, possible mechanisms, detection with platelet function tests, and its clinical outcomes. Journal of Thrombosis and Thrombolysis 23:3, 213-222
CrossRef968
Giuseppe G.L. Biondi-Zoccai, Marzia Lotrionte, Pierfrancesco Agostoni, Marco Valgimigli, Antonio Abbate, Giuseppe Sangiorgi, Claudio Moretti, Imad Sheiban. (2007) Benefits of clopidogrel in patients undergoing coronary stenting significantly depend on loading dose: Evidence from a meta-regression. American Heart Journal 153:4, 587-593
CrossRef969
Dominick J Angiolillo. (2007) Antiplatelet therapy in type 2 diabetes mellitus. Current Opinion in Endocrinology, Diabetes and Obesity 14:2, 124-131
CrossRef970
Kristi L Emmons, Nicole R Taylor. (2007) Contemporary Issues in Clopidogrel Therapy: New Evidence Shaping Clinical Practice. Pharmacotherapy 27:4, 553-563
CrossRef971
M. Keltai, M. Tonelli, J. F. E. Mann, E. Sitkei, B. S. Lewis, S. Hawken, S. R. Mehta, S. Yusuf, . (2007) Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. European Journal of Cardiovascular Prevention & Rehabilitation 14:2, 312-318
CrossRef972
George Howard, Leslie A McClure, John W Krakauer, Christopher S Coffey. (2007) Stroke and the statistics of the aspirin/clopidogrel secondary prevention trials. Current Opinion in Internal Medicine 6:2, 171-177
CrossRef973
Nicolas W Shammas. (2007) Epidemiology, classification, and modifiable risk factors of peripheral arterial disease. Vascular Health and Risk Management 3:2, 229-234
CrossRef974
M. Weber, C. Hamm. (2007) Myokardinfarkt und instabile Angina Pectoris. Der Internist 48:4, 399-412
CrossRef975
Joseph A. Jakubowski, Nobuko Matsushima, Fumitoshi Asai, Hideo Naganuma, John T. Brandt, Takashi Hirota, Stephen Freestone, Kenneth J. Winters. (2007) A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y 12 inhibitor, compared with clopidogrel in healthy humans. British Journal of Clinical Pharmacology 63:4, 421-430
CrossRef976
H. Metzler, K. Huber, S. Kozek-Langenecker, M.N. Vicenzi, A. Münch. (2007) Koronare Stents, duale Antiplättchentherapie und die perioperative Problematik. Der Anaesthesist 56:4, 401-412
CrossRef977
Dominick J. Angiolillo, Antonio Fernandez-Ortiz, Esther Bernardo, Fernando Alfonso, Carlos Macaya, Theodore A. Bass, Marco A. Costa. (2007) Variability in Individual Responsiveness to Clopidogrel. Journal of the American College of Cardiology 49:14, 1505-1516
CrossRef978
G Y H Lip, A H Barnett, A Bradbury, F P Cappuccio, P S Gill, E Hughes, C Imray, K Jolly, K Patel. (2007) Ethnicity and cardiovascular disease prevention in the United Kingdom: a practical approach to management. Journal of Human Hypertension 21:3, 183-211
CrossRef979
Ramiro López Menchaca, Juan María Herrero Martínez, Carmen Suárez Fernández. (2007) Asociación de antiagregantes, ¿cuándo y cómo?. Medicina Clínica 128:10, 383-389
CrossRef980
B. Brüggenjürgen, P. Lindgren, B. Ehlken, H.-J. Rupprecht, S. N. Willich. (2007) Long-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome without ST-segment elevation in Germany. The European Journal of Health Economics 8:1, 51-57
CrossRef981
A. Blinc, P. Poredoš. (2007) Pharmacological prevention of atherothrombotic events in patients with peripheral arterial disease. European Journal of Clinical Investigation 37:3, 157-164
CrossRef982
R. Zambahari, O-H Kwok, S. Javier, K. H. Mak, S. Piyamitr, H. Q. Tri Ho, J. J. Hwang, R. Suryawan, W. H. Chow. (2007) Clinical use of clopidogrel in acute coronary syndrome. International Journal of Clinical Practice 61:3, 473-481
CrossRef983
Joseph A Jakubowski, Christopher D Payne, Govinda J Weerakkody, John T Brandt, Nagy A Farid, Ying G Li, Hideo Naganuma, D Richard Lachno, Kenneth J Winters. (2007) Dose-Dependent Inhibition of Human Platelet Aggregation by Prasugrel and its Interaction With Aspirin in Healthy Subjects. Journal of Cardiovascular Pharmacology 49:3, 167-173
CrossRef984
Alexander Hirsch, Fons Windhausen, Jan GP Tijssen, Freek WA Verheugt, Jan Hein Cornel, Robbert J de Winter. (2007) Long-term outcome after an early invasive versus selective invasive treatment strategy in patients with non-ST-elevation acute coronary syndrome and elevated cardiac troponin T (the ICTUS trial): a follow-up study. The Lancet 369:9564, 827-835
CrossRef985
Nicholas E. Walker, Mary B. Fasano, Ryan A. Hobbs, Phillip A. Horwitz. (2007) Clopidogrel Desensitization Protocol for the Treatment of Thienopyridine Hypersensitivity. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 6:1, 26-29
CrossRef986
M. Marietta, P. Pedrazzi, M. Girardis, G. Torelli. (2007) Intracerebral haemorrhage: an often neglected medical emergency. Internal and Emergency Medicine 2:1, 38-45
CrossRef987
Alexander Zarbock, Renata K. Polanowska-Grabowska, Klaus Ley. (2007) Platelet-neutrophil-interactions: Linking hemostasis and inflammation. Blood Reviews 21:2, 99-111
CrossRef988
David H Fitchett. (2007) Future strategies for improving outcomes in patients with diabetes and acute coronary syndromes. Future Cardiology 3:2, 115-121
CrossRef989
Tibor Szük, Mariann Gyöngyösi, Nóra Homorodi, Èva Kristóf, Csaba Király, István F. Èdes, Andrea Facskó, Noemi Pavo, Gottfried Sodeck, Christoph Strehblow, Serdar Farhan, Gerald Maurer, Dietmar Glogar, Hans Domanovits, Kurt Huber, István Èdes. (2007) Effect of timing of clopidogrel administration on 30-day clinical outcomes: 300-mg loading dose immediately after coronary stenting versus pretreatment 6 to 24 hours before stenting in a large unselected patient cohort. American Heart Journal 153:2, 289-295
CrossRef990
Udaya S Tantry, Kevin P Bliden, Paul A Gurbel. (2007) AZD6140. Expert Opinion on Investigational Drugs 16:2, 225-229
CrossRef991
R APPLEGATE, M SACRINTY, M KUTCHER, T BAKI, S GANDHI, R SANTOS, W LITTLE. (2007) Comparison of Drug-Eluting Versus Bare Metal Stents on Later Frequency of Acute Myocardial Infarction and Death. The American Journal of Cardiology 99:3, 333-338
CrossRef992
Michael C. Nguyen, Yean L. Lim. (2007) Benefits of Drug-Eluting Stents in Coronary Heart Disease Treatment with Emphasis on the Diabetic Subgroup. Heart, Lung and Circulation 16:1, 7-9
CrossRef993
Stephen H Pennefather. (2007) Anaesthesia for oesophagectomy. Current Opinion in Anaesthesiology 20:1, 15-20
CrossRef994
James S. W. Kong, Suzanne S. Teuber, M. Eric Gershwin. (2007) Aspririn and nonsteroidal anti-inflammatory drug hypersensitivity. Clinical Reviews in Allergy & Immunology 32:1, 97-109
CrossRef995
L. Norgren, W.R. Hiatt, J.A. Dormandy, M.R. Nehler, K.A. Harris, F.G.R. Fowkes. (2007) Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). European Journal of Vascular and Endovascular Surgery 33:1, S1-S75
CrossRef996
Uwe Zeymer, Hans-Richard Arntz, Harald Darius, Kurt Huber, Jochen Senges. (2007) Efficacy and Safety of Clopidogrel 600 mg Administered Pre-Hospitally to Improve Primary Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction (CIPAMI): Study Rationale and Design. Cardiology 108:4, 265-272
CrossRef997
Marco Cattaneo. (2007) Platelet P2 receptors: old and new targets for antithrombotic drugs. Expert Review of Cardiovascular Therapy 5:1, 45-55
CrossRef998
Elod Papp, Viktoria Havasi, Judit Bene, Katalin Komlosi, Gabor Talian, Gergely Feher, Beata Horvath, Laszlo Szapary, Kalman Toth, Bela Melegh. (2007) Does Glycoprotein IIIa Gene (PlA) Polymorphism Influence Clopidogrel Resistance?. Drugs & Aging 24:4, 345-350
CrossRef999
Vijay S Ramanath, Kim A Eagle. (2007) Evidence-Based Medical Therapy of Patients with Acute Coronary Syndromes. American Journal of Cardiovascular Drugs 7:2, 95-116
CrossRef1000
PATRICIA O'MALLEY. (2007) Aspirin and Plavix. Clinical Nurse Specialist 21:1, 13-15
CrossRef1001
Thomas J Helton, Anthony A Bavry, Dharam J Kumbhani, Sandeep Duggal, Henri Roukoz, Deepak L Bhatt. (2007) Incremental Effect of Clopidogrel on Important??Outcomes in Patients with Cardiovascular Disease. American Journal of Cardiovascular Drugs 7:4, 289-297
CrossRef1002
Bart M S Heeg, Ron J G Peters, Marc Botteman, Ben A van Hout. (2007) Long-Term Clopidogrel Therapy in Patients Receiving Percutaneous Coronary Intervention. PharmacoEconomics 25:9, 769-782
CrossRef1003
Andrew King, Neeraj Bhala. (2007) Prevention of vascular events in atrial fibrillation. The Lancet 369:9556, 106
CrossRef1004
P GURBEL, K BLIDEN, A ETHERINGTON, U TANTRY. (2007) Assessment of clopidogrel responsiveness: Measurements of maximum platelet aggregation, final platelet aggregation and their correlation with vasodilator-stimulated phosphoprotein in resistant patients. Thrombosis Research 121:1, 107-115
CrossRef1005
Allan Bybeck Nielsen, Louise Bochsen, Daniel A. Steinbrüchel. (2007) Hypercoagulability and platelet inhibition after OPCAB. Randomized intervention with clopidogrel. Scandinavian Cardiovascular Journal 41:5, 325-330
CrossRef1006
Aslam M Khaja, James C Grotta. (2007) Established treatments for acute ischaemic stroke. The Lancet 369:9558, 319-330
CrossRef1007
A. Tiede. (2007) Perioperatives hämostaseologisches Management. Der Chirurg 78:1, 69-82
CrossRef1008
T POULSEN, B JORGENSEN, L KORSHOLM, P BJORNLICHT, T HAGHFELT, H MICKLEY. (2007) Prevalence of aspirin resistance in patients with an evolving acute myocardial infarction. Thrombosis Research 119:5, 555-562
CrossRef1009
P GURBEL, U TANTRY. (2007) Clopidogrel resistance?. Thrombosis Research 120:3, 311-321
CrossRef1010
Dominick J Angiolillo. (2007) ADP Receptor Antagonism. American Journal of Cardiovascular Drugs 7:6, 423-432
CrossRef1011
J.-P. Collet, G. Montalescot. (2007) Prise en charge du syndrome coronaire aigu à la phase aiguë. Annales de Cardiologie et d Angéiologie 56, S21
CrossRef1012
Martine Gilard, Eric Bezon, Jean C. Cornily, Jacques Mansourati, Philippe Mondine, Jean A. Barra, Jacques Boschat. (2007) Same-Day Combined Percutaneous Coronary Intervention and Coronary Artery Surgery. Cardiology 108:4, 363-367
CrossRef1013
Thomas Cuisset, Corinne Frere, Jacques Quilici, Pierre-Emmanuel Morange, Noémie Saut, Marc Lambert, Laurence Camoin, Irène Juhan Vague, Jean-Louis Bonnet, Marie-Christine Alessi. (2007) Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome. Thrombosis Research 120:6, 893-899
CrossRef1014
G. VILAHUR, B. G. CHOI, M. U. ZAFAR, J. F. VILES-GONZALEZ, D. A. VORCHHEIMER, V. FUSTER, J. J. BADIMON. (2007) Normalization of platelet reactivity in clopidogrel-treated subjects. Journal of Thrombosis and Haemostasis 5:1, 82-90
CrossRef1015
Grant Chow, Roy C Ziegelstein. (2007) Clopidogrel. American Journal of Cardiovascular Drugs 7:3, 169-171
CrossRef1016
Sophie Leclerc-Foucras, Haleh Bagheri, Kamran Samii, Jean-Louis Montastruc, Maryse Lapeyre-Mestre. (2007) Modifications of Low-Molecular Weight Heparin Use in a French University Hospital after Implementation of New Guidelines. Drug Safety 30:5, 409-417
CrossRef1017
Suk-Won Song, Young-Nam Youn, Gijong Yi, Sak Lee, Kyung-Jong Yoo. (2007) Effects of Continuous Administration of Clopidogrel Before Off-Pump Coronary Artery Bypass Grafting in Patients With Acute Coronary Syndrome. Circulation Journal 72:4, 626-632
CrossRef1018
Roman M. Sniecinski, Susan Wright, Jerrold H. Levy. 2007. Cardiovascular Pharmacology. , 33-52.
CrossRef1019
Bart Heeg, Joep Damen, Ben Van Hout. (2007) Oral Antiplatelet Therapy in Secondary Prevention of Cardiovascular Events. PharmacoEconomics 25:12, 1063-1082
CrossRef1020
A MALININ, A POKOV, M SPERGLING, A DEFRANCO, K SCHWARTZ, D SCHWARTZ, E MAHMUD, D ATAR, V SEREBRUANY. (2007) Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12® rapid analyzer: The VERIfy Thrombosis risk ASsessment (VERITAS) study. Thrombosis Research 119:3, 277-284
CrossRef1021
Ulrica Alström, Hans Tydén, Jonas Oldgren, Agneta Siegbahn, Elisabeth Ståhle. (2007) The platelet inhibiting effect of a clopidogrel bolus dose in patients on long-term acetylsalicylic acid treatment. Thrombosis Research 120:3, 353-359
CrossRef1022
B.J. Gersh. (2007) Effect of Clopidogrel Premedication in Off-Pump Cardiac Surgery: Are We Forfeiting the Benefits of Reduced Hemorrhagic Sequelae?. Yearbook of Cardiology 2007, 264-266
CrossRef1023
Jang-Young Kim, Junghan Yoon. (2007) Aspirin and Clopidogrel Resistance in Drug Eluting Stent Era. Korean Circulation Journal 37:4, 135
CrossRef1024
Greg L Plosker, Katherine A Lyseng-Williamson. (2007) Clopidogrel. Drugs 67:4, 613-646
CrossRef1025
(2007) Invited Synopses. Acute Cardiac Care 9:3, 134-174
CrossRef1026
Ingo Ahrens, Meike Schwarz, Karlheinz Peter, Christoph Bode. (2007) Therapeutic Inhibitors of Platelet Aggregation – from Aspirin to Integrin Blockersf. Transfusion Medicine and Hemotherapy 34:1, 44-54
CrossRef1027
L MOYE, S BARANIUK. (2007) Dependence, hyper-dependence and hypothesis testing in clinical trials. Contemporary Clinical Trials 28:1, 68-78
CrossRef1028
William E. Boden, Robert A. O’Rourke, Koon K. Teo, Pamela M. Hartigan, David J. Maron, William Kostuk, Merril Knudtson, Marcin Dada, Paul Casperson, Crystal L. Harris, John A. Spertus, Leslee Shaw, Bernard R. Chaitman, G.B. John Mancini, Daniel S. Berman, Gerald Gau, William S. Weintraub. (2007) The Evolving Pattern of Symptomatic Coronary Artery Disease in the United States and Canada: Baseline Characteristics of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) Trial. The American Journal of Cardiology 99:2, 208-212
CrossRef1029
Richard C. Becker. 2007. Hemostatic Aspects of Cardiovascular Medicine. , 339-369.
CrossRef1030
Hochman, Judith S., Lamas, Gervasio A., Buller, Christopher E., Dzavik, Vladimir, Reynolds, Harmony R., Abramsky, Staci J., Forman, Sandra, Ruzyllo, Witold, Maggioni, Aldo P., White, Harvey, Sadowski, Zygmunt, Carvalho, Antonio C., Rankin, Jamie M., Renkin, Jean P., Steg, P. Gabriel, Mascette, Alice M., Sopko, George, Pfisterer, Matthias E., Leor, Jonathan, Fridrich, Viliam, Mark, Daniel B., Knatterud, Genell L., . (2006) Coronary Intervention for Persistent Occlusion after Myocardial Infarction. New England Journal of Medicine 355:23, 2395-2407
Full Text1031
Sauyu Lin, Richard Konstance, James Jollis, Deborah A. Fisher. (2006) The Utility of Upper Endoscopy in Patients with Concomitant Upper Gastrointestinal Bleeding and Acute Myocardial Infarction. Digestive Diseases and Sciences 51:12, 2377-2383
CrossRef1032
Huyen Tran, Shamir R Mehta, John W Eikelboom. (2006) Clinical update on the therapeutic use of clopidogrel: treatment of acute ST-segment elevation myocardial infarction (STEMI). Vascular Health and Risk Management 2:4, 379-387
CrossRef1033
John J. Mahmarian, Habib A. Dakik, Neil G. Filipchuk, Leslee J. Shaw, Sherif S. Iskander, Terrence D. Ruddy, Felix Keng, Milena J. Henzlova, Adel Allam, Lemuel A. Moyé, Craig M. Pratt. (2006) An Initial Strategy of Intensive Medical Therapy Is Comparable to That of Coronary Revascularization for Suppression of Scintigraphic Ischemia in High-Risk But Stable Survivors of Acute Myocardial Infarction. Journal of the American College of Cardiology 48:12, 2458-2467
CrossRef1034
Marie Lordkipanidzé, Chantal Pharand, Donald A. Palisaitis, Jean G. Diodati. (2006) Aspirin resistance: Truth or dare. Pharmacology & Therapeutics 112:3, 733-743
CrossRef1035
Udaya S Tantry, Kevin P Bliden, Paul A Gurbel. (2006) Prasugrel. Expert Opinion on Investigational Drugs 15:12, 1627-1633
CrossRef1036
J LONDON. (2006) Pharmacologic Support of the Failing Heart. Surgical Clinics of North America 86:6, 1503-1521
CrossRef1037
Robert A. Harrington, Robert M. Califf. (2006) Late Ischemic Events After Clopidogrel Cessation Following Drug-Eluting Stenting. Journal of the American College of Cardiology 48:12, 2592-2595
CrossRef1038
Wei C. Lau, Paul A. Gurbel. (2006) Antiplatelet Drug Resistance and Drug-Drug Interactions: Role of Cytochrome P450 3A4. Pharmaceutical Research 23:12, 2691-2708
CrossRef1039
Robert D. Ecker, Elad I. Levy, Eric Sauvageau, Ricardo A. Hanel, L Nelson Hopkins. (2006) Current Concepts in the Management of Intracranial Atherosclerotic Disease. Neurosurgery 59:SUPPLEMENT, S3-210-S3-218
CrossRef1040
Glen E Cooke, Pascal J Goldschmidt-Clermont. (2006) The safety and efficacy of aspirin and clopidogrel as a combination treatment in patients with coronary heart disease. Expert Opinion on Drug Safety 5:6, 815-826
CrossRef1041
Hadi Ghadimi, Faraz Bishehsari, Farshad Allameh, Ali H. Bozorgi, Nassim Sodagari, Nazli Karami, Mahboubeh Yaghoubi, Sara Emami, Fariba Ghadimi, Bibi F. Haerizadeh, Archimedes Sanati. (2006) Clinical characteristics, hospital morbidity and mortality, and up to 1-year follow-up events of acute myocardial infarction patients: the first report from Iran. Coronary Artery Disease 17:7, 585-591
CrossRef1042
G LASHERAS. (2006) Clopidogrel y déficit de glucosa-6-fosfato deshidrogenasa. Medicina Clínica 127:19, 757-757
CrossRef1043
Sorin V. Pislaru, Adriana Harbuzariu, Rajiv Gulati, Tyra Witt, Nicole P. Sandhu, Robert D. Simari, Gurpreet S. Sandhu. (2006) Magnetically Targeted Endothelial Cell Localization in Stented Vessels. Journal of the American College of Cardiology 48:9, 1839-1845
CrossRef1044
D Charytan, R E Kuntz. (2006) The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease. Kidney International
CrossRef1045
2006. Alzheimer's Disease. .
CrossRef1046
Johan Herlitz, Leif Svensson. (2006) Prehospital evaluation and treatment of a presumed acute coronary syndrome: what are the options?. European Journal of Emergency Medicine 13:5, 308-312
CrossRef1047
Alpesh Amin. (2006) Improving the management of patients after myocardial infarction, from admission to discharge. Clinical Therapeutics 28:10, 1509-1539
CrossRef1048
Thomas Cuisset, Corinne Frere, Jacques Quilici, Pierre-Emmanuel Morange, Lyassine Nait-Saidi, Joseph Carvajal, Agnès Lehmann, Marc Lambert, Jean-Louis Bonnet, Marie-Christine Alessi. (2006) Benefit of a 600-mg Loading Dose of Clopidogrel on Platelet Reactivity and Clinical Outcomes in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome Undergoing Coronary Stenting. Journal of the American College of Cardiology 48:7, 1339-1345
CrossRef1049
Naveed Akhtar, Dirk Deleu, Ashfaq Shuaib. (2006) Antithrombotic therapy in secondary stroke prevention. Aging Health 2:5, 787-797
CrossRef1050
James T. Willerson, Paul W Armstrong. 2006. Acute Myocardial Infarction. , 611-646.
CrossRef1051
Walter S. Schroeder, Linda Ghobrial, Pritesh J. Gandhi. (2006) Possible mechanisms of drug-induced aspirin and clopidogrel resistance. Journal of Thrombosis and Thrombolysis 22:2, 139-150
CrossRef1052
Anthony A. Bavry, Dharam J. Kumbhani, Andrew N. Rassi, Deepak L. Bhatt, Arman T. Askari. (2006) Benefit of Early Invasive Therapy in Acute Coronary Syndromes. Journal of the American College of Cardiology 48:7, 1319-1325
CrossRef1053
Arun Kalyanasundaram, James C. Blankenship, Jamshid Shirani. (2006) Non-ST Segment Elevation Acute Coronary Syndromes. Southern Medical Journal 99:10, 1053-1054
CrossRef1054
Ronald Goldberg. 2006. Type 2 Diabetes. , 187-254.
CrossRef1055
PAUL A. GURBEL, UDAYA S. TANTRY. (2006) Aspirin and Clopidogrel Resistance: Consideration and Management. Journal of Interventional Cardiology 19:5, 439-448
CrossRef1056
Shyam Prabhakaran, Bernardo Liberato, Ralph L. Sacco. 2006. Stroke Prevention. , 545-584.
CrossRef1057
Stanley G Rockson, Emil M deGoma. 2006. Peripheral Arterial Disease. , 585-610.
CrossRef1058
Tobias Geisler, Meinrad Gawaz. (2006) Clopidogrel resistance / Clopidogrel-Resistenz. LaboratoriumsMedizin 30:5, 310-316
CrossRef1059
Zaher K. Otrock, Jaber I. Sawaya, Rami C. Zebian, Ali T. Taher. (2006) Spontaneous abdominal hematoma in a patient treated with clopidogrel and aspirin. Annals of Hematology 85:10, 743-744
CrossRef1060
JAMES E. TCHENG. (2006) Debate of Adjunctive Pharmacology for Percutaneous Coronary Intervention: Anticoagulation and Clopidogrel Are Not (Always) Enough. Journal of Interventional Cardiology 19:5, 456-463
CrossRef1061
Michael Cuffe. (2006) The patient with cardiovascular disease: Treatment strategies for preventing major events. Clinical Cardiology 29:S2, 4-12
CrossRef1062
Shen Wong, Christopher M. Ward, Michael Appleberg, David R. Lewis. (2006) POINT OF CARE TESTING OF ASPIRIN RESISTANCE IN PATIENTS WITH VASCULAR DISEASE. ANZ Journal of Surgery 76:10, 873-877
CrossRef1063
PIERLUIGI TRICOCI, ERIC D. PETERSON. (2006) The Evolving Role of Glycoprotein IIb/IIIa Inhibitor Therapy in Contemporary Care of Acute Coronary Syndrome Patients. Journal of Interventional Cardiology 19:5, 449-455
CrossRef1064
Adnan K. Chhatriwalla, Deepak L. Bhatt. 2006. Anticoagulation and Antiplatelet Agents. , 501-524.
CrossRef1065
T. WÆHRE, J. K. DAMÅS, T. M. PEDERSEN, L. GULLESTAD, A. YNDESTAD, A. K. ANDREASSEN, S. S. FRØLAND, A. G. SEMB, V. HANSTEEN, E. GJERTSEN, T. UELAND, F. BROSSTAD, N.O. SOLUM, P. AUKRUST. (2006) Clopidogrel increases expression of chemokines in peripheral blood mononuclear cells in patients with coronary artery disease: results of a double-blind placebo-controlled study. Journal of Thrombosis and Haemostasis 4:10, 2140-2147
CrossRef1066
Robert J Adams. (2006) Should all patients at high risk of atherothrombotic events receive dual antiplatelet therapy?. Nature Clinical Practice Neurology 2:10, 532-533
CrossRef1067
Francesco Violi, Pasquale Pignatelli. (2006) Aspirin resistance: is this term meaningful?. Current Opinion in Hematology 13:5, 331-336
CrossRef1068
Philippa Lavallée. (2006) Antithrombotiques et infarctus cérébral : essais cliniques et besoins médicaux. Thérapie 61:5, 401-405
CrossRef1069
Dennis L. DeSilvey. (2006) Clopidogrel Plus Aspirin vs Oral Anticoagulation for Atrial Fibrillation: The ACTIVE W Trial. The American Journal of Geriatric Cardiology 15:5, 326-327
CrossRef1070
Gilles Montalescot, Georges Sideris, Catherine Meuleman, Claire Bal-dit-Sollier, Nicolas Lellouche, Ph. Gabriel Steg, Michel Slama, Olivier Milleron, Jean-Philippe Collet, Patrick Henry, Farzin Beygui, Ludovic Drouet. (2006) A Randomized Comparison of High Clopidogrel Loading Doses in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes. Journal of the American College of Cardiology 48:5, 931-938
CrossRef1071
Florian B. Mayr, Bernd Jilma. (2006) Current developments in anti-platelet therapy. Wiener Medizinische Wochenschrift 156:17-18, 472-480
CrossRef1072
Whilbert S. Aronow. (2006) Use of antiplatelet drugs in secondary prevention in patients with atherothrombotic disease. Comprehensive Therapy 32:3, 182-188
CrossRef1073
Rohan Jagathesan, Stuart D Rosen, Rodney A Foale, Paolo G Camici, Eugenio Picano. (2006) Effects of Long-Term Oral Dipyridamole Treatment on Coronary Microcirculatory Function in Patients With Chronic Stable Angina: A Substudy of the Persantine In Stable Angina (PISA) Study. Journal of Cardiovascular Pharmacology 48:3, 110-116
CrossRef1074
H Mesquita Gabriel, Eduardo Infante Oliveira. (2006) Role of abciximab in the treatment of coronary artery disease. Expert Opinion on Biological Therapy 6:9, 935-942
CrossRef1075
V. Wenzel, S. Russo, H. R. Arntz, J. Bahr, M. A. Baubin, B. W. Böttiger, B. Dirks, V. Dörges, C. Eich, M. Fischer, B. Wolcke, S. Schwab, W. G. Voelckel, H. W. Gervais. (2006) Die neuen Reanimationsleitlinien 2005 des European Resuscitation Council. Der Anaesthesist 55:9, 958-979
CrossRef1076
Darko Jurisic, Marko Doko, Elizabet Glavan, Dinko Vidovic, Kristijan Matkovic, Vlatka Pitlovic. (2006) Spontaneous retroperitoneal haematoma associated with clopidogrel therapy mimicking acute appendicitis. British Journal of Clinical Pharmacology 62:2, 248-249
CrossRef1077
Pierre Théroux, Benoît Labarthe. (2006) Coping with new challenges in acute coronary syndromes. Canadian Journal of Cardiology 22, 13C-20C
CrossRef1078
Marie-Germaine Bousser. (2006) Life after CHARISMA. International Journal of Stroke 1:3, 167-168
CrossRef1079
Karen E Thomas, Duane S Pinto. (2006) Should all patients at high risk of atherothrombotic events receive dual antiplatelet therapy?. Nature Clinical Practice Cardiovascular Medicine 3:8, 416-417
CrossRef1080
(2006) Clopidogrel for the Prevention of Atherothrombotic Events. New England Journal of Medicine 355:4, 418-421
Full Text1081
Michel R Hoenig, Jenny Doust, Constantine N Aroney, Ian A Scott, Michel R Hoenig. 2006. Early invasive versus conservative strategies for unstable angina & non-ST-elevation myocardial infarction in the stent era. .
CrossRef1082
Dominick J. Angiolillo, Esther Bernardo, Celia Ramírez, Marco A. Costa, Manel Sabaté, Pilar Jimenez-Quevedo, Rosana Hernández, Raul Moreno, Javier Escaned, Fernando Alfonso, Camino Bañuelos, Theodore A. Bass, Carlos Macaya, Antonio Fernandez-Ortiz. (2006) Insulin Therapy Is Associated With Platelet Dysfunction in Patients With Type 2 Diabetes Mellitus on Dual Oral Antiplatelet Treatment. Journal of the American College of Cardiology 48:2, 298-304
CrossRef1083
K. Cassar, P. Bachoo, I. Ford, M. Greaves, J. Brittenden. (2006) Variability in Responsiveness to Clopidogrel in Patients with Intermittent Claudication. European Journal of Vascular and Endovascular Surgery 32:1, 71-75
CrossRef1084
Bryan P. Yan, Ronen Gurvitch, Andrew E. Ajani. (2006) Double jeopardy: balance between bleeding and stent thrombosis with prolonged dual antiplatelet therapy after drug-eluting stent implantation. Cardiovascular Revascularization Medicine 7:3, 155-158
CrossRef1085
Jennifer A Ng, Neil Goldberg, Mohammad J Tafreshi. (2006) Clopidogrel-Induced Hepatotoxicity and Fever. Pharmacotherapy 26:7, 1023-1026
CrossRef1086
Alanna Coolong, Laura Mauri. (2006) Clopidogrel treatment surrounding percutaneous coronary intervention: When should it be started and stopped?. Current Cardiology Reports 8:4, 267-271
CrossRef1087
Matt Fisher, Volker Knappertz. (2006) The dose of aspirin for the prevention of cardiovascular and cerebrovascular events. Current Medical Research and Opinion 22:7, 1239-1248
CrossRef1088
Rajendra H. Mehta, Matthew T. Roe, Jyotsna Mulgund, E. Magnus Ohman, Christopher P. Cannon, W. Brian Gibler, Charles V. Pollack, Sidney C. Smith, T. Bruce Ferguson, Eric D. Peterson. (2006) Acute Clopidogrel Use and Outcomes in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery. Journal of the American College of Cardiology 48:2, 281-286
CrossRef1089
&NA;. (2006) Clopidogrel (Plavix) Revisited. Obstetrics & Gynecology 108:1, 200-202
CrossRef1090
Wai-Hong Chen. (2006) Antiplatelet resistance with aspirin and clopidogrel: Is it real and does it matter?. Current Cardiology Reports 8:4, 301-306
CrossRef1091
Paul A Gurbel, Udaya S Tantry. (2006) Drug Insight: clopidogrel nonresponsiveness. Nature Clinical Practice Cardiovascular Medicine 3:7, 387-395
CrossRef1092
Avital Porter, Yuval Konstantino, Zaza Iakobishvili, Leeor Shachar, Alexander Battler, David Hasdai. (2006) Short-term triple therapy with aspirin, warfarin, and a thienopyridine among patients undergoing percutaneous coronary intervention. Catheterization and Cardiovascular Interventions 68:1, 56-61
CrossRef1093
Dalton S. McLean, Christopher P. Cannon. (2006) The Clinical Potential of a Point-of-Care Assay to Assess Interindividual Variability in Platelet Aggregation Among Patients Taking Clopidogrel. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 5:2, 103-113
CrossRef1094
Freek WA Verheugt. (2006) Good old warfarin for stroke prevention in atrial fibrillation. The Lancet 367:9526, 1877-1878
CrossRef1095
(2006) Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. The Lancet 367:9526, 1903-1912
CrossRef1096
Manolis Vavuranakis, George Latsios, Dimitris Aggelis, Irini Bosinakou, Ioannis Karambelas, Dimitrios Tousoulis, Kostas Toutouzas, Christodoulos Stefanadis. (2006) Randomized comparison of the effects of ASA plus clopidogrel versus ASA alone on early platelet activation in acute coronary syndromes with elevated high-sensitivity C-reactive protein and soluble CD40 ligand levels. Clinical Therapeutics 28:6, 860-871
CrossRef1097
Thomas Lecompte, Jean-François Hardy. (2006) Antiplatelet agents and perioperative bleeding. Canadian Journal of Anesthesia/Journal canadien d'anesthésie 53:S2, S103-S112
CrossRef1098
Antònia Agustí, Montserrat Bosch. (2006) Prevención de la enfermedad aterotrombótica con la combinación de dos antiagregantes plaquetarios. Medicina Clínica 127:4, 153-155
CrossRef1099
Rhondalyn C. McLean, Emile R. Mohler, Roger S. Blumenthal. (2006) Vascular Disease, Hypertension, and Prevention. Journal of the American College of Cardiology 47:11, D3-D8
CrossRef1100
J.F. Meco, X. Pintó. (2006) Controversia terapéutica: clopidogrel y estatinas. Clínica e Investigación en Arteriosclerosis 18, 34-48
CrossRef1101
Ralph G. Brindis, Edward Fischer, Gary Besinque, Alan Gjedsted, Philip C. Lee, Tom Padgett, Michael Petru, Jenni Raley, Eleanor Levin, Anita Strohmeier. (2006) Acute Coronary Syndromes Clinical Practice Guidelines. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 5:2, 69-102
CrossRef1102
M HAROESTARRIOL. (2006) Hemotórax bilateral secundario al tratamiento antiagregante con clopidogrel y ácido acetilsalicílico. Archivos de Bronconeumología 42:6, 307-309
CrossRef1103
Simon J Walsh, Anthony J McClelland, Jennifer A Adgey. (2006) Clopidogrel in the treatment of ischaemic heart disease. Expert Opinion on Pharmacotherapy 7:9, 1109-1120
CrossRef1104
Shen Wong, Michael Appleberg, David R. Lewis. (2006) ANTIPLATELET THERAPY IN PERIPHERAL OCCLUSIVE ARTERIAL DISEASE. ANZ Journal of Surgery 76:5, 364-372
CrossRef1105
Mohan Shenoy, Carrie B. Chapman, M. Zaim Nawaz, NancyK. Sweitzer. (2006) Diagnosis and Management of Stage A Heart Failure. Congestive Heart Failure 12:3, 146-152
CrossRef1106
Silke Abele, Michael Weyand, Martina Wollin, Nicola E. Hiemann, Frank Harig, Teddy Fischlein, Stephan M. Ensminger. (2006) Clopidogrel reduces the development of transplant arteriosclerosis. The Journal of Thoracic and Cardiovascular Surgery 131:5, 1161-1166
CrossRef1107
E. M. L. Wong, E. B. Wu, W. W. M. Chan, C. M. Yu. (2006) A review of the management of patients after percutaneous coronary intervention. International Journal of Clinical Practice 60:5, 582-589
CrossRef1108
Dalton S McLean, Christopher P Cannon. (2006) A point-of-care assay to measure platelet aggregation in patients taking clopidogrel. Future Cardiology 2:3, 255-267
CrossRef1109
Theresa Nguyen, William H. Frishman, James Nawarskas, Robert G. Lerner. (2006) Variability of Response to Clopidogrel. Cardiology in Review 14:3, 136-142
CrossRef1110
Matthew F. Giles, Peter M. Rothwell. (2006) Prognosis and management in the first few days after a transient ischemic attack or minor ischaemic stroke. International Journal of Stroke 1:2, 65-73
CrossRef1111
Udaya S Tantry, Amena Etherington, Kevin P Bliden, Paul A Gurbel. (2006) Antiplatelet therapy: current strategies and future trends. Future Cardiology 2:3, 343-366
CrossRef1112
Mary Lee-Wong, Deval Gadhvi, David Resnick. (2006) CLOPIDOGREL DESENSITIZATION. Annals of Allergy, Asthma & Immunology 96:5, 756-757
CrossRef1113
Karl Isaaz, Christophe Robin, Alexis Cerisier, Michel Lamaud, Laure Richard, Antoine Da Costa, Mohamed Hassan Sabry, Claude Gerenton, Jean Louis Blanc. (2006) A new approach of primary angioplasty for ST-elevation acute myocardial infarction based on minimalist immediate mechanical intervention. Coronary Artery Disease 17:3, 261-269
CrossRef1114
Pfeffer, Marc A., Jarcho, John A., . (2006) The Charisma of Subgroups and the Subgroups of CHARISMA. New England Journal of Medicine 354:16, 1744-1746
Full Text1115
Bhatt, Deepak L., Fox, Keith A.A., Hacke, Werner, Berger, Peter B., Black, Henry R., Boden, William E., Cacoub, Patrice, Cohen, Eric A., Creager, Mark A., Easton, J. Donald, Flather, Marcus D., Haffner, Steven M., Hamm, Christian W., Hankey, Graeme J., Johnston, S. Claiborne, Mak, Koon-Hou, Mas, Jean-Louis, Montalescot, Gilles, Pearson, Thomas A., Steg, P. Gabriel, Steinhubl, Steven R., Weber, Michael A., Brennan, Danielle M., Fabry-Ribaudo, Liz, Booth, Joan, Topol, Eric J., . (2006) Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events. New England Journal of Medicine 354:16, 1706-1717
Full Text1116
The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. (2006) Comparison of Fondaparinux and Enoxaparin in Acute Coronary Syndromes. New England Journal of Medicine 354:14, 1464-1476
Full Text1117
K. K. Ray, P. J. Sheridan, J. Bolton, T. C. Clayton, A. Veitch, R. Manivarmane, A. Al Rifai, G. Payne, W. Baig. (2006) Management and outcomes of acute coronary syndrome with minimal myocardial necrosis: analysis of a large prospective registry from a non-interventional centre*. International Journal of Clinical Practice 60:4, 383-390
CrossRef1118
Deepak L Bhatt. (2006) Can clopidogrel and aspirin lower mortality in patients with acute myocardial infarction?. Nature Clinical Practice Cardiovascular Medicine 3:4, 182-183
CrossRef1119
Amgad N. Makaryus. (2006) Aspirin resistance, an emerging, often overlooked, factor in the management of patients with coronary artery disease. Clinical Cardiology 29:4, 144-148
CrossRef1120
Albrecht Elsässer, Helge Möllmann, Holger M. Nef, Christian W. Hamm. (2006) How to revascularize patients with diabetes mellitus—. Clinical Research in Cardiology 95:4, 195-203
CrossRef1121
Mark D Schleinitz. (2006) The cost–effectiveness of clopidogrel: a review by indication. Expert Review of Pharmacoeconomics & Outcomes Research 6:2, 123-130
CrossRef1122
Julio J. Ferrer Hita, Alberto Domínguez Rodríguez, Martín J. García González, Pedro Abreu González, Miguel Bethencourt Muñoz, Francisco Marrero Rodríguez. (2006) Influencia de la diabetes mellitus en el tratamiento y el pronóstico del síndrome coronario agudo sin elevación del segmento ST. Revista Española de Cardiología 59:4, 383-386
CrossRef1123
D. SIBBING, O. VON BECKERATH, A. SCHOMIG, A. KASTRATI, N. VON BECKERATH. (2006) P2Y1 gene A1622G dimorphism is not associated with adenosine diphosphate-induced platelet activation and aggregation after administration of a single high dose of clopidogrel. Journal of Thrombosis and Haemostasis 4:4, 912-914
CrossRef1124
E. D. Michos, R. Ardehali, R. S. Blumenthal, R. A. Lange, H. Ardehali. (2006) Aspirin and Clopidogrel Resistance. Mayo Clinic Proceedings 81:4, 518-526
CrossRef1125
Stefano De Servi, Matteo Mariani, Pietro Vandoni, Antonio Dellavalle, Alessandro Politi, Fabrizio Poletti, Erminio Bonizzoni, Mario Leoncini, Claudio Cavallini. (2006) Use of glycoprotein IIb/IIIa inhibitors in invasively-treated patients with non-ST elevation acute coronary syndrome. Journal of Cardiovascular Medicine 7:3, 159-165
CrossRef1126
Jose Antonio Gonzalez-Correa, Jose Pedro De La Cruz. (2006) Triflusal: An Antiplatelet Drug with a Neuroprotective Effect?. Cardiovascular Drug Reviews 24:1, 11-24
CrossRef1127
P. W. Serruys, P. Vranckx, K. Allikmets. (2006) Clinical development of bivalirudin (Angiox®): rationale for thrombin-specific anticoagulation in percutaneous coronary intervention and acute coronary syndromes. International Journal of Clinical Practice 60:3, 344-350
CrossRef1128
Michael E. Halkos, William A. Cooper, Rebecca Petersen, John D. Puskas, Omar M. Lattouf, Joseph M. Craver, Robert A. Guyton. (2006) Early Administration of Clopidogrel Is Safe After Off-Pump Coronary Artery Bypass Surgery. The Annals of Thoracic Surgery 81:3, 815-819
CrossRef1129
T. CUISSET, C. FRERE, J. QUILICI, F. BARBOU, P. E. MORANGE, T. HOVASSE, J-L. BONNET, M-C. ALESSI. (2006) High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. Journal of Thrombosis and Haemostasis 4:3, 542-549
CrossRef1130
JW van Werkum, AACM Heestermans, VHM Deneer, CM Hackeng, JM ten Berg. (2006) Clopidogrel resistance: fact and fiction. Future Cardiology 2:2, 215-228
CrossRef1131
Alan T. Hirsch, Ziv J. Haskal, Norman R. Hertzer, Curtis W. Bakal, Mark A. Creager, Jonathan L. Halperin, Loren F. Hiratzka, William R.C. Murphy, Jeffrey W. Olin, Jules B. Puschett, Kenneth A. Rosenfield, David Sacks, James C. Stanley, Lloyd M. Taylor, Christopher J. White, John White, Rodney A. White, Elliott M. Antman, Sidney C. Smith, Cynthia D. Adams, Jeffrey L. Anderson, David P. Faxon, Valentin Fuster, Raymond J. Gibbons, Jonathan L. Halperin, Loren F. Hiratzka, Sharon A. Hunt, Alice K. Jacobs, Rick Nishimura, Joseph P. Ornato, Richard L. Page, Barbara Riegel. (2006) ACC/AHA 2005 Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic): A Collaborative Report from the American Association for Vascular Surgery/Society for Vascular Surgery,
CrossRef1132
Jean Ferrières, Jean-Pierre Cambou, Christelle Cantet, Louis Guize. (2006) Prognosis at 6 Months for Coronary and Cerebrovascular Patients: Impact of Antiplatelet Agents and Statins: Results from the Prevenir III Study. Cardiovascular Drugs and Therapy 20:1, 55-61
CrossRef1133
Hans-Christoph Diener. (2006) Secondary stroke prevention with antiplatelet drugs: have we reached the ceiling?. International Journal of Stroke 1:1, 4-8
CrossRef1134
Antònia Agustí-Escasany, Antonio Vallano-Ferraz. (2006) Gastroprotección y tratamiento con ácido acetilsalicílico a dosis bajas. Medicina Clínica 126:6, 232-233
CrossRef1135
H. R. Arntz, L. Bossart, G. Fillipatos. (2006) Initiales Management von Patienten mit akutem Koronarsyndrom. Notfall + Rettungsmedizin 9:1, 81-89
CrossRef1136
Ruchira Glaser, Henry A. Glick, Howard C. Herrmann, Stephen E. Kimmel. (2006) The Role of Risk Stratification in the Decision to Provide Upstream Versus Selective Glycoprotein IIb/IIIa Inhibitors for Acute Coronary Syndromes. Journal of the American College of Cardiology 47:3, 529-537
CrossRef1137
Graeme J Hankey, John W Eikelboom. (2006) Aspirin resistance. The Lancet 367:9510, 606-617
CrossRef1138
Glen E. Cooke, Yiwen Liu-Stratton, Amy K. Ferketich, Melvin L. Moeschberger, David J. Frid, Raymond D. Magorien, Paul F. Bray, Philip F. Binkley, Pascal J. Goldschmidt-Clermont. (2006) Effect of Platelet Antigen Polymorphism on Platelet Inhibition by Aspirin, Clopidogrel, or Their Combination. Journal of the American College of Cardiology 47:3, 541-546
CrossRef1139
Heart Failure Society of America. (2006) Section 13: Evaluation and Therapy for Heart Failure in the Setting of Ischemic Heart Disease. Journal of Cardiac Failure 12:1, e104-e111
CrossRef1140
L BELLE, J LABARERE, O MEUNIER, V AMON, M FOURNY, H BOUVAIST, O GUENOT, V HUGON, P BROIN, P FROMAGE. (2006) Facteurs associés à la réalisation d'une coronarographie précoce en présence d'un syndrome coronarien aigu sans sus-décalage du segment ST. Résultats d'une étude multicentrique. Annales de Cardiologie et d'Angéiologie 55:1, 39-48
CrossRef1141
Nerses Sanossian, Bruce Ovbiagele. (2006) Multimodality Stroke Prevention. The Neurologist 12:1, 14-31
CrossRef1142
Erlend Aune, Jøran Hjelmesæth, Keith A. A. Fox, Knut Endresen, Jan Erik Otterstad. (2006) High mortality rates in conservatively managed patients with acute coronary syndrome. Scandinavian Cardiovascular Journal 40:3, 137-144
CrossRef1143
Monisha Dutta, Elias Hanna, Pranab Das, Steven R. Steinhubl. (2006) Incidence and Prevention of Ischemic Stroke following Myocardial Infarction: Review of Current Literature. Cerebrovascular Diseases 22:5-6, 331-339
CrossRef1144
Michael J Lipinski, George W Vetrovec. (2006) Medical Treatment of Patients with Heart Failure or Left Ventricular Dysfunction Undergoing Percutaneous Coronary Intervention. American Journal of Cardiovascular Drugs 6:5, 313-325
CrossRef1145
M. Klutmann, C. Tillmanns, D. C. Gulba. (2006) Postoperative antithrombotische Therapie bei diabetischen Patienten. Clinical Research in Cardiology 95:S1, i74-i77
CrossRef1146
Paraj Patel, Rafael Gonzales, Hisham Dokainish, Nasser Lakkis. (2006) Impact of Adenosine Diphosphate and Calcium Chelation on Platelet Aggregation Testing in Patients Receiving Clopidogrel Therapy. Journal of the American College of Cardiology 47:2, 464-465
CrossRef1147
J VANWERKUM, A HEESTERMANS, J TENBERG. (2006) Point-of-care devices for monitoring anti-platelet therapy. Thrombosis Research 118:6, 769-770
CrossRef1148
Karen P. Alexander, Eric D. Peterson. (2006) Treatment of Non?ST-Elevation Acute Coronary Syndrome in the Elderly: Current Practice and Future Opportunities. The American Journal of Geriatric Cardiology 15:1, 42-49
CrossRef1149
Katherine A Lyseng-Williamson, Greg L Plosker. (2006) Clopidogrel. PharmacoEconomics 24:7, 709-726
CrossRef1150
Deepak Thatai, Vineeta Ahooja, Patrick M Pullicino. (2006) Pharmacological Prevention of Thromboembolism in Patients with Left Ventricular Dysfunction. American Journal of Cardiovascular Drugs 6:1, 41-49
CrossRef1151
Jianmin Yang, Ningfu Wang, Xingwei Zhang, Jian Xu, Feng Ling, Liang Zhou, Xianhua Ye. (2006) Late Angiographic Stent Thrombosis in a Drug-Eluting Stent That Occurred 20 Months After Premature Discontinuation of Clopidogrel Administration. International Heart Journal 47:5, 707-713
CrossRef1152
Aaron L Baggish, Marc S Sabatine. (2006) Clopidogrel use in coronary artery disease. Expert Review of Cardiovascular Therapy 4:1, 7-15
CrossRef1153
Vivian W.Y. Lee, Wai Kwong Chan, Kenneth K.C. Lee. (2006) A Cost Analysis in Patients With Acute Coronary Syndrome Using Clopidogrel in Addition to Aspirin in a Hong Kong Public Hospital. International Heart Journal 47:5, 739-744
CrossRef1154
Evangelos N. Liberopoulos, Moses S. Elisaf, Alexandros D. Tselepis, Athanasios Archimandritis, Dimitris Kiskinis, Dennis Cokkinos, Dimitri P. Mikhailidis. (2006) Upper gastrointestinal haemorrhage complicating antiplatelet treatment with aspirin and/or clopidogrel: Where we are now?. Platelets 17:1, 1-6
CrossRef1155
A SOHAL, A GANGJI, M CROWTHER, D TRELEAVEN. (2006) Uremic bleeding: Pathophysiology and clinical risk factors. Thrombosis Research 118:3, 417-422
CrossRef1156
Charles V. Pollack, Frank D. Sites, Frances S. Shofer, Keara L. Sease, Judd E. Hollander. (2006) Application of the TIMI Risk Score for Unstable Angina and Non-ST Elevation Acute Coronary Syndrome to an Unselected Emergency Department Chest Pain Population. Academic Emergency Medicine 13:1, 13-18
CrossRef1157
David Murdoch, Greg L Plosker. (2006) Triflusal. Drugs 66:5, 671-692
CrossRef1158
Hon-Kan Yip, Li-Teh Chang, Cheuk-Kwan Sun, Mien-Cheng Chen, Cheng-Hsu Yang, Wei-Chin Hung, Yuan-Kai Hsieh, Chih-Yuan Fang, Chi-Ling Hang, Chiung-Jen Wu, Hsueh-Wen Chang. (2006) Platelet Activity is a Biomarker of Cardiac Necrosis and Predictive of Untoward Clinical Outcomes in Patients With Acute Myocardial Infarction Undergoing Primary Coronary Stenting. Circulation Journal 70:1, 31-36
CrossRef1159
Tsukasa OHMORI, Kazuomi KARIO. (2006) Antiplatelet therapy. Japanese Journal of Thrombosis and Hemostasis 17:6, 649-663
CrossRef1160
George A Makar, Gregory G Ginsberg. (2006) Therapy Insight: approaching endoscopy in anticoagulated patients. Nature Clinical Practice Gastroenterology & Hepatology 3:1, 43-52
CrossRef1161
Costas Hanjis, William H. Frishman, Robert G. Lerner. (2006) Aspirin Resistance. Cardiology in Review 14:1, 18-25
CrossRef1162
B.J. Gersh. (2006) Analysis of Risk of Bleeding Complications After Different Doses of Aspirin in 192,036 Patients Enrolled in 31 Randomized Controlled Trials. Yearbook of Cardiology 2006, 268-270
CrossRef1163
Yuval Konstantino<sup>a</sup>, Zaza Iakobishvili, Avital Porter, Amir Sandach, Doron Zahger, Hanoch Hod, Haim Hammerman, Shmuel Gottlieb, Solomon Behar, David Hasdai. (2006) Aspirin, Warfarin and a Thienopyridine for Acute Coronary Syndromes. Cardiology 105:2, 80-85
CrossRef1164
Sidney C. Smith, Ted E. Feldman, John W. Hirshfeld, Alice K. Jacobs, Morton J. Kern, Spencer B. King, Douglass A. Morrison, William W. O’Neill, Hartzell V. Schaff, Patrick L. Whitlow, David O. Williams, Elliott M. Antman, Sidney C. Smith, Cynthia D. Adams, Jeffrey L. Anderson, David P. Faxon, Valentin Fuster, Jonathan L. Halperin, Loren F. Hiratzka, Sharon Ann Hunt, Alice K. Jacobs, Rick Nishimura, Joseph P. Ornato, Richard L. Page, Barbara Riegel. (2006) ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention—Summary Article. Journal of the American College of Cardiology 47:1, 216-235
CrossRef1165
James J Ferguson. (2006) The Role of Oral Antiplatelet Agents in Atherothrombotic Disease. American Journal of Cardiovascular Drugs 6:3, 149-157
CrossRef1166
Udho Thadani. (2006) Selection of optimal therapy for chronic stable angina. Current Treatment Options in Cardiovascular Medicine 8:1, 23-35
CrossRef1167
, Sidney C. Smith, Ted E. Feldman, John W. Hirshfeld, Alice K. Jacobs, Morton J. Kern, Spencer B. King, Douglass A. Morrison, William W. O'Neill, Hartzell V. Schaff, Patrick L. Whitlow, David O. Williams, , Elliott M. Antman, Sidney C. Smith, Cynthia D. Adams, Jeffrey L. Anderson, David P. Faxon, Valentin Fuster, Jonathan L. Halperin, Loren F. Hiratzka, Sharon Ann Hunt, Alice K. Jacobs, Rick Nishimura, Joseph P. Ornato, Richard L. Page, Barbara Riegel. (2006) ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention—summary article: A report of the American college of cardiology/American heart association task force on practice guidelines(ACC/AHA/SCAI writing committee to update the 2001 guidelines for percutaneous coronary intervention). Catheterization and Cardiovascular Interventions 67:1, 87-112
CrossRef1168
Sidney C. Smith, Ted E. Feldman, John W. Hirshfeld, Alice K. Jacobs, Morton J. Kern, Spencer B. King, Douglass A. Morrison, William W. O’Neill, Hartzell V. Schaff, Patrick L. Whitlow, David O. Williams, Elliott M. Antman, Sidney C. Smith, Cynthia D. Adams, Jeffrey L. Anderson, David P. Faxon, Valentin Fuster, Jonathan L. Halperin, Loren F. Hiratzka, Sharon Ann Hunt, Alice K. Jacobs, Rick Nishimura, Joseph P. Ornato, Richard L. Page, Barbara Riegel. (2006) ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention. Journal of the American College of Cardiology 47:1, e1-e121
CrossRef1169
Abraham Majluf-Cruz, Adriana Ruiz de Chavez-Ochoa, Karim Majluf-Cruz, Erika Coria-Ramirez, Ignacio Pineda Del Aguila, Sandra Treviño-Perez, Lisneth Matías-Aguilar, Julio César López-Armenta, Norma Corona de la Peña. (2006) Effect of combined administration of clopidogrel and lysine acetylsalicylate versus clopidogrel and aspirin on platelet aggregation and activated GPIIb/IIIa expression in healthy volunteers. Platelets 17:2, 105-107
CrossRef1170
Benjamin M. Scirica, David A. Morrow. (2006) Appropriate invasive and conservative treatment approaches for patients with non-ST-elevation MI. Current Treatment Options in Cardiovascular Medicine 8:1, 13-21
CrossRef1171
D. A. Vorchheimer, R. Becker. (2006) Platelets in Atherothrombosis. Mayo Clinic Proceedings 81:1, 59-68
CrossRef1172
(2005) Management of Acute Coronary Syndromes. New England Journal of Medicine 353:25, 2714-2718
Full Text1173
Patrono, Carlo, García Rodríguez, Luis A., Landolfi, Raffaele, Baigent, Colin, . (2005) Low-Dose Aspirin for the Prevention of Atherothrombosis. New England Journal of Medicine 353:22, 2373-2383
Full Text1174
Lisa K Jennings. (2005) Current strategies with eptifibatide and other antiplatelet agents in percutaneous coronary intervention and acute coronary syndromes. Expert Opinion on Drug Metabolism & Toxicology 1:4, 727-737
CrossRef1175
Sean M Donahoe, Marc S Sabatine. (2005) Adding clopidogrel to aspirin improves outcome in ST-elevation myocardial infarction patients receiving fibrinolytic therapy. Expert Review of Pharmacoeconomics & Outcomes Research 5:6, 751-761
CrossRef1176
David B Brieger. (2005) Medications for the treatment of acute coronary syndromes. Expert Opinion on Pharmacotherapy 6:16, 2843-2854
CrossRef1177
J. W. EIKELBOOM, G. J. HANKEY, J. THOM, A. CLAXTON, Q. YI, G. GILMORE, J. STATON, A. BARDEN, P. E. NORMAN. (2005) Enhanced antiplatelet effect of clopidogrel in patients whose platelets are least inhibited by aspirin: a randomized crossover trial. Journal of Thrombosis and Haemostasis 3:12, 2649-2655
CrossRef1178
Francesc X. Borrás Pérez. (2005) Los análisis de coste-efectividad como guía para la implementación clínica de los nuevos tratamientos. Revista Española de Cardiología 58:12, 1377-1380
CrossRef1179
George Y.H. Chi. (2005) Some issues with composite endpoints in clinical trials. Fundamental and Clinical Pharmacology 19:6, 609-619
CrossRef1180
Xavier Badia, Héctor Bueno, José R. González Juanatey, Vicent Valentín, Marta Rubio. (2005) Análisis de la relación coste-efectividad a corto y largo plazo de clopidogrel añadido a terapia estándar en pacientes con síndrome coronario agudo en España. Revista Española de Cardiología 58:12, 1385-1395
CrossRef1181
Vijay K Verma, Steven M Hollenberg. (2005) Update on acute coronary syndromes and ST-elevation myocardial infarction. Current Opinion in Internal Medicine 4:6, 614-618
CrossRef1182
S. Nitschmann, J. Mössner. (2005) ASS oder Clopidogrel plus Esomeprazol bei Patienten nach Ulkusblutungen. Der Internist 46:12, 1405-1408
CrossRef1183
Hans-Richard Arntz, Leo Bossaert, Gerasimos S. Filippatos. (2005) European Resuscitation Council Guidelines for Resuscitation 2005. Resuscitation 67, S87-S96
CrossRef1184
Kevin L. Thomas, Eric J. Velazquez. (2005) Therapies to prevent heart failure post-myocardial infarction. Current Heart Failure Reports 2:4, 174-182
CrossRef1185
Tammy L. Burns, Aryan N. Mooss, Daniel E. Hilleman. (2005) Antiplatelet Drug Resistance: Not Ready for Prime Time. Pharmacotherapy 25:11, 1621-1628
CrossRef1186
(2005) Part 5: Acute coronary syndromes. Resuscitation 67:2-3, 249-269
CrossRef1187
Sonia S. Anand, Chang Chun Xie, Shamir Mehta, Maria Grazia Franzosi, Campbell Joyner, Susan Chrolavicius, Keith A.A. Fox, Salim Yusuf. (2005) Differences in the Management and Prognosis of Women and Men Who Suffer From Acute Coronary Syndromes. Journal of the American College of Cardiology 46:10, 1845-1851
CrossRef1188
Christian Gachet. (2005) The platelet P2 receptors as molecular targets for old and new antiplatelet drugs. Pharmacology & Therapeutics 108:2, 180-192
CrossRef1189
Jeffrey Tabas, Erin McNutt. (2005) Treatment of Patients with Unstable Angina and Non-ST Elevation Myocardial Infarction. Emergency Medicine Clinics of North America 23:4, 1027-1042
CrossRef1190
Amar M Salam, Jassim Al Suwaidi. (2005) Evolving role of clopidogrel in acute coronary syndromes. Expert Review of Cardiovascular Therapy 3:6, 977-980
CrossRef1191
Glenn N. Levine, A. Michael Lincoff, James J. Ferguson, Kenneth W. Mahaffey, Shaun G. Goodman, Christopher P. Cannon, Pierre Theroux, Keith A.A. Fox. (2005) Utilization of catheterization and revascularization procedures in patients with non-ST segment elevation acute coronary syndrome over the last decade. Catheterization and Cardiovascular Interventions 66:2, 149-157
CrossRef1192
Deanne J Crosbie. (2005) Use of glycoprotein IIb/IIIa inhibitors in unstable angina and non-ST-elevation myocardial infarction. Emergency Medicine Australasia 17:5-6, 500-510
CrossRef1193
C. CHRISTERSSON, J. OLDGREN, A. BYLOCK, L. WALLENTIN, A. SIEGBAHN. (2005) Long-term treatment with ximelagatran, an oral direct thrombin inhibitor, persistently reduces the coagulation activity after a myocardial infarction. Journal of Thrombosis and Haemostasis 3:10, 2245-2253
CrossRef1194
Peter Eriksson. (2005) Economic Effects of Extended Clopidogrel Therapy—A Word of Caution. Journal of the American College of Cardiology 46:7, 1376
CrossRef1195
Gaietá Permanyer-Miralda, Ignacio Ferreira-González, Jaume Marrugat de la Iglesia, Héctor Bueno-Zamora. (2005) Bases conceptuales y metodológicas del estudio MASCARA: el reto de la efectividad. Medicina Clínica 125:15, 580-584
CrossRef1196
David A Halon. (2005) Acute coronary syndromes in the old and very old. Aging Health 1:2, 241-252
CrossRef1197
Xin Yang, Karen P. Alexander, Anita Y. Chen, Matthew T. Roe, Ralph G. Brindis, Sunil V. Rao, W. Brian Gibler, E. Magnus Ohman, Eric D. Peterson. (2005) The Implications of Blood Transfusions for Patients With Non–ST-Segment Elevation Acute Coronary Syndromes. Journal of the American College of Cardiology 46:8, 1490-1495
CrossRef1198
Nicholas Valettas. (2005) Does clopidogrel provide additional benefit to aspirin and fibrinolytic therapy in patients after STEMI?. Nature Clinical Practice Cardiovascular Medicine 2:10, 500-501
CrossRef1199
J Thomas Murphy, Brenda G. Fahy. (2005) Thrombosis of Sirolimus-Eluting Coronary Stent in the Postanesthesia Care Unit. Anesthesia & Analgesia 101:4, 971-973
CrossRef1200
Harjot K. Saini, Yan-Jun Xu, Amarjit S. Arneja, Paramjit S. Tappia, Naranjan S. Dhalla. (2005) Pharmacological basis of different targets for the treatment of atherosclerosis. Journal of Cellular and Molecular Medicine 9:4, 818-839
CrossRef1201
Udaya S Tantry, Kevin P Bliden, Paul A Gurbel. (2005) Resistance to antiplatelet drugs: current status and future research. Expert Opinion on Pharmacotherapy 6:12, 2027-2045
CrossRef1202
Karen P. Alexander, Matthew T. Roe, Anita Y. Chen, Barbara L. Lytle, Charles V. Pollack, Joanne M. Foody, William E. Boden, Sidney C. Smith, W. Brian Gibler, E. Magnus Ohman, Eric D. Peterson. (2005) Evolution in Cardiovascular Care for Elderly Patients With Non–ST-Segment Elevation Acute Coronary Syndromes. Journal of the American College of Cardiology 46:8, 1479-1487
CrossRef1203
JOHN J V MCMURRAY. (2005) Chronic kidney disease in patients with cardiac disease: A review of evidence-based treatment. Kidney International 68:4, 1419-1426
CrossRef1204
de Winter, Robbert J., Windhausen, Fons, Cornel, Jan Hein, Dunselman, Peter H.J.M., Janus, Charles L., Bendermacher, Peter E.F., Michels, H. Rolf, Sanders, Gerard T., Tijssen, Jan G.P., Verheugt, Freek W.A., . (2005) Early Invasive versus Selectively Invasive Management for Acute Coronary Syndromes. New England Journal of Medicine 353:11, 1095-1104
Full Text1205
Boden, William E., . (2005) Acute Coronary Syndromes without ST-Segment Elevation — What Is the Role of Early Intervention?. New England Journal of Medicine 353:11, 1159-1161
Full Text1206
Peter J. Mason, Alice K. Jacobs, Jane E. Freedman. (2005) Aspirin Resistance and Atherothrombotic Disease. Journal of the American College of Cardiology 46:6, 986-993
CrossRef1207
Alan Michelson. (2005) Platelet function testing in cardiovascular diseases. Hematology 10:4, 132-137
CrossRef1208
Gabriella Lindvall, Ulrik Sartipy, Jan van der Linden. (2005) Aprotinin Reduces Bleeding and Blood Product Use in Patients Treated With Clopidogrel Before Coronary Artery Bypass Grafting. The Annals of Thoracic Surgery 80:3, 922-927
CrossRef1209
R. Jaumdally, G. Y. H. Lip, C. Varma. (2005) Percutaneous coronary interventions for coronary artery disease: the long and short of optimizing medical therapy. International Journal of Clinical Practice 59:9, 1070-1081
CrossRef1210
James J Ferguson. (2005) Clopidogrel plus aspirin in patients with acute myocardial infarction treated with fibrinolytic therapy – CLARITY-TIMI 28. Future Cardiology 1:5, 605-610
CrossRef1211
Jee-Yoong Leong, Robert A. Baker, Pallav J. Shah, Vijit K. Cherian, John L. Knight. (2005) Clopidogrel and Bleeding After Coronary Artery Bypass Graft Surgery. The Annals of Thoracic Surgery 80:3, 928-933
CrossRef1212
Jehangir N. Din, Keith A.A. Fox. (2005) Clopidogrel in Acute Coronary Heart Disease. The American Heart Hospital Journal 3:4, 234-242
CrossRef1213
James M. Gebel. (2005) Secondary Stroke Prevention With Antiplatelet Therapy With Emphasis on the Cardiac Patient. Journal of the American College of Cardiology 46:5, 752-755
CrossRef1214
Keith AA Fox. (2005) Is clopidogrel plus aspirin more cost-effective than aspirin alone in high-risk patients with acute coronary syndromes?. Nature Clinical Practice Cardiovascular Medicine 2:9, 444-445
CrossRef1215
Daniel C Bezerra, Julien Bogousslavky. (2005) Clopidogrel: cardiologists’ panacea or neurologists’ headache?. Future Cardiology 1:5, 579-590
CrossRef1216
Sean C. Beinart, Paul Kolm, Emir Veledar, Zefeng Zhang, Elizabeth M. Mahoney, Olivier Bouin, Sylvie Gabriel, Joseph Jackson, Roland Chen, Jaime Caro, Steven Steinhubl, Eric Topol, William S. Weintraub. (2005) Long-Term Cost Effectiveness of Early and Sustained Dual Oral Antiplatelet Therapy With Clopidogrel Given for Up to One Year After Percutaneous Coronary Intervention. Journal of the American College of Cardiology 46:5, 761-769
CrossRef1217
Tomoko Komatsu, Yoshiko Tamai, Hideki Takami, Kazufumi Yamagata, Shinsaku Fukuda, Akihiro Munakata. (2005) Study for determination of the optimal cessation period of therapy with anti-platelet agents prior to invasive endoscopic procedures. Journal of Gastroenterology 40:7, 698-707
CrossRef1218
Aziz Maksoud, Robert C. Candipan, David B. Wilson, James L. Vacek. (2005) Aspirin and Clopidogrel: Efficacy, Treatment, and Resistance in Coronary Artery Disease. International Journal of Angiology 14:3, 109-114
CrossRef1219
D. R. PHILLIPS, P. B. CONLEY, U. SINHA, P. ANDRE. (2005) Therapeutic approaches in arterial thrombosis. Journal of Thrombosis and Haemostasis 3:8, 1577-1589
CrossRef1220
Sheila A Doggrell. (2005) CLARITY about the use of clopidogrel in patients with acute coronary syndromes and myocardial infarction. Expert Opinion on Pharmacotherapy 6:10, 1761-1764
CrossRef1221
Matthias Bramkamp, Konstantin J. Dedes, Thomas D. Szucs. (2005) Pharmacotherapy of Acute Coronary Syndromes: Medical Economics with an Emphasis on Clopidogrel. Cardiovascular Drugs and Therapy 19:4, 291-299
CrossRef1222
Andrew L. Frelinger, Alan D. Michelson. (2005) Clopidogrel. Journal of the American College of Cardiology 46:4, 646-647
CrossRef1223
G. J. HANKEY. (2005) Preventable stroke and stroke prevention. Journal of Thrombosis and Haemostasis 3:8, 1638-1645
CrossRef1224
Kevin Cassar, Paul Bachoo, Isobel Ford, Mike Greaves, Julie Brittenden. (2005) Clopidogrel has no effect on D-dimer and thrombin-antithrombin III levels in patients with peripheral arterial disease undergoing peripheral percutaneous transluminal angioplasty. Journal of Vascular Surgery 42:2, 252-258
CrossRef1225
F PHILIPPE, A DIBIE, F LARRAZET, T MEZIANE, T FOLLIGUET, F LABORDE. (2005) Les stents à élution de médicaments : preuves, incertitudes et pratiques. Annales de Cardiologie et d'Angéiologie 54:4, 201-211
CrossRef1226
Christopher P. Cannon, Shamir R. Mehta, Sary F. Aranki. (2005) Balancing the Benefit and Risk of Oral Antiplatelet Agents in Coronary Artery Bypass Surgery. The Annals of Thoracic Surgery 80:2, 768-779
CrossRef1227
Sasidhar Guthikonda, Eli I. Lev, Neal S. Kleiman. (2005) Resistance to antiplatelet therapy. Current Cardiology Reports 7:4, 242-248
CrossRef1228
Pilar Jiménez-Quevedo, Manel Sabaté. (2005) Percutaneous coronary revascularization in diabetics: from balloon angioplasty to drug-eluting stents. Expert Review of Cardiovascular Therapy 3:4, 635-646
CrossRef1229
Enoch Akowuah, Vivek Shrivastava, Binal Jamnadas, David Hopkinson, Pradeep Sarkar, Robert Storey, Peter Braidley, Graham Cooper. (2005) Comparison of Two Strategies for the Management of Antiplatelet Therapy During Urgent Surgery. The Annals of Thoracic Surgery 80:1, 149-152
CrossRef1230
Mary F. McMullin, D. Bareford, P. Campbell, A. R. Green, Claire Harrison, Beverley Hunt, D. Oscier, M. I. Polkey, J. T. Reilly, E. Rosenthal, Kate Ryan, T. C. Pearson, Bridget Wilkins, . (2005) Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. British Journal of Haematology 130:2, 174-195
CrossRef1231
PM Rothwell, MF Giles, E Flossmann, CE Lovelock, JNE Redgrave, CP Warlow, Z Mehta. (2005) A simple score (ABCD) to identify individuals at high early risk of stroke after transient ischaemic attack. The Lancet 366:9479, 29-36
CrossRef1232
Christopher J Boos, Gregory YH Lip. (2005) Ximelagatran for stroke prevention in atrial fibrillation. Expert Review of Cardiovascular Therapy 3:4, 551-563
CrossRef1233
A. Elsässer, H. Nef, H. Möllmann, C. W. Hamm. (2005) Clopidogrel in acute coronary syndrome: when, how much, how long?. Zeitschrift für Kardiologie 94:6, 377-382
CrossRef1234
Masami Kosuge, Kazuo Kimura, Toshiyuki Ishikawa, Toshiaki Ebina, Tomoaki Shimizu, Kiyoshi Hibi, Noritaka Toda, Yoshio Tahara, Kengo Tsukahara, Masahiko Kanna, Jyunn Okuda, Naoki Nozawa, Hiroyuki Ozaki, Hideto Yano, Satoshi Umemura. (2005) Predictors of Left Main or Three-Vessel Disease in Patients Who Have Acute Coronary Syndromes With Non–ST-Segment Elevation. The American Journal of Cardiology 95:11, 1366-1369
CrossRef1235
(2005) Guías de Práctica Clínica sobre intervencionismo coronario percutáneo. Revista Española de Cardiología 58:6, 679-728
CrossRef1236
H. Bouzguenda, A. Ouattara, P. Léger, N. Hamdi, Y. Le Manach, N. Mabrouk, P. Coriat. (2005) Continuation of clopidogrel in combination with aspirin before coronary artery bypass grafting increases neither postoperative bleeding nor transfusion requirement. European Journal of Anaesthesiology 22:Supplement 35, 1
CrossRef1237
David Rott, Jesaia Benhorin, Andre Keren, Mario Baras, David Leibowitz, Shmuel Banai. (2005) Prediction of coronary artery disease severity in patients referred for coronary angiography. Clinical Cardiology 28:6, 288-292
CrossRef1238
Alan Muskett, W Henry Barber, William C. Lineaweaver. (2005) The Plastic Surgeon??s Guide to Drugs Affecting Hemostasis. Annals of Plastic Surgery 54:5, 570-576
CrossRef1239
Hans-Christoph Diener, Peter A Ringleb, Pierre Savi. (2005) Clopidogrel for the secondary prevention of stroke. Expert Opinion on Pharmacotherapy 6:5, 755-764
CrossRef1240
Gregory A Volturo, Jennifer L Mazzola, Karin Przylenk. (2005) The role of antiplatelet therapy in the management of acute coronary syndromes. Expert Opinion on Drug Safety 4:3, 541-556
CrossRef1241
Rosemarie A Reiter, Bernd Jilma. (2005) Platelets and new antiplatelet drugs. Therapy 2:3, 465-502
CrossRef1242
Rory O'Hanlon, Donal N. Reddan. (2005) Treatment of Acute Coronary Syndromes in Patients Who Have Chronic Kidney Disease. Medical Clinics of North America 89:3, 563-585
CrossRef1243
A. Assadian, C. Senekowitsch, O. Assadian, U. Eidher, G.W. Hagmüller, P. Knöbl. (2005) Antithrombotic Strategies in Vascular Surgery: Evidence and Practice. European Journal of Vascular and Endovascular Surgery 29:5, 516-521
CrossRef1244
D. SHIMBO, K. W. DAVIDSON, D. C. HAAS, V. FUSTER, J. J. BADIMON. (2005) Negative impact of depression on outcomes in patients with coronary artery disease: mechanisms, treatment considerations, and future directions. Journal of Thrombosis and Haemostasis 3:5, 897-908
CrossRef1245
(2005) Clopidogrel versus Aspirin and Esomeprazole to Prevent Recurrent Bleeding. New England Journal of Medicine 352:16, 1716-1718
Full Text1246
J-L Mas. (2005) Atherothrombosis: management of patients at risk. International Journal of Clinical Practice 59:4, 407-414
CrossRef1247
Raimondo Ascione, Arup Ghosh, Chris A. Rogers, Alan Cohen, Chris Monk, Gianni D. Angelini. (2005) In-Hospital Patients Exposed to Clopidogrel Before Coronary Artery Bypass Graft Surgery: A Word of Caution. The Annals of Thoracic Surgery 79:4, 1210-1216
CrossRef1248
Michael A Weber. (2005) Managing the patient at risk for a second stroke. Journal of Hypertension 23:Suppl 1, S41-S47
CrossRef1249
Marius Hartmann, Olav Jansen. (2005) Angioplasty and stenting of intracranial stenosis. Current Opinion in Internal Medicine 4:2, 132-138
CrossRef1250
Thuy Anh Nguyen, Jean G. Diodati, Chantal Pharand. (2005) Resistance to clopidogrel: A review of the evidence. Journal of the American College of Cardiology 45:8, 1157-1164
CrossRef1251
Ji Y Chong, Jay P Mohr. (2005) Anticoagulation and platelet antiaggregation therapy in stroke prevention. Current Opinion in Internal Medicine 4:2, 127-131
CrossRef1252
Ricardo A. Hanel, Elad I. Levy, Lee R. Guterman, L. Nelson Hopkins. (2005) Cervical carotid revascularization: the role of angioplasty with stenting. Neurosurgery Clinics of North America 16:2, 263-278
CrossRef1253
Lange, Richard A., Hillis, L. David, . (2005) Concurrent Antiplatelet and Fibrinolytic Therapy. New England Journal of Medicine 352:12, 1248-1250
Full Text1254
Sabatine, Marc S., Cannon, Christopher P., Gibson, C. Michael, López-Sendón, Jose L., Montalescot, Gilles, Theroux, Pierre, Claeys, Marc J., Cools, Frank, Hill, Karen A., Skene, Allan M., McCabe, Carolyn H., Braunwald, Eugene, . (2005) Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction with ST-Segment Elevation. New England Journal of Medicine 352:12, 1179-1189
Full Text1255
L SZTRIHA, K SAS, L VECSEI. (2005) Aspirin resistance in stroke: 2004. Journal of the Neurological Sciences 229-230, 163-169
CrossRef1256
Christopher P. Cannon. (2005) What Is the Optimal Timing of Clopidogrel in Acute Coronary Syndromes?. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 4:1, 46-50
CrossRef1257
Hugh S. Markus. (2005) Current treatments in neurology: Stroke. Journal of Neurology 252:3, 260-267
CrossRef1258
Peter A Ringleb, Christian Schwark, Markus Schwaninger, Peter D Schellinger. (2005) Efficacy and costs of secondary prevention with antiplatelets after ischaemic stroke. Expert Opinion on Pharmacotherapy 6:3, 359-367
CrossRef1259
Héctor Bueno, Alfredo Bardají, Antonio Fernández-Ortiz, Jaume Marrugat, Helena Martí, Magda Heras. (2005) Manejo del síndrome coronario agudo sin elevación del segmento ST en España. Estudio DESCARTES (Descripción del Estado de los Síndromes Coronarios Agudos en un Registro Temporal ESpañol). Revista Española de Cardiología 58:3, 244-252
CrossRef1260
Guilherme H. M. Oliveira. (2005) Novel serologic markers of cardiovascular risk. Current Atherosclerosis Reports 7:2, 148-154
CrossRef1261
William S. Weintraub, Elizabeth M. Mahoney, Andre Lamy, Steven Culler, Yong Yuan, Jaime Caro, Sylvie Gabriel, Salim Yusuf. (2005) Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation. Journal of the American College of Cardiology 45:6, 838-845
CrossRef1262
Y. Joseph Woo. (2005) Cardiac surgery in patients on antiplatelet and antithrombotic agents. Seminars in Thoracic and Cardiovascular Surgery 17:1, 66-72
CrossRef1263
V. RAJAGOPAL, D. L. BHATT. (2005) Factor Xa inhibitors in acute coronary syndromes: moving from mythology to reality. Journal of Thrombosis and Haemostasis 3:3, 436-438
CrossRef1264
Robert P Giugliano, Eugene Braunwald. (2005) 2004 ACC/AHA guideline for the management of patients with STEMI: the implications for clinicians. Nature Clinical Practice Cardiovascular Medicine 2:3, 114-115
CrossRef1265
(2005) Carotid-Artery Stenting versus Endarterectomy. New England Journal of Medicine 352:6, 624-627
Full Text1266
Ji Y Chong, Jay P Mohr. (2005) Anticoagulation and platelet antiaggregation therapy in stroke prevention. Current Opinion in Neurology 18:1, 53-57
CrossRef1267
K. Cassar, I. Ford, M. Greaves, P. Bachoo, J. Brittenden. (2005) Randomized clinical trial of the antiplatelet effects of aspirin-clopidogrel combinationversus aspirin alone after lower limb angioplasty. British Journal of Surgery 92:2, 159-165
CrossRef1268
Tina Svenstrup Poulsen, Pernille Vinholt, Hans Mickley, Lars Korsholm, Soren Risom Kristensen, Per Damkier. (2005) Existence of a Clinically Relevant Interaction between Clopidogrel and HMG-CoA Reductase Inhibitors? Re-evaluating the Evidence. Basic <html_ent glyph="@amp;" ascii="&"/> Clinical Pharmacology <html_ent glyph="@amp;" ascii="&"/> Toxicology 96:2, 103-110
CrossRef1269
Harry L. Messmore, Walter P. Jeske, William Wehrmacher, Erwin Coyne, Sohrab Mobarhan, Leslie Cho, Fred S. Leya, John F. Moran. (2005) Antiplatelet Agents: Current Drugs and Future Trends. Hematology/Oncology Clinics of North America 19:1, 87-117
CrossRef1270
Marius Hartmann, Olav Jansen. (2005) Angioplasty and stenting of intracranial stenosis. Current Opinion in Neurology 18:1, 39-45
CrossRef1271
TT Keller, A Squizzato, VB Weeda, S Middeldorp, Tymen Keller. 2005. Clopidogrel and aspirin versus aspirin for preventing cardiovascular disease in those at high risk. .
CrossRef1272
Chan, Francis K.L., Ching, Jessica Y.L., Hung, Lawrence C.T., Wong, Vincent W.S., Leung, Vincent K.S., Kung, Nelson N.S., Hui, Aric J., Wu, Justin C.Y., Leung, Wai K., Lee, Vivian W.Y., Lee, Kenneth K.C., Lee, Yuk T., Lau, James Y.W., To, Ka F., Chan, Henry L.Y., Chung, S.C. Sydney, Sung, Joseph J.Y., . (2005) Clopidogrel versus Aspirin and Esomeprazole to Prevent Recurrent Ulcer Bleeding. New England Journal of Medicine 352:3, 238-244
Full Text1273
E BERNALMORELL. (2005) Resistencia a la aspirina. Medicina Clínica 124:1, 30-36
CrossRef1274
Jong S. Kim, Dong-Wha Kang, Sun U. Kwon. (2005) Intracranial Atherosclerosis: Incidence, Diagnosis and Treatment. Journal of Clinical Neurology 1:1, 1
CrossRef1275
Jesse Weinberger. (2005) Clinical trials report. Current Cardiology Reports 7:1, 7-9
CrossRef1276
Y CADROY, C THALAMAS, K SAKARIASSEN, B BONEU. (2005) Superior efficacy of clopidogrel plus acetylsalicylic acid compared with extended-release dipyridamole plus acetylsalicylic acid in preventing arterial thrombogenesis in healthy volunteers. Thrombosis Research 116:4, 293-300
CrossRef1277
Abdallah G Rebeiz, Joseph Adams, Robert A Harrington. (2005) Interventional Cardiovascular Pharmacotherapy. American Journal of Cardiovascular Drugs 5:2, 93-102
CrossRef1278
Pierre Amarenco. (2005) Cryptogenic Stroke, Aortic Arch Atheroma, Patent Foramen Ovale, and the Risk of Stroke. Cerebrovascular Diseases 20:2, 68-74
CrossRef1279
Peter Bogaty, James M Brophy. (2005) GRACIA: implications for clinical practice. The Lancet 365:9457, 381
CrossRef1280
F. Philippe, F. Larrazet, A. Dibie, K. Bouabdallah, D. Carbognani, T. Folliguet, D. Czitrom, A. Lagier, F. Laborde, A. Cohen. (2005) Évaluation des quatre premières années d'activité d'une unité de soins intensifs cardiologiques pour la prise en charge des syndromes coronaires aigus comparativement aux données régionales du registre GRACE (Global Registry of Acute Coronary Events). Annales de Cardiologie et d Angéiologie 54:2, 68
CrossRef1281
Wolfgang Bocksch, Suzanne Fateh-Moghadam, Eda Mueller, Sonja Huehns, Juergen Waigand, Rainer Dietz. (2005) Percutaneous Coronary Intervention in Patients with End-Stage Renal Disease. Kidney and Blood Pressure Research 28:5-6, 275-279
CrossRef1282
Bryan PY Yan, David J Clark, Andrew E Ajani. (2005) Oral antiplatelet therapy and percutaneous coronary intervention. Expert Opinion on Pharmacotherapy 6:1, 3-12
CrossRef1283
Fausto Biancari, Tatu Juvonen. (2005) Does clopidogrel improve the long-term outcome after coronary artery bypass surgery?. Scandinavian Cardiovascular Journal 39:3, 135-136
CrossRef1284
Arduino A Mangoni. (2005) Cardiovascular Drug Therapy in Elderly Patients. Drugs & Aging 22:11, 913-941
CrossRef1285
Margarite J Vale, Michael V Jelinek, James D Best. (2005) Impact of Coaching Patients on Coronary Risk Factors. Disease Management & Health Outcomes 13:4, 225-244
CrossRef1286
B. ALEIL, C. RAVANAT, J. P. CAZENAVE, G. ROCHOUX, A. HEITZ, C. GACHET. (2005) Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. Journal of Thrombosis and Haemostasis 3:1, 85-92
CrossRef1287
James D. Fleck. (2005) Antiplatelet medications in the secondary prevention of ischemic stroke. Current Neurology and Neuroscience Reports 5:1, 1-3
CrossRef1288
Daniel C. Bezerra, Julien Bogousslavsky. (2005) Antiplatelets in Stroke Prevention: The MATCH Trial. Cerebrovascular Diseases 20:2, 109-118
CrossRef1289
Brendan Duffy, Deepak L Bhatt. (2005) Antiplatelet Agents in Patients Undergoing Percutaneous Coronary Intervention. American Journal of Cardiovascular Drugs 5:5, 307-318
CrossRef1290
Carey Kimmelstiel, Jehangir Badar, Lidija Covic, Sergio Waxman, Andrew Weintraub, Suzanne Jacques, Athan Kuliopulos. (2005) Pharmacodynamics and pharmacokinetics of the platelet GPIIb/IIIa inhibitor tirofiban in patients undergoing percutaneous coronary intervention: implications for adjustment of tirofiban and clopidogrel dosage. Thrombosis Research 116:1, 55-66
CrossRef1291
Hon-Kan Yip, Chiung-Jen Wu, Chi-Ling Hang, Hsueh-Wen Chang, Wei-Chin Hung, Kuo-Ho Yeh, Cheng-Hsu Yang. (2005) Serial Changes in Platelet Activation in Patients With Unstable Angina Following Coronary Stenting. Circulation Journal 69:10, 1208-1211
CrossRef1292
Peter Lindgren, Ulf Stenestrand, Klas Malmberg, Bengt Jönsson. (2005) The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden. Clinical Therapeutics 27:1, 100-110
CrossRef1293
Jesse Weinberger. (2005) Adverse Effects and Drug Interactions of Antithrombotic Agents Used in Prevention of Ischaemic Stroke. Drugs 65:4, 461-471
CrossRef1294
R STOREY, J MAY, S HEPTINSTALL. (2005) Potentiation of platelet aggregation by heparin in human whole blood is attenuated by P2Y12 and P2Y1 antagonists but not aspirin. Thrombosis Research 115:4, 301-307
CrossRef1295
Waiel M. Samara, Kevin P. Bliden, Udaya S. Tantry, Paul A. Gurbel. (2005) The difference between clopidogrel responsiveness and posttreatment platelet reactivity
CrossRef1296
Bartlomiej Piechowski-Jozwiak, Alexander Maulaz, Julien Bogousslavsky. (2005) Secondary Prevention of Stroke with Antiplatelet Agents in Patients with Diabetes mellitus. Cerebrovascular Diseases 20:1, 15-23
CrossRef1297
Peter M. Rothwell. (2005) Prevention of Stroke in Patients with Diabetes mellitus and the Metabolic Syndrome. Cerebrovascular Diseases 20:1, 24-34
CrossRef1298
Brett D Atwater, Matthew T Roe, Kenneth W Mahaffey. (2005) Platelet Glycoprotein IIb/IIIa Receptor Antagonists in Non-ST Segment Elevation Acute Coronary Syndromes. Drugs 65:3, 313-324
CrossRef1299
D ANGIOLILLO, A FERNANDEZORTIZ, E BERNARDO, C RAMIREZ, U CAVALLARI, E TRABETTI, M SABATE, P JIMENEZQUEVEDO, R HERNANDEZ, R MORENO. (2005) Lack of association between the P2Y receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease. Thrombosis Research 116:6, 491-497
CrossRef1300
Norberto Andaluz, Mario Zuccarello. (2005) Place of Drug Therapy in the Treatment of Carotid Stenosis. CNS Drugs 19:7, 597-622
CrossRef1301
Eric T. Chou, Robert M. Minutello, Manish Parikh, Geoffrey Bergman, S. Chiu Wong, Mun K. Hong. (2004) Can we identify vulnerable patients at risk for ST-segment elevation myocardial infarction based on their clinical characteristics?. Coronary Artery Disease 15:8, 467-469
CrossRef1302
Andrew J. Feiring, Amy A. Wesolowski, Susan Lade. (2004) Primary stent-supported angioplasty for treatment of below-knee critical limb ischemia and severe claudication. Journal of the American College of Cardiology 44:12, 2307-2314
CrossRef1303
Andre Lamy, Bengt J??nsson, William S. Weintraub, Feng Zhao, Susan Chrolavicius, Ameet Bakhai, Steven Culler, Amiram Gafni, Peter Lindgren, Elizabeth Mahoney, Salim Yusuf. (2004) The cost-effectiveness of the use of clopidogrel in acute coronary syndromes in five countries based upon the CURE study. European Journal of Cardiovascular Prevention & Rehabilitation 11:6, 460-465
CrossRef1304
Christopher J Boos, Gregory YH Lip. (2004) Novel therapies for the prevention of stroke. Expert Opinion on Investigational Drugs 13:12, 1615-1630
CrossRef1305
Santiago Garcia, Mariana J. Canoniero, Julio A. Chirinos, Eduardo de Marchena, Tomas Salerno, Alexandre Ferreira. (2004) Development of a Score to Predict the Need for Coronary Artery Bypass Graft Surgery in Patients With Non-ST Segment Elevation Acute Coronary Syndromes. The Annals of Thoracic Surgery 78:6, 2022-2026
CrossRef1306
Mehmet Akbulut, Yilmaz Ozbay, Ozlem Gundogdu, Necati Daglı, Polat Durukan, Erdogan Ilkay, Nadi Arslan. (2004) Effects of tirofiban on acute systemic inflammatory response in elective percutaneous coronary interventions. Current Medical Research and Opinion 20:11, 1759-1767
CrossRef1307
Jeffrey J. Cavendish, Randolph V. Fugit, Michael Safani. (2004) Role of antiplatelet therapy in cardiovascular disease I: acute coronary syndromes. Current Medical Research and Opinion 20:11, 1839-1843
CrossRef1308
Piet W. Boonstra, Wim van Oeveren. (2004) Clopidogrel and Postoperative Bleeding. The Annals of Thoracic Surgery 78:5, 1522
CrossRef1309
Barbara L. Maglish Ehrman, Holly A. Moore. (2004) Blood Conservation Strategies in Cardiovascular Surgery. Dimensions of Critical Care Nursing 23:6, 244-252
CrossRef1310
J.A. Páramo Fernández, J. Feliú Sánchez, M.P. Sánchez Antón, E. Rocha Hernando. (2004) Nuevas estrategias antitrombóticas en la trombosis arterial. Medicine - Programa de Formación Médica Continuada Acreditado 9:22, 1414-1422
CrossRef1311
Daniel F. Hogan, Dina A. Andrews, Henry W. Green, Kristen K. Talbott, Michael P. Ward, Betsy M. Calloway. (2004) Antiplatelet effects and pharmacodynamics of clopidogrel in cats. Journal of the American Veterinary Medical Association 225:9, 1406-1411
CrossRef1312
Stella S. Daskalopoulou, Gerard Stansby, Dimitri P. Mikhailidis. (2004) Clopidogrel and vascular disease prevention. Current Medical Research and Opinion 20:11, 1835-1838
CrossRef1313
Michael W.A. Chu, Steve R. Wilson, Richard J. Novick, Larry W. Stitt, MacKenzie A. Quantz. (2004) Does Clopidogrel Increase Blood Loss Following Coronary Artery Bypass Surgery?. The Annals of Thoracic Surgery 78:5, 1536-1541
CrossRef1314
M. Woodward, G. D. O. Lowe, L. M. A. Francis, A. Rumley, S. M. Cobbe, . (2004) A randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and C-reactive protein following myocardial infarction: the CADET trial. Journal of Thrombosis and Haemostasis 2:11, 1934-1940
CrossRef1315
James L Frey. (2004) The results of MATCH: light or heat?. The Lancet Neurology 3:11, 642
CrossRef1316
Athanasios Stoyioglou, Michael R. Jaff. (2004) Medical Treatment of Peripheral Arterial Disease: A Comprehensive Review. Journal of Vascular and Interventional Radiology 15:11, 1197-1207
CrossRef1317
Arvind K. Sharma, Andrew E. Ajani, Shadi M. Hamwi, Parimal Maniar, Shilen V. Lakhani, Ron Waksman, Joseph Lindsay. (2004) Major noncardiac surgery following coronary stenting: When is it safe to operate?. Catheterization and Cardiovascular Interventions 63:2, 141-145
CrossRef1318
David Bergqvist. (2004) Bleeding profiles of anticoagulants, including the novel oral direct thrombin inhibitor ximelagatran: definitions, incidence and management. European Journal of Haematology 73:4, 227-242
CrossRef1319
LiQian Chen, Arthur W. Bracey, Rajko Radovancevic, John R. Cooper, Charles D. Collard, William K. Vaughn, Nancy A. Nussmeier. (2004) Clopidogrel and bleeding in patients undergoing elective coronary artery bypass grafting. The Journal of Thoracic and Cardiovascular Surgery 128:3, 425-431
CrossRef1320
William Simonson, Judith L. Beizer. (2004) Antiplatelet Therapy for Secondary Prevention of the Complications of Atherothrombotic Disease. The Consultant Pharmacist 19:9, 813-823
CrossRef1321
Liviu Klein, Mihai Gheorghiade. (2004) Coronary artery disease and prevention of heart failure. Medical Clinics of North America 88:5, 1209-1235
CrossRef1322
Kim A. Eagle, Robert A. Guyton, Ravin Davidoff, Fred H. Edwards, Gordon A. Ewy, Timothy J. Gardner, James C. Hart, Howard C. Herrmann, L. David Hillis, Adolph M. Hutter, Bruce Whitney Lytle, Robert A. Marlow, William C. Nugent, Thomas A. Orszulak, Elliott M. Antman, Sidney C. Smith, Joseph S. Alpert, Jeffrey L. Anderson, David P. Faxon, Valentin Fuster, Raymond J. Gibbons, Gabriel Gregoratos, Jonathan L. Halperin, Loren F. Hiratzka, Sharon Ann Hunt, Alice K. Jacobs, Joseph P. Ornato. (2004) ACC/AHA 2004 Guideline Update for Coronary Artery Bypass Graft Surgery: Summary Article. Journal of the American College of Cardiology 44:5, 1146-1154
CrossRef1323
Richard W. Smalling, Gregory M. Giesler. (2004) Early and Aggressive Treatment of Patients With Acute ST Segment Elevation and Non-ST Segment Elevation Myocardial Infarction Leads to Improved Clinical Outcomes. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 3:3, 121-127
CrossRef1324
John G. Byrne, Alexandros N. Karavas, Tomas Gudbjartson, Marzia Leacche, James D. Rawn, Gregory S. Couper, Robert J. Rizzo, Lawrence H. Cohn, Sary F. Aranki. (2004) Left anterior descending coronary endarterectomy: Early and late results in 196 consecutive patients. The Annals of Thoracic Surgery 78:3, 867-873
CrossRef1325
Michael Moore, Michael Power. (2004) Perioperative Hemorrhage and Combined Clopidogrel and Aspirin Therapy. Anesthesiology 101:3, 792-794
CrossRef1326
Mehmet Akbulut, Yilmaz Ozbay, Ilgin Karaca, Erdogan Ilkay, Ozlem Gundogdu, Nadi Arslan. (2004) The effect of long-term clopidogrel use on neointimal formation after percutaneous coronary intervention. Coronary Artery Disease 15:6, 347-352
CrossRef1327
Mario Leoncini, Mauro Maioli, Francesco Bellandi, Marcello Galvani, Filippo Ottani, Anna Toso, Emilio Di Vincenzo, Michela Gallopin, Roberto Piero Dabizzi. (2004) Therapeutic strategies, immediate and mid-term outcomes in non-ST-segment elevation acute coronary syndromes with respect to age: A single-center registry of 488 consecutive patients. Clinical Cardiology 27:8, 475-479
CrossRef1328
Elliott M. Antman, Daniel T. Anbe, Paul Wayne Armstrong, Eric R. Bates, Lee A. Green, Mary Hand, Judith S. Hochman, Harlan M. Krumholz, Frederick G. Kushner, Gervasio A. Lamas, Charles J. Mullany, Joseph P. Ornato, David L. Pearle, Michael A. Sloan, Sidney C. Smith, Elliott M. Antman, Sidney C. Smith, Joseph S. Alpert, Jeffrey L. Anderson, David P. Faxon, Valentin Fuster, Raymond J. Gibbons, Gabriel Gregoratos, Jonathan L. Halperin, Loren F. Hiratzka, Sharon Ann Hunt, Alice K. Jacobs, Joseph P. Ornato. (2004) ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction—Executive Summary. Journal of the American College of Cardiology 44:3, 671-719
CrossRef1329
Manel Sabaté, Gela Pimentel, Carlos Prieto, José María Corral, Camino Bañuelos, Dominick J. Angiolillo, Fernando Alfonso, Rosana Hernández-Antolín, Javier Escaned, Panayotis Fantidis, Cristina Fernández, Antonio Fernández-Ortiz, Raúl Moreno, Carlos Macaya. (2004) Intracoronary Brachytherapy After Stenting De Novo Lesions in Diabetic Patients. Journal of the American College of Cardiology 44:3, 520-527
CrossRef1330
Saihari Sadanandan, Christopher P. Cannon, C.Michael Gibson, Sabina A. Murphy, Peter M. DiBattiste, Eugene Braunwald. (2004) A risk score to estimate the likelihood of coronary artery bypass surgery during the index hospitalization among patients with unstable angina and non–ST-segment elevation myocardial infarction. Journal of the American College of Cardiology 44:4, 799-803
CrossRef1331
Jessica L. Kerr, Thomas F. Oppelt, Randall C. Rowen. (2004) Role of Clopidogrel in Unstable Angina and Non–ST-Segment Elevation Myocardial Infarction: From Literature and Guidelines to Practice. Pharmacotherapy 24:8, 1037-1049
CrossRef1332
Sven Nylander, Christer Mattsson, Sofia Ramström, Tomas L Lindahl. (2004) Synergistic action between inhibition of P2Y 12 /P2Y 1 and P2Y 12 /thrombin in ADP- and thrombin-induced human platelet activation. British Journal of Pharmacology 142:8, 1325-1331
CrossRef1333
Hans-Christoph Diener, Julien Bogousslavsky, Lawrence M Brass, Claudio Cimminiello, Laszlo Csiba, Markku Kaste, Didier Leys, Jordi Matias-Guiu, Hans-Jürgen Rupprecht. (2004) Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. The Lancet 364:9431, 331-337
CrossRef1334
Peter M Rothwell. (2004) Lessons from MATCH for future randomised trials in secondary prevention of stroke. The Lancet 364:9431, 305-307
CrossRef1335
Brian D. Guth, Hans Narjes, Hans-Dieter Schubert, Paul Tanswell, Axel Riedel, Gerhard Nehmiz. (2004) Pharmacokinetics and pharmacodynamics of terbogrel, a combined thromboxane A2 receptor and synthase inhibitor, in healthy subjects. British Journal of Clinical Pharmacology 58:1, 40-51
CrossRef1336
W.H Wilson Tang, Anjli Maroo, James B Young. (2004) Ischemic heart disease and congestive heart failure in diabetic patients. Medical Clinics of North America 88:4, 1037-1061
CrossRef1337
Patricia J.M. Best, Verghese Mathew, Svetomir N. Markovic. (2004) Clopidogrel-associated autoimmune thrombocytopenic purpura. Catheterization and Cardiovascular Interventions 62:3, 339-340
CrossRef1338
Susan K. Bennett, Rita F. Redberg. (2004) Acute coronary syndromes in women: Is treatment different? should it be?. Current Cardiology Reports 6:4, 243-252
CrossRef1339
David E. Kandzari. (2004) Current concepts in the antithrombotic management of non-ST-elevation acute coronary syndromes. Current Cardiology Reports 6:4, 279-286
CrossRef1340
Michael L Stadius. (2004) Diminishing returns …and too many choices …the saga of pharmacologic therapy to reduce the complications of percutaneous coronary intervention. Journal of the American College of Cardiology 44:1, 25-27
CrossRef1341
Francesco Saia, Pedro A. Lemos, Angela Hoye, Georgios Sianos, Chourmouzios A. Arampatzis, Pim J. de Feyter, Willem J. van der Giessen, Pieter C. Smits, Ron T. van Domburg, Patrick W. Serruys. (2004) Clinical outcomes for sirolimus-eluting stent implantation and vascular brachytherapy for the treatment of in-stent restenosis. Catheterization and Cardiovascular Interventions 62:3, 283-288
CrossRef1342
Daniel F. Hogan, Michael P. Ward. (2004) Effect of clopidogrel on tissue-plasminogen activator-induced in vitro thrombolysis of feline whole blood thrombi. American Journal of Veterinary Research 65:6, 715-719
CrossRef1343
Christopher P. Cannon. (2004) Risk Stratification and the Management of Non–ST-Segment Elevation Acute Coronary Syndromes. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 3:2, 83-86
CrossRef1344
Maarten L. Simoons, Inge W.G. Bobbink, Jean Boland, Martin Gardien, Peter Klootwijk, Anthonie W.A. Lensing, Witold Ruzyllo, Victor A.W.M. Umans, Alec Vahanian, Frans Van De Werf, Uwe Zeymer. (2004) A dose-finding study of fondaparinux in patients with non–ST-segment elevation acute coronary syndromes. Journal of the American College of Cardiology 43:12, 2183-2190
CrossRef1345
Zihui Xiao, Pierre Théroux. (2004) Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome. Journal of the American College of Cardiology 43:11, 1982-1988
CrossRef1346
Neal S Kleiman. (2004) Platelets, the cardiologist, and coronary artery disease: moving beyond aggregation. Journal of the American College of Cardiology 43:11, 1989-1991
CrossRef1347
F PHILIPPE. (2004) Prescription m
dicamenteuse au d
CrossRef1348
(2004) Paclitaxel-Eluting Coronary Stents. New England Journal of Medicine 350:20, 2099-2100
Full Text1349
P. Lindgren, B. Jonsson, S. Yusuf. (2004) Cost-effectiveness of clopidogrel in acute coronary syndromes in Sweden: a long-term model based on the cure trial. Journal of Internal Medicine 255:5, 562-570
CrossRef1350
Michael Ezekowitz. (2004) Medical prevention of secondary stroke: A cardiologist's perspective. Clinical Cardiology 27:S2, 36-42
CrossRef1351
James S Kalus, Michael F Caron. (2004) Novel uses for current and future direct thrombin inhibitors: focus on ximelagatran and bivalirudin. Expert Opinion on Investigational Drugs 13:5, 465-477
CrossRef1352
Giuseppe Mancia. (2004) Prevention and treatment of stroke in patients with hypertension. Clinical Therapeutics 26:5, 631-648
CrossRef1353
Jean-Marc Herbert. (2004) Effects of ADP-receptor antagonism beyond traditional inhibition of platelet aggregation. Expert Opinion on Investigational Drugs 13:5, 457-460
CrossRef1354
Mitchell S. V. Elkind. (2004) Secondary stroke prevention: Review of clinical trials. Clinical Cardiology 27:S2, 25-35
CrossRef1355
S Wong, M Appleberg, C.M Ward, D.R Lewis. (2004) Aspirin Resistance in Cardiovascular Disease: A Review. European Journal of Vascular and Endovascular Surgery 27:5, 456-465
CrossRef1356
MR Hoenig, JA Doust, CN Aroney, IA Scott, Michel Hoenig. 2004. Early invasive versus ischemia-guided strategies for unstable angina & non-ST-elevation myocardial infarction. .
CrossRef1357
Marco Zimarino, Raffaele De Caterina. (2004) Glycoprotein IIb-IIIa Antagonists in Non-ST Elevation Acute Coronary Syndromes and Percutaneous Interventions: From Pharmacology to Individual Patient???s Therapy. Journal of Cardiovascular Pharmacology 43:4, 477-484
CrossRef1358
P.A. Ringleb, P.D. Schellinger, C. Schwark. (2004) Clopidogrel in the management of cerebrovascular events. International Journal of Clinical Practice 58:4, 402-410
CrossRef1359
Clyde W. Yancy. (2004) Improving Outcomes in the Post-Myocardial Infarction Setting. The Journal of Clinical Hypertension 6:s4, 34-41
CrossRef1360
Michael H Rosove. (2004) Platelet glycoprotein IIb/IIIa inhibitors. Best Practice & Research Clinical Haematology 17:1, 65-76
CrossRef1361
Wai Khoon Ho, Graeme J Hankey, John W Eikelboom. (2004) Prevention of coronary heart disease with aspirin and clopidogrel: efficacy, safety, costs and cost-effectiveness. Expert Opinion on Pharmacotherapy 5:3, 493-503
CrossRef1362
Victor J Marder, Michael H Rosove, Dena M Minning. (2004) Foundation and sites of action of antithrombotic agents. Best Practice & Research Clinical Haematology 17:1, 3-22
CrossRef1363
Eric David Peterson. (2004) Reply. Journal of the American College of Cardiology 43:5, 927-928
CrossRef1364
Claudia Stöllberger, Josef Finsterer, Birke Schneider. (2004) Percutaneous Left Atrial Appendage Transcatheter Occlusion: An Effective and Safe Protection Against Stroke or Embolism?. Journal of Cardiovascular Electrophysiology 15:3, 373-373
CrossRef1365
Michael J Schneck, Jose Biller. (2004) Antithrombotic therapy for prevention of recurrent stroke in the new millenium. Expert Review of Neurotherapeutics 4:2, 145-149
CrossRef1366
Neil L. Coplan. (2004) Glycoprotein IIb/IIIa inhibitors and the guidelines for treatment of non–ST-elevation myocardial infarction. Journal of the American College of Cardiology 43:5, 926-927
CrossRef1367
J. I. Osende, D. Shimbo, V. Fuster, M. Dubar, J. J. Badimon. (2004) Antithrombotic effects of S 18886, a novel orally active thromboxane A2 receptor antagonist. Journal of Thrombosis and Haemostasis 2:3, 492-498
CrossRef1368
Alan K Jacobson. (2004) Platelet ADP receptor antagonists: ticlopidine and clopidogrel. Best Practice & Research Clinical Haematology 17:1, 55-64
CrossRef1369
Mitchell S. V. Elkind. (2004) The role of warfarin and aspirin in secondary prevention of stroke. Current Cardiology Reports 6:2, 135-142
CrossRef1370
Martin J Quinn, Herbert D Aronow, Robert M Califf, Deepak L Bhatt, Shelly Sapp, Neal S Kleiman, Robert A Harrington, David F Kong, David E Kandzari, Eric J Topol. (2004) Aspirin dose and six-month outcome after an acute coronary syndrome. Journal of the American College of Cardiology 43:6, 972-978
CrossRef1371
F PHILIPPE. (2004) Quelle m
CrossRef1372
Y Gomez. (2004) Analysis of purity in 19 drug product tablets containing clopidogrel: 18 copies versus the original brand. Journal of Pharmaceutical and Biomedical Analysis 34:2, 341-348
CrossRef1373
F.-H. Ng, B. C.-Y. Wong, S.-Y. Wong, W.-H. Chen, C.-M. Chang. (2004) Clopidogrel plus omeprazole compared with aspirin plus omeprazole for aspirin-induced symptomatic peptic ulcers/erosions with low to moderate bleeding/re-bleeding risk - a single-blind, randomized controlled study. Alimentary Pharmacology and Therapeutics 19:3, 359-365
CrossRef1374
D.J. Betteridge, J. Belch, M.M. Brown, M. Gent, D. Julian, S. Long, S. Morris, J. Pittard, M. Pye. (2004) Guidelines on the management of secondary prophylaxis of vascular events in stable patients in primary care. International Journal of Clinical Practice 58:2, 153-168
CrossRef1375
Lange, Richard A., Hillis, L. David, . (2004) Antiplatelet Therapy for Ischemic Heart Disease. New England Journal of Medicine 350:3, 277-280
Full Text1376
John W Eikelboom, Graeme J Hankey. (2004) Failure of Aspirin to Prevent Atherothrombosis. American Journal of Cardiovascular Drugs 4:1, 57-67
CrossRef1377
Miles Dalby, Gilles Montalescot, Claire Bal dit Sollier, Eric Vicaut, Thierry Soulat, Jean-Philippe Collet, Rémi Choussat, Vanessa Gallois, Gérard Drobinski, Ludovic Drouet, Daniel Thomas. (2004) Eptifibatide provides additional platelet inhibition in Non–ST-Elevation myocardial infarction patients already treated with aspirin and clopidogrel. Journal of the American College of Cardiology 43:2, 162-168
CrossRef1378
John A Colwell. (2004) Antiplatelet Agents for the Prevention of Cardiovascular Disease in Diabetes Mellitus. American Journal of Cardiovascular Drugs 4:2, 87-106
CrossRef1379
C. Perneby, N.H. Wallén, H. Hu, N. Li, P. Hjemdahl. (2004) Prothrombotic responses to exercise are little influenced by clopidogrel treatment. Thrombosis Research 114:4, 235-243
CrossRef1380
Ahmet Çamsari, Oben Döven, Hasan Pekdemir, Dilek Çiçek, Tuna Katircibasi, Tuncay Parmaksiz, M. Necdet Akkus, V. Gökhan Cin. (2004) Early and Late Angiographic and Clinical Outcome Following Helistent Stent Implantation. Japanese Heart Journal 45:1, 1-10
CrossRef1381
Jan Erik Otterstad, Frank Brosstad. (2004) Antithrombotic treatment of NSTEMI/UAP. The interaction with PCI. Scandinavian Cardiovascular Journal 38:1, 9-15
CrossRef1382
Harold P. Adams, Patricia H. Davis. 2004. Antithrombotic Therapy for Acute Ischemic Stroke. , 953-969.
CrossRef1383
Babette B. Weksler. 2004. Antiplatelet Therapy for Secondary Prevention of Stroke. , 1107-1128.
CrossRef1384
Mark J Alberts, Richard Atkinson. (2004) Risk Reduction Strategies in Ischaemic Stroke. Clinical Drug Investigation 24:5, 245-254
CrossRef1385
Sebastian Harder, Ute Klinkhardt, John M Alvarez. (2004) Avoidance of Bleeding During Surgery in Patients Receiving Anticoagulant and/or Antiplatelet Therapy. Clinical Pharmacokinetics 43:14, 963-981
CrossRef1386
William Weintraub, Bengt J??nsson, Michel Bertrand. (2004) The Value of Clopidogrel in Addition to Standard Therapy in Reducing Atherothrombotic Events. PharmacoEconomics 22:Supplement 4, 29-41
CrossRef1387
David M. Cocchetto. (2004) Regulatory Decision‐Making in the United States Based on a Single Pivotal Clinical Study: Principles and Precedents. Clinical Research and Regulatory Affairs 21:2, 101-143
CrossRef1388
Jason T. Call, Efthymios N. Deliargyris, L Kristin Newby. (2004) Focusing on Inflammation in the Treatment of Atherosclerosis. Cardiology in Review 12:4, 194-200
CrossRef1389
Jaime Latour-Pérez, Andrés Navarro-Ruiz, Manuel Ridao-López, Manuel Cervera-Montes. (2004) Using Clopidogrel in Non-ST-Segment Elevation Acute Coronary Syndrome Patients: A Cost–Utility Analysis in Spain. Value in Health 7:1, 52-60
CrossRef1390
Dominick J Angiolillo, Antonio Fernandez-Ortiz, Esther Bernardo, Fernando Alfonso, Manel Sabaté, Cristina Fernández, Chiara Stranieri, Elisabetta Trabetti, Pier Franco Pignatti, Carlos Macaya. (2004) PlA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation. Blood Coagulation & Fibrinolysis 15:1, 89-93
CrossRef1391
Akshay S. Desai, Peter H. Stone. (2004) Risk stratification in patients with unstable angina and non-ST-elevation myocardial infarction. Current Treatment Options in Cardiovascular Medicine 6:1, 3-14
CrossRef1392
Christopher P Cannon. (2004) Cost-Effectiveness of Clopidogrel. PharmacoEconomics 22:Supplement 4, 1-3
CrossRef1393
Stefan James. (2004) Coagulation, inflammation and myocardial dysfunction in unstable coronary artery disease and the influence of glycoprotein IIb/IIIa inhibition and low molecular weight heparin. Upsala Journal of Medical Sciences 109:2, 71-122
CrossRef1394
Victor L. Serebruany, Alex I. Malinin, Roswith M. Eisert, David C. Sane. (2004) Risk of bleeding complications with antiplatelet agents: Meta-analysis of 338,191 patients enrolled in 50 randomized controlled trials. American Journal of Hematology 75:1, 40-47
CrossRef1395
J.J. Connors. (2004) Pharmacologic Agents in Stroke Prevention, Acute Stroke Therapy, and Interventional Procedures. Journal of Vascular and Interventional Radiology 15:1, S87-S101
CrossRef1396
Sunil V. Rao. (2003) Controversies Surrounding the Use of Glycoprotein IIb/IIIa Inhibitors. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 2:4, 231-238
CrossRef1397
William J. Powers. (2003) Atherosclerotic carotid artery occlusion. Current Treatment Options in Cardiovascular Medicine 5:6, 501-509
CrossRef1398
Paul D Hayes, Helen Box, Samantha Tull, Peter R.F Bell, Alison Goodall, A.Ross Naylor. (2003) Patients' thromboembolic potential after carotid endarterectomy is related to the platelets' sensitivity to adenosine diphosphate. Journal of Vascular Surgery 38:6, 1226-1231
CrossRef1399
Gerard X Brogan. (2003) Update on acute coronary syndromes and implications for therapy. Expert Opinion on Investigational Drugs 12:12, 1971-1983
CrossRef1400
Harold P. Adams. (2003) 10 Most Commonly Asked Questions About Which Antiplatelet Agent To Prescribe. The Neurologist 9:6, 318-322
CrossRef1401
Hani Jneid, Deepak L Bhatt. (2003) Advances in antiplatelet therapy. Expert Opinion on Emerging Drugs 8:2, 349-363
CrossRef1402
Steven R Steinhubl, Jo E Rodgers. (2003) Clopidogrel’s role in the management of atherosclerotic disease: a focus on acute coronary syndromes. Expert Review of Cardiovascular Therapy 1:4, 507-522
CrossRef1403
MR Macleod, GA Donnan. (2003) Atheroma of the aortic arch: the missing link in the secondary prevention of stroke?. Expert Review of Cardiovascular Therapy 1:4, 487-489
CrossRef1404
Ian D. Conde, Neal S. Kleiman. (2003) Arterial thrombosis for the interventional cardiologist: From adhesion molecules and coagulation factors to clinical therapeutics. Catheterization and Cardiovascular Interventions 60:2, 236-246
CrossRef1405
Charles Warlow, Cathie Sudlow, Martin Dennis, Joanna Wardlaw, Peter Sandercock. (2003) Stroke. The Lancet 362:9391, 1211-1224
CrossRef1406
Robert A. Henderson, Stuart J. Pocock, Tim C. Clayton, Rosemary Knight, Keith A.A. Fox, Desmond G. Julian, Douglas A. Chamberlain. (2003) Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy. Journal of the American College of Cardiology 42:7, 1161-1170
CrossRef1407
Douglas B Wilhite, Anthony J Comerota, Frank A Schmieder, Richard C Throm, John P Gaughan, A Koneti Rao. (2003) Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time. Journal of Vascular Surgery 38:4, 710-713
CrossRef1408
R. Hodl, W. Klein. (2003) The role of low-molecular-weight heparins in cardiovascular medicine. Journal of Clinical Pharmacy and Therapeutics 28:5, 371-378
CrossRef1409
W. S. Aronow. (2003) Review Article: Treatment of Unstable Angina Pectoris/Non-ST-Segment Elevation Myocardial Infarction in Elderly Patients. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 58:10, M927-M933
CrossRef1410
E.Murat Tuzcu, Paul Schoenhagen. (2003) Acute coronary syndromes, plaque vulnerability,and carotid artery disease. Journal of the American College of Cardiology 42:6, 1033-1036
CrossRef1411
Jocelyn S Fernandez, Betty T Sadaniantz, Ara Sadaniantz. (2003) Review of antithrombotic agents used for acute coronary syndromes in renal patients. American Journal of Kidney Diseases 42:3, 446-455
CrossRef1412
Robert P Giugliano, Eugene Braunwald. (2003) Improving antithrombotic treatment in patients after myocardial infarction. The Lancet 362:9386, 757
CrossRef1413
Richard P Gerraty. (2003) Clinical diagnosis of subcortical cerebral infarction. Expert Review of Neurotherapeutics 3:5, 703-711
CrossRef1414
Christopher P. Cannon, Eugene Braunwald. (2003) Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE) Acute Coronary Syndromes Critical Pathway Toolkit. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 2:3, 153-177
CrossRef1415
Mori J. Krantz. (2003) Secondary Prevention of Coronary Artery Disease: Combining the Evidence. Primary Care Case Reviews 6:3, 110-120
CrossRef1416
Pamela B. Conley, Suzanne M. Delaney. (2003) Scientific and therapeutic insights into the role of the platelet P2Y12 receptor in thrombosis. Current Opinion in Hematology 10:5, 333-338
CrossRef1417
Lars Wallentin, Robert G Wilcox, W Douglas Weaver, Håkan Emanuelsson, Andrew Goodvin, Per Nyström, Anders Bylock. (2003) Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. The Lancet 362:9386, 789-797
CrossRef1418
William J. Powers. (2003) Atherosclerotic carotid artery occlusion. Current Treatment Options in Neurology 5:5, 381-389
CrossRef1419
Jacqueline Saw, David J. Moliterno. (2003) Contemporary use of antiplatelet therapies in percutaneous coronary interventions. Coronary Artery Disease 14:5, 373-380
CrossRef1420
Patrick André, Suzanne M. Delaney, Thomas LaRocca, Diana Vincent, Francis DeGuzman, Marzena Jurek, Beverley Koller, David R. Phillips, Pamela B. Conley. (2003) P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries. Journal of Clinical Investigation 112:3, 398-406
CrossRef1421
Anna M. Wodlinger, John A. Pieper. (2003) The role of clopidogrel in the management of acute coronary syndromes. Clinical Therapeutics 25:8, 2155-2181
CrossRef1422
F. H. Ng, S. Y. Wong, C. M. Chang, W. H. Chen, C. Kng, A. I. Lanas, B. C. Y. Wong. (2003) High incidence of clopidogrel-associated gastrointestinal bleeding in patients with previous peptic ulcer disease. Alimentary Pharmacology and Therapeutics 18:4, 443-449
CrossRef1423
Christopher P. Cannon. (2003) Oral platelet glycoprotein IIb/IIIa receptor inhibitors-part I. Clinical Cardiology 26:8, 358-364
CrossRef1424
Irina Otel, François Ledru, Nicolas Danchin. (2003) Ischemic heart disease in type 2 diabetes. Metabolism 52, 6-12
CrossRef1425
H.Mehrdad Sadeghi, Cindy L Grines, Harish R Chandra, Simon R Dixon, Judith A Boura, Srinivas Dukkipati, Kishore J Harjai, William W O’Neill. (2003) Percutaneous coronary interventions in octogenarians. Journal of the American College of Cardiology 42:3, 428-432
CrossRef1426
Nick R Bijsterveld, Arno H Moons, Joost C.M Meijers, Marcel Levi, Harry R Büller, Ron J.G Peters. (2003) The impact on coagulation of an intravenous loading dose in addition to a subcutaneousregimen of low-molecular-weight heparinin the initial treatment of acute coronary syndromes. Journal of the American College of Cardiology 42:3, 424-427
CrossRef1427
H Lévesque. (2003) Atorvastatine et clopidogrel. Une interaction médicamenteuse potentielle aux conséquences cliniques encore inconnues. La Revue de Médecine Interne 24:8, 498-500
CrossRef1428
Walter S. Schroeder, Pritesh J. Gandhi. (2003) Emergency management of hemorrhagic complications in the era of glycoprotein IIb/IIIa receptor antagonists, clopidogrel, low molecular weight heparin, and third-generation fibrinolytic agents. Current Cardiology Reports 5:4, 310-317
CrossRef1429
Debabrata Mukherjee, Kim A. Eagle. (2003) Revised guidelines for the management of non-ST-segment elevation acute coronary syndromes. Current Cardiology Reports 5:4, 289-295
CrossRef1430
Michele Genoni, Reza Tavakoli, Christoph Hofer, Osmund Bertel, Marko Turina. (2003) Clopidogrel before urgent coronary artery bypass graft. The Journal of Thoracic and Cardiovascular Surgery 126:1, 288-289
CrossRef1431
(2003) Antiplatelet Therapy in Peripheral Arterial Disease. Consensus Statement. European Journal of Vascular and Endovascular Surgery 26:1, 1-16
CrossRef1432
Rosaire P. Gray, John S. Yudkin. 2003. Clinical Features and Treatment of Coronary Heart Disease in Diabetes. .
CrossRef1433
Curtis Benesch. (2003) Antithrombotic and thrombolytic therapy for ischemic stroke. Current Atherosclerosis Reports 5:4, 267-275
CrossRef1434
Stephanie H Wilson, Panayotis Fasseas, James L Orford, Ryan J Lennon, Terese Horlocker, Nina E Charnoff, Steven Melby, Peter B Berger. (2003) Clinical outcome of patients undergoing non-cardiac surgery in the two months following coronary stenting. Journal of the American College of Cardiology 42:2, 234-240
CrossRef1435
Catharina Borna, Lingwei Wang, Tomas Gudbjartsson, Lena Karlsson, Sverker Jern, Malin Malmsjö, David Erlinge. (2003) Contractions in human coronary bypass vessels stimulated by extracellular nucleotides. The Annals of Thoracic Surgery 76:1, 50-57
CrossRef1436
Thomas F. Oppelt, Rodel V. Bobadilla. (2003) Better Living Through Chemistry: Does It Still Apply to Patients After Myocardial Infarction?. Pharmacotherapy 23:6, 816-822
CrossRef1437
G Helft. (2003) Clopidogrel et thrombopénie. À propos d'un casClopidogrel and thrombocytopenia. A case report. Annales de Cardiologie et d'Angéiologie 52:3, 191-193
CrossRef1438
Geoffrey A. Donnan, Stephen M. Davis, Elizabeth F. Jones, Pierre Amarenco. (2003) Aortic source of brain embolism. Current Treatment Options in Cardiovascular Medicine 5:3, 211-219
CrossRef1439
Peter Bogaty, James Brophy. (2003) Increasing burden of treatment in the acute coronary syndromes: is it justified?. The Lancet 361:9371, 1813-1816
CrossRef1440
Daniel Soffer, Issam Moussa, Kishore J. Harjai, Judith A. Boura, Simon R. Dixon, Cindy L. Grines, William W. O'Neill, Gary S. Roubin, Jeffrey W. Moses. (2003) Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: Do we need more aggressive dosing regimens in unstable angina?. Catheterization and Cardiovascular Interventions 59:1, 21-25
CrossRef1441
Shawn M Bauer. (2003) ADP receptor antagonists as antiplatelet therapeutics. Expert Opinion on Emerging Drugs 8:1, 93-101
CrossRef1442
MICHAEL S. CHEN, DEEPAK L. BHATT. (2003) Highlights of the 2002 Update to the 2000 American College of Cardiology/American Heart Association Acute Coronary Syndrome Guidelines. Cardiology in Review 11:3, 113-121
CrossRef1443
R. P. Gerraty. (2003) Stroke prevention: what's new?. Internal Medicine Journal 33:4, 177-181
CrossRef1444
Umesh N Khot, Steven E Nissen. (2003) Statistical versus clinical significance of the CURE study in acute coronary syndromes: Reply. Journal of the American College of Cardiology 41:7, 1234-1235
CrossRef1445
Sheila A Doggrell. (2003) Warfarin and aspirin give more benefit than aspirin alone but also more bleeding after myocardial infarction. Expert Opinion on Pharmacotherapy 4:4, 587-590
CrossRef1446
Steven E Lipshultz, Stacy D Fisher, Wyman W Lai, Tracie L Miller. (2003) Cardiovascular risk factors, monitoring, and therapy for HIV-infected patients. AIDS 17, S96-S122
CrossRef1447
Campbell D Joyner, Marcus Flather. (2003) Statistical versus clinical significance of the cure study in acute coronary syndromes. Journal of the American College of Cardiology 41:7, 1233-1234
CrossRef1448
(2003) International Society of Hypertension (ISH). Journal of Hypertension 21:4, 651-663
CrossRef1449
Howard S. Kirshner. (2003) Medical Prevention of Stroke, 2003. Southern Medical Journal 96:4, 354-358
CrossRef1450
Erdal Cavusoglu, Judy Cheng, Rajat Bhatt, Prabhakara B. Kunamneni, Jonathan D. Marmur, Calvin Eng. (2003) Clopidogrel in the Management of Ischemic Heart Disease. Heart Disease 5:2, 144-152
CrossRef1451
Lemuel A. Moy??, Anita Deswal. (2003) Perils of the Random Experiment. American Journal of Therapeutics 10:2, 112-121
CrossRef1452
John W Eikelboom, Graeme J Hankey. (2003) Aspirin resistance:a new independent predictor of vascular events?. Journal of the American College of Cardiology 41:6, 966-968
CrossRef1453
M.I. Matsagas, I.A. Jagroop, D.P. Mikhailidis, G. Geroulakos. (2003) Is Aspirin Still the Antiplatelet Drug of Choice for Patients with Peripheral Arterial Disease?. European Journal of Vascular and Endovascular Surgery 25:3, 281-282
CrossRef1454
Thomas O Mayer, José Biller. (2003) Antiplatelet prescribing patterns for TIA and ischemic stroke: the Indiana University experience. Journal of the Neurological Sciences 207:1-2, 5-10
CrossRef1455
S Anand. (2003) Oral anticoagulants in patients with coronary artery disease: an inexpensive and effective strategy. Thrombosis Research 109:4, 159-161
CrossRef1456
(2003) Aspirin, Clopidogrel, or Both for Secondary Prevention of Coronary Disease. New England Journal of Medicine 348:6, 560-563
Full Text1457
Waiel M. Samara, Paul A. Gurbel. (2003) The role of platelet receptors and adhesion molecules in coronary artery disease. Coronary Artery Disease 14:1, 65-79
CrossRef1458
Alex I Malinin, Dan Atar, Kevin P Callahan, Marcus E McKenzie, Victor L Serebruany. (2003) Effect of a single dose aspirin on platelets in humans with multiple risk factors for coronary artery disease. European Journal of Pharmacology 462:1-3, 139-143
CrossRef1459
Steven E Nissen. (2003) Pathobiology, not angiography, should guide managementin acute coronary syndrome/non–ST-segment elevation myocardial infarction. Journal of the American College of Cardiology 41:4, S103-S112
CrossRef1460
William E Boden. (2003) “Routine invasive” versus “selective invasive” approaches to non–ST-segment elevation acute coronary syndromes management in the post-stent/platelet inhibition era. Journal of the American College of Cardiology 41:4, S113-S122
CrossRef1461
John Eikelboom, Harvey White, Salim Yusuf. (2003) The evolving role of direct thrombin inhibitors in acute coronary syndromes. Journal of the American College of Cardiology 41:4, S70-S78
CrossRef1462
Shamir R Mehta, Salim Yusuf. (2003) Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention. Journal of the American College of Cardiology 41:4, S79-S88
CrossRef1463
Sonia S Anand, Salim Yusuf. (2003) Oral anticoagulants in patients with coronary artery disease. Journal of the American College of Cardiology 41:4, S62-S69
CrossRef1464
N Danchin. (2003) Les nouveautés 2002 en pathologie coronaire. Annales de Cardiologie et d'Angéiologie 52:1, 52-53
CrossRef1465
Jean-Philippe Collet, Gilles Montalescot, Erika Fine, Jean-Louis Golmard, Miles Dalby, R.émi Choussat, Annick Ankri, Raphaëlle Dumaine, Claude Lesty, Nicolas Vignolles, Daniel Thomas. (2003) Enoxaparin in unstable angina patients who would have been excluded from randomized pivotal trials. Journal of the American College of Cardiology 41:1, 8-14
CrossRef1466
Joseph Murphy, R Scott Wright, Ihor Gussak, Brent Williams, Robert N Daly, Valerie A Cain, Henry J Pieniaszek, Sherwin K B Sy, William Ebling, Kristen Simonson, Racehl A Wilcox, Stephen L Kopecky. (2003) The Use of Roxifiban (DMP754), a Novel Oral Platelet Glycoprotein IIb/IIIa Receptor Inhibitor, in Patients with Stable Coronary Artery Disease. American Journal of Cardiovascular Drugs 3:2, 101-112
CrossRef1467
Steven K. Feske. 2003. Pharmacology of Commonly Used Drugs. , 225-238.
CrossRef1468
P. C. A. Kam, C. M. Nethery. (2003) The thienopyridine derivatives (platelet adenosine diphosphate receptor antagonists), pharmacology and clinical developments. Anaesthesia 58:1, 28-35
CrossRef1469
Archibald McNicol, Sara J. Israels. (2003) Platelets and Anti-platelet Therapy. Journal of Pharmacological Sciences 93:4, 381-396
CrossRef1470
Ramesh Madhavan, Seemant Chaturvedi. (2003) Transient Ischaemic Attacks. CNS Drugs 17:5, 293-305
CrossRef1471
Gordon .O. Lowe. (2003) Different Locations of Atherosclerosis – Different Risk Factors, Different Therapies?. Pathophysiology of Haemostasis and Thrombosis 33:5-6, 262-266
CrossRef1472
C Bal dit Sollier. (2003) Reduced thrombus cohesion in an ex vivo human model of arterial thrombosis induced by clopidogrel treatment: kinetics of the effect and influence of single and double loading-dose regimens. Thrombosis Research 111:1-2, 19-27
CrossRef1473
Lian Zhao, Philip M.W. Bath, Sue Fox, Jane May, Heather Judge, Wolfgang Lösche, Stan Heptinstall. (2003) The effects of GPIIb-IIIa antagonists and a combination of three other antiplatelet agents on platelet-leukocyte interactions. Current Medical Research and Opinion 19:3, 178-186
CrossRef1474
Udho Thadani. (2003) The Pursuit of Optimum Outcomes in Stable Angina. American Journal of Cardiovascular Drugs 3:Supplement 1, 11-20
CrossRef1475
U Klinkhardt. (2003) Effects of the NHE-1 inhibitor cariporide alone or together with the P2Y12 antagonist AR-C 69331 MX on CD62p expression and formation of platelet–leukocyte aggregates. Thrombosis Research 111:4-5, 251-257
CrossRef1476
Mark J. Alberts. (2003) Update on the treatment and prevention of ischaemic stroke. Current Medical Research and Opinion 19:5, 438-441
CrossRef1477
Ravi K Yarlagadda, William E Boden. (2002) Cardioprotective effects of an early invasive strategy for non–ST-segment elevationacute coronary syndromes. Journal of the American College of Cardiology 40:11, 1915-1918
CrossRef1478
Giovanni Melandri. (2002) The RITA 3 Trial. The Lancet 360:9349, 1971-1972
CrossRef1479
Kenneth Butcher, Tracey Baird, Mark Parsons, Stephen Davis. (2002) Medical Management of Intracerebral Hemorrhage. Neurosurgery Quarterly 12:4, 261-278
CrossRef1480
James W. Hoekstra, Charles V. Pollack, Matthew T. Roe, Eric D. Peterson, Ralph Brindis, Robert A. Harrington, Robert H. Christenson, Sidney C. Smith, E. Magnus Ohman, W. Brian Gibler. (2002) Improving the Care of Patients with Non-ST-elevation Acute Coronary Syndromes in the Emergency Department: The CRUSADE Initiative. Academic Emergency Medicine 9:11, 1146-1155
CrossRef1481
James J. Ferguson. (2002) Defining the scope of evidence-based practice for low-molecular-weight heparin therapy in high-risk patients with unstable angina and non-st-elevation myocardial infarction. Clinical Cardiology 25:S1, 16-22
CrossRef1482
Eric J. Topol. (2002) Economics and quality of care for patients with acute coronary syndromes: The impending crisis. Clinical Cardiology 25:S1, 9-15
CrossRef1483
Stephen Woodworth, Devraj Nayak, Wilbert S. Aronow, Anthony L. Pucillo, Srinivas Koneru. (2002) Cardiovascular Medications Taken by Patients Aged ?70 Years Hospitalized for Acute Coronary Syndromes Before Hospitalization and at Hospital Discharge. Preventive Cardiology 5:4, 173-176
CrossRef1484
Gerard X. Brogan. (2002) Bench to Bedside: Pathophysiology of Acute Coronary Syndromes and Implications for Therapy. Academic Emergency Medicine 9:10, 1029-1044
CrossRef1485
Robert L. Talbert, Sarah A. Spinler, Jean M. Nappi, Michael B. Bottorff. (2002) Combination Antiplatelet Therapy: Implications for Pharmacists. Pharmacotherapy 22:10, 1211-1215
CrossRef1486
Eugene Braunwald, Elliott M Antman, John W Beasley, Robert M Califf, Melvin D Cheitlin, Judith S Hochman, Robert H Jones, Dean Kereiakes, Joel Kupersmith, Thomas N Levin, Carl J Pepine, John W Schaeffer, Earl E Smith, David E Steward, Pierre Theroux, Raymond J Gibbons, Elliott M Antman, Joseph S Alpert, David P Faxon, Valentin Fuster, Gabriel Gregoratos, Loren F Hiratzka, Alice K Jacobs, Sidney C Smith. (2002) ACC/AHA 2002 guideline update for the management of patients with unstable angina and non–ST-segment elevation myocardial infarction—summary article. Journal of the American College of Cardiology 40:7, 1366-1374
CrossRef1487
Matthew T. Roe, Karen L. Staman, Charles Pollack, Rebecca Teaff, Patricia A. French, Eric D. Peterson. (2002) A Practical Guide to Understanding the 2002 ACC/AHA Guidelines for the Management of Patients With Non-ST Segment Elevation Acute Coronary Syndromes. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 1:3, 129-149
CrossRef1488
Judy WM Cheng. (2002) Pharmacotherapeutic options for the management of myocardial infarction. Expert Opinion on Pharmacotherapy 3:8, 1153-1168
CrossRef1489
Sridhar Kamath, Andrew D Blann, Bernard S.P Chin, Gregory Y.H Lip. (2002) A prospective randomized trial of aspirin-clopidogrel combination therapy and dose-adjusted warfarin on indices of thrombogenesis and platelet activation in atrial fibrillation. Journal of the American College of Cardiology 40:3, 484-490
CrossRef1490
Andreas W Bonz, Björn Lengenfelder, Jörg Strotmann, Stefanie Held, Oliver Turschner, Kerstin Harre, Christian Wacker, Christiane Waller, Nikolaus Kochsiek, Malte Meesmann, Ludwig Neyses, Peter Schanzenbächer, Georg Ertl, Wolfram Voelker. (2002) effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR trial). Journal of the American College of Cardiology 40:4, 662-668
CrossRef1491
L MACCHI, L CHRISTIAENS, S BRABANT, N SOREL, J ALLAL, G MAUCO, A BRIZARD. (2002) Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thrombosis Research 107:1-2, 45-49
CrossRef1492
William E. Boden. (2002) The role of pharmacotherapy and catheter-based intervention in the management of patients with non-st-segment elevation acute coronary syndromes. Current Cardiology Reports 4:4, 260-271
CrossRef1493
Martin J. Quinn, Sorin J. Brener. (2002) Early invasive strategies for acute coronary syndromes. Current Cardiology Reports 4:4, 334-340
CrossRef1494
Gordon D. O. Lowe. (2002) Measurement of thrombosis and its prevention. British Journal of Clinical Pharmacology 54:1, 96-100
CrossRef1495
Robert F van Es, Jan JC Jonker, Freek WA Verheugt, Jaap W Deckers, Diederick E Grobbee. (2002) Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. The Lancet 360:9327, 109-113
CrossRef1496
Umesh N. Khot, Steven E. Nissen. (2002) Is CURE a cure for acute coronary syndromes? Statistical versus clinical significance. Journal of the American College of Cardiology 40:2, 218-219
CrossRef1497
Henock Saint-Jacques, Robert A. Harrington. (2002) Glycoprotein receptor inhibitors in the management of acute coronary syndromes. Current Cardiology Reports 4:4, 301-312
CrossRef1498
SA Harding, NA Boon, AD Flapan. (2002) Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. The Lancet 360:9328, 256-257
CrossRef1499
Gaspoz, Jean-Michel, Coxson, Pamela G., Goldman, Paula A., Williams, Lawrence W., Kuntz, Karen M., Hunink, M.G. Myriam, Goldman, Lee, . (2002) Cost Effectiveness of Aspirin, Clopidogrel, or Both for Secondary Prevention of Coronary Heart Disease. New England Journal of Medicine 346:23, 1800-1806
Full Text1500
Lauer, Michael S., . (2002) Aspirin for Primary Prevention of Coronary Events. New England Journal of Medicine 346:19, 1468-1474
Full Text1501
Tamara B. Horwich, Gregg C. Fonarow. (2002) Prevention of heart failure. Current Cardiology Reports 4:3, 194-199
CrossRef1502
Filip Jacobsson, Eva Swahn, Lars Wallentin, Mikael Dellborg. (2002) Safety profile and tolerability of intravenous AR-C69931MX, a new antiplatelet drug, in unstable angina pectoris and non—Q-wave myocardial infarction. Clinical Therapeutics 24:5, 752-765
CrossRef1503
Jacques R. Leclerc. (2002) Platelet glycoprotein IIb/IIIa antagonists: Lessons learned from clinical trials and future directions. Critical Care Medicine 30:Supplement, S332-S340
CrossRef1504
Derek J Ward, Rod Taylor. (2002) Guidelines for acute coronary syndrome without ST elevation. The Lancet 359:9314, 1349
CrossRef1505
Mats Eriksson, Kjeld Christensen, Tomas L Lindahl, Anders Larsson. (2002) Pharmaceutical thrombosis prevention in cardiovascular disease. Expert Opinion on Investigational Drugs 11:4, 553-563
CrossRef1506
DAVID E. KANDZARI, KENNETH W. MAHAFFEY. (2002) Experience with Glycoprotein IIb/IIIa Antagonists in Patients with Acute Coronary Syndromes. Journal of Interventional Cardiology 15:2, 121-129
CrossRef1507
DEEPAK P. VIVEKANANTHAN, VASANT B. PATEL, DAVID J. MOLITERNO. (2002) Glycoprotein IIb/IIIa Antagonism and Fibrinolytic Therapy for Acute Myocardial Infarction. Journal of Interventional Cardiology 15:2, 131-139
CrossRef1508
JOEL P. REGINELLI, DEREK CHEW. (2002) Direct Thrombin Inhibitors for Percutaneous Coronary Intervention in the Current Era of Platelet Glycoprotein IIb/IIIa Inhibition. Journal of Interventional Cardiology 15:2, 141-146
CrossRef1509
Stone, Gregg W., Grines, Cindy L., Cox, David A., Garcia, Eulogio, Tcheng, James E., Griffin, John J., Guagliumi, Giulio, Stuckey, Thomas, Turco, Mark, Carroll, John D., Rutherford, Barry D., Lansky, Alexandra J., . (2002) Comparison of Angioplasty with Stenting, with or without Abciximab, in Acute Myocardial Infarction. New England Journal of Medicine 346:13, 957-966
Full Text1510
Christopher P. Cannon, Joseph P. Ornato. (2002) How to Develop a Critical Pathway. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 1:1, 53-60
CrossRef1511
Thomas Mooe. (2002) Risk, mechanisms and prevention of stroke after an acute myocardial infarction. Expert Review of Neurotherapeutics 2:2, 177-186
CrossRef1512
Sheila A Doggrell. (2002) Clopidogrel: a CURE in acute coronary syndromes?. Expert Opinion on Pharmacotherapy 3:3, 351-353
CrossRef1513
Christopher P. Cannon. (2002) Critical Pathway for Unstable Angina and Non-ST Elevation Myocardial Infarction. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 1:1, 12-21
CrossRef1514
Michel Accad, Andrew D. Michaels. (2002) Management after myocardial infarction. Current Treatment Options in Cardiovascular Medicine 4:1, 41-54
CrossRef1515
Yerem Yeghiazarians, Peter H. Stone. (2002) ST-segment elevation myocardial infarction. Current Treatment Options in Cardiovascular Medicine 4:1, 3-23
CrossRef1516
R. Donnelly, J.M.C. Yeung. (2002) Management of Intermittent Claudication: the Importance of Secondary Prevention. European Journal of Vascular and Endovascular Surgery 23:2, 100-107
CrossRef1517
(2002) Treatment of Acute Coronary Syndromes. New England Journal of Medicine 346:3, 206-208
Full Text1518
Jan Erik Otterstad, Keith A. A. Fox. (2002) Clinical Implications of CURE and PCI-CURE in Patients with the Acute Coronary Syndrome without Persistent ST-elevation. Scandinavian Cardiovascular Journal 36:5, 261-271
CrossRef1519
Eric Boersma, Robert A Harrington, David J Moliterno, Harvey White, Pierre Théroux, Frans Van de Werf, Anneke de Torbal, Paul W Armstrong, Lars C Wallentin, Robert G Wilcox, John Simes, Robert M Califf, Eric J Topol, Maarten L Simoons. (2002) Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. The Lancet 359:9302, 189-198
CrossRef1520
Manesh R. Patel, Matthew T. Roe. (2002) Pharmacological Treatment of Elderly Patients with Acute Coronary Syndromes without Persistent ST Segment Elevation. Drugs & Aging 19:9, 633-646
CrossRef1521
Deepak L Bhatt, Michel E Bertrand, Peter B Berger, Philippe L L’Allier, Issam Moussa, Jeffrey W Moses, George Dangas, Megumi Taniuchi, John M Lasala, David R Holmes, Stephen G Ellis, Eric J Topol. (2002) Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. Journal of the American College of Cardiology 39:1, 9-14
CrossRef1522
Timothy D. Gladwell. (2002) Bivalirudin: A direct thrombin inhibitor. Clinical Therapeutics 24:1, 38-58
CrossRef1523
John W. Eikelboom, John French. (2002) Management of Patients with Acute Coronary Syndromes. Drugs 62:13, 1839-1852
CrossRef1524
A. Michael Lincoff. (2001) Anticoagulant and antiplatelet drugs. Catheterization and Cardiovascular Interventions 54:4, 514-520
CrossRef1525
J Collet. (2001) Le traitement antithrombotique à la phase aiguë de l'angor instableAntithrombotic therapy in the acute phase of unstable angina. Annales de Cardiologie et d'Angéiologie 50:7-8, 366-376
CrossRef1526
Michael W. Rich. (2001) Treatment of Acute Myocardial Infarction. The American Journal of Geriatric Cardiology 10:6, 328-336
CrossRef1527
Christian W Hamm, Michel Bertrand, Eugene Braunwald. (2001) Acute coronary syndrome without ST elevation: implementation of new guidelines. The Lancet 358:9292, 1533-1538
CrossRef1528
Kenneth Cusi. (2001) Cardiovascular Risk Management in Type 2 Diabetes: From Clinical Trials to Clinical Practice. The Endocrinologist 11:6, 474-490
CrossRef1529
Xavier Bosch, Pablo Loma-Osorio, Jaume Marrugat, Xavier Bosch. 2001. Platelet glycoprotein IIb/IIIa blockers for percutaneous coronary intervention and the initial treatment of non-ST segment elevation acute coronary syndromes. .
CrossRef1530
&NA;. (2001) Adding clopidogrel to aspirin beneficial in CURE study .... Inpharma Weekly &NA;:1302, 15
CrossRef1531
Derek P. Chew, Deepak L. Bhatt, Eric J. Topol. (2001) Oral Glycoprotein IIb/IIIa Inhibitors. American Journal of Cardiovascular Drugs 1:6, 421-428
CrossRef
